Page last updated: 2024-12-04

atenolol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2977
CHEMBL ID46518
SCHEMBL ID120839
MeSH IDM0001900
PubMed CID2249
CHEMBL ID24
CHEBI ID2904
SCHEMBL ID4362
MeSH IDM0001900

Synonyms (356)

Synonym
cannabinol, 1-trans-.delta.-(sup8)-tetrahydro-
.delta.6-tetrahydrocannabinol
.delta.8-tetrahydrocannabinol
(-)-.delta.6-tetrahydrocannabinol
.delta.8-trans-tetrahydrocannabinol
(-)-.delta.8-tetrahydrocannabinol
6h-dibenzo[b, 6a,7,10,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, (6ar-trans)-
.delta.1(6)-tetrahydrocannabinol
.delta.8-thc
.delta.-(sup6)-thc
6h-dibenzo[b, 6a,7,10,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-
.delta.-(sup8)-thc
.delta.1(6)-trans-tetrahydrocannabinol
.delta.6-thc
6h-dibenzo[b, 6a,7,10,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, trans-(-)-
1-trans-.delta.-(sup8)-tetrahydrocannabinol
cannabinol, .delta.1(6)-tetrahydro-
(-)-.delta.-(sup8)-trans-tetrahydrocannabinol
.delta.-8-thc
(-)-.delta.8-trans-tetrahydrocannabinol
nsc134453
KBIO1_000978
DIVK1C_000978
delta-8-tetrahydrocannabinol
IDI1_000978
NINDS_000978
CHEMBL46518
HMS503C17
6,6,9-trimethyl-3-pentyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
SCHEMBL120839
HCAWPGARWVBULJ-UHFFFAOYSA-N
(-)-trans-.delta.8-tetrahydrocannabinol
6,6,9-trimethyl-3-pentyl-6a,7,10,10a-tetrahydro-6h-benzo[c]chromen-1-ol, trans-(-) #
.delta.8-l-tetrahydrocannabinol
cannabinol, 1-trans-.delta.8-tetrahydro-
l-.delta.8-tetrahydrocannabinol
1-trans-.delta.8-tetrahydrocannabinol
6h-dibenzo[b,d]pyran-1-ol, 6a,7,10,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, trans-(-)-
6h-dibenzo[b,d]pyran-1-ol, 6a,7,10,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, (6ar-trans)-
6a,7,10,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6h-dibenzo[b,d]pyran-1-ol
14132-18-4
MLS001066372
2-(4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}phenyl)acetamide
MLS001074163
HMS3266K13
BRD-A20239487-001-02-5
gtpl548
MLS000069622 ,
KBIO1_000057
DIVK1C_000057
tensotin
neatenol
2-[4-({2-hydroxy-3-[(1-methylethyl)amino]propyl}oxy)phenyl]acetamide
EU-0100121
atenolol, >=98% (tlc), powder
atendol
ici 66082
atenolin
prenolol
altol
lo-ten
tenolol
atenol heumann
atenomel
atenil
atenol 1a pharma
unibloc
hypoten
atehexal
premorine
xaten
2-(p-(2-hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide
atenol nordic
atenol von ct
apo-atenolol
felo-bits
2-(4-(2-hydroxy-3-isopropylaminopropoxy)phenyl)acetamid
farnormin
aterol
atenol gnr
myocord
hsdb 6526
cardaxen
juvental
atenet
ibinolo
internolol
tredol
atcardil
atenol ct
ormidol
evitocor
lotenal
brn 2739235
atenol pb
seles beta
tenidon
atenol al
4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)benzeneacetamide
atenol-ratiopharm
selobloc
blocotenol
ateni
stermin
noten
wesipin
cuxanorm
atenol acis
atenol tika
atenololum [inn-latin]
atenol fecofar
1-p-carbamoylmethylphenoxy-3-isopropylamino-2-propanol
atenol genericon
normalol
plenacor
tenoprin
blokium
uniloc
hipres
scheinpharm atenol
benzeneacetamide, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-
antipressan
prenormine
cardiopress
betatop ge
atenol gador
atenol atid
duraatenolol
prinorm
SPECTRUM_001364
betasyn
atenol cophar
tenormin
atenol stada
serten
atecard
normiten
tenobloc
atenblock
atenol-wolff
duratenol
tensimin
corotenol
atenol msd
panapres
betablok
tenormine
aircrit
ccris 4196
atereal
jenatenol
servitenol
atenol quesada
alinor
atenol nm pharma
vascoten
einecs 249-451-7
loten
tenormine [french]
betacard
vericordin
ici-66082
anselol
oraday
acetamide, 2-(p-(2-hydroxy-3-(isopropylamino)propoxy)phenyl)-
atenol-mepha
tenoblock
atenol trom
ici 66,082
OPREA1_448775
LOPAC0_000121
einecs 262-544-7
atenolol
BSPBIO_002915
IDI1_000057
SPECTRUM5_001509
2-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}acetamide
artrenolol
bdbm25753
chembl24 ,
BIM-0050109.0001
DB00335
29122-68-7
atenolol (jp17/usp/inn)
D00235
tenormin (tn)
NCGC00024566-04
NCGC00024566-05
NCGC00024566-07
smr000036768
KBIO2_001844
KBIOGR_000790
KBIO2_004412
KBIO2_006980
KBIOSS_001844
KBIO3_002415
NINDS_000057
SPECTRUM3_001448
SPECTRUM4_000435
SPBIO_001482
SPECTRUM2_001411
SPECTRUM1501127
MLS001304038
NCGC00024566-03
(?)-atenolol
NCGC00024566-06
NCGC00015007-07
A 7655 ,
HMS2092D19
HMS2090I19
( inverted question mark)-atenolol
atenololum
2-[4-(2-hydroxy-3-isopropylaminopropoxy)phenyl]acetamide
NCGC00015007-13
L000116
chebi:2904 ,
c07ab03
nsc-757832
novaten
HMS500C19
AKOS005111050
FT-0662316
FT-0662315
FT-0693045
inchi=1/c14h22n2o3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17h,7-9h2,1-2h3,(h2,15,18)
metkimkyrpqlgs-uhfffaoysa-
HMS1921H09
HMS1569L13
2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide
HMS3260I04
HMS3259K08
cas-29122-68-7
dtxcid202628
dtxsid2022628 ,
NCGC00255122-01
tox21_302426
STK528649
BBL009276
2-(4-{[(2s)-2-hydroxy-3-(propan-2-ylamino)propyl]oxy}phenyl)acetamide
pharmakon1600-01501127
nsc757832
2-(4-(2-hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide
atenol
teno-basan
HMS2233E06
CCG-39010
NCGC00015007-06
NCGC00015007-11
NCGC00015007-08
NCGC00015007-10
NCGC00015007-09
nsc 757832
dl-atenolol
(rs)-atenolol
unii-50vv3vw0ti
atcard
50vv3vw0ti ,
atenolol [usan:usp:inn:ban:jan]
(+/-)-atenolol
LP00121
S4817
HMS3369D20
HMS3369B14
HMS3369P20
atenololum [who-ip latin]
atenolol [hsdb]
atenolol [jan]
atenolol component of tenoretic
atenolol [usan]
atenolol [orange book]
atenolol [usp-rs]
atenolol [mi]
atenolol [vandf]
atenolol [who-dd]
atenolol [usp monograph]
atenolol [who-ip]
atenolol [usp impurity]
atenolol [mart.]
2-(p-(hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide
atenolol [ep monograph]
tenoretic component atenolol
2-(p-(2-hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide (racemate)
atenolol [inn]
HY-17498
AB00052208-13
2-{4-[2-hydroxy-3-(isopropylamino)propoxy]-phenyl}acetamide
NC00548
SCHEMBL4362
KS-5341
AB00052208-15
NCGC00260806-01
(y)-atenolol
tox21_500121
(r,s)-atenolol
2-(4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl)acetamide
tenoretic (salt/mix)
benzeneacetamide, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-
Q-200656
GEO-03413
(+/-)-4-(2-hydroxy-3-[(1-methylethyl)amino]propoxy)benzeneacetamide
atenolol, pharmaceutical secondary standard; certified reference material
(rs)-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]benzeneacetamide
(a+/-)-atenolol
AB00052208_16
OPERA_ID_1283
mfcd00057645
(+)-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]benzeneacetamide
60966-51-0
atenolol [usan:ban:inn:jan]
atenolol, analytical reference material
atenolol, european pharmacopoeia (ep) reference standard
AC-8245
SR-01000000159-2
sr-01000000159
atenolol, united states pharmacopeia (usp) reference standard
atenolol (jan/usp)
EN300-119532
atenolol 1.0 mg/ml in acetonitrile
SR-01000000159-8
SR-01000000159-4
SR-01000000159-5
MRF-0000571
SBI-0050109.P003
2-[4-({(2r)-2-hydroxy-3-[(1-methylethyl)amino]propyl}oxy)phenyl]acetamide
Q411325
4-(2-hydroxy-3-[(1-methylethyl)amino]propoxy)benzeneacetamide
HMS3675G21
phenyl)acetamide
2-(4-(2-hydroxy-3-(isopropylamino)propoxy)
atenolol,(s)
106020-65-9
BCP12899
HMS3411G21
BRD-A20239487-001-15-7
SDCCGSBI-0050109.P004
NCGC00015007-24
HMS3886G03
O10469
(+/-)-2-[4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl]acetamide
atenalol (rs)
BA166036
(rs)-2-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}acetamide
Z1521553991
2-(4-((2rs)-2-hydroxy-3-((1-methylethyl)amino)propyloxy)phenyl)acetamide
2-(4-(2-hydroxy-3-((propan-2-yl)amino)propoxy)phenyl)acetamide
atenololum (inn-latin)
c07ab11
atenolol (mart.)
atenolol (ep monograph)
atenololo
atenolol (usan:usp:inn:ban:jan)
atenolol (usp monograph)
atenolol (usp impurity)
2-(p-(2-hydroxy-3-(isopropylamino)propoxy)phenylacetamide
atenolol (usp-rs)
atenolol, 1mg/ml in acetonitrile

Research Excerpts

Overview

Atenolol is a highly prescribed anti-hypertensive pharmaceutical and a member of the group of β-blockers. It is a beta-1 adrenergic antagonist commonly prescribed for the treatment of systemic hypertension or coronary artery disease yet its use in individuals with type 2 diabetes mellitus (T2DM) is controversial due to potentially negative side effects.

ExcerptReferenceRelevance
"Atenolol is a type of beta-blocker extensively used to cure cardiovascular disorders."( Investigating the biological degradation of the drug β-blocker atenolol from wastewater using the SBR.
Aghapour, AA; Khorsandi, H; Rezaei, R, 2022
)
1.68
"Atenolol is a drug widely used for the treatment of hypertension. "( Ion-pair approach coupled with nanoparticle formation to increase bioavailability of a low permeability charged drug.
Bermejo, M; González-Álvarez, I; González-Álvarez, M; Lozoya-Agullo, I; Merino-Sanjuán, M; Planelles, M; Sarmento, B, 2019
)
1.96
"Atenolol is a β-blocker drug and an identified emerging pollutant. "( Sonochemical degradation of a pharmaceutical waste, atenolol, in aqueous medium.
Aravind, UK; Aravindakumar, CT; Manoj, PR; Nejumal, KK, 2014
)
2.1
"Atenolol is a cardioselective beta-blocker that may have fewer adverse events."( Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study.
Ábarzúa-Araya, A; Heusser, F; Navarrete-Dechent, CP; Retamal, J; Zegpi-Trueba, MS, 2014
)
2.57
"Atenolol is a highly prescribed anti-hypertensive pharmaceutical and a member of the group of β-blockers. "( The sub-lethal effects and tissue concentration of the human pharmaceutical atenolol in rainbow trout (Oncorhynchus mykiss).
Burkina, V; Fedorova, G; Grabic, R; Grabicova, K; Kocour Kroupova, H; Schmidt-Posthaus, H; Stara, A; Steinbach, C; Velisek, J; Zlabek, V, 2014
)
2.07
"Atenolol is a β-blocker widely used in the treatment of hypertension. "( Atenolol Renal Secretion Is Mediated by Human Organic Cation Transporter 2 and Multidrug and Toxin Extrusion Proteins.
Duan, H; Prasad, B; Shirasaka, Y; Wang, J; Yin, J, 2015
)
3.3
"Atenolol is a hydrophilic, selective β1-blocker and therefore may be not associated with side effects attributable to β2-adrenergic receptor blockade and lipophilicity."( Oral atenolol therapy for proliferating infantile hemangioma: A prospective study.
Chen, S; Ji, Y; Jiang, X; Li, Y; Wang, Q; Xiang, B; Xu, Z; Yang, X; Zhong, L, 2016
)
1.67
"Atenolol is an antihypertensive drug with low oral bioavailability and gastrointestinal side effects."( Impact of feed counterion addition and cyclone type on aerodynamic behavior of alginic-atenolol microparticles produced by spray drying.
Bucalá, V; Ceschan, NE; Ramírez-Rigo, MV; Smyth, HD, 2016
)
1.38
"Atenolol is a beta-1 adrenergic antagonist commonly prescribed for the treatment of systemic hypertension or coronary artery disease yet its use in individuals with type 2 diabetes mellitus (T2DM) is controversial due to potentially negative side effects on insulin resistance. "( The beta-1 adrenergic antagonist, atenolol, decreases acylation stimulating protein, exercise capacity and plasma free fatty acids in men with type 2 diabetes.
Brassard, P; Cianflone, K; Ferland, A; Lacroix, S; Méthot, J; Poirier, P; Smith, J, 2012
)
2.1
"Atenolol is a cardioselective beta-blocker, which is considered a doping agent in shoot practice, so that its determination in urine can be required for monitoring the drug."( Determination of atenolol in human urine by emission-excitation fluorescence matrices and unfolded partial least-squares with residual bilinearization.
Damiani, PC, 2011
)
1.43
"Atenolol is a cardioselective β1-adrenergic blocker widely used for the treatment of hypertension, angina pectoris and cardiac arrhythmias. "( Determination of atenolol in human plasma by HPLC with fluorescence detection: validation and application in a pharmacokinetic study.
Niopas, I; Spanakis, M, 2013
)
2.17
"Atenolol is a water-soluble, ionizable drug and suffers from poor bioavailability when given by oral route due to its incomplete intestinal absorption and first-pass metabolism."( Design and Characterization of Atenolol Transdermal Therapeutic Systems: Enhancement of Permeability via Iontophoresis.
Keerthi, H; Panakanti, PK; Yamsani, MR,
)
1.14
"Atenolol is a selective β1 receptor antagonist that is available as a racemic mixture. "( Comparative pharmacokinetics and bioequivalence of two 50 mg atenolol tablet formulations in healthy Korean male volunteers.
Chang, MJ; Shin, WG, 2012
)
2.06
"Atenolol (ATL) is a photostable and hydrolysis resistant beta-blocker and has been frequently detected in natural water. "( The role of dissolved organic matters in the aquatic photodegradation of atenolol.
Ji, Y; Yang, X; Zeng, C; Zhang, Y; Zhou, L, 2012
)
2.05
"Atenolol is a hydrophilic betablocker which is characterized by gastrointestinal absorption, small extent of distribution and renal function-dependent elimination."( Influence of cardiopulmonary bypass on the plasma concentrations of atenolol.
Auler, JO; Bonafé, WW; Carmona, MJ; Chignalia, AZ; dos Santos, LM; Leite, Fda S; Malbouisson, LM; Santos, SR; Suyama, MJ, 2007
)
1.3
"Atenolol is a beta-adrenergic receptor antagonist ('beta-blocker') widely used for the treatment of angina, glaucoma, high blood pressure and other related conditions. "( Defining the chronic impacts of atenolol on embryo-larval development and reproduction in the fathead minnow (Pimephales promelas).
Alder, AC; Caunter, JE; Giltrow, E; Hutchinson, TH; Lillicrap, AD; Ramil, M; Schaffner, C; Sumpter, JP; Ternes, TA; Winter, MJ, 2008
)
2.07
"Atenolol is a beta(1)-selective drug, which exerts greater blocking activity on beta(1)-adrenoreceptors than on beta(2)-adrenoreceptors, with the S-enantiomer being more active than R-enantiomer. "( Comparative proteomics analysis of vascular smooth muscle cells incubated with S- and R-enantiomers of atenolol using iTRAQ-coupled two-dimensional LC-MS/MS.
Chen, WN; Ching, CB; Sui, J; Tan, TL; Zhang, J, 2008
)
2
"Atenolol was shown to be an effective oral antihypertensive that has no apparent deleterious hemodynamic effects on the renal and splanchnic circulations."( Hemodynamics, biochemical and reflexive changes produced by atenolol in hypertension.
Dreslinski, GR; Dunn, FG; Frohlich, ED; Messerli, FH; Reisin, E; Suarez, DH, 1982
)
1.23
"Atenolol is an alternative drug in the treatment of PVC in patients with coronary heart disease."( [Atenolol in the treatment of premature ventricular contractions. A double blind study in 68 patients (author's transl)].
Brandes, JW; Körst, HA; Lembcke, HJ; Littmann, KP, 1981
)
1.89
"Atenolol was shown to be an effective anti-anginal agent when given once daily, and there were no major differences between the doses studied."( A comparison of once and twice daily atenolol for angina pectoris.
Boyle, RM; Bray, CL; Croxson, RS; Cruickshank, JM; Naqvi, N, 1983
)
1.26
"Atenolol was found to be an effective antihypertensive agent, reducing both systolic and diastolic blood pressure."( Increased platelet adhesion and aggregation in hypertensive patients: effect of atenolol.
Aviram, M; Brook, JG; Levy, Y; Markel, A; Youdim, MB, 1983
)
1.21
"Atenolol is a hydrophilic betareceptor blocking drug, which is predominantly eliminated via the kidneys, only about 5% of the atenolol is metabolised by the liver. "( Clinical pharmacokinetics of atenolol--a review.
Görg, KG; Kirch, W, 1982
)
2
"Atenolol is a cardioselective beta-blocker. "( A comparison of antihypertensive effects between two formulations of atenolol: tenolol and tenormin.
Chen, CY; Chiang, HT; Hou, ZY; Lee, DK; Wu, TL, 1995
)
1.97
"Atenolol is a long-acting cardioselective beta-blocking agent and is devoid of additional vasodilatory properties."( Effects of atenolol as add-on therapy to fosinopril in heart failure.
Berger, R; Dukat, A; Frey, B; Hülsmann, M; Koller-Strametz, J; Kos, T; Pacher, R; Stanek, B, 1997
)
1.41
"Atenolol is a beta-blocker commonly used for treating hypertension. "( Atenolol-induced lupus erythematosus.
Deng, JS; Frye, RA; McGuiness, M, 1997
)
3.18
"Atenolol is a selective beta 1-adrenergic antagonist with negative chronotropic, bathmotropic, dromotropic and inotropic actions."( [Pharmacologic importance of the combination atenolol/nifedipine in hypertensive patients].
Carré, A, 1998
)
1.28
"Atenolol is a beta-selective (cardioselective) adrenoceptor blocking drug without partial agonist or membrane stabilising activity. "( Atenolol: a review of its pharmacological properties and therapeutic efficacy in angina pectoris and hypertension.
Avery, GS; Brogden, RN; Heel, RC; Speight, TM, 1979
)
3.15
"Atenolol is a potent antianginal agent which, in most patients, is likely to be effective once daily."( Comparison of atenolol with propranolol in the treatment of angina pectoris with special reference to once daily administration of atenolol.
Harry, JD; Jackson, G; Jewitt, DE; Kitson, D; Robinson, C, 1978
)
1.34
"Atenolol was shown to be a beta-adrenoceptor blocker in man, as in animals, in that it antagonized the chronotropic effects of isoprenaline and of exercise."( Human pharmacokinetic and pharmacodynamic studies on the atenolo (ICI 66,082), a new cardioselective beta-adrenoceptor blocking drug.
Conway, FJ; Fitzgerald, JD; McAinsh, J; Rowlands, DJ; Simpson, WT, 1976
)
0.98
"6 Atenolol is an effective blood pressure lowering drug in mild and moderate hypertension, but the drop in blood pressure is associated with marked reduction in heart rate and cardiac output at rest as well as during exercise."( Haemodynamic long-term effects of a new beta-adrenoceptor blocking drug, atenolol (ICI 66082), in essential hypertension.
Lund-Johansen, P, 1976
)
1.05
"Atenolol is a pure beta 1-selective antagonist with more pronounced effects on blood pressure and heart rate at rest."( The effects of beta blockade with (epanolol) and without (atenolol) intrinsic sympathomimetic activity in stable angina pectoris. The Visacor Study Group.
Boberg, J; Larsen, FF; Pehrsson, SK, 1992
)
1.25
"Atenolol is a beta 1-selective blocker without ISA."( An interactive computer program for randomization analysis of response curves with facilities for multiple comparisons.
Does, RJ; Roos, JM; Tan, ES; Van Baak, MA; Volovics, A, 1992
)
1
"Atenolol is a selective beta 1-adrenoceptor antagonist with a duration of activity of at least 24 hours. "( Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.
Brogden, RN; Murdoch, D; Wadworth, AN, 1991
)
3.17
"Atenolol is a newer betablocker, widely used as an antihypertensive drug. "( A clinical study of effect of oral atenolol on normal intraocular pressure and systemic blood pressure.
Chauhan, JK; Khilnani, K; Mishra, YC,
)
1.85
"Atenolol is a predominate beta 1-blocker which can decrease plasma renin activity and inhibit the urinary excretion of aldosterone."( Atenolol treatment of late luteal phase dysphoric disorder.
Golshan, S; Janowsky, DS; Kuhn, K; Rausch, JL; Risch, SC,
)
2.3
"Atenolol is a beta-blocker antihypertensive agent that reportedly has little central nervous system action. "( Severe confusion in a patient receiving electroconvulsive therapy and atenolol.
Kramer, BA, 1986
)
1.95

Effects

Atenolol has a negative effect on the respiratory system, so it is necessary to control external respiratory function in the course of treatment.

Atenolol has been shown to be effective treatment for hypertension, angina pectoris and cardiac arrhythmia. The drug has beta-adrenolytic properties similar to those of propranolol.

ExcerptReferenceRelevance
"Atenolol has a negative effect on the respiratory system, so it is necessary to control external respiratory function in the course of treatment."( [What is the danger of long-term application of beta blockers in patients with ischemic heart disease and concomitant chronic obstructive pulmonary disease?].
Aĭsanov, ZR; Chuchalin, AG; Kozlova, LI, 2005
)
1.05
"Atenolol has a useful antihypertensive effect and, at least theoretically, has advantages over other beta-adrenergic blocking agents."( Controlled study of atenolol in treatment of hypertension.
Aberg, H; Hansson, L; Karlberg, BE; Westerlund, A, 1975
)
1.3
"Atenolol (ATL) has been widely detected in wastewater and aquatic environment. "( Oxidative degradation of atenolol by heat-activated persulfate: Kinetics, degradation pathways and distribution of transformation intermediates.
Gao, S; Miao, D; Peng, J; Qian, L; Wang, M; Zhai, L; Zhou, X, 2018
)
2.23
"Atenolol has been used to treat angina and hypertension, either alone or with other antihypertensives. "( Synthesis, Characterization, and Atenolol Delivery Application of Functionalized Mesoporous Hydroxyapatite Nanoparticles Prepared by Microwave-Assisted Co-precipitation Method.
Ghoreishi, SM; Mortazavi-Derazkola, S; Naimi-Jamal, MR, 2016
)
2.16
"Atenolol has a negative effect on the respiratory system, so it is necessary to control external respiratory function in the course of treatment."( [What is the danger of long-term application of beta blockers in patients with ischemic heart disease and concomitant chronic obstructive pulmonary disease?].
Aĭsanov, ZR; Chuchalin, AG; Kozlova, LI, 2005
)
1.05
"Atenolol has many reported adverse reactions, both common and rare; however, until this report, breast pain and swelling had not been documented adverse reactions. "( Atenolol-induced breast pain in a woman with hypertension.
Kelleher, JA, 2006
)
3.22
"Atenolol and nadolol have been ascertained to be effective long acting antianginal drugs."( [Comparative study of the action of a series of new beta-adrenergic receptor blockaders in patients with effort angina].
Desiatnichenko, VM; Romakov, AIu; Sagirov, AM; Sobol', IuS; Sumarokov, AB, 1983
)
0.99
"Atenolol has been studied prospectively in the management of ten patients with essential hypertension during pregnancy. "( Atenolol in the treatment of essential hypertension during pregnancy.
Butters, L; Low, RA; Reid, JL; Rubin, PC, 1982
)
3.15
"Atenolol has beta-adrenolytic properties similar to those of propranolol, the most commonly named comparator drug."( [Pharmacologic importance of the combination atenolol/nifedipine in hypertensive patients].
Carré, A, 1998
)
1.28
"Atenolol has been shown to be effective treatment for hypertension, angina pectoris and cardiac arrhythmia."( Fixed drug eruption due to atenolol: a case report.
Palungwachira, P, 1999
)
1.32
"Atenolol has been well studied and is effective in the treatment of hypertension and in the prophylactic management of angina."( Atenolol: a review of its pharmacological properties and therapeutic efficacy in angina pectoris and hypertension.
Avery, GS; Brogden, RN; Heel, RC; Speight, TM, 1979
)
2.42
"Atenolol has a useful antihypertensive effect and, at least theoretically, has advantages over other beta-adrenergic blocking agents."( Controlled study of atenolol in treatment of hypertension.
Aberg, H; Hansson, L; Karlberg, BE; Westerlund, A, 1975
)
1.3
"Atenolol has been shown to be stored and secreted from PC12 cells by calcium-dependent and stereoselective mechanisms. "( Stereoselective uptake of atenolol into storage granules isolated from PC12 cells.
Bagwell, EE; Gaffney, TE; Walle, T; Webb, JG, 1989
)
2.02

Actions

Atenolol did not lower the maximal heart rate response to ICI 118,587. The atenolol group had lower normalized LF and the LF/HF ratio (P < 0.05)

ExcerptReferenceRelevance
"The atenolol group had lower normalized LF and the LF/HF ratio (P < 0.05) higher HF before induction; and lower LF/HF ratio after induction and before intubation (P < 0.05)."( Instant centre frequency at anaesthetic induction--a new way to analyse sympathovagal balance.
Cerutti, C; Chiari, P; Custaud, MA; de Souza Neto, EP; Lehot, JJ; Loufoua, J; Saroul, C, 2003
)
0.8
"Atenolol did not produce any effect in preventing doxorubicin-induced ROS generation and cardiac apoptosis."( Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro.
Altieri, P; Ballestrero, A; Barsotti, A; Brunelli, C; Fabbi, P; Garibaldi, S; Ghigliotti, G; Manca, V; Nasti, S; Patrone, F; Rossettin, P; Spallarossa, P, 2004
)
1.04
"Atenolol presented lower LF and higher HF of PI."( Antihypertensive agents have different ability to modulate arterial pressure and heart rate variability in 2K1C rats.
Coelho, EB; da Silva, CA; Fazan, R; Nobre, F; Salgado, HC, 2006
)
1.06
"Atenolol did not lower the maximal heart rate response to ICI 118,587."( Facilitation of calcium blocking and membrane effects by intrinsic sympathomimetic activity.
Briscoe, MG; Halliday, SE; Smith, HJ; Snow, HM, 1984
)
0.99
"Atenolol appeared to suppress PRA in an all-or-none fashion."( A dose ranging study of atenolol in hypertension: fall in blood pressure and plasma renin activity, beta-blockade and steady-state pharmacokinetics.
Ishizaki, T; Nakaya, H; Oyama, Y; Sasaki, T; Sato, T; Shibuya, T; Suganuma, T, 1983
)
1.29
"Atenolol did not suppress cardiotocographic signs of foetal distress."( Atenolol in the treatment of essential hypertension during pregnancy.
Butters, L; Low, RA; Reid, JL; Rubin, PC, 1982
)
2.43
"Atenolol can suppress PVC during exercise testing better in patients with exercise induced VA compared to those without."( Effect of atenolol on symptomatic ventricular arrhythmia without structural heart disease.
Bhuripanyo, K; Chaithiraphan, S; Cheumsuk, W; Kangkagate, C; Krittayaphong, R; Punlee, K; Raungratanaamporn, O; Sriratanasathavorn, C, 2000
)
1.43
"Atenolol did not enhance the effect of physical training upon blood pressure and had little if any effect upon the training-induced increase in exercise tolerance."( Effects of mild physical activity, atenolol and the combination on ambulatory blood pressure in hypertensive subjects.
Adamopoulos, S; Casadei, B; Clark, SJ; Coats, AJ; Meyer, TE; Piepoli, M; Pipilis, A; Radaelli, A, 1992
)
2
"Atenolol abolished the increase in HR by isoproterenol but did not affect the increases in coronary and muscular arterial conductances."( Effects of beta 1- and beta 2-adrenoceptor stimulation on hemodynamics in the anesthetized rat.
Abdelrahman, A; Pang, CC; Tabrizchi, R, 1990
)
1
"Atenolol did not produce a reduction in the left-ventricular-mass index (109 +/- 9 g per square meter before treatment vs."( The effects of antihypertensive therapy on left ventricular mass in elderly patients.
Becker, LC; Gerstenblith, G; Gottlieb, SO; Schulman, SP; Weisfeldt, ML; Weiss, JL; Woodruff, KM, 1990
)
1
"Atenolol failed to produce significant systemic toxic effects not only on weight gains and daily intakes of food but also on death rates."( Role of endogenous beta-adrenergic mechanism in the pathogenesis of spontaneous myocardial fibrosis in rats.
Hashimoto, K; Yoshimura, S, 1988
)
1
"Atenolol caused an increase in working capacity in group B, but not in group A."( The effect of atenolol on the left ventricular performance in patients with angina pectoris measured with isotope technique.
Balldin, M; Boström, PA; Johansson, B; Lilja, B, 1988
)
1.36
"Atenolol did not cause any significant change in the total cholesterol but increased HDL cholesterol by 7% at 1 month, the change being due to rise of the HDL3."( Lipoprotein lipids and apoproteins during beta-blocker administration: comparison of penbutolol and atenolol.
Harno, K; Maass, L; Nikkilä, EA; Välimäki, M, 1986
)
1.21
"Atenolol did not lower the Km value, but reduced significantly the Vmax value of the 10 weeks treated heart MAO."( [Effect of atenolol on MAO activities in SHR].
Nakayama, S; Ohba, T; Sakamoto, K; Tsuji, T, 1986
)
1.38

Treatment

Atenolol treatment initiation was associated with lower 90-day risk of mortality than metoprolol tartrate (incidence, 0.97% vs 1.44%) The atenolol Treatment also lowered visceral adiposity (by 24%), decreased mitochondrial protein oxidative, glycoxidative, and lipoxidative damage in both organs.

ExcerptReferenceRelevance
"The atenolol treatment also lowered visceral adiposity (by 24%), decreased mitochondrial protein oxidative, glycoxidative, and lipoxidative damage in both organs, and lowered oxidative damage in heart mitochondrial DNA."( Lifelong treatment with atenolol decreases membrane fatty acid unsaturation and oxidative stress in heart and skeletal muscle mitochondria and improves immunity and behavior, without changing mice longevity.
Barja, G; Cruces, J; De la Fuente, M; Gómez, A; Gomez, J; Lopez-Torres, M; Mate, I; Naudi, A; Pamplona, R; Portero-Otin, M; Sánchez-Roman, I, 2014
)
1.19
"Atenolol treatment initiation was associated with lower 90-day risk of mortality than metoprolol tartrate (incidence, 0.97% vs 1.44%; relative risk, 0.68; 95%CI, 0.61-0.74)."( Kidney function and population-based outcomes of initiating oral atenolol versus metoprolol tartrate in older adults.
Devereaux, PJ; Fleet, JL; Garg, AX; Jain, AK; McArthur, E; Ozair, S; Roberts, MA; Weir, MA, 2014
)
1.36
"atenolol-based treatment in the LIFE study, we tested whether BP variability assessed as SD and range for BP6-24 months measured at 6, 12, 18 and 24 months of treatment was associated with target organ damage (TOD) defined by LVH on ECG and urine albumin/creatinine ratio at 24 months, and predicted the composite endpoint (CEP) of cardiovascular death, nonfatal myocardial infarction (MI) or stroke occurring after 24 months (CEP = 630 events)."( Blood pressure variability predicts cardiovascular events independently of traditional cardiovascular risk factors and target organ damage: a LIFE substudy.
Dahlöf, B; Devereux, RB; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Mancia, G; Okin, PM; Olsen, MH; Rothwell, PM; Vishram, JK; Wachtell, K, 2015
)
1.14
"Atenolol treatment promoted dramatic decreases in HAS scores after week 1."( Oral atenolol therapy for proliferating infantile hemangioma: A prospective study.
Chen, S; Ji, Y; Jiang, X; Li, Y; Wang, Q; Xiang, B; Xu, Z; Yang, X; Zhong, L, 2016
)
1.67
"Atenolol and prazosin treatment lowered heart rates and blood pressures respectively, but neither agent given alone affected the incidence of phase 2 ventricular tachycardia or fibrillation. "( Complex adrenergic and inflammatory mechanisms contribute to phase 2 ventricular arrhythmias in anaesthetized rats.
Andrag, E; Clements-Jewery, H; Curtis, MJ; Hearse, DJ, 2009
)
1.8
"Atenolol treatment did not change the rate of mitROS production and oxidative damage to mitDNA (8-oxo-7,8-dihydro-2'-deoxyguanosine [8-oxodG]), but strongly decreased the degree of fatty acid unsaturation and the peroxidizability index, mainly due to decreases in 22:6n-3 and 20:4n-6 and to increases in 18:1n-9, 16:1n-7 and 16:0 in the atenolol group."( The β-blocker atenolol lowers the longevity-related degree of fatty acid unsaturation, decreases protein oxidative damage, and increases extracellular signal-regulated kinase signaling in the heart of C57BL/6 mice.
Ayala, V; Barja, G; Gomez, J; Lopez-Torres, M; Naudi, A; Pamplona, R; Portero-Otín, M; Sanchez-Roman, I, 2010
)
1.44
"Atenolol treatment decreased fasting and postprandial glycerol (p < 0.0001) and NEFA (p < 0.0001), postprandial epinephrine (p = 0.048), postprandial cortisol (p = 0.02), postprandial ASP (p = 0.04) and postprandial dopamine (p < 0.004)."( The beta-1 adrenergic antagonist, atenolol, decreases acylation stimulating protein, exercise capacity and plasma free fatty acids in men with type 2 diabetes.
Brassard, P; Cianflone, K; Ferland, A; Lacroix, S; Méthot, J; Poirier, P; Smith, J, 2012
)
1.38
"Atenolol treatment improved LVEF (19.5 +/- 1.9% vs."( Atenolol improves ventricular function without changing plasma noradrenaline but decreasing plasma atrial natriuretic factor in chronic heart failure.
Armando, I; Barontini, M; De Rosa, A; Gabrielli, O; Levin, G; Puyó, AM,
)
2.3
"Atenolol treatment did not induce significant changes in any test score, whereas losartan significantly increased the score of both the word list memory (+2.2, P<0.05 vs baseline) and the word list recall test (+2.1, P<0.05 vs baseline)."( Influence of losartan and atenolol on memory function in very elderly hypertensive patients.
Derosa, G; Fogari, E; Fogari, R; Mugellini, A; Pasotti, C; Preti, P; Zoppi, A, 2003
)
1.34
"In atenolol-treated patients, Nt-proANP (1100-1640 pmol/l, P < 0.001) and Nt-proBNP (20.0-37.7 pmol/l, P < 0.001) increased during the first month, and remained elevated throughout the study."( Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy.
Bang, LE; Devereux, RB; Fossum, E; Hall, C; Hildebrandt, PR; Ibsen, H; Olsen, MH; Rokkedal, J; Tuxen, C; Wachtell, K, 2005
)
1.12
"Atenolol treated patients demonstrated more pronounced respiratory disorders. "( [What is the danger of long-term application of beta blockers in patients with ischemic heart disease and concomitant chronic obstructive pulmonary disease?].
Aĭsanov, ZR; Chuchalin, AG; Kozlova, LI, 2005
)
1.77
"In atenolol-treated patients, the arterial wall became stiffer, whereas in the eplerenone-treated patients, it became less stiff and similar to that of a normotensive control group."( Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients.
Amiri, F; Savoia, C; Schiffrin, EL; Touyz, RM, 2008
)
0.86
"Atenolol-treated SHR and Wistar rat pups showed a decrease in salivary gland weight, salivary flow, and protein concentration, with no alteration in salivary amylase activity."( Atenolol reduces salivary activity in pups of spontaneously hypertensive and normotensive rats treated during pregnancy and lactation.
Antoniali, C; Delbem, AC; Elias, GP; Sassaki, KT, 2008
)
2.51
"Atenolol treatment abolished almost completely these hemodynamic changes."( [Effect of pretreatment with atenolol and propranolol on sympatho-adrenal and cardiovascular responses to acute insulin-induced hypoglycaemia in the hypertensive patient].
Cannella, G; Cesura, AM; Giambelli, A; Maiorca, R; Picotti, GB; Scolari, F; Tosoni, S, 1982
)
1.28
"Atenolol as sole treatment had no appreciable effect on blood pressure as compared with placebo."( Trial of atenolol and chlorthalidone for hypertension in black South Africans.
Seedat, YK, 1980
)
1.4
"Atenolol treatment of hyperthyroid rats attenuated the increases in heart rate (HR), rectal temperature, and O2 consumption but did not alter cardiac hypertrophy, hypertension, decreased positive inotropic responses or increased beta-adrenoceptor density."( Beta-adrenoceptor antagonism and the hyperthyroid rat heart.
Amos, G; Brown, L; Kerr, D; Sernia, C, 1994
)
1.01
"Atenolol-treated MI rats had a significantly higher LVEDP, RAP and LVEDVI than did rats with untreated MI."( Effect of prolonged beta-adrenergic blockade induced by atenolol on left ventricular remodeling after acute myocardial infarction in the rat.
Kawarabayashi, T; Nishikimi, T; Shimada, K; Takeda, T; Takeuchi, K, 1995
)
1.26
"Atenolol treatment reduced daily life ischemia and was associated with reduced risk for adverse outcome in asymptomatic and mildly symptomatic patients compared with placebo."( Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The Atenolol Silent Ischemia Study (ASIST)
Cohn, PF; Deedwania, PC; Gibson, RS; Handberg, E; Hill, JA; Marks, RG; Miller, E; Pepine, CJ; Thadani, U, 1994
)
1.95
"Atenolol treatment significantly increased triglyceride levels and decreased the HDL-cholesterol levels after 9 months in both groups."( Comparative effects of atenolol versus nifedipine on serum lipids and other biochemical parameters in diabetic and non-diabetic hypertensive subjects.
Goyal, RK; Satia, MC; Shukla, ML, 1995
)
1.32
"Atenolol treatment had neutral properties in some metabolic aspects, but deleterious effects on lipid status."( Urapidil treatment decreases plasma fibrinogen concentration in essential hypertension.
Haenni, A; Lithell, H, 1996
)
1.02
"Atenolol treatment reduced REE by 77+/-14 kcal/day and propranolol by 48+/-13 kcal/day, respectively (P<0.05 versus pretreatment values)."( Beta-adrenoceptor activity and resting energy metabolism in weight losing cancer patients.
Daneryd, P; Hyltander, A; Körner, U; Lundholm, K; Sandström, R, 2000
)
1.03
"Atenolol treatment prevented the increase in both protein expression (low sodium plus atenolol, 27.6+/-5.33, P=NS versus normal sodium) and activity (6.54+/-1.19, P=NS versus normal sodium)."( Cardiac betaARK1 upregulation induced by chronic salt deprivation in rats.
Barbato, E; Cipolleta, E; Esposito, A; Fiorillo, A; Iaccarino, G; Koch, WJ; Trimarco, B, 2001
)
1.03
"Atenolol treatment never was discharged in order to side effects."( [Efficacy and tolerability of a cardioselective beta-blocking drug (atenolol) in the treatment of essential hypertension. A double blind study (author's transl)].
Bonaduce, D; Chiariello, M; Condorelli, M; Ferrara, N; Petretta, M; Rengo, F; Trimarco, B, 1978
)
1.22
"4. Atenolol treatment stimulated prostaglandin synthesis in the kidney and vascular wall in a dose-dependent manner."( Stimulating effects of atenolol on vasodepressor prostaglandin generation in spontaneously hypertensive rats.
Hirawa, N; Ikeda, T; Ishii, M; Matsuoka, H; Numabe, A; Sugimoto, T; Takada, S; Uehara, Y; Yagi, S, 1991
)
1.11
"Atenolol treatment (30 mg/kg body weight per day for 2 weeks) reduced systolic blood pressure by 11%, being accompanied by a decrease in heart rate."( Inhibitory effects of beta adrenoceptor antagonist, atenolol, on the thromboxane system in the kidney of spontaneously hypertensive rats.
Hirawa, N; Ikeda, T; Ishii, M; Numabe, A; Sugimoto, T; Uehara, Y; Yagi, S, 1991
)
1.25
"In atenolol-treated subjects the sympathetic response is strongly attenuated."( [Hemodynamic effects of the cold pressor test in patients with heart failure treated with beta blockers for a long time].
Bettelli, G; Cappello, C; Mattioli, AV; Mattioli, G, 1990
)
0.79
"In atenolol-treated patients with severe effort angina pectoris, nifedipine 20 mg tid improved exercise capacity, while nisoldipine 20 mg once daily did not have a similar effect."( Nisoldipine tablets once daily versus nifedipine capsules three times daily in patients with stable effort angina pectoris pretreated with atenolol.
Kantor, M; Pedersen, TR, 1990
)
1
"Atenolol treatment reduced blood pressure both in the awake state and during micropuncture."( Effects of beta 1-adrenergic blockade on glomerular dynamics and angiotensin II response.
Blantz, RC; Mundy, CA; Tucker, BJ, 1989
)
1
"With atenolol treatment the BP fall is greater in patients with a more unstable BP."( Predicting the blood pressure response to atenolol.
Bird, RJ; Coats, AJ; Conway, J, 1989
)
1
"With atenolol pretreatment, however, all these variables were significantly greater at 1000 hrs (03HALO) than at 2200 hrs (15HALO) as observed in the previous study."( Chronopharmacological study of furosemide in rats: (II). Influence of beta-adrenoceptor blockade.
Ebihara, A; Fujimura, A, 1988
)
0.73
"Atenolol treatment generally resulted in performance levels that did not differ from those observed with placebo."( Impact of beta-blockade on complex cognitive functioning.
DePadova, A; McGlynn, T; Piasecki, M; Pogash, R; Streufert, S, 1988
)
1
"Atenolol pretreatment caused the hemodynamic changes expected of beta 1-blockade but did not blunt the effects of terbutaline on heart rate, peripheral resistance, or venous return."( The role of cardiac beta-1 receptors in the hemodynamic response to a beta-2 agonist.
Leenen, FH; Reeves, RA; Smith, DL; Strauss, MH, 1986
)
0.99
"Pretreatment with atenolol alone and combination with alprazolam/escitalopram also ameliorated tissue glutathione (GSH) and decreased malondialdehyde (MDA) level significantly which explore antioxidant properties of drugs, and combination augments the therapeutic response of monotherapy in depression."( Interactions of atenolol with alprazolam/escitalopram on anxiety, depression and oxidative stress.
Ahmad, J; Ain, MR; Akhtar, M; Al-Ghamdi, SS; Ibrahim, IA; Khan, W; Khanam, R; Shahzad, N, 2014
)
1.07
"Pretreatment with atenolol did not affect the pressor response but reduced tachycardia."( Role of the autonomic nervous system and baroreflex in stress-evoked cardiovascular responses in rats.
Corrêa, FM; Dos Reis, DG; Fortaleza, EA; Tavares, RF, 2014
)
0.73
"Treatment with atenolol was associated with symptomatic improvement and increase of the total exercise time."( [Atenolol induced bradycardia in patients with stable angina: effects on exercise tolerance, myocardial perfusion and left ventricular contractility].
Safonova, EV; Samoĭlenko, LE; Sergienko, VB; Zharova, EA, 2002
)
1.56
"Treatment with atenolol did not change PIP and KLV in either subgroup of hypertensives."( The A1166C polymorphism of the AT1 receptor gene is associated with collagen type I synthesis and myocardial stiffness in hypertensives.
Beloqui, O; Díez, J; González, A; Laviades, C; López, B; Mayor, G; Orbe, J; Páramo, JA; Zalba, G, 2003
)
0.66
"Treatment with atenolol, young age at diagnosis, initial presentation with ACA, KVLQT1 genotype, and noncompliance may be important factors underlying beta-blocker therapy failures."( Beta-blocker therapy failures in symptomatic probands with genotyped long-QT syndrome.
Ackerman, MJ; Bell, CM; Chatrath, R,
)
0.47
"Treatment with atenolol, midodrine and their combination prevented VVS in 89% patients."( [Comparative efficacy and tolerance of atenolol and midodrine in patients with vasovagal syncopes].
Al'bitskaia, KV; Golitsyn, SP; Kheĭmets, GI; Kuchinskaia, EA; Pevzner, AV; Rogoza, AN; Vershuta, EV, 2006
)
0.94
"Pretreatment with atenolol attenuated the cardiac stimulation and thereby accentuated the hypotensive effect of hydralazine, 0.3 mg/kg."( Interaction of atenolol with the systemic and regional hemodynamic effects of hydralazine in conscious renal hypertensive rabbits.
Bolt, GR; Saxena, PR, 1984
)
0.94
"Pretreatment with atenolol blunted this increase."( Angiotensin II is the mediator of the increase in hepatic angiotensinogen synthesis after bilateral nephrectomy.
Hilgenfeldt, U; Schwind, S, 1993
)
0.61
"Treatment with atenolol alone did not change these levels significantly, however administration of metformin or atenolol/metformin increased significantly the GSH levels in both liver and blood, and returned the liver Mg content back to normal values."( Influence of atenolol and/or metformin on glutathione and magnesium levels in diabetic rats.
Abdel-Rahman, MS; Ewis, SA,
)
0.84
"Treatment with atenolol reduced the incidence of preeclampsia from 5 of 28 (18%) to 1 of 28 (3.8%), (P = .04). "( Prevention of preeclampsia: a randomized trial of atenolol in hyperdynamic patients before onset of hypertension.
Brateng, D; Brown, Z; Easterling, TR; Millard, SP; Schmucker, B, 1999
)
0.91
"Treatment with atenolol decreased the incidence of preeclampsia."( Prevention of preeclampsia: a randomized trial of atenolol in hyperdynamic patients before onset of hypertension.
Brateng, D; Brown, Z; Easterling, TR; Millard, SP; Schmucker, B, 1999
)
0.9
"Pretreatment with atenolol, a beta(1)-adrenoceptor antagonist (1 mg kg(-1)), or bilateral ligation of adrenal blood vessels inhibited the increase in exhaled NO in response to veratrine."( Activation of sympathoadrenomedullary system increases pulmonary nitric oxide production in the rabbit.
Adding, LC; Agvald, P; Artlich, A; Gustafsson, LE, 2001
)
0.63
"Pre-treatment with atenolol before GHRH administration produced no significant increase in peak and AUC GH response in both groups, which remained lower in the elderly men than in their young counterparts (peak 5.5 +/- 1.8 ng/ml v."( Contribution of growth hormone-releasing hormone and somatostatin to decreased growth hormone secretion in elderly men.
Levitt, NS; Macfarlane, P; Millar, RP; Soule, SG, 2001
)
0.63
"treatment with atenolol (beta(1)-adrenoceptor antagonist, 5 mg kg(-1)) while that evoked by [Sar(9),Met(O(2))(11)]SP was reduced."( Modulation of cardiac activity by tachykinins in the rat substantia nigra.
Couture, R; Lessard, A, 2001
)
0.65
"Treatment with atenolol markedly inhibited the onset of genetic hypertension, reduced HR and PRC from the outset and diminished the heart weight/body weight ratio."( Chronic atenolol treatment and hypertension development in spontaneously hypertensive rats.
Boissier, JR; Giudicelli, JF; Richer, C, 1978
)
1.03
"5. Treatment with atenolol is remarkably well tolerated."( [Atenolol: its effects on pressure in open-angle glaucoma].
Collignon-Brach, J; Weekers, R, 1978
)
1.49
"Pretreatment with atenolol (50 or 100 mg orally in subjects with body weight less than or greater than 40 kg, respectively, administered 120 min before the GHRH injection) significantly increased the GH response to GHRH in the obese subjects, such that their mean peak GH levels and mean integrated area under the curve after atenolol plus GHRH were similar to those of the control children after GHRH."( The effect of atenolol on the growth hormone response to growth hormone-releasing hormone in obese children.
Carta, D; Civolani, P; Congiu, G; Loche, S; Muntoni, AC; Pintor, C; Pintus, S, 1992
)
0.97
"Treatment with atenolol was started when blood pressure was 150/100 mm Hg or higher after 48 hours' rest."( Effectiveness of atenolol in the treatment of hypertension during pregnancy.
Alvarez, L; Baglivo, HP; Cerrato, C; Drisaldi, S; Esper, RJ; Fabregues, G; Moschettoni, C; Pituelo, D; Varas Juri, P, 1992
)
0.96
"Treatment with atenolol prevented progression of microalbuminuria with a median (range) urinary albumin excretion rate before treatment of 74 (33 to 196) micrograms/min and 50 (5 to 123) micrograms/min after 3 years of therapy (p less than 0.05)."( Treatment with atenolol prevents progression of microalbuminuria in type I diabetic patients.
Davies, JA; Stickland, M; Tindall, H; Urquhart, S, 1991
)
0.97
"Pre-treatment with atenolol reduced the resting blood pressure and the maximum heart rate achieved, but did not affect the percentage increase in heart rate during PHV infusion."( Heart rate response to peptide histidine valine in human subjects is not mediated through beta receptors.
Bloom, SR; Dixon, CM; Ind, PW; Lynn, WA; Yiangou, Y, 1990
)
0.6
"Treatment with atenolol was associated with a marked reduction in maximum treadmill walking distance (mean 356 m) as compared both with placebo (mean 421 m, p less than 0.01) and verapamil (mean 439 m, p less than 0.01)."( Effects of atenolol, verapamil, and xamoterol on heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation.
Lewis, RV; McDevitt, DG; McMurray, J, 1989
)
1.01
"Pretreatment with atenolol diminished the chronotropic response to the higher dose of terbutaline to 27 +/- 4 beats/min."( Role of beta 1-receptors and vagal tone in cardiac inotropic and chronotropic responses to a beta 2-agonist in humans.
Leenen, FH; Levine, MA, 1989
)
0.6
"Pretreatment with atenolol did not change this pattern, although the changes in S-FFA and S-Mg were of a smaller magnitude but still statistically significant."( S-Mg does not change inversely to S-FFA during acute stress situations.
Hansen, O; Johansson, BW, 1989
)
0.6
"Treatment with atenolol produced slight increases in plasma triglyceride levels and little change in total or low-density lipoprotein cholesterol."( The long-term antihypertensive effects of prazosin and atenolol.
Itskovitz, HD; Khoury, S; Krug, K; Mollura, JL, 1989
)
0.86
"Treatment with atenolol or the combination appeared to improve exercise tests measured by time to onset of pain, time to greater than or equal to 1mm ST segment depression and duration."( Atenolol with and without nifedipine in the treatment of angina pectoris. Preliminary report.
Foale, RA; Sandberg, M, 1988
)
2.06
"When treated with atenolol the changes in EF during exercise were reversed in the two groups."( The effect of atenolol on the left ventricular performance in patients with angina pectoris measured with isotope technique.
Balldin, M; Boström, PA; Johansson, B; Lilja, B, 1988
)
0.96

Toxicity

Atenolol, a cardio-selective beta-blocker, has been shown to be a safe and effective antihypertensive agent. melatonin and atenolol appear to have some adverse effects in CO intoxication on the myocardial cells.

ExcerptReferenceRelevance
" There were no significant differences regarding nature and incidence of adverse events between the groups."( Comparison of the safety and efficacy of bisoprolol versus atenolol in stable exercise-induced angina pectoris: a Multicenter International Randomized Study of Angina Pectoris (MIRSA).
Buchner-Moell, D; de Muinck, ED; Lie, KI; van de Ven, LL, 1992
)
0.53
" Sixteen patients withdrew from the study; nine were attributed to adverse events, two in the perindopril group and seven, including one death, in the atenolol group."( Antihypertensive efficacy and safety of perindopril in mild-to-moderate essential hypertension: results of a double-blind multicenter study versus atenolol.
Anderson, AI; Bartholomeusz, LC; Cameron, DP; Conway, EL; Donnelly, T; Frewin, DB; Hooper, MJ; Louis, WJ; MacDonald, GJ; Morgan, TO, 1992
)
0.68
" Ramipril was well tolerated by diabetic patients, and no serious adverse events occurred."( Assessment of the efficacy, tolerance, and safety of ramipril in diabetic patients with mild-to-moderate hypertension: a retrospective analysis.
Breitstadt, A; Erhard, W; Krall, H; Lindner, U; Pfeiffer, C, 1991
)
0.28
" The incidence of adverse events was also similar for both drugs, and serious adverse events were rare and thought to be unrelated to the study drug therapy."( A double-blind comparison of the efficacy and safety of lacidipine with atenolol in the treatment of essential hypertension. The United Kingdom Lacidipine Study Group.
, 1991
)
0.51
"Carvedilol has been shown to be effective and safe in patients with essential hypertension when given as monotherapy."( Safety and antihypertensive efficacy of carvedilol and atenolol alone and in combination with hydrochlorothiazide.
Hörrmann, M; Machwirth, M; van der Does, R; Widmann, L, 1990
)
0.53
" It improved the side effect profile in some but not all patients."( Effect of partial agonist activity on the side effects of beta-blockade in patients with chronic stable angina.
Adam, G; Akhras, F; Chambers, J; Jackson, G; Ong, ML, 1989
)
0.28
" During follow-up (1 to 37 months), drug tolerance and compliance have been excellent with a low incidence of adverse reactions (11%)."( Long-term efficacy and safety of beta-adrenergic receptor antagonists for supraventricular tachycardia.
Barr, MJ; Herman, S; Lindsay, BD; Rothbart, ST; Saksena, S, 1987
)
0.27
" The adverse experience safety data derived from 18 double-blind trials (n = 2884) were evaluated."( Safety profile of celiprolol.
Lamon, KD, 1988
)
0.27
" Bisoprolol is effective, well-tolerated and safe in the treatment of hypertension."( Efficacy and safety of bisoprolol and atenolol in patients with mild to moderate hypertension: a double-blind, parallel group international multicentre study.
Frithz, G; Hosie, J; Lithell, H; Selinus, I; Weiner, L, 1987
)
0.54
" The type and incidence of adverse events seen with both drugs are characteristic of the dihydropyridine class of drugs and were mainly due to pharmacologically induced vasodilation, but lacidipine caused a significantly lower incidence of ankle edema than nifedipine SR."( A long-term study comparing lacidipine and nifedipine SR in hypertensive patients: safety data.
Leonetti, G; Salvi, S, 1994
)
0.29
" Overall, losartan, whether administered alone or in combination with a low dose of hydrochlorothiazide (HCTZ), was effective and well-tolerated in these clinical trials, with an incidence of adverse experiences similar to that of placebo."( Efficacy and safety of losartan.
Goldberg, A; Sweet, C, 1995
)
0.29
"1%) were the clinical adverse experiences most often reported in patients treated with losartan."( Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension.
Dunlay, MC; Goldberg, AI; Sweet, CS, 1995
)
0.5
" Since beta-blockers cross the placenta, it is essential to consider possible adverse effects on the embryo."( Toxicity of beta-blockers in a rat whole embryo culture: concentration-response relationships and tissue concentrations.
Klug, S; Merker, HJ; Neubert, D; Schwabe, R; Thiel, R, 1994
)
0.29
" Adverse events were generally mild or moderate and most reflected the vasodilatory properties of nifedipine (eg, edema, headache)."( The safety and efficacy of once-daily nifedipine coat-core in combination with atenolol in hypertensive patients. Adalat CC Cooperative Study Group.
Feig, PU; Gibson, L; Mac Carthy, EP; Pettis, PP; Schwartz, L,
)
0.36
" No clinically significant abnormalities in laboratory variables and no serious adverse effects were encountered."( Randomised double-blind comparative study of efficacy and safety of hydroflumethiazide and reserpine and chlortalidone and atenolol in the treatment of mild to moderate hypertension in black patients.
Maharaj, B; van der Byl, K, 1993
)
0.49
" Five children had some adverse effects."( Long-term efficacy and safety of atenolol for supraventricular tachycardia in children.
Anand, R; Mehta, AV; Subrahmanyam, AB,
)
0.41
" Atenolol, a cardio-selective beta-blocker, has been shown to be a safe and effective antihypertensive agent."( Comparison of clinical efficacy and adverse effects between extended-release felodipine and atenolol in patients with mild and moderate essential hypertension.
Chern, MS; Lin, FC; Wu, D, 1997
)
1.43
"Sitting blood pressure (BP), heart rate, body weight, adverse reaction and serum biochemistry were assessed in 70 patients with mild-moderate essential hypertension treated either with felodipine ER (37 patients), or atenolol (33 patients) for 10 weeks."( Comparison of clinical efficacy and adverse effects between extended-release felodipine and atenolol in patients with mild and moderate essential hypertension.
Chern, MS; Lin, FC; Wu, D, 1997
)
0.7
" Overall, patients in the felodipine ER group had a higher rate of adverse reaction (70."( Comparison of clinical efficacy and adverse effects between extended-release felodipine and atenolol in patients with mild and moderate essential hypertension.
Chern, MS; Lin, FC; Wu, D, 1997
)
0.52
"Concern based on the reported short-term adverse effects of antihypertensive agents on plasma lipid and lipoprotein profiles (PLPPs) has complicated the therapy for hypertension."( Diuretics and beta-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.
Cushman, WC; Freis, ED; Lakshman, MR; Materson, BJ; Reda, DJ, 1999
)
0.3
" Patients achieving positive DBP control using hydrochlorothiazide (responders) showed no adverse changes in PLPPs, whereas nonresponders exhibited increases in triglycerides, total cholesterol, and low-density lipoprotein cholesterol levels."( Diuretics and beta-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.
Cushman, WC; Freis, ED; Lakshman, MR; Materson, BJ; Reda, DJ, 1999
)
0.3
"None of these 6 antihypertensive drugs has any long-term adverse effects on PLPPs and, therefore, may be safely prescribed."( Diuretics and beta-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.
Cushman, WC; Freis, ED; Lakshman, MR; Materson, BJ; Reda, DJ, 1999
)
0.3
" In addition, combination therapy enhances tolerability because one drug of fixed combination can antagonize some of the adverse effects of the second drug."( [Fixed-dose combination therapy: reduction of side effects with enhanced tolerance and antihypertensive efficacy].
Gómez Guindal, JA; González Lama, I; González Maqueda, I, 1999
)
0.3
" In another instance heart block and hypotension was noted in association with a diltiazem and atenolol adverse interaction."( Aminophylline reversal of antihypertensive agent toxicity.
Roberge, RJ; Rosetti, JM; Rossetti, ML, 2001
)
0.53
" Psoriasis may be an inconvenient side effect of beta blockade."( Beta-blocker-induced psoriasis: a rare side effect--a case report.
Akin, Y; Kisacik, HL; Korkmaz, S; Turhan, H; Yilmaz, MB,
)
0.13
"The comparison is based on the following criteria: comparability of pharmacokinetic/pharmacodynamic characteristics, type of adverse outcome, lowest adverse effect levels, and specificity and selectivity of effect."( Atenolol developmental toxicity: animal-to-human comparisons.
Hansen, D; Kimmel, CA; Tabacova, S; Wall, K, 2003
)
1.76
" The human seems to be more sensitive, however, because adverse embryo-fetal effects are reported at doses much lower than those in the tested species."( Atenolol developmental toxicity: animal-to-human comparisons.
Hansen, D; Kimmel, CA; Tabacova, S; Wall, K, 2003
)
1.76
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" Thus, melatonin and atenolol appear to have some adverse effects in CO intoxication on the myocardial cells."( Effect of melatonin and atenolol on carbon monoxide cardiotoxicity: an experimental study in rats.
Celbiş, O; Mizrak, B; Olmez, E; Parlakpinar, H, 2006
)
0.96
"In this experimental study both biological treatability of pharmaceuticals and their potential toxic effect in biological processes were evaluated."( Biodegradability and toxicity of pharmaceuticals in biological wastewater treatment plants.
Cappai, G; Carucci, A; Piredda, M, 2006
)
0.33
"1%) were the most commonly reported clinical adverse experiences in patients treated with losartan."( Safety and tolerability of losartan compared with atenolol, felodipine and angiotensin converting enzyme inhibitors.
Dunlay, MC; Goldberg, AI; Sweet, CS, 1995
)
0.54
" Toxic hepatitis was suspected and atenolol was stopped."( Atenolol hepatotoxicity: report of a complicated case.
Boillot, O; Dumortier, J; Gouraud, A; Guillaud, O; Pittau, G; Scoazec, JY; Vial, T, 2009
)
2.07
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" Overall, DCF was the most cytotoxic drug for zebra mussel cells, followed by GEM, CBZ, while ATL has not a noteworthy toxic potential."( Cytotoxicity assessment of four pharmaceutical compounds on the zebra mussel (Dreissena polymorpha) haemocytes, gill and digestive gland primary cell cultures.
Binelli, A; Parolini, M; Provini, A; Quinn, B, 2011
)
0.37
"Efficacy of losartan versus atenolol in the prevention of progressive dilation of the aorta, improved aortic distensibility, and prevention of adverse events (aortic dissection or rupture, cardiovascular surgery, or death) will be assessed in this study."( [Study of the efficacy and safety of losartan versus atenolol for aortic dilation in patients with Marfan syndrome].
Centeno, J; Cortina, J; Evangelista, A; Forteza, A; García, D; García-Dorado, D; Gutiérrez, L; Rodríguez-Palomares, J; Sánchez, V; Sanz, P; Teixidó, G, 2011
)
0.91
" There were small, nonsignificant differences in the number of adverse events between the two groups (66 in Iva and 73 in Aten, p > 0."( The efficacy and safety of ivabradine hydrochloride versus atenolol in Chinese patients with chronic stable angina pectoris.
Jia, Y; Jiang, J; Jiang, R; Jing, L; Li, T; Li, X; Li, Y; Liu, S; Lu, Q; Shou, X; Wang, L; Wang, X; Wang, Z; Wei, J; Xia, H; Xie, P; Xing, B; Yang, Z, 2014
)
0.65
" Results suggest that the photolysis by-products of diclofenac were more toxic than those from the other compounds tested, showing an increase in GST and CAT levels, which are also supported by higher MDA levels."( Ecotoxicity of ketoprofen, diclofenac, atenolol and their photolysis byproducts in zebrafish (Danio rerio).
Carvalho, G; Diniz, MS; Noronha, JP; Oehmen, A; Pereira, VJ; Reis, MA; Salgado, R, 2015
)
0.69
" We searched PubMed (Medline), Central, Embase, Web of Science and EBSCOhost (until May 2018) for the eligible studies reporting more than 10 IH patients who were treated with oral atenolol with detailed original data, including outcomes, regimens and adverse events (AEs)."( Efficacy and safety of oral atenolol for the treatment of infantile haemangioma: A systematic review.
Chen, S; Ji, Y; Wang, Q; Xiang, B, 2019
)
1
"Chronic hypertension is associated with adverse perinatal outcomes, although the optimal treatment is unclear."( Comparative efficacy and safety of oral antihypertensive agents in pregnant women with chronic hypertension: a network metaanalysis.
Bellos, I; Daskalakis, G; Loutradis, D; Papapanagiotou, A; Pergialiotis, V, 2020
)
0.56
" However, different adverse events have been reported during propranolol treatment."( Efficacy and Safety of Propranolol vs Atenolol in Infants With Problematic Infantile Hemangiomas: A Randomized Clinical Trial.
Chen, S; Dai, S; Ji, Y; Jiang, X; Kong, F; Li, L; Lu, G; Qiu, L; Qiu, T; Xiang, B; Yang, K; Zhang, X; Zhang, Y; Zhou, J, 2021
)
0.89
" Adverse events were more common in the propranolol group (70."( Efficacy and Safety of Propranolol vs Atenolol in Infants With Problematic Infantile Hemangiomas: A Randomized Clinical Trial.
Chen, S; Dai, S; Ji, Y; Jiang, X; Kong, F; Li, L; Lu, G; Qiu, L; Qiu, T; Xiang, B; Yang, K; Zhang, X; Zhang, Y; Zhou, J, 2021
)
0.89
"In this randomized clinical trial, when compared with propranolol, atenolol had similar efficacy and fewer adverse events in the treatment of infants with problematic IHs."( Efficacy and Safety of Propranolol vs Atenolol in Infants With Problematic Infantile Hemangiomas: A Randomized Clinical Trial.
Chen, S; Dai, S; Ji, Y; Jiang, X; Kong, F; Li, L; Lu, G; Qiu, L; Qiu, T; Xiang, B; Yang, K; Zhang, X; Zhang, Y; Zhou, J, 2021
)
1.13

Pharmacokinetics

Study compared the pharmacokinetic and pharmacodynamic profiles of an extemporaneously prepared (compounded) atenolol paste and suspension for oral administration, against the commercially available divided tablet in healthy cats. Theophylline clearance, volume of distribution and half-life were not influenced by atenlol pretreatment.

ExcerptReferenceRelevance
"The authors describe a simple method of fluorimetric estimation of atenolol, applicable to blood and urine, sufficiently sensitive to permit a pharmacokinetic study."( [Spectrofluorimetric estimation in biological fluids of a new beta-blockader: atenolol. Application to its pharmacokinetic study (author's transl)].
Bazin, M; Flouvat, B; Guedon, J; Lucsko, M; Roux, A, 1978
)
0.72
" There was no significant difference in atenolol half-life when administered by the two routes."( Pharmacokinetics, pharmacology of atenolol and effect of renal disease.
Koda, RT; Maronde, RF; Wan, SH, 1979
)
0.81
" In patients with normal renal function the atenolol half-life was calculated to be about six hours following single 100 mg oral doses."( Pharmacokinetics of atenolol in patients with renal impairment.
Legheand, J; McAinsh, J; Pozet, N; Sassard, J; Zech, P, 1977
)
0.84
"The non-stimulant cardioselective beta adrenocepter antagonist atenolol has been studied in volunteers in order to define its pharmacokinetic characteristics."( Studies on the pharmacokinetics and pharmacodynamics of atenolol in man.
Fitzgerald, JD; McAinsh, J; Roberts, R; Ruffin, R; Smedstad, KG, 1978
)
0.74
" The changes in the volumes of distribution of propranolol and verapamil during exercise may contribute to preventing an increase in the half-life of these drugs in patients performing prolonged physical exercise."( Exercise and the pharmacokinetics of propranolol, verapamil and atenolol.
Mooij, JM; Schiffers, PM; van Baak, MA, 1992
)
0.52
" The half-life (t1/2) was significantly prolonged on day 2 as compared with day 6, but the tmax, Cmax, and area under the curve (AUC) were all comparable to what has been reported in patients without MI."( Pharmacokinetic and pharmacodynamic properties of atenolol in acute myocardial infarction.
Held, P; Regårdh, CG; Swedberg, K, 1990
)
0.53
"This double-blind randomized, crossover study was undertaken to determine the pharmacokinetic properties of nifedipine retard and atenolol when given separately, as a free or a fixed combination, compared with placebo in 15 healthy male volunteers."( A study of the pharmacokinetics and pharmacodynamics of nifedipine in combination with atenolol.
Adam, HK; Fitzsimons, TJ; McAinsh, J; Norris, SC; Ryan, J,
)
0.56
" In the hyperthyroid state, the time to peak plasma concentration (Tmax) occurred significantly earlier, the elimination half-life was significantly shorter, and the areas under the curve were also significantly less compared to the euthyroid state, but there was no significant difference in peak plasma concentrations (Cmax) between these states."( Pharmacokinetics and clinical effects of atenolol in therapy of hyperthyroidism.
Geffner, DL; Hershman, JM; Sladek, J, 1990
)
0.54
" The ACVF method of cardiovascular monitoring should prove useful in human pharmacodynamic studies."( Pharmacodynamic monitoring during acute intervention in ischaemic heart disease using a new echo-Doppler device.
Silke, B; Taylor, SH; Verma, SP, 1990
)
0.28
"2 ng/ml) and terminal half-life of atenolol (9."( Interaction between nifedipine and atenolol: pharmacokinetics and pharmacodynamics in normotensive volunteers.
Frölich, JC; Ledermann, H; Rosenkranz, B,
)
0.69
" There was a significant decrease in the maximal plasma concentration and AUC of metoprolol after 28 days of treatment with felodipine, but its elimination half-life was not changed."( Haemodynamic effects and pharmacokinetics of felodipine at rest and during exercise in hypertensive patients treated with metoprolol or atenolol.
Bengtsson-Hasselgren, B; Elmfeldt, D; Moberg, L; Rönn, O, 1989
)
0.48
"The pharmacokinetic and pharmacodynamic effects of Ro31-1118 were examined in groups of healthy volunteers."( Human pharmacokinetic and pharmacodynamic studies on Ro31-1118, a new beta-adrenoceptor antagonist.
Arnold, JM; Brown, AN; Finch, MB; Francis, RJ; Galloway, DB; Harron, DW; McDevitt, DG; O'Connor, PC; Shanks, RG, 1985
)
0.27
"Comparative pharmacokinetic studies with the beta-receptor blocking drugs propranolol, metoprolol, sotalol and atenolol, differing greatly in lipophilicity, and their main route of elimination were performed in light-dark-synchronized rats after equimolar single (6 mumoles/kg) or multiple (6 X 6 mumoles/kg) drug application."( Chronopharmacokinetics of beta-receptor blocking drugs of different lipophilicity (propranolol, metoprolol, sotalol, atenolol) in plasma and tissues after single and multiple dosing in the rat.
Fink, M; Lemmer, B; Ohm, T; Winkler, H, 1985
)
0.69
"The pharmacodynamic profile of bisoprolol, a new beta 1-selective adrenoceptor antagonist, was investigated in four independent studies including 36 healthy male volunteers."( Pharmacodynamic profile of bisoprolol, a new beta 1-selective adrenoceptor antagonist.
Bühring, KU; Leopold, G; Pabst, J; Simane, Z; Ungethüm, W; Wiemann, H, 1986
)
0.27
" Mean plasma concentrations of doxazosin were proportional to dose and the plasma half-life was 11."( The pharmacokinetics and pharmacodynamics of doxazosin compared with atenolol during long-term double-blind treatment.
Faulkner, JK; Himanen, P; Karjalainen, U; Saraste, M, 1987
)
0.51
" Theophylline clearance, volume of distribution and half-life were not influenced by atenolol pretreatment."( Lack of effect of atenolol on the pharmacokinetics of theophylline.
Bertino, JS; Cerasa, LA; Ludwig, EA; Middleton, E; Savliwala, M; Slaughter, RL, 1988
)
0.83
"Pharmacokinetic and pharmacodynamic properties of a new controlled-release (CR) formulation of metoprolol have been compared with those of atenolol."( Pharmacokinetics and pharmacodynamics of controlled-release metoprolol: a comparison with atenolol.
Blomqvist, I; Jonsson, UE; Lundborg, P; Sandberg, A; Westergren, G, 1988
)
0.7
" No difference in any of the drug pharmacokinetic parameters could be detected between the hypertensives and the normal elderly subjects."( A comparative study of the pharmacokinetics and pharmacodynamics of atenolol, hydrochlorothiazide and amiloride in normal young and elderly subjects and elderly hypertensive patients.
Adam, HK; Castleden, CM; Fitzsimons, TJ; Ryan, J; Sabanathan, K, 1987
)
0.51
" The suitability of the model for pharmacokinetic and pharmacodynamic studies was borne out by administering atenolol (i."( Experimental model for pharmacokinetic studies during continuous peritoneal dialysis in the rabbit.
Arboix, M; Bonati, M; Celardo, A; Traina, GL, 1986
)
0.48
"The pharmacokinetic properties of propranolol and atenolol were evaluated both in 9 patients with cirrhosis and in 12 healthy subjects."( Hemodynamic and pharmacokinetic study of propranolol and atenolol in cirrhosis patients.
Decourt, S; Flouvat, B; Lebrec, D; Leneveu, A; Rocher, I; Rosier, SP, 1985
)
0.77
" The present study did not show significant pharmacokinetic and pharmacodynamic interactions between nifedipine and lipophilic beta-adrenoceptor blockers."( Study of the influence of nifedipine on the pharmacokinetics and pharmacodynamics of propranolol, metoprolol and atenolol.
Bellens, R; Degre, S; Degreve, M; Fitzsimons, TJ; Gangji, D; Herchuelz, A; Juvent, M; Niset, G; Poortmans, J; Wathieu, M, 1984
)
0.48
" The study reported here was designed to show whether the pharmacokinetics of verapamil are influenced by concurrent treatment with three different beta-adrenoceptor blockers, and whether there is any pharmacodynamic interaction between these drugs."( Pharmacokinetics and pharmacodynamics of verapamil in combination with atenolol, metoprolol and propranolol.
Fitzsimons, TJ; Holt, D; Johnston, A; Warrington, SJ, 1984
)
0.5
" The data suggest that in the treatment of angina on effort, beta blockers should be prescribed according to their pharmacokinetic properties to achieve adequate suppression of the heart rate during exercise."( Atenolol, nadolol, and pindolol in angina pectoris on effort: effect of pharmacokinetics.
Cosgrove, NM; Kostis, JB; Krieger, SD; Lacy, CR, 1984
)
1.71
"We conducted pharmacodynamic studies with a new vasodilator, MDL-899."( Pharmacodynamic studies in normal volunteers with MDL-899, a new arteriolar vasodilator.
Elliott, HL; Howden, CW; Lawrie, CB; Reid, JL,
)
0.13
" Plasma and urine drug concentrations were measured and the relevant pharmacokinetic parameters calculated."( Lack of a pharmacokinetic interaction between nifedipine and the beta-adrenoceptor blockers metoprolol and atenolol.
Jack, DB; Kendall, MJ; Laugher, SJ; Lobo, J; Rolf Smith, S, 1984
)
0.48
" The elimination half-life of atenolol, about 10 h, was not affected by the health status of the subjects."( Influence of inflammatory disease on the clinical pharmacokinetics of atenolol and metoprolol.
Heinz, U; Kirch, W; Köhler, H; Mutschler, E; Ohnhaus, EE; Spahn, H,
)
0.65
" 3 Without dialysis treatment, the apparent plasma half-life of atenolol was greatly increased (73."( Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysis.
Aubert, P; Baglin, A; Decourt, S; Domart, M; Flouvat, B; Goupil, A; Potaux, L, 1980
)
0.82
"This study demonstrates the application of neural networks to predict the pharmacokinetic properties of beta-adrenoreceptor antagonists in humans."( Quantitative structure-pharmacokinetic relationships (QSPR) of beta blockers derived using neural networks.
Gobburu, JV; Shelver, WH, 1995
)
0.29
" A one-compartment, steady-state pharmacokinetic model with first-order absorption and elimination was fitted to the concentration-time data for each patient using nonlinear regression."( Absorption pharmacokinetics of atenolol in patients with the Marfan syndrome.
Alpert, BS; Lima, JJ; Phelps, SJ; Pieper, JA; Ward, JL, 1995
)
0.58
" Pharmacodynamic parameters derived from plasma S(-)-atenolol concentration-effect (HR) curves after SATN, RSATN, and total atenolol plasma concentrations after RSATN did not differ significantly."( Pharmacodynamics of racemic and S(-)-atenolol in humans.
Clementi, WA; Clifton, GD; Garvey, TQ; McCoy, RA; Schwartz, SE; Smith, MD; Wermeling, DP, 1994
)
0.81
" Mean area under the plasma level time curve (AUC0-24) and mean Cmax for SATN for SEF were significantly lower than for SATN after TMN."( Single dose pharmacokinetics of (S)-atenolol administered orally as a single enantiomer formulation and as a racemic mixture (Tenormin).
Brandt, S; Clementi, WA; Clifton, GD; Garvey, TQ; McCoy, RA; Schwartz, S, 1994
)
0.56
" The assay was applied to a human pharmacokinetic study which was performed in a randomized cross-over, double-blind fashion in 12 healthy volunteers, administering single oral doses of 100 mg (R,S)-, 50 mg (R)-, and 50 mg (S)-atenolol."( Stereoselective HPLC bioanalysis of atenolol enantiomers in plasma: application to a comparative human pharmacokinetic study.
Egginger, G; Kahr, S; Lindner, W; Stoschitzky, K, 1993
)
0.74
" No significant difference was observed in the elimination half-life between the two trials."( Differences of chronopharmacokinetic profiles between propranolol and atenolol in hypertensive subjects.
Ebihara, A; Fujimura, A; Ohashi, K; Shiga, T; Tateishi, T, 1993
)
0.52
" For both enantiomers, the volume of distribution decreases and the half-life increases in the uraemic rats."( Stereoselective pharmacokinetics of atenolol in the rat: influence of aging and of renal failure.
Belpaire, FM; Bogaert, MG; De Smet, F; Rosseel, MT; Vermeulen, AM, 1993
)
0.56
"The plasma concentration time profiles and the pharmacokinetic parameters estimated for these drugs were in the expected range, except for furosemide, whose bioavailability was lower than reported in the literature."( Effect of the lipase inhibitor orlistat on the pharmacokinetics of four different antihypertensive drugs in healthy volunteers.
Jonkmann, JH; Schmidtke-Schrezenmeier, G; Tam, YK; van Brummelen, P; Weber, C, 1996
)
0.29
"The pharmacokinetic parameters (Cmax, Tmax, t1/2, AUC0-30h, AUC0-infinity) of following a single oral administration of 100 mg of a test product (Tenolol, The United Pharmaceutical Manufacturing Company, Amman, Jordan) were compared to those of a reference product (Tenormin, ICI Pharmaceuticals)."( Comparative pharmacokinetics of two brands of atenolol following a single oral administration.
Awwadi, FF; Irshaid, YM; Kato, MK; Rawashdeh, NM, 1996
)
0.55
" Therefore, an interaction trial was performed to evaluate the effects of co-administration of V on the pharmacokinetics of atenolol (A), and vice versa, and to monitor the pharmacodynamic response of plasma angiotensin II (ANG II) concentrations and plasma renin activity (PRA), as well as of heart rate and blood pressure, under resting and exercise conditions."( Pharmacokinetic and pharmacodynamic interaction of single doses of valsartan and atenolol.
Czendlik, CH; Howald, H; Preiswerk, G; Sioufi, A, 1997
)
0.73
" To test this hypothesis, we conducted three randomized, double-masked, placebo-controlled studies to evaluate how coadministration of tamsulosin would affect the pharmacodynamic profiles of nifedipine, enalapril, and atenolol."( Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: pharmacodynamic effect.
Lowe, FC,
)
0.32
"The purpose of this study was to evaluate the possible advantages of floating and high-density dosage forms and their influence on pharmacokinetic parameters."( Comparative pharmacokinetic study of a floating multiple-unit capsule, a high-density multiple-unit capsule and an immediate-release tablet containing 25 mg atenolol.
Allémann, E; Balant, L; Buri, P; Cole, ET; Doelker, E; Gex-Fabry, M; Rouge, N, 1998
)
0.5
"In support of clinical antianginal studies, the vasodilator nicorandil (NIC) was combined with the beta-adrenergic receptor antagonists propranolol (PRO) and atenolol (ATN) and with the calcium channel blocker diltiazem (DTZ) to determine their cardiovascular and pharmacokinetic interactions."( Cardiovascular and pharmacokinetic interactions between nicorandil and adjunctive propranolol, atenolol or diltiazem in conscious dogs.
Humphrey, SJ, 1998
)
0.72
" Furthermore, the pharmacodynamic action of diuretics was not significantly altered in the elderly."( Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged.
Bischoff, I; Block, S; Fliser, D; Hanses, A; Joest, M; Mutschler, E; Ritz, E, 1999
)
0.3
" Propranolol and atenolol, as representatives of lipophilic and hydrophilic beta-adrenoreceptor antagonists, have been studied in order to define their pharmacokinetic characteristics in patients after partial gastrectomy."( Pharmacokinetics of propranolol and atenolol in patients after partial gastric resection: a comparative study.
Drozdzik, M; Gawronska-Szklarz, B; Kostyrka, R; Kozlowski, K; Pawlik, A; Sterna, R; Wójcicki, J; Wójcicki, M; Wojciechowski, G, 2000
)
0.92
" Pharmacokinetic parameters of propranolol and atenolol were calculated using a one-compartment open model with first-order absorption."( Pharmacokinetics of propranolol and atenolol in patients after partial gastric resection: a comparative study.
Drozdzik, M; Gawronska-Szklarz, B; Kostyrka, R; Kozlowski, K; Pawlik, A; Sterna, R; Wójcicki, J; Wójcicki, M; Wojciechowski, G, 2000
)
0.84
" Pharmacokinetic parameters of propranolol were different in subjects submitted to surgery compared with healthy persons."( Pharmacokinetics of propranolol and atenolol in patients after partial gastric resection: a comparative study.
Drozdzik, M; Gawronska-Szklarz, B; Kostyrka, R; Kozlowski, K; Pawlik, A; Sterna, R; Wójcicki, J; Wójcicki, M; Wojciechowski, G, 2000
)
0.58
" As a class, the beta blockers are quite diverse from a pharmacokinetic perspective, as they display a high range of values in plasma protein binding, percent of drug eliminated by metabolism or unchanged in the urine, and in hepatic extraction ratio."( Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans.
Brocks, DR; Mehvar, R,
)
0.13
" Pharmacokinetic parameters of atenolol were calculated using a one-compartment open model."( Effect of unilateral nephrectomy on the pharmacokinetics of atenolol in humans.
Domanski, L; Drozdzik, M; Machoy, P; Pudlo, A; Wojcicki, J, 2003
)
0.85
"The lipophilic beta-adrenoreceptor antagonist propranolol and hydrophilic atenolol have been studied to define their pharmacokinetic and pharmacodynamic characteristics in obese patients."( Comparative pharmacokinetics and pharmacodynamics of propranolol and atenolol in normolipaemic and hyperlipidaemic obese subjects.
Droździk, M; Gawrońska-Szklarz, B; Jaroszynska, M; Pawlik, A; Sterna, R; Wójcicki, J, 2003
)
0.78
" Pharmacokinetic parameters of the drugs were calculated using a noncompartmental open model."( Comparative pharmacokinetics of propranolol and atenolol in primary hyperlipidemia.
Droździk, M; Gawrońska-Szklarz, B; Sterna, R; Sulzyc-Bielicka, V; Telatyńska, B; Wójcicki, J,
)
0.39
" Pharmacokinetic parameters were calculated according to the noncompartmental open model."( [Pharmacokinetic comparison of propranolol and atenolol in people with primary hypertension].
Telatyńska-Smieszek, B, 2002
)
0.57
" A comparison is also presented between several methods based on animal pharmacokinetic data, using the same set of proprietary compounds, and it lends further support for the use of this method, as opposed to methods that require the gathering of pharmacokinetic data in laboratory animals."( Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY, 2004
)
0.32
" In the light of the results obtained, the following conclusions were drawn: 1) hyperlipidemia affects pharmacodynamic properties of lipophilic propranolol and hydrophilic atenolol, 2) a modification of the drug dosage in hyperlipidemia is warranted."( [Effect of hyperlipidemia on pharmacodynamics of propranolol and atenolol].
Droździk, M; Gawrońska-Szklarz, B; Sterna, R; Sulzyc-Bielicka, V; Telatyńska-Smieszek, B; Wójcicki, J, 2004
)
0.76
" The time of the peak concentration (t(max)) and the elimination half-life (t(1/2)) of atenolol remained unchanged by orange juice."( Effects of orange juice on the pharmacokinetics of atenolol.
Lilja, JJ; Neuvonen, PJ; Raaska, K, 2005
)
0.8
" The pharmacokinetic analysis revealed that sotalol concentrations from microdialysates were not different from conventional plasma samples (100+/-11%, n=33) resulting in subsequent comparable pharmacokinetic parameters."( Development of an intravenous microdialysis method for pharmacokinetic investigations in humans.
Elshoff, JP; Läer, S,
)
0.13
"This stepwise approach using an in vitro device enabled us to demonstrate the determination of pharmacokinetic parameters of sotalol."( Development of an intravenous microdialysis method for pharmacokinetic investigations in humans.
Elshoff, JP; Läer, S,
)
0.13
"Four separate studies investigated the pharmacokinetic interaction between single oral doses of aliskiren and lovastatin, atenolol, celecoxib or cimetidine, respectively."( Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine.
Corynen, S; Dieterle, W; Mann, J; Vaidyanathan, S, 2005
)
0.76
" Aliskiren mean Cmax was not affected by either lovastatin or atenolol, although a non-significant 36% increase was observed with celecoxib."( Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine.
Corynen, S; Dieterle, W; Mann, J; Vaidyanathan, S, 2005
)
0.79
"Overall, single doses of aliskiren showed no evidence of clinically important pharmacokinetic interactions with lovastatin, atenolol, celecoxib or cimetidine."( Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine.
Corynen, S; Dieterle, W; Mann, J; Vaidyanathan, S, 2005
)
0.76
" Itraconazole had no statistically significant effect on any of the pharmacokinetic or pharmacodynamic variables of atenolol."( Effect of itraconazole on the pharmacokinetics of atenolol.
Backman, JT; Lilja, JJ; Neuvonen, PJ, 2005
)
0.79
" The aim was to validate heart rate as a pharmacodynamic endpoint under continuous isoprenaline-induced tachycardia by means of PK-PD modelling of S(-)-atenolol."( Pharmacokinetic-pharmacodynamic modelling of S(-)-atenolol in rats: reduction of isoprenaline-induced tachycardia as a continuous pharmacodynamic endpoint.
Danhof, M; de Lange, EC; Freijer, J; van Steeg, TJ, 2007
)
0.79
"Reduction of heart rate during isoprenaline-induced tachycardia is a reliable pharmacodynamic endpoint for beta-blockers in vivo in rats."( Pharmacokinetic-pharmacodynamic modelling of S(-)-atenolol in rats: reduction of isoprenaline-induced tachycardia as a continuous pharmacodynamic endpoint.
Danhof, M; de Lange, EC; Freijer, J; van Steeg, TJ, 2007
)
0.59
"We report microwave-assisted synthetic routes, the pharmacokinetic profile along with results from ulcerogenicity and mutagenicity studies of atenolol aspirinate, and an already described derivative, in which acetyl salicylic acid (aspirin) was connected to atenolol by an ester linkage."( Pharmacokinetic profile of atenolol aspirinate.
Alves, DP; Caliendo, G; de Nucci, G; Donato, JL; Fiorino, F; Lavecchia, A; Lilla, S; Mendes, GD; Montes-Gil, AC; Okuyama, CE; Perissutti, E; Priviero, FB; Santagada, V; Severino, B; Zanfolin, M, 2007
)
0.84
"The purpose of the study was to evaluate the pharmacokinetic effects obtained by gastroretentive dosage form (GRDF) for drugs absorbed by passive paracellular diffusion (atenolol, acyclovir) or active transport (valacyclovir)."( Selection of drug candidates for gastroretentive dosage forms: pharmacokinetics following continuous intragastric mode of administration in a rat model.
Hoffman, A; Kagan, L, 2008
)
0.54
" Reduction of isoprenaline-induced tachycardia was used as a pharmacodynamic endpoint."( Mechanism-based pharmacodynamic modeling of S(-)-atenolol: estimation of in vivo affinity for the beta1-adrenoceptor with an agonist-antagonist interaction model.
Danhof, M; de Lange, EC; Freijer, J; van Steeg, TJ, 2008
)
0.6
"To describe the disposition of and pharmacodynamic response to atenolol when administered as a novel transdermal gel formulation to healthy cats."( Comparison of pharmacodynamic variables following oral versus transdermal administration of atenolol to healthy cats.
Belmonte, AA; Boothe, DM; Freeman, LM; Macgregor, JM; Rozanski, EA; Rush, JE, 2008
)
0.81
"2 hours after oral administration, 6 of 7 cats reached therapeutic plasma atenolol concentrations with a mean peak concentration of 579 +/- 212 ng/mL."( Comparison of pharmacodynamic variables following oral versus transdermal administration of atenolol to healthy cats.
Belmonte, AA; Boothe, DM; Freeman, LM; Macgregor, JM; Rozanski, EA; Rush, JE, 2008
)
0.8
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" The most promising compounds of this study show enhanced IC 50 values in the low nanomolar range, a high selectivity toward 17beta-HSD2, a low binding affinity to ERalpha, a good metabolic stability in rat liver microsomes, and a reasonable pharmacokinetic profile after peroral application."( Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1).
Al-Soud, YA; Bey, E; Birk, B; Frotscher, M; Hartmann, RW; Kruchten, P; Marchais-Oberwinkler, S; Negri, M; Oster, A; Werth, R, 2008
)
0.35
" Bioequivalence was established for all pharmacokinetic parameters."( Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects.
Bolbrinker, J; Huber, M; Kreutz, R; Scholze, J, 2009
)
0.57
" Studies were undertaken using an in situ-perfused rat liver and multiple indicator dilution, and outflow data were analyzed with a physiologically based organ pharmacokinetic model."( Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
Crawford, DH; Fletcher, LM; Li, P; Roberts, MS; Robertson, TA; Thorling, CA; Zhang, Q, 2011
)
0.37
" The mean Cmax and area under concentration-time curve from 0 to 24 h after administration (AUC0-24 h) of SRPs were significantly lower than that of IRPs (p<0."( Evaluation of pharmacokinetic and pharmacodynamic relationship for oral sustained-release atenolol pellets in rats.
Cui, Y; Dong, C; Jia, J; Liu, J; Zhang, W, 2011
)
0.59
"The authors evaluated the contribution of the SLCO2B1 polymorphism to the pharmacokinetics of celiprolol at a microdose (MD) and therapeutic dose (TD) and compared pharmacokinetic proportionality between the 2 dose forms in 30 SLCO2B1 genotype-matched healthy volunteers."( Microdosing clinical study: pharmacokinetic, pharmacogenomic (SLCO2B1), and interaction (grapefruit juice) profiles of celiprolol following the oral microdose and therapeutic dose.
Chiyoda, T; Doi, Y; Hirota, T; Ieiri, I; Irie, S; Iwasaki, K; Kimura, M; Maeda, K; Miyagawa, M; Sasaki, T; Sugiyama, Y, 2012
)
0.38
"In vitro anti-resorptive activity, mechanism of action, pharmacokinetic profile and in vivo anti-resorptive activity of N(1),N(1)-diisopropyl-N(2)-(diphenylphosphoryl)-2-(4-nitrophenyl)acetamidine (1) were evaluated."( Anti-resorptive activity and pharmacokinetic study of N(1),N(1)-diisopropyl-N(2)-(diphenylphosphoryl)-2-(4-nitrophenyl)acetamidine.
Kim, MH; Kim, SH; Park, M; Park, SJ; Song, JS, 2011
)
0.37
"This study compared the pharmacokinetic and pharmacodynamic profiles of an extemporaneously prepared (compounded) atenolol paste and suspension for oral administration, against the commercially available divided tablet in healthy cats."( Comparative pharmacokinetics and pharmacodynamics of tablet, suspension and paste formulations of atenolol in cats.
Campbell, FE; Charles, BG; Greer, RM; Khor, KH; Mills, PC; Norris, RL; Rathbone, MJ, 2012
)
0.81
" Hepatic pharmacokinetic modelling was performed with a two-phase physiologically-based organ pharmacokinetic model with the vascular space and dispersion evaluated with the MID technique."( Hepatocellular necrosis, fibrosis and microsomal activity determine the hepatic pharmacokinetics of basic drugs in right-heart-failure-induced liver damage.
Crawford, DH; Fletcher, LM; Li, P; Roberts, MS; Robertson, TA; Weiss, M; Zhang, Q, 2012
)
0.38
" Hepatic pharmacokinetic analysis showed that both the CL int and PS were significantly decreased in the RHF rat livers."( Hepatocellular necrosis, fibrosis and microsomal activity determine the hepatic pharmacokinetics of basic drugs in right-heart-failure-induced liver damage.
Crawford, DH; Fletcher, LM; Li, P; Roberts, MS; Robertson, TA; Weiss, M; Zhang, Q, 2012
)
0.38
" The method was found to be suitable for the quantification of atenolol in a pharmacokinetic study after a single oral administration of 100 mg atenolol to 18 healthy subjects."( Determination of atenolol in human plasma by HPLC with fluorescence detection: validation and application in a pharmacokinetic study.
Niopas, I; Spanakis, M, 2013
)
0.97
" The area under the curve (AUC)0-24 h and Cmax of 50 mg atenolol were the primary criteria for evaluation of bioequivalence."( Comparative pharmacokinetics and bioequivalence of two 50 mg atenolol tablet formulations in healthy Korean male volunteers.
Chang, MJ; Shin, WG, 2012
)
0.87
" The validated assay method was successfully applied to a pharmacokinetic study in humans."( Sensitive LC-MS/MS-ESI method for simultaneous determination of nifedipine and atenolol in human plasma and its application to a human pharmacokinetic study.
Inamadugu, JK; Kallem, RR; Ramesh, M; Seshagirirao, JV, 2013
)
0.62
"This review aims to analyze pharmacokinetic profile, plasma level variations so as the metabolism, interactions and possible relation to clinical effect of several drugs which are used primarily as anxiolytics."( Understanding the pharmacokinetics of anxiolytic drugs.
Altamura, AC; Bareggi, S; Maffini, M; Mauri, MC; Moliterno, D; Paletta, S, 2013
)
0.39
"There is a need for a more balanced assessment of the benefits and risks associated with benzodiazepine use, particularly considering pharmacokinetic profile of the drugs to ensure that patients, who would truly benefit from these agents, are not denied appropriate treatment."( Understanding the pharmacokinetics of anxiolytic drugs.
Altamura, AC; Bareggi, S; Maffini, M; Mauri, MC; Moliterno, D; Paletta, S, 2013
)
0.39
"Dietary sodium, the main determinant of the pharmacodynamic response to renin-angiotensin system blockade, influences the pharmacokinetics of various cardiovascular drugs."( Effect of contrasted sodium diets on the pharmacokinetics and pharmacodynamic effects of renin-angiotensin system blockers.
Azizi, M; Blanchard, A; Charbit, B; Ezan, E; Funck-Brentano, C; Ménard, J; Peyrard, S; Wuerzner, G, 2013
)
0.39
" The developed method was applied for the trace analysis of atenolol enantiomers in plasma and for the pharmacokinetic investigation of atenolol enantiomers in mouse plasma."( Enantioselective quantification of atenolol in mouse plasma by high performance liquid chromatography using a chiral Stationary phase: application to a pharmacokinetic study.
Abounassif, MA; Al-Shehri, MM; Hefnawy, MM; Mostafa, GA,
)
0.65
" Colesevelam (3750mg once daily) was dosed throughout the pharmacokinetic sampling period."( Lack of effect of colesevelam HCl on the single-dose pharmacokinetics of aspirin, atenolol, enalapril, phenytoin, rosiglitazone, and sitagliptin.
He, L; Lee, J; Mendell-Harary, J; Tao, B; Walker, J; Wickremasingha, P; Wight, D, 2014
)
0.63
"For all six test drugs, 90% CIs for geometric least-squares mean ratios of AUC and Cmax for the measured analytes were within specified limits, indicating no interaction between the test drug and colesevelam."( Lack of effect of colesevelam HCl on the single-dose pharmacokinetics of aspirin, atenolol, enalapril, phenytoin, rosiglitazone, and sitagliptin.
He, L; Lee, J; Mendell-Harary, J; Tao, B; Walker, J; Wickremasingha, P; Wight, D, 2014
)
0.63
" Although the phenytoin study indicated no pharmacokinetic interaction, phenytoin should continue to be taken ≥4h before colesevelam in accordance with current prescribing information."( Lack of effect of colesevelam HCl on the single-dose pharmacokinetics of aspirin, atenolol, enalapril, phenytoin, rosiglitazone, and sitagliptin.
He, L; Lee, J; Mendell-Harary, J; Tao, B; Walker, J; Wickremasingha, P; Wight, D, 2014
)
0.63
" Though P-gp-mediated efflux may contribute to the limited brain penetration of etamicastat, the low permeability along with the pharmacokinetic properties of etamicastat may be perceived as the main contributors for its peripheral selectivity, which is advantageous for a cardiovascular drug candidate."( Role of P-glycoprotein and permeability upon the brain distribution and pharmacodynamics of etamicastat: a comparison with nepicastat.
Bonifácio, MJ; Fernandes-Lopes, C; Igreja, B; Loureiro, AI; Pires, N; Soares-da-Silva, P; Wright, LC, 2015
)
0.42
" Compared to the pure crystalline form, amorphous form and physical mixture, HCT in the co-amorphous form exhibited the significantly increased intrinsic dissolution rate, as well as the enhanced bioavailability in the pharmacokinetic study."( Facile formation of co-amorphous atenolol and hydrochlorothiazide mixtures via cryogenic-milling: Enhanced physical stability, dissolution and pharmacokinetic profile.
Cai, B; Cai, T; Gao, Q; Huang, Y; Moinuddin, SM; Ruan, S; Shi, Q, 2017
)
0.74
" Comparable results were observed in an in vivo pharmacokinetic study in rats."( Effect of Osmolality on the Pharmacokinetic Interaction between Apple Juice and Atenolol in Rats.
Funai, Y; Ichijo, K; Inoue, K; Ishihara, M; Kishimoto, H; Shirasaka, Y; Takemura, M, 2019
)
0.74
" Pharmacokinetic parameters were obtained using a compartmental fitting approach, and the estimated clearance, volume of distribution, and half-life values were the following: atenolol (6."( Ocular Intracameral Pharmacokinetics for a Cocktail of Timolol, Betaxolol, and Atenolol in Rabbits.
Del Amo, EM; Fayyaz, A; Gardner, I; Heikkinen, EM; Jamei, M; Ranta, VP; Reinisalo, M; Ricci, GD; Toropainen, E; Urtti, A; Vellonen, KS, 2020
)
0.98
"Ocular bioavailability after eye drops administration is an important, but rarely determined, pharmacokinetic parameter."( Topical ocular pharmacokinetics and bioavailability for a cocktail of atenolol, timolol and betaxolol in rabbits.
Del Amo, EM; Fayyaz, A; Gardner, I; Jamei, M; Puranen, J; Ranta, VP; Ruponen, M; Toropainen, E; Urtti, A; Valtari, A; Vellonen, KS, 2020
)
0.79

Compound-Compound Interactions

Pravastatin can be used in combination with captopril or atenolol in the treatment of hypertensive and hypercholesterolaemic patients. Doxazosin (mean dose 11 mg) given once daily in combinationwith 100 mg atenlol (n = 44) was compared with placebo and atenalol ( n = 43) in a double-blind, multicenter study in patients with mild to moderate essential hypertension. Chronic oral administration of nifedipine in conjunction with atenilol precipitated LV failure only in those with the lowest EF and highest LVEDP.

ExcerptReferenceRelevance
"This report examines the effect of weight loss, alone and in combination with drugs, on diastolic blood pressure change in the Trial of Antihypertensive Interventions and Management (TAIM), which is a randomized, multicenter, placebo-controlled clinical trial of drug and diet combinations in the treatment of mild hypertension among 787 patients."( The Trial of Antihypertensive Interventions and Management (TAIM) study. Adequate weight loss, alone and combined with drug therapy in the treatment of mild hypertension.
Blaufox, MD; Davis, BR; Langford, HG; Oberman, AS; Wassertheil-Smoller, S; Wylie-Rosett, J, 1992
)
0.28
" The patients who received carvedilol in combination with HCTZ and were evaluated for efficacy (n = 38) showed a decrease in SBP/DBP from 156/97 at the end of monotherapy to 145/88 mmHg after 10 weeks; the combination of atenolol with HCTZ (n = 44) reduced BP from 162/97 to 147/88."( Safety and antihypertensive efficacy of carvedilol and atenolol alone and in combination with hydrochlorothiazide.
Hörrmann, M; Machwirth, M; van der Does, R; Widmann, L, 1990
)
0.71
"Doxazosin (mean dose 11 mg) given once daily in combination with 100 mg atenolol (n = 44) was compared with placebo and atenolol (n = 43) in a double-blind, multicenter study in patients with mild to moderate essential hypertension."( Doxazosin in combination with atenolol in essential hypertension: a double-blind placebo-controlled multicentre trial.
Christensen, CC; Dathan, R; Dean, S; Searle, M; Westheim, A, 1990
)
0.8
"9% NaCl solution; vehicle) was given, alone and in combination with lidocaine (L), to groups of six pentobarbital (32."( Effects of metoprolol, alone and in combination with lidocaine, on ventricular fibrillation threshold: comparison with atenolol, propranolol, and pindolol.
Beil, ME; Cabot, CF; Coram, WM; Olson, RW; Weiss, GB, 1987
)
0.48
"The study was a comparison of the effects on respiratory function produced by four antihypertensive agents with receptor-blocking properties (atenolol, oxprenolol, labetalol, metoprolol), when used in combination with a diuretic (chlorthalidone) in four homogeneous groups of hypertensive patients also suffering from chronic obstructive lung disease."( Respiratory effects of four adrenergic blocking agents combined with a diuretic in treating hypertension with concurrent chronic obstructive lung disease.
Dal Negro, RW; Pomari, C; Trevisan, F; Turco, P; Zoccatelli, O, 1986
)
0.47
" Slow-release nifedipine was as effective as nifedipine in the treatment of these patients, both alone and in combination with atenolol."( Treatment of angina pectoris with nifedipine: a double blind comparison of nifedipine and slow-release nifedipine alone and in combination with atenolol.
Crake, T; Fox, KM; Mockus, L; Quyyumi, AA; Wright, C, 1987
)
0.68
" Chronic oral administration of nifedipine in combination with atenolol precipitated LV failure only in those with the lowest EF and highest LVEDP; usually LV failure was present with atenolol alone."( Hemodynamic effects of nifedipine given alone and in combination with atenolol in patients with impaired left ventricular function.
de Buitleir, M; Krikler, DM; Rowland, E, 1985
)
0.74
" By using programmed electrical stimulation in combination with MAP recordings at different pacing rates in the intact dog heart, it was possible to classify and to a certain extent to elucidate the mode of action of various cardioactive drugs in vivo."( Classification of cardioactive drugs in vivo by using programmed electrical stimulation in combination with monophasic action potential recordings at different pacing rates.
Amlie, JP; Landmark, K; Refsum, H, 1981
)
0.26
" In these patients, the doubling of diuretic dose (hydrochlorothiazide 50 mg + amiloride 5 mg) in combination with atenolol resulted in a further drop in systolic pressure (to 142."( Effects of hydrochlorothiazide combined with amiloride in atenolol-resistant hypertensive patients.
Bentivoglio, M; Corea, L; Verdecchia, P, 1983
)
0.72
" After a 4 week run-in period on atenolol, patients were randomly allocated to receive either atenolol alone or its combination with nifedipine and then crossed over to the alternative treatment for a further 4 weeks."( Comparison of the efficacy of atenolol and its combination with slow-release nifedipine in chronic stable angina.
Adnams, C; Commerford, P; Meyer, TE, 1993
)
0.86
" Nitrendipine 3 mg kg-1 was administered alone and in combination with atenolol 50 mg mg-1 day for 21 days to male normotensive Wistar rats and to spontaneously hypertensive Japanese Okamoto rats."( Response of the rat mesenteric vasculature to chronic treatment with nitrendipine alone and in combination with atenolol: evidence of a significant drug interaction.
Draper, AJ; Kingsbury, MP; Redfern, PH; Todd, MH, 1993
)
0.73
" Forty patients with moderate to severe hypertension and daytime ambulatory diastolic blood pressure > or = 90 mm Hg were randomized double-blind to once-daily treatment with either quinapril up to 20 mg (n = 20) or atenolol up to 100 mg (n = 20) as single drugs or in combination with hydrochlorothiazide 25 mg over a period of 12 weeks."( Comparison of quinapril and atenolol as single drugs or in combination with hydrochlorothiazide in moderate to severe hypertensives, using automated ambulatory monitoring.
Lacourcière, Y; Lefebvre, J; Poirier, L; Provencher, P, 1993
)
0.77
"To elucidate the effect on blood pressure and blood lipids of an angiotensin converting enzyme inhibitor (captopril), and a beta-receptor blocking agent (atenolol), given alone or in combination with a cholesterol reducing drug, the beta-hydroxy-methylglutaryl-coenzyme A reductase inhibitor pravastatin, in patients who were also encouraged to improve their lifestyle."( Treatment of hypertensive and hypercholesterolaemic patients in general practice. The effect of captopril, atenolol and pravastatin combined with life style intervention.
Foss, OP; Graff-Iversen, S; Graving, B; Istad, H; Søyland, E; Tjeldflaat, L, 1999
)
0.71
" II: Continued lifestyle intervention combined with captopril or atenolol."( Treatment of hypertensive and hypercholesterolaemic patients in general practice. The effect of captopril, atenolol and pravastatin combined with life style intervention.
Foss, OP; Graff-Iversen, S; Graving, B; Istad, H; Søyland, E; Tjeldflaat, L, 1999
)
0.75
"Pravastatin can be used in combination with captopril or atenolol in the treatment of hypertensive and hypercholesterolaemic patients."( Treatment of hypertensive and hypercholesterolaemic patients in general practice. The effect of captopril, atenolol and pravastatin combined with life style intervention.
Foss, OP; Graff-Iversen, S; Graving, B; Istad, H; Søyland, E; Tjeldflaat, L, 1999
)
0.76
" We previously demonstrated that Ang II combined with evolving cardiodepression (48-hour tachycardia pacing, 48hP) induces marked chamber stiffening and increases metalloproteinases (MMPs)."( beta-blockade prevents sustained metalloproteinase activation and diastolic stiffening induced by angiotensin II combined with evolving cardiac dysfunction.
Crow, MT; Gluzband, YA; Janicki, JS; Kass, DA; Lindsey, ML; Paolocci, N; Senzaki, H, 2000
)
0.31
" However, this component may take part in vivo and contribute to drug-drug interactions involving P-gp."( pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions.
Artursson, P; Neuhoff, S; Ungell, AL; Zamora, I, 2003
)
0.32
"To assess antiischemic efficacy, safety and effect on myocardial perfusion of a course treatment with mildronate (as monotherapy and in combination with atenolol) in patients with postinfarction left ventricular dysfunction associated with moderate heart failure."( [The use of fatty acid beta-oxidation inhibitor mildronate as monotherapy or in combination with atenolol in patients with left ventricular dysfunction after myocardial infarction].
Mamchur, SE; Sankevitch, TV; Stepatcheva, TA; Teplyakov, AT, 2003
)
0.73
"The enantiomeric separation of a series of basic pharmaceuticals (beta-blockers, local anesthetics, sympathomimetics) has been investigated in nonaqueous capillary electrophoresis (NACE) systems using heptakis(2,3-di-O-methyl-6-O-sulfo)-beta-cyclodextrin (HDMS-beta-CD) in combination with potassium camphorsulfonate (camphorSO3-)."( Enantiomeric separation of basic compounds using heptakis(2,3-di-O-methyl-6-O-sulfo)-beta-cyclodextrin in combination with potassium camphorsulfonate in nonaqueous capillary electrophoresis: optimization by means of an experimental design.
Chiap, P; Crommen, J; Dewé, W; Fillet, M; Hubert, P; Servais, AC, 2004
)
0.32
" In the current paper, this new extraction technique was combined with liquid chromatography-mass spectrometry (LC-MS) for the first time."( Liquid-phase microextraction based on carrier mediated transport combined with liquid chromatography-mass spectrometry. New concept for the determination of polar drugs in a single drop of human plasma.
Anthonsen, HS; Ho, TS; Pedersen-Bjergaard, S; Rasmussen, KE; Reubsaet, JL, 2005
)
0.33
" We analysed pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in two separate studies."( Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects.
Bolbrinker, J; Huber, M; Kreutz, R; Scholze, J, 2009
)
0.79
"We evaluated the bioavailability of each ingredient of the Polycap and determined any drug-drug interactions relative to single component reference preparations."( Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (polycap): a five-arm phase I crossover trial in healthy volunteers.
Chakraborty, BS; Desai, J; Ghosh, C; Jha, V; Khamar, B; Patel, A; Shah, G; Shah, T, 2010
)
0.36
"Comparative bioavailability was computed and no drug-drug interactions and no difference in comparative bioavailability were concluded for each ingredient based on point estimates of the T/R ratio of the geometric means falling within 80-125% for peak plasma concentration (C(max)), area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC(t)), and AUC from time zero to infinity (AUC(infinity))."( Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (polycap): a five-arm phase I crossover trial in healthy volunteers.
Chakraborty, BS; Desai, J; Ghosh, C; Jha, V; Khamar, B; Patel, A; Shah, G; Shah, T, 2010
)
0.36
" The present study in healthy volunteers establishes that Polycap is safe (no serious adverse events) and well tolerated, and that there is no indication of pharmacokinetic drug-drug interactions for any of the ingredients, with their bioavailabilities being well preserved."( Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (polycap): a five-arm phase I crossover trial in healthy volunteers.
Chakraborty, BS; Desai, J; Ghosh, C; Jha, V; Khamar, B; Patel, A; Shah, G; Shah, T, 2010
)
0.36
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38
"The present study deals with the application of mechanochemical approach for the preparation of drug-drug multicomponent solid forms of three poorly soluble antihypertensive drugs (telmisartan, irbesartan and hydrochlorothiazide) using atenolol as a coformer."( Drug-Drug Multicomponent Solid Forms: Cocrystal, Coamorphous and Eutectic of Three Poorly Soluble Antihypertensive Drugs Using Mechanochemical Approach.
Chadha, R; Haneef, J, 2017
)
0.64
"A rapid and accurate method for the sensitive detection of illegal drug additives including atenolol (ATN), metformin hydrochloride (MET), and phenformin hydrochloride (PHE) in health products using solvent microextraction (SME) combined with surface-enhanced Raman spectroscopy (SERS) was developed."( Highly sensitive detection of an antidiabetic drug as illegal additives in health products using solvent microextraction combined with surface-enhanced Raman spectroscopy.
He, H; Li, P; Lin, D; Yang, L, 2019
)
0.73

Bioavailability

Study was conducted to compare the bioavailability of a generic product of atenolol (Normaten FC) with the innovator product, Tenormin. The fixed combination of nifedipine and atanolol is bioequivalent to the free combination. Bioavailability of both drugs in the fixed combination is equivalent to the single entities.

ExcerptReferenceRelevance
" Comparison of AUC O leads to chi after oral and intravenous administration of 50 mg showed the bioavailability to be 63% after oral drug."( Clinical pharmacologic observations on atenolol, a beta-adrenoceptor blocker.
Brown, HC; Carruthers, SG; Johnston, GD; Kelly, JG; McAinsh, J; McDevitt, DG; Shanks, RG, 1976
)
0.52
" Bioavailability of the orally administered atenolol was 50%."( Pharmacokinetics, pharmacology of atenolol and effect of renal disease.
Koda, RT; Maronde, RF; Wan, SH, 1979
)
0.8
"The influence of food intake on the bioavailability of the beta-adrenoceptor blocker atenolol was assessed by measurement of its single-dose kinetics in ten healthy volunteers, who took 100 mg both in the fasting state and together with a standardized breakfast."( Food-induced reduction in bioavailability of atenolol.
Liedholm, H; Melander, A; Scherstén, B; Stenberg, P; Wåhlin-Boll, E, 1979
)
0.74
" The bioavailability of approximately 50% is due to reduced absorption."( Studies on the pharmacokinetics and pharmacodynamics of atenolol in man.
Fitzgerald, JD; McAinsh, J; Roberts, R; Ruffin, R; Smedstad, KG, 1978
)
0.5
" We found that salicylic acid absorption from this solution was delayed but complete whereas the absorption of atenolol, cimetidine, frusemide and hydrochlorothiazide was four- to five-fold lower than expected from oral bioavailability studies."( Absorption of polar drugs following caecal instillation in healthy volunteers.
Kim, M; Riley, SA; Rowland, M; Sutcliffe, F; Turnberg, LA, 1992
)
0.5
" Corresponding values for the rate of absorption were in the mean 102."( Bioequivalence of a new atenolol formulation.
Günzel, R; Rostock, G; Stulich, M; Vogel, I, 1992
)
0.59
" Thus, it is concluded that the fixed combination of nifedipine and atenolol is bioequivalent to the free combination and that the bioavailability of both drugs in the fixed combination is equivalent to that of the single entities."( A study of the pharmacokinetics and pharmacodynamics of nifedipine in combination with atenolol.
Adam, HK; Fitzsimons, TJ; McAinsh, J; Norris, SC; Ryan, J,
)
0.59
" The relative bioavailability of CR/ZOK to CT was 69."( Pharmacokinetic and pharmacodynamic properties of controlled release (CR/ZOK) metoprolol in healthy Oriental subjects: a comparison with conventional formulations of metoprolol and atenolol.
Darmansjah, I; Irawati, D; Moeloek, D; Muchtar, A; Setiawati, A; Siagian, M; Wong, E, 1990
)
0.47
" The results suggest an increase in the bioavailability of atenolol when hypothyroidism is corrected."( Evolution of atenolol kinetics when hypothyroidism is corrected.
Courtois, H; Fresel, J; Gancel, A; Levesque, H; Moore, N; Richard, MO, 1990
)
0.89
" administration of the beta blockers, no significant increase in area under the plasma drug concentration-time curve was observed for propranolol and metoprolol as a function of age, but for atenolol, a significant increase in area under the plasma drug concentration-time curve was seen in the 24-month-old rats, due to a decrease in renal function, as bioavailability of atenolol did not change in function of age."( Effect of aging on the pharmcokinetics of atenolol, metoprolol and propranolol in the rat.
Belpaire, FM; Bogaert, MG; Chauvelot-Moachon, L; de Smet, F; Rosseel, MT; Vermeulen, AM; Vynckier, LJ, 1990
)
0.73
" The pharmacokinetic parameters obtained from eight healthy humans involved in a clinical bioavailability trial are also presented."( Determination of serum atenolol using HPLC with fluorescence detection following isolation with activated charcoal.
Alebić-Kolbah, T; Plavsić, F; Wolf-Coporda, A, 1989
)
0.59
"The bioavailability of two formulations of atenolol was compared in an open, randomized crossover study."( Oral bioavailability of atenolol.
Nitsche, V; Vergin, H,
)
0.7
" In five subjects studied after both oral and intravenous administration of 20 mg Ro31-1118 the average bioavailability was 57% (range 41-73%)."( Human pharmacokinetic and pharmacodynamic studies on Ro31-1118, a new beta-adrenoceptor antagonist.
Arnold, JM; Brown, AN; Finch, MB; Francis, RJ; Galloway, DB; Harron, DW; McDevitt, DG; O'Connor, PC; Shanks, RG, 1985
)
0.27
"In this comparative bioavailability study in 12 healthy volunteers the blood level profiles and urinary recoveries of both atenolol and chlorthalidone were studied following the administration of the drugs as a fixed combination ('Tenoret 50'), as a free combination, and individually, at doses of 50 mg atenolol and 12."( Bioavailability in man of atenolol and chlorthalidone from a combination formulation.
Fitzsimons, TJ; Holmes, BH; McAinsh, J; Young, J,
)
0.64
" Although the reports prepared by the DICs and pharmacies contained the same amount of information, the DIC-prepared reports included data more frequently on supply sources, therapeutic indications, approved labeling, comparison with established treatment, bioavailability and pharmacokinetics, and recommendations."( Evaluation of pharmacy and therapeutics committee drug evaluation reports.
Johnson, MH; Longe, RL; Majercik, PL; May, JR, 1985
)
0.27
" 2 Cimetidine caused no significant changes in the bioavailability of any of the two beta-adrenoceptor blockers and the rate of elimination of metoprolol was unaffected by the histamine H2-receptor blocker."( The effect of pretreatment with cimetidine on the bioavailability and disposition of atenolol and metoprolol.
Houtzagers, JJ; Regårdh, CG; Streurman, O, 1982
)
0.49
" After a single oral dose of 100 mg atenolol combined with 1 gm ampicillin, the bioavailability of atenolol was reduced to 36 +/- 5% compared to 60 +/- 8% after monotherapy."( Atenolol interaction with aspirin, allopurinol, and ampicillin.
Axthelm, T; Kirch, W; Köhler, H; Mutschler, E; Schäfer-Korting, M, 1983
)
1.98
" It is concluded that the negative effect of the antacid on the bioavailability of atenolol is caused by a reduction in the in vivo dissolution rate due to increased gastric pH."( The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol.
Lundborg, P; Persson, BA; Regårdh, CG,
)
0.57
"In this comparative bioavailability study in 12 healthy volunteers the blood level profiles and urinary recoveries of both atenolol and chlorthalidone were studied following the administration of the drug as a fixed combination ('Tenoretic'), as a free combination, and individually, at doses of 100 mg atenolol, and 25 mg chlorthalidone."( Bioavailability in man of atenolol and chlorthalidone from a combination formulation.
Bastain, W; Harry, JD; McAinsh, J; Young, J,
)
0.64
"In this comparative bioavailability study two tablet formulations of atenolol (sales and clinical trial) were compared with an oral solution."( Bioavailability of atenolol formulations.
Ellis, SH; Holmes, BF; Mcainsh, J; Simpson, WT; Young, J,
)
0.69
" The systemic bioavailability ranged from 61% for atenolol to 100% for timolol."( Systemic absorption pathways of topically applied beta adrenergic antagonists in the pigmented rabbit.
Kompella, UB; Lee, VH; Lee, YH, 1993
)
0.54
"Previous studies have shown that the absorption rate of a lipophilic, but not hydrophilic, agent is faster after the night dosage than after the morning dosage in nocturnal rodents."( Differences of chronopharmacokinetic profiles between propranolol and atenolol in hypertensive subjects.
Ebihara, A; Fujimura, A; Ohashi, K; Shiga, T; Tateishi, T, 1993
)
0.52
" Bioavailability was 90 +/- 9% after oral administration."( Pharmacokinetics of atenolol in clinically normal cats.
Dyer, DC; Mehvar, R; Quiñones, M; Ware, WA, 1996
)
0.62
"AT has high oral bioavailability in cats, resulting in small interindividual variability in its kinetics in this species."( Pharmacokinetics of atenolol in clinically normal cats.
Dyer, DC; Mehvar, R; Quiñones, M; Ware, WA, 1996
)
0.62
"The plasma concentration time profiles and the pharmacokinetic parameters estimated for these drugs were in the expected range, except for furosemide, whose bioavailability was lower than reported in the literature."( Effect of the lipase inhibitor orlistat on the pharmacokinetics of four different antihypertensive drugs in healthy volunteers.
Jonkmann, JH; Schmidtke-Schrezenmeier, G; Tam, YK; van Brummelen, P; Weber, C, 1996
)
0.29
" Thus, the 2 products could be considered bioequivalent regarding rate of absorption (Cmax and Tmax), extent of absorption (Cmax and AUC), and elimination (t1/2)."( Comparative pharmacokinetics of two brands of atenolol following a single oral administration.
Awwadi, FF; Irshaid, YM; Kato, MK; Rawashdeh, NM, 1996
)
0.55
"The bioavailability of 2 atenolol tablet formulations (Angipress from Laboratórios Biosintética, and Atenol from Wellcome ICI Laboratory, Brazil) were compared in 18 healthy male volunteers who received a single 50 mg dose of each atenolol formulation."( Comparative bioavailability of two atenolol tablet formulations in healthy male volunteers after a single dose administration.
Abbib Júnior, E; De Nucci, G; Martins, ML; Mendes, GB; Moraes, LA; Muscará, MN; Pierossi, MA; Poli, A; Ribeiro, W, 1997
)
0.88
" Recently a new method has been proposed to determine absolute bioavailability in the absence of intravenous dose."( Prediction of absolute bioavailability for drugs using oral and renal clearance following a single oral dose: a critical view.
Mahmood, I, 1997
)
0.3
" Although the results obtained in this study are promising, pharmacokinetic and toxicological studies are required to investigate if this delivery system is a suitable and safe candidate for improving the oral bioavailability of hexarelin."( The effect of a drug-delivery system consisting of soybean phosphatidyl choline and medium-chain monoacylglycerol on the intestinal permeability of hexarelin in the rat.
Fagerholm, U; Lennernäs, H; Sjöström, B; Sroka-Markovic, J; Svensson, M; Wijk, A, 1998
)
0.3
" The bioavailability of the two gastroretentive preparations with sustained release characteristics was significantly decreased when compared to the immediate-release tablet."( Comparative pharmacokinetic study of a floating multiple-unit capsule, a high-density multiple-unit capsule and an immediate-release tablet containing 25 mg atenolol.
Allémann, E; Balant, L; Buri, P; Cole, ET; Doelker, E; Gex-Fabry, M; Rouge, N, 1998
)
0.5
" The clearance and oral bioavailability values for theophylline, atenolol, propranolol, warfarin, BMS-182874 and BMS-A were determined from continuous withdrawal or intermittent sampling experiments."( Continuous blood withdrawal as a rapid screening method for determining clearance of oral bioavailability in rats.
Humphreys, WG; Morrison, RA; Obermeier, MT, 1998
)
0.54
" The method should prove useful in drug discovery screening, where the evaluation of large numbers of compounds for systemic clearance or oral bioavailability is often necessary."( Continuous blood withdrawal as a rapid screening method for determining clearance of oral bioavailability in rats.
Humphreys, WG; Morrison, RA; Obermeier, MT, 1998
)
0.3
"A study was conducted to compare the bioavailability of a generic product of atenolol (Normaten FC) with the innovator product, Tenormin."( Comparative bioavailability study of two atenolol tablet preparations.
Peh, KK; Toh, WT; Wong, JW; Yuen, KH, 1999
)
0.8
" In this study, the effects of chitosans with varying molecular weights and degrees of acetylation on the absorption of a poorly absorbed model drug (atenolol) were studied in intestinal epithelial cell layers with or without a mucus layer and in an in situ perfusion model of rat ileum."( Chitosans as absorption enhancers of poorly absorbable drugs. 3: Influence of mucus on absorption enhancement.
Artursson, P; Lennernäs, H; Ocklind, G; Schipper, NG; Stenberg, P; Vârum, KM, 1999
)
0.5
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
" The new methodology may, therefore, be used for fast bioavailability screening of virtual libraries having millions of molecules."( Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.
Ertl, P; Rohde, B; Selzer, P, 2000
)
0.31
" The bioavailability of the two formulations was compared through the 90% confidence intervals (C."( Comparative bioavailability of two formulations containing atenolol and chlortalidone associated in a 4:1 fixed combination.
Crivelli, F; Dal Bo, L; Ismaili, S; Marzo, A; Mazzucchelli, P; Monti, NC; Porziotta, E; Ronchi, C; Tettamanti, RA; Uhr, MR, 2000
)
0.55
" Conclusively, nipradilol, beta-blocker with nitric oxide-releasing action, in contrast to the other beta-blockers and nitric oxide donors, showed a successful anti-atherosclerotic effect through the restoration of nitric oxide bioavailability and possible interaction with oxygen radicals."( Anti-atherosclerotic effect of beta-blocker with nitric oxide-releasing action on the severe atherosclerosis.
Hayashi, T; Iguchi, A; Kano, H; Matsui-Hirai, H; Sumi, D; Thakur, NK; Tsunekawa, T, 2002
)
0.31
"A study was carried out in human volunteers to investigate whether ileal brake activators could alter the bioavailability of atenolol from the small intestine by slowing intestinal transit and thereby increasing the time available for absorption."( The effect of ileal brake activators on the oral bioavailability of atenolol in man.
Chauhan, S; Davis, SS; Dobson, CL; Sparrow, RA; Wilding, IR, 2002
)
0.76
"An accurate, precise, and sensitive high-performance liquid chromatography (HPLC) assay was developed for the determination of atenolol in human plasma samples to compare the bioavailability of 2 atenolol tablet (50 mg) formulations in 24 volunteers of both sexes."( Atenolol quantification in human plasma by high-performance liquid chromatography: application to bioequivalence study.
de Abreu, LR; de Castro, SA; Pedrazzoli, J, 2003
)
1.97
"The pharmacokinetics and bioavailability of atenolol, a antihypertensive, were studied to determine the feasibility of enhanced transdermal delivery of atenolol from the ethylene-vinyl acetate (EVA) matrix system containing polyoxyethylene-2-oleyl ether as an enhancer in rabbits."( Enhanced bioavailability of atenolol by transdermal administration of the ethylene-vinyl acetate matrix in rabbits.
Choi, JS; Shin, SC, 2003
)
0.87
"The purpose of this study was to develop and validate a method for separately evaluating the roles of gastrointestinal absorption and hepatic extraction as barriers to oral bioavailability (BA)."( Evaluating barriers to bioavailability in vivo: validation of a technique for separately assessing gastrointestinal absorption and hepatic extraction.
Aungst, B; Dobson, G; Hidalgo, I; Letendre, L; Scott, M, 2004
)
0.32
" Pharmacokinetic parameters including bioavailability were calculated for each compound for each route of administration."( Evaluating barriers to bioavailability in vivo: validation of a technique for separately assessing gastrointestinal absorption and hepatic extraction.
Aungst, B; Dobson, G; Hidalgo, I; Letendre, L; Scott, M, 2004
)
0.32
" Antipyrine was highly bioavailable by all routes."( Evaluating barriers to bioavailability in vivo: validation of a technique for separately assessing gastrointestinal absorption and hepatic extraction.
Aungst, B; Dobson, G; Hidalgo, I; Letendre, L; Scott, M, 2004
)
0.32
" Because there are no data on the bioavailability of atenolol given by nasogastric tube in the postoperative period, we assessed the efficacy of this route of administration in 18 patients scheduled for abdominal surgery."( Atenolol administration via a nasogastric tube after abdominal surgery: an unreliable route.
Aymard, G; Coriat, P; Diquet, B; Fléron, MH; Gosgnach, M; Huraux, C, 2005
)
2.02
" Atenolol was chosen as a model drug because it is poorly absorbed from the lower gastrointestinal tract."( Oral sustained delivery of atenolol from floating matrix tablets-formulation and in vitro evaluation.
Mishra, B; Ridhurkar, D; Srivastava, AK; Wadhwa, S, 2005
)
1.54
"An open-label, randomized study was designed to determine the bioavailability (BA); pharmacokinetic (PK) and pharmacodynamic (PD) behaviour of Atenolol 50 mg (two pills) and 100 mg (one pill) tablet manufactured by a national pharmaceutical industry."( Biopharmaceutical evaluation of oral tablet Atenolol (100 and 50 mg) on local population.
Ahmed, SW; Ali, O; Obaid, R; Saify, ZS, 2005
)
0.79
" The bioavailability of the compound following the colon administration in dogs, relative to the same formulation administered orally (relative bioavailability), was determined."( Dog colonoscopy model for predicting human colon absorption.
Evans, LA; Fortner, JH; McCarthy, JM; Sutton, SC; Sweeney, K, 2006
)
0.33
"Except for atenolol, a small hydrophillic molecule, the relative bioavailability from administration to the colon of the dog correlated well with the following compound properties: high solubility and high, passive permeability > high solubility, low permeability > low solubility, high, passive permeability approximately low solubility, low permeability."( Dog colonoscopy model for predicting human colon absorption.
Evans, LA; Fortner, JH; McCarthy, JM; Sutton, SC; Sweeney, K, 2006
)
0.72
" However, no human intubation or dog colon studies are required for Class 1 (HS/HP), as these compounds are likely to be well absorbed from the colon."( Dog colonoscopy model for predicting human colon absorption.
Evans, LA; Fortner, JH; McCarthy, JM; Sutton, SC; Sweeney, K, 2006
)
0.33
" The effects of nebivolol on the bioavailability of NO and ONOO, indicators of endothelial function and dysfunction, respectively, were measured in vitro using nanosensors placed in mesenteric arteries."( Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: Role of antioxidant activity.
Boychuk, B; Jacob, RF; Kubant, R; Malinski, T; Mason, RP; Walter, MF, 2006
)
0.33
" Using the Caco-2 human colonic cell line as an in vitro model of the human intestinal mucosal barrier, the bioavailability of dianthrones was studied in apical to basolateral (absorptive) and basolateral to apical (secretive) direction."( Transport of sennosides and sennidines from Cassia angustifolia and Cassia senna across Caco-2 monolayers--an in vitro model for intestinal absorption.
Avula, B; Ganzera, M; Khan, IA; Khan, SI; Stuppner, H; Waltenberger, B, 2008
)
0.35
" Topotecan, an anti-cancer drug widely used in metastatic carcinoma, is a P-glycoprotein substrate having oral bioavailability of 30% with large inter-patient variability."( Concurrent determination of topotecan and model permeability markers (atenolol, antipyrine, propranolol and furosemide) by reversed phase liquid chromatography: utility in Caco-2 intestinal absorption studies.
Bansal, T; Jaggi, M; Khar, RK; Mishra, G; Mukherjee, R; Singh, M; Talegaonkar, S, 2007
)
0.57
" For atenolol (highly soluble drug), GInf resulted in a prolonged Tmax and reduced Cmax in comparison to PO, whereas bioavailability was similar."( Selection of drug candidates for gastroretentive dosage forms: pharmacokinetics following continuous intragastric mode of administration in a rat model.
Hoffman, A; Kagan, L, 2008
)
0.86
" Levels of erythrocyte cellular superoxide dismutase increased with nebivolol, indirectly suggesting increased bioavailability of nitric oxide (P<."( Nebivolol in high-risk, obese African Americans with stage 1 hypertension: effects on blood pressure, vascular compliance, and endothelial function.
Ferdinand, KC; Khan, BV; Merchant, N; Pandian, A; Rahman, ST; Searles, CD; Umpierrez, GE, 2009
)
0.35
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
"We evaluated the bioavailability of each ingredient of the Polycap and determined any drug-drug interactions relative to single component reference preparations."( Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (polycap): a five-arm phase I crossover trial in healthy volunteers.
Chakraborty, BS; Desai, J; Ghosh, C; Jha, V; Khamar, B; Patel, A; Shah, G; Shah, T, 2010
)
0.36
"The bioavailability of the ingredients of the Polycap (T; test) when formulated as a single capsule was compared with that of identical capsules with each of its ingredients administered separately (R; reference) in a five-arm, randomized, single-dose, two-period, two-treatment, two-sequence, crossover trial with at least a 2-week washout period in a total of 195 healthy volunteers."( Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (polycap): a five-arm phase I crossover trial in healthy volunteers.
Chakraborty, BS; Desai, J; Ghosh, C; Jha, V; Khamar, B; Patel, A; Shah, G; Shah, T, 2010
)
0.36
"Comparative bioavailability was computed and no drug-drug interactions and no difference in comparative bioavailability were concluded for each ingredient based on point estimates of the T/R ratio of the geometric means falling within 80-125% for peak plasma concentration (C(max)), area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC(t)), and AUC from time zero to infinity (AUC(infinity))."( Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (polycap): a five-arm phase I crossover trial in healthy volunteers.
Chakraborty, BS; Desai, J; Ghosh, C; Jha, V; Khamar, B; Patel, A; Shah, G; Shah, T, 2010
)
0.36
"The Biopharmaceutical Classification System (BCS) guidance issued by the FDA allows waivers for in vivo bioavailability and bioequivalence studies for immediate-release (IR) solid oral dosage forms only for BCS class I drugs."( The biowaiver extension for BCS class III drugs: the effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulation.
Amidon, GL; Tsume, Y, 2010
)
0.36
" In vivo studies revealed that the absolute bioavailability of microsphere formulations was higher than that of reference in spite of a lower dosage of drug, suggesting a possible dose reduction by AT microparticles orotransmucosal administration."( Poloxamer 407 microspheres for orotransmucosal drug delivery. Part II: In vitro/in vivo evaluation.
Albertini, B; Burgalassi, S; Chetoni, P; Monti, D; Passerini, N; Rodriguez, L; Rossato, MS, 2010
)
0.36
"Dispensing medicines into compliance aids is a common practice in pharmacy contrary to manufacturers' advice and studies have shown the appearance of light-sensitive tablets is compromised by such storage; we previously found evidence of reduced bioavailability at elevated temperature and humidity."( Quality of medicines stored together in multi-compartment compliance aids.
Donyai, P, 2010
)
0.36
" The chemical stability of atenolol was not affected and we did not find evidence of changes to bioavailability with either make."( Quality of medicines stored together in multi-compartment compliance aids.
Donyai, P, 2010
)
0.66
"Development of liposomal mucoadhesive drug delivery system, which is able to improve the bioavailability of poorly absorbed oral drugs by prolonging their gastric and intestinal residence time, through facilitating the intimate contact of the delivery system with the absorption membrane."( Mucoadhesive liposomal delivery systems: the choice of coating material.
Karn, PR; Pepić, I; Skalko-Basnet, N; Vanić, Z, 2011
)
0.37
" Further work is now required to assess the amount and stability of the active ingredient and the robustness of the paste and suspension formulations prior to any bioavailability comparisons between the formulations."( Acceptability and compliance of atenolol tablet, compounded paste and compounded suspension prescribed to healthy cats*.
Campbell, F; Greer, RM; Khor, KH; Mills, PC; Rathbone, MJ, 2012
)
0.66
"Aloe vera gel previously showed the ability to increase the bioavailability of vitamins and to enhance the in vitro transport of a macromolecular drug across intestinal epithelial cell monolayers."( In vitro drug permeation enhancement potential of aloe gel materials.
Hamman, J; Lebitsa, T; Lu, Z; Viljoen, A, 2012
)
0.38
" Atenolol is a water-soluble, ionizable drug and suffers from poor bioavailability when given by oral route due to its incomplete intestinal absorption and first-pass metabolism."( Design and Characterization of Atenolol Transdermal Therapeutic Systems: Enhancement of Permeability via Iontophoresis.
Keerthi, H; Panakanti, PK; Yamsani, MR,
)
1.33
" Methyl ester 20 has promising oral bioavailability and pharmacokinetics and may target 5-HT4 receptors in both CNS and peripheral organs."( Acidic biphenyl derivatives: synthesis and biological activity of a new series of potent 5-HT(4) receptor antagonists.
Andressen, KW; Brudeli, B; Klaveness, J; Levy, FO; Moltzau, LR; Nilsen, NO, 2013
)
0.39
"The objective of the present study was to develop, optimize, in vitro, and in vivo evaluation of floating matrix tablet of atenolol using polymer blend derived from Xanthomonas campesteris and Cyamopsis tetragonolobus that are characterized by release requirements of sustained-release product and to improve the oral bioavailability of the drug."( Polymers derived from Xanthomonas campesteris and Cyamopsis tetragonolobus used as retardant materials for the formulation of sustained release floating matrix tablet of atenolol.
Chattopadhyay, S; Das, MK; De, K; Dey, S; Ganguly, S; Mazumder, B; Mishra, M; Sinha, S, 2014
)
0.8
" The pharmacokinetic study illustrated that the fast absorption and increased oral bioavailability of atorvastatin as well as therapeutic concentration of atenolol in blood were made available through adoption of formulation strategy of bilayer tablets."( Formulation and evaluation of fixed-dose combination of bilayer gastroretentive matrix tablet containing atorvastatin as fast-release and atenolol as sustained-release.
Chattopadhyay, S; Dey, S; Mazumder, B, 2014
)
0.8
"Niosomes have been reported as possible approach to improve the low corneal penetration and bioavailability characteristics for many drugs."( Potential use of niosomal hydrogel as an ocular delivery system for atenolol.
Abd-Elgawad, AE; Abu Hashim, II; Arima, H; El-Dahan, MS; Yusif, RM, 2014
)
0.64
" The absorption rate coefficients of all the assayed compounds did not show statistically significant differences between male and female rats consequently all the individual values were combined to compare between reabsorption methods."( Validation of phenol red versus gravimetric method for water reabsorption correction and study of gender differences in Doluisio's absorption technique.
Bermejo, M; Gonzalez-Alvarez, I; Gonzalez-Alvarez, M; Tuğcu-Demiröz, F, 2014
)
0.4
"A reliable prediction of the oral bioavailability in humans is crucial and of high interest for pharmaceutical and food industry."( A new approach to predict human intestinal absorption using porcine intestinal tissue and biorelevant matrices.
Grossouw, D; Krul, CA; van de Steeg, E; Verwei, M; Westerhout, J; Wortelboer, HM; Zeijdner, EE, 2014
)
0.4
" Despite its lower bioavailability and higher clearance, as compared to nepicastat, etamicastat showed preferential distribution to peripheral tissues and high plasma free fraction (15."( Role of P-glycoprotein and permeability upon the brain distribution and pharmacodynamics of etamicastat: a comparison with nepicastat.
Bonifácio, MJ; Fernandes-Lopes, C; Igreja, B; Loureiro, AI; Pires, N; Soares-da-Silva, P; Wright, LC, 2015
)
0.42
"An increasing number of macrocyclic peptides that cross biological membranes are being reported, suggesting that it might be possible to develop peptides into orally bioavailable therapeutics; however, current understanding of what makes macrocyclic peptides cell permeable is still limited."( Exploring experimental and computational markers of cyclic peptides: Charting islands of permeability.
Chaousis, S; Colless, B; Craik, DJ; Liras, S; Northfield, SE; Price, DA; Swedberg, JE; Wang, CK, 2015
)
0.42
", ip) indicate that the liver is the primary site of biotransformation of the compound, suggesting that both 22a and its metabolite(s) are active, compensating probably low bioavailability of the parent molecule."( Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
Bednarski, M; Gunia-Krzyżak, A; Marona, H; Nitek, W; Pękala, E; Powroźnik, B; Słoczyńska, K; Walczak, M; Waszkielewicz, AM; Żesławska, E, 2016
)
0.43
"The development of oral modified-release (MR) dosage forms requires an active pharmaceutical ingredient (API) with a sufficiently high absorption rate in both the small and large intestine."( Regional Intestinal Permeability in Dogs: Biopharmaceutical Aspects for Development of Oral Modified-Release Dosage Forms.
Abrahamsson, B; Dahlgren, D; Johansson, P; Lennernäs, H; Lundqvist, A; Roos, C; Sjögren, E; Tannergren, C, 2016
)
0.43
" Atenolol is an antihypertensive drug with low oral bioavailability and gastrointestinal side effects."( Impact of feed counterion addition and cyclone type on aerodynamic behavior of alginic-atenolol microparticles produced by spray drying.
Bucalá, V; Ceschan, NE; Ramírez-Rigo, MV; Smyth, HD, 2016
)
1.57
"L exhibited prominent higher oral bioavailability and more efficient sustained-release effect than the drug alone or the commercial tablet product."( Potential Use of Polyvinyl Acetate-Polyvinylpyrrolidone Mixture for the Development of Atenolol Sustained Release Matrix Tablets: Optimization of Formulation through in Vitro-in Vivo Assessment Study.
Abd El-Ghany, GM; Abu Hashim, II; Owayez, AS, 2017
)
0.68
"The development of poorly water-soluble drugs faces the risk of low bioavailability and therapeutic efficacy."( Facile formation of co-amorphous atenolol and hydrochlorothiazide mixtures via cryogenic-milling: Enhanced physical stability, dissolution and pharmacokinetic profile.
Cai, B; Cai, T; Gao, Q; Huang, Y; Moinuddin, SM; Ruan, S; Shi, Q, 2017
)
0.74
" However, the great drawback it presents is a low bioavailability after oral administration."( Ion-pair approach coupled with nanoparticle formation to increase bioavailability of a low permeability charged drug.
Bermejo, M; González-Álvarez, I; González-Álvarez, M; Lozoya-Agullo, I; Merino-Sanjuán, M; Planelles, M; Sarmento, B, 2019
)
0.51
" However, the frequency of oral administration may result in poor patient compliance, and reduced bioavailability owing to the first-pass effect can also prove problematic."( Poly(Acrylic Acid)-Modified MoS
He, S; Li, J; Liu, X; Zhang, K; Zhuang, Y, 2020
)
0.56
"Ocular bioavailability after eye drops administration is an important, but rarely determined, pharmacokinetic parameter."( Topical ocular pharmacokinetics and bioavailability for a cocktail of atenolol, timolol and betaxolol in rabbits.
Del Amo, EM; Fayyaz, A; Gardner, I; Jamei, M; Puranen, J; Ranta, VP; Ruponen, M; Toropainen, E; Urtti, A; Valtari, A; Vellonen, KS, 2020
)
0.79
" The most common method to facilitate drug administration in dysphagia patients is to mix the powdered drug with a small amount of thickened water, however little is known about the effects of this method on in vivo bioavailability of drugs."( Do Thickening Agents Used in Dysphagia Diet Affect Drug Bioavailability?
Erdem, ÇE; Eroğlu, H; Eylem, CC; Gökmen-Özel, H; Ilgaz, F; Nemutlu, E; Timur, SS, 2022
)
0.72

Dosage Studied

The clinical efficacy of bopindolol, a new, long-acting beta-adrenoceptor blocking drug, in a dosage of 1-2 mg daily was compared with that of atenolol (50-100 mg daily) in 33 patients with mild or moderate arterial hypertension. The daily administration of 240 to 360 mg of diltiazem lowered blood pressure in a dose-related pattern.

ExcerptRelevanceReference
" Neither multiple preimmunization dosings nor a single postimmunization dosing was effective."( Alterations in murine delayed type hypersensitivity responses by delta-8-THC and cannabinol.
Heppner, GH; Levy, JA,
)
0.13
" A biphasic log dose-response curve was observed for each of the cannabinoid drugs, such that reversal of the inhibition occurred at 3-10 microM."( Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes.
Fleming, RM; Howlett, AC, 1984
)
0.27
" With both beta-blockers, cardiac blockade and hypotensive effect increased in a parallel fashion when the dosage was increased suggesting that the hypotensive effect is related to cardiac beta-blockade."( The relationship between beta-blockade, hyporeninaemic and hypotensive effect of two beta-blocking agents.
Amery, A; De Plaen, JF; Fagard, R; Linjen, P; Reybrouck, T, 1976
)
0.26
" The plasma elimination half-life, area under the plasma concentration-time curve, and peak plasma concentration after 200 mg atenolol were not changed by chronic dosing for 8 days."( Clinical pharmacologic observations on atenolol, a beta-adrenoceptor blocker.
Brown, HC; Carruthers, SG; Johnston, GD; Kelly, JG; McAinsh, J; McDevitt, DG; Shanks, RG, 1976
)
0.73
" The dose-response curves obtained were compared with similar curves previously reported for sotalol, practolol, and atenolol with identical experimental methods."( Influence of intrinsic sympathomimetic activity and cardioselectivity on beta adrenoceptor blockade.
Brown, HC; Carruthers, SG; McDevitt, DG; Shanks, RG, 1977
)
0.47
" Both timolol and acebutolol had a significant hypotensive effect at 24 hours and a low incidence of side effects, suggesting that further increases in dosage might be effective and well tolerated."( Randomised study of six beta-blockers and a thiazide diuretic in essential hypertension.
Wilcox, RG, 1978
)
0.26
" At dosage levels of atenolol giving a mean resting systolic blood pressure equal to that during nonselective beta-blockade, diastolic levels on atenolol tended to be lower at rest and during the mental and handgrip forms of stress."( Atenolol and three nonselective beta-blockers in hypertension.
Waal-Manning, HJ, 1979
)
2.02
" In patients with angina its long duration of beta-blocking activity allows once daily dosage, whereas other beta-blockers, unless in sustained release dosage forms, need to be given in divided doses."( Atenolol: a review of its pharmacological properties and therapeutic efficacy in angina pectoris and hypertension.
Avery, GS; Brogden, RN; Heel, RC; Speight, TM, 1979
)
1.7
"13 The vasoconstrictor actions of phenylephrine, noradrenaline and adrenaline were all antagonized by the systemic administration of phentolamine, all three dose-response curves being shifted to the right."( The role of beta-adrenoceptors in the responses of the hepatic arterial vascular bed of the dog to phenylephrine, isoprenaline, noradrenaline and adrenaline.
Richardson, PD; Withrington, PG, 1977
)
0.26
" The results clearly indicate that at the dosage used, the four antiarrhythmic agents (quinidine, disopyramide, prajmaliumbitartrate, propafenone) exert a negative inotropic effect on left ventricular function as far as it can be judged from the measurement of STI."( [The effect of some antiarrhythmic drugs on systolic time intervals in normal subjects (author's transl)].
Breithardt, G; Jochum, E; Kuhn, H; Seipel, L, 1978
)
0.26
" Mean duration of treatment was 16 months (range 8--36) and mean dosage 163 mg/day."( Long-term clinical experience with atenolol--a new selective beta-1-blocker with few side-effects from the central nervous system.
Henningsen, NC; Mattiasson, I, 1979
)
0.54
"1 The hypotensive effect of single daily dosing with atenolol 100 mg and chlorthalidone 25 mg given alone or in combination has been assessed in a double-blind, crossover, placebo controlled trial in fifteen hypertensive patients."( Atenolol and chlorthalidone in combination for hypertension.
Bateman, DN; Bulpitt, CJ; Dean, CR; Dollery, CT; Mucklow, JC, 1979
)
1.95
" Beta-blockers showed little evidence of useful antiarrhythmic action in the dosage used, but increasing the dosage in suspected myocardial infarction is not practicable because of the risk of hypotension."( Effect of beta-blockers on arrhythmias during six weeks after suspected myocardial infarction.
Banks, DC; Edwards, B; Fentem, PH; Hampton, JR; Roland, JM; Wilcox, RG, 1979
)
0.26
" If the MAP was more than 108 mm Hg at the end of the week, dosage of the beta-blocker was doubled the following week; when necessary, doubling was repeated to a maximum dose of 640 mg propranolol and 400 mg atenolol daily."( Effects of atenolol and propranolol when added to long-term antihypertensive diuretic therapy.
Boer, P; Dorhout Mees, EJ; Geyskes, GG; van Rooijen, GJ, 1979
)
0.84
" The simple dosage regime, combined with proven effectiveness and a relative lack of side-effects makes atenolol a useful treatment for the hypertensive patient."( Multicentre general practitioner assessment of 'Tenormin' and methyldopa.
Mason, B; Sleigh, R; Tweed, JA, 1979
)
0.47
"The pharmacokinetics of atenolol, a new cardioselective beta-adrenoceptor blocking agent, were determined following both acute and chronic dosing in 33 hypertensive patients with widely differing levels of renal impairment."( Pharmacokinetics of atenolol in patients with renal impairment.
Legheand, J; McAinsh, J; Pozet, N; Sassard, J; Zech, P, 1977
)
0.89
" This suggests that some were apparent non-responders due to too low dosing of atenolol rather than true non-responders."( Haemodynamic findings and response rates to beta-blocker--and diuretic monotherapy in mild and moderate hypertension. A one year randomized, double blind study in 100 men.
Erikssen, J; Froeland, G; Otterstad, JE; Saltvedt, E; Soeyland, AK, 1992
)
0.51
" The optimal dose should be determined on a case-by-case basis, by increasing the daily dosage gradually."( [Beta-blockers and migraine].
Bousser, MG; Massiou, H, 1992
)
0.28
"Spontaneous motor activity of normotensive and renovascular hypertensive baboons was measured during oral dosing with the beta-adrenergic antagonists atenolol HCl (2."( Beta-blocker effects on 24-h activity in normotensive and renovascular hypertensive baboons.
Allen, RP; Bezold, HJ; Hienz, RD; Turkkan, JS, 1992
)
0.48
" Moreover, these agonists caused a shift of the dose-response curve for phenylephrine to the right in a parallel fashion in non-preconstricted preparations."( Vascular alpha-1 antagonistic and agonistic effects of beta adrenoceptor agonists in rabbit common carotid arteries.
Chiba, S; Fujiwara, T, 1992
)
0.28
"Repeated acquisition behavioral performances of normotensive and renovascular hypertensive baboons were tested before, during, and following chronic oral dosing with the beta-adrenergic antagonists atenolol HCl (2."( Performance of baboons under a repeated acquisition procedure during chronic oral exposure to atenolol and propranolol.
Hienz, RD; Turkkan, JS, 1992
)
0.69
"The efficacy and safety of carvedilol, a beta-blocker with vasodilating properties, were compared at a dosage of 25 to 50 mg once daily with those of atenolol at a dosage of 50-100 mg once daily in a double-blind, randomized, parallel-group, multicenter study."( A comparison of carvedilol with atenolol in the treatment of mild-to-moderate essential hypertension. INT-CAR-07 (U.K.) Study Group.
Young, PH, 1992
)
0.77
" Twenty-four-hour ambulatory HR recording demonstrated that this difference existed for the last 6 h of the dosage cycle."( Twenty-four-hour beta-blockade in stable angina pectoris: a study of atenolol and betaxolol.
Dargie, HJ; Findlay, IN; McLenachan, JM; Wilson, JT, 1992
)
0.52
" This study demonstrates that once-daily administration of amlodipine or atenolol to mild-to-moderate hypertensive patients was well-tolerated and provided adequate blood pressure control throughout the 24-h dosing interval."( A randomized, placebo-controlled, double-blind comparison of amlodipine and atenolol in patients with essential hypertension.
Brobyn, R; Brown, RD; Frishman, WH; Johnson, BF; Reeves, RL; Wombolt, DG, 1992
)
0.74
" Gingival changes in the nifedipine patients were not related to drug dosage or plaque scores."( The incidence and severity of nifedipine-induced gingival overgrowth.
Barclay, S; Idle, JR; Seymour, RA; Thomason, JM, 1992
)
0.28
" Prereduction dosage of atenolol was 100 mg in 26 and 50 mg in 15 patients."( [Effect of halving the dosage of atenolol in essential hypertension].
Brack, T; Edmonds, D; Greminger, P; Grüne, S; Vetter, W, 1992
)
0.87
" Rigorous methods must be used to determine the doses recommended and the amount of drug to be put into a tablet or other dosage form."( How much drug in the tablet?
Herxheimer, A, 1991
)
0.28
" Dose-response curves were constructed, and doses of isoprenaline required to increase finger tremor by 100% (IT100), heart rate by 25 beats/min (IH25), SBP by 25 mmHg (IS25), cardiac output by 35% (IC35), and decrease DBP by 10 mmHg (ID10), after each treatment were calculated."( A dose-ranging study to evaluate the beta 1-adrenoceptor selectivity of bisoprolol.
Irvine, NA; Lipworth, BJ; McDevitt, DG, 1991
)
0.28
" They were treated with effective dosage of digoxin and diuretics."( [Tolerance of beta blockader treatment in dilated cardiomyopathy].
Bettelli, G; Mattioli, AV; Mattioli, G, 1991
)
0.28
" (as a bolus or by increments) produced significant alpha 1-adrenoceptor antagonism (with rightward shifts of more than two-fold in the phenylephrine pressor dose-response curves) but no significant effects on supine or erect blood pressure and heart rate."( Studies with abanoquil (UK-52,046) a novel quinoline alpha 1-adrenoceptor antagonist: I. Effects on blood pressure, heart rate and pressor responsiveness in normotensive subjects.
Elliott, HL; Howie, CA; Reid, JL; Schafers, RF, 1991
)
0.28
" All patients were treated with atenolol at dosage of 50 mg/die."( [Neurohumoral changes in patients with heart failure treated chronically with beta-blockers].
Mattioli, AV; Mattioli, G, 1991
)
0.56
" Dosage titration occurred at weekly intervals for labetalol and biweekly for atenolol."( Renin profile, race, and antihypertensive efficacy with atenolol and labetalol.
DiPette, DJ; Goodman, RP; McKenney, JM; Townsend, R; Wright, JT, 1991
)
0.76
"This randomised, double-blind, crossover study compared enalapril 5 mg, and atenolol 50 mg, each dosed once daily for 4 weeks, and investigated casual and diurnal BP changes using 24 hour ambulatory BP monitoring."( Effect of atenolol or enalapril on diurnal changes of blood pressure in Japanese mild to moderate hypertensives: a double-blind, randomised, crossover trial.
Hara, H; Ishida, Y; Kobayashi, K; Nakamura, S; Ohta, H; Takabatake, T; Takakuwa, H; Yamamoto, Y, 1991
)
0.91
" The apparent volume of distribution (Vz) was greater for bisoprolol than for atenolol after single dosing (235 1 vs 146 1) and at steady state (216 1 vs 137 1), but clearances were similar for both drugs."( A randomized double-blind study of bisoprolol versus atenolol in mild to moderate essential hypertension.
Dixon, MS; Sheridan, DJ; Thomas, P, 1990
)
0.76
" In I, four cumulative noradrenaline (NA) dose-response curves (10(-9) to 10(-3) M) were constructed."( Reversal of alpha-adrenoceptor blockade by propranolol in isolated rat pulmonary artery.
Abdelrahman, A; Nguyen, H; Pang, CC, 1990
)
0.28
"The dose-response curves of betaxolol and atenolol were compared in 140 patients with mild to moderate essential hypertension."( Population dose versus response of betaxolol and atenolol: a comparison of potency and variability.
Sambol, NC; Sheiner, LB, 1991
)
0.8
" Whether dose reduction will lead to reduced corneal toxicity in glaucoma filtration surgery following topical or subconjunctival dosing is an interesting therapeutic opportunity that remains to be determined."( Corneal penetration of 5-fluorouracil and its improvement by prodrug derivatization in the albino rabbit: implication in glaucoma filtration surgery.
Bundgaard, H; Buur, A; Lee, VH; Wang, W, 1991
)
0.28
" Each drug was given separately in a random fashion in fixed dosage for 4 weeks with a washout period of 2 weeks in between the drugs."( The effects of antihypertensive agents on the quality of life in Indian hypertensives.
Kumar, K; Rajan, AG; Somani, PN; Sundar, S, 1991
)
0.28
" Three hours after dosing beta-adrenoceptor blocker treatments significantly reduced exercise heart rate, prolonged time to complete exercise, and increased subjective fatigue measured by visual analogue scale."( Influence of debrisoquine oxidation phenotype on exercise tolerance and subjective fatigue after metoprolol and atenolol in healthy subjects.
Jackson, PR; Lennard, MS; Lewis, RV; Ramsay, LE; Tucker, GT; Yeo, WW, 1991
)
0.49
"The antihypertensive effect of a fixed dosage combination of the cardioselective beta-adrenoceptor blocker, atenolol, and the oral thiazide-like diuretic, chlorthalidone (Tenoretic) was studied in 24 hypertensive Nigerians in a double-blind, cross-over comparison with three other treatments."( Assessment of a fixed-dosage combination of atenolol and chlorthalidone (Tenoretic) in hypertensive Nigerians.
Aderounmu, AF; Falase, AO; Salako, LA; Walker, O, 1990
)
0.75
" Nitrendipine alone had no significant effect on blood pressure 24 h after dosing (165/104 sitting: 165/110 standing)."( Comparison of once daily atenolol, nitrendipine and their combination in mild to moderate essential hypertension.
Coulson, RR; Fitzsimons, TJ; Irvine, N; Lewis, R; Maclean, D; McDevitt, DG; McEwen, J; McLay, JS; Mitchell, ET; Slater, ND, 1990
)
0.58
" In 5- and 10-day-old animals, prenalterol treatment produced minimal stimulation of PRA and the dose-response curve was essentially flat."( Effects of sympathetic activation on plasma renin activity in the developing rat.
Johnson, AK; Kirby, RF, 1990
)
0.28
"Cardioselectivity of a single oral dose of metoprolol oral osmotic (OROS) (14/190 mg) and atenolol (100 mg) was compared in 12 patients with reversible obstructive airway disease by assessing the dose-response curve to increasing doses of inhaled salbutamol."( Comparative evaluation of cardioselectivity of metoprolol OROS and atenolol: a double-blind, placebo-controlled crossover study.
Bruni, B; Dottorini, ML; Grassi, V; Lecaillon, JB; Motolese, M; Peccini, F; Sorbini, CA; Tantucci, C, 1990
)
0.74
" Sitting (and standing) blood pressure and heart rate one to four hours after dosing were recorded at entry (191/95 mmHg) and at the end of the run-in period (186/93 mmHg)."( Hypertension in the elderly: a study of a combination of atenolol and nifedipine.
Cheadle, B; Duckett, GK, 1990
)
0.52
" More specifically, a comparison of the two drugs during the final 6 hours (3 AM to 9 AM) of the dosing interval showed that the mean decrease in diastolic BP of 10."( Antihypertensive effects of beta-blockers administered once daily: 24-hour measurements.
Cheung, DG; Graettinger, WF; Neutel, JM; Schnaper, H; Weber, MA, 1990
)
0.28
" Following titration patients were maintained at constant dosage for 12 weeks."( A randomized double-blind study of atenolol and celiprolol in mild to moderate hypertension.
Rosenthal, F; Silke, B; Taylor, S, 1986
)
0.55
" Its hemodynamic profile was compared with that of atenolol (cardioselective; no ISA) in a comparative dose-response study of 24 patients with angiographically documented coronary artery disease."( Differential actions of atenolol and celiprolol on cardiac performance in ischemic heart disease.
Frais, MA; Reynolds, G; Silke, B; Taylor, SH; Verma, SP, 1986
)
0.83
"The effects of once-daily dosing with celiprolol 200 mg, celiprolol 400 mg, and atenolol 100 mg have been studied in 19 male patients with chronic stable angina pectoris."( A single-blind randomized comparison of the 24-h antianginal efficacy of celiprolol versus atenolol.
Jackson, NC; Lee, PS; Taylor, SH, 1986
)
0.72
"The clinical efficacy of bopindolol, a new, long-acting beta-adrenoceptor blocking drug, in a dosage of 1-2 mg daily was compared with that of atenolol (50-100 mg daily) in 33 patients with mild or moderate arterial hypertension who were treated for a total period of 12 months."( Evaluation of the antihypertensive effect of a beta-blocker with the aid of daily blood pressure profiles.
Abetel, G; Genoud, G; Karly, M, 1986
)
0.47
" It is concluded that once-daily dosing with either amlodipine or atenolol significantly reduces blood pressures."( Multicenter placebo-controlled comparison of amlodipine and atenolol in mild to moderate hypertension.
Cocco, G; de Bruijn, B; Tyler, HM, 1988
)
0.75
" Its haemodynamic profile was compared with that of atenolol (cardioselective; no ISA) in a comparative dose-response study of 24 ischaemic patients with diminished cardiac reserve."( Comparative effects of atenolol and cicloprolol on cardiac performance in coronary heart disease.
Frais, MA; Reynolds, G; Sharma, SK; Silke, B; Taylor, SH; Verma, SP, 1989
)
0.84
" The patients were re-examined monthly and their treatment was modified if their BP was insufficiently controlled (DAP greater than 90 mmHg): first, the dosage of the drug was doubled, then another antihypertensive agent was added, which was either a diuretic (studies with C or A) or a beta-blocker (studies with D)."( [Perindopril: first-line treatment of arterial hypertension].
Desche, P; Zanchetti, A, 1989
)
0.28
" However, 2 h after dosing there was a significant prolongation during stress testing in the time to onset of both 1 mm ST depression on the ECG (by 28%) and to angina (by 37%) compared with atenolol alone, but no benefit was apparent by 12 h after dosing."( Slow release nifedipine plus atenolol in chronic stable angina pectoris.
Challenor, VF; George, CF; Renwick, AG; Waller, DG, 1989
)
0.76
" Atenolol, ICI 111,581 and propranolol were given at low, medium and high doses calculated to shift dose-response curves to exogenous agonists by factors of 10-30, 100-300 and 1000-3000, respectively."( Mechanisms underlying the antiarrhythmic properties of beta-adrenoceptor blockade against ischaemia-induced arrhythmias in acutely prepared rats.
Abraham, S; Beatch, GN; Paletta, MJ; Walker, MJ, 1989
)
1.19
" The dosage was increased every month up to 2 mg bopindolol and 200 mg atenolol."( Bopindolol and atenolol in patients with stable angina pectoris. Double-blind randomized comparative trial.
Hertzeanu, H; Kellermann, JJ; Loidl, AF; Shemesh, J, 1989
)
0.86
" These factors would be expected to provide a more consistent therapeutic response and more dependable dosage adjustment."( Steady-state fluctuation and variability of betaxolol and atenolol plasma levels.
Andersen, RL; Haack, DG; Kunka, RL; Wong, YY, 1989
)
0.52
" The dose-response effects of atenolol and acebutolol, two cardioselective compounds, the latter also possessing a degree of ISA, were therefore compared in a single-blind, dose-response, crossover study in patients within 18 h of suffering an uncomplicated acute myocardial infarction."( Cardioselective beta-blockade with atenolol and acebutolol following acute myocardial infarction: a multiple-dose haemodynamic comparison.
Ahuja, RC; Frais, MA; Nelson, GI; Silke, B; Taylor, SH; Verma, SP,
)
0.7
" Further studies are necessary to determine the optimal oral dose and dosing frequency of atenolol and to access the response of children to long-term treatment."( Pharmacokinetics and pharmacodynamics of atenolol in children.
Buck, ML; Gillette, PC; Krull, J; O'Neal, W; Trippel, D; Wiest, D, 1989
)
0.76
" Treatment was titrated to produce at least a 30% increase in treadmill exercise duration over placebo baseline and then maintained at that dosage for an additional 3 weeks."( Comparison of atenolol and nifedipine in chronic stable angina pectoris.
Kostis, JB; Narahara, KA; Shapiro, W; Thandroyen, F; Zohman, LR, 1989
)
0.64
"4 mg/kg by intraperitoneal injection Animals were dosed once every 2 hr for a total of five doses."( Nonlinear distribution of atenolol between plasma and cerebrospinal fluid.
Fagan, SC; Gengo, FM; Hopkins, LN; Schuster, DP; Wagner, D, 1989
)
0.58
" The doses for each drug were selected based on the results of dose-response curves."( Adrenergic effects on internal cardiac defibrillation threshold.
Jones, DL; Klein, GJ; Rattes, MF; Sharma, AD; Szabo, T, 1987
)
0.27
" After two weeks, the dosage was doubled (to 40 mg of enalapril and 100 mg of atenolol) in those patients with diastolic blood pressure higher than 95 mm Hg."( The neglected time factor and antihypertensive therapy. A pitfall in evaluating side effects in a cross-over study.
Baumgart, P; Edmonds, D; Greminger, P; Vetter, H; Vetter, W, 1988
)
0.5
" Twenty-four healthy young men were studied in three dosing groups (eight subjects per group) before and after 1 wk on placebo, atenolol (50 mg twice a day), or nadolol (40 mg twice a day)."( beta-2 Adrenergic blockade evaluated with epinephrine after placebo, atenolol, and nadolol.
Brammell, HL; Hiatt, WR; Horwitz, LD; Nies, AS; Stoll, S; Wolfel, EE; Zerbe, GO, 1985
)
0.71
" However, as dosage adjustment and close observation may be necessary to minimise side effects, the use of this combination should be limited to hospital practice."( Tolerability of combined treatment with verapamil and beta-blockers in angina resistant to monotherapy.
McGourty, JC; Silas, JH; Solomon, SA, 1985
)
0.27
" Dose-response curves were constructed for the changes in these parameters with increasing doses of isoproterenol."( Effects of betaxolol, propranolol, and atenolol on isoproterenol-induced beta-adrenoceptor responses.
Riddell, JG; Shanks, RG, 1985
)
0.54
"A double-blind randomized study was designed to investigate differences in the recovery of finger skin temperature after finger cooling during dosing with placebo or one of four beta-blockers: propranolol, atenolol, pindolol, and acebutolol."( The influence of intrinsic sympathomimetic activity and beta-1 receptor selectivity on the recovery of finger skin temperature after finger cooling in normotensive subjects.
de Boo, T; Lemmens, WA; Lenders, JW; Salemans, J; Thien, T; van't Laar, A, 1986
)
0.46
" Dose-response curves were constructed for the changes in heart rate, finger tremor, blood pressure and forearm blood flow produced by each infusion."( Effects of ICI 141,292 on exercise tachycardia and isoprenaline-induced beta-adrenoceptor responses in man.
Finch, MB; McNeill, AJ; O'Connor, PC; Pringle, TH; Riddell, JG; Shanks, RG, 1986
)
0.27
" If standard doses of some beta-blockers are used in poor metabolizers, these patients may be susceptible to concentration-related adverse reactions and they may also require lower and less frequent dosing for control of angina pectoris."( Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propranolol and atenolol.
Lennard, MS; Silas, JH; Tucker, GT; Woods, HF, 1986
)
0.49
" The dose-response relationship using individual maximal reduction of ET showed, on a molar basis, that bisoprolol is about 5, 7 and 10 times more effective than propranolol, atenolol and metoprolol, respectively."( Pharmacodynamic profile of bisoprolol, a new beta 1-selective adrenoceptor antagonist.
Bühring, KU; Leopold, G; Pabst, J; Simane, Z; Ungethüm, W; Wiemann, H, 1986
)
0.46
" Intrapericardial propranolol or atenolol (50 micrograms/kg) had the same effect on isoprenaline heart rate dose-response curves and on the sympathetic component of the arterial baroreceptor-heart rate reflex as did conventional, 5-fold greater, intravenous doses of the drugs."( Selective manipulation of neurohumoral control of the cardiac pacemaker by drugs given intrapericardially.
Lew, MJ; Ludbrook, J; Pavia, JM; Quail, AW; Rutter, PC, 1987
)
0.55
"Thirty-six patients with Raynaud's disease (RD) were treated with a low dosage of beta-blockers, atenolol (50 mg/day) or propranolol (20 mg/day)."( Beta-blockers: a new therapeutic approach to Raynaud's disease.
Brotzu, G; Palmina, P; Roberto, M; Susanna, F, 1987
)
0.49
" Recordings were obtained 2 and 24 h following a single dose and 24 h after continuous dosage for 7 days."( Peripheral vascular effects of beta-adrenoceptor blockade: comparison of two agents.
Bowcock, SA; Camm, AJ; Cooke, ED; Maltz, MB; Smith, RE; Watkins, CJ, 1987
)
0.27
" Patients were treated with propranolol 40 to 160 mg bid for 8 weeks, followed by atenolol 50 to 100 mg given once daily for 8 weeks, and then rechallenged with the required dosage of propranolol for 8 weeks."( A comparison of the side effects of atenolol and propranolol in the treatment of patients with hypertension.
Chockalingam, A; Drover, A; Fifield, F; Fodor, JG; Pauls, CJ, 1987
)
0.77
" Isoprenaline dose-response curves were constructed for cardiovascular parameters and finger tremor."( The assessment of the beta-adrenoceptor blocking activity and cardioselectivity of Koe 3290 in normal subjects.
McNeill, AJ; Pringle, TH; Riddell, JG; Shanks, RG, 1987
)
0.27
" After a placebo run-in period the patients received increasing dosages of medication every 2 weeks until the target diastolic blood pressure of 90 mm Hg or less was achieved on two consecutive visits, the maximum dosage was reached, or the patient withdrew because of adverse effects."( Comparison of monotherapy with enalapril and atenolol in mild to moderate hypertension. The Canadian Enalapril Study Group.
, 1987
)
0.53
" The results demonstrated a wide margin of safety for celiprolol over the recommended dosage range of 200 to 600 mg once daily."( Safety profile of celiprolol.
Lamon, KD, 1988
)
0.27
" In the first series of experiments cumulative dose-response curves for propranolol, atenolol and ICI 118,551, nonselective beta-, beta 1- and beta 2-selective antagonists, respectively, were constructed in rats subjected to a continuous intravenous infusion of phentolamine."( Pressor response to beta 1- and beta 2-blockers in conscious rats treated with phentolamine.
King, KA; Pang, CC; Tabrizchi, R, 1988
)
0.5
" Once blood pressure control was established, patients received maintenance therapy at that dosage and were followed for up to 12 months."( The long-term antihypertensive effects of prazosin and atenolol.
Itskovitz, HD; Khoury, S; Krug, K; Mollura, JL, 1989
)
0.52
" In controlled double-blind studies involving approximately 550 patients on doxazosin 1-16 mg once daily, significant reductions in both standing and supine BP were maintained throughout the 24 h dosing interval."( The antihypertensive effects of doxazosin: a clinical overview.
Cox, DA; Leader, JP; Milson, JA; Singleton, W, 1986
)
0.27
" All three dosage regimens were well tolerated."( A comparison of once daily bisoprolol, 5 and 10 mg, and atenolol 100 mg in the treatment of angina pectoris.
Camm, AJ; Dymond, DS; Maltz, MB; Nathan, AW, 1987
)
0.52
" The commonest adverse reaction with enalapril was dizziness which occurred in two cases and resolved on dosage reduction."( Enalapril maleate and atenolol combined with hydrochlorothiazide in moderate to severe essential hypertension.
Gray, D; Moon, R; Musgrove, J; Pascoe, J, 1985
)
0.58
" After hydrochlorothiazide was added to patients not achieving 'target' blood pressure, the fall in systolic pressure was significantly greater in the enalapril group than in the atenolol group, despite similar dosage of hydrochlorothiazide in the two groups."( Enalapril in moderate to severe hypertension: a comparison with atenolol.
Burgess, J; Cooper, WD; Davidson, C; Fairhurst, G; Petrie, JC; Richardson, PJ; Robb, OJ; Trafford, J; Vandenburg, MJ; Webster, J, 1986
)
0.7
" With bolus injections, atropine displaced the heart rate dose-response curve for atenolol to the right, implying reflex withdrawal of cardiac vagal tone, but did not alter the heart rate dose-response curve for propranolol."( Reflex vagal withdrawal and the hemodynamic response to intravenous isoproterenol in the presence of beta-antagonists.
Arnold, JM; McDevitt, DG, 1986
)
0.5
"Twenty-one patients with mild or moderate hypertension were randomised to receive either Atenolol 100 mg (N = 10) or Pindolol 15 mg (N = 11) in a once daily dosage over a two month period."( [Comparative effects of pindolol and atenolol on blood pressure and lipids in mild to moderate arterial hypertension].
Amiel, A; Boutaud, P; Ciber, MA; Demange, J; Guillard, O; Herpin, D; Piriou, A, 1988
)
0.77
" To investigate whether a shift in localization of the bronchodilator effect occurs when terbutaline is inhaled repeatedly, dose-response curves with terbutaline were performed for parameters derived from MEFV curves when breathing air and for density dependence of expiratory airflow."( Effects of terbutaline and atenolol on large and small airways in asthmatic patients.
Folgering, HT; Lammers, JW; Müller, ME; van Herwaarden, CL, 1988
)
0.57
" Renal clearance of atenolol was shown to be decreased by more than 25% in 2 subjects studied using intravenous dosing of atenolol."( Extent and pharmacokinetic mechanisms of oral atenolol-verapamil interaction in man.
Harper, RW; Harrison, PM; Keech, AC; McLean, AJ; Pitt, A, 1988
)
0.86
"The daily administration of 240 to 360 mg of diltiazem lowered blood pressure in a dose-related pattern similar to that seen in patients taking a daily dosage of 50 to 100 mg of atenolol."( Sustained-release diltiazem compared with atenolol monotherapy for mild to moderate systemic hypertension.
Giard, MJ; Josselson, J; Lam, YW; Posner, JN; Saunders, E; Warren, JB; Weir, MR; Zaske, DE, 1987
)
0.73
" The mean supine BP 24 hours post dosing were 177/110 mmHg (placebo), 173/109 mmHg (propranolol) and 164/100 mmHg (atenolol)."( Atenolol or propranolol in hypertensive patients poorly controlled on captopril and frusemide.
Lovell, HG; Petrie, JC; Robb, OJ; Webster, J; Witte, K, 1987
)
1.93
" Healthy young and elderly volunteers received 20 mg nifedipine (slow release) orally for 2 weeks with concomitant dosing of atenolol 50 mg orally during the second week."( The effect of ageing on the disposition of nifedipine and atenolol.
Adam, HK; Castleden, CM; Fitzsimons, TJ; Scott, M; Smith, RP, 1988
)
0.73
"The hemodynamic dose-response effects of intravenous (0."( Circulatory effects of intravenous and oral atenolol in acute myocardial infarction.
Hafizullah, M; Midtbø, K; Reynolds, GW; Silke, B; Taylor, SH; Verma, SP, 1988
)
0.54
" In NL-AMI, pretreatment of cats with D at the same dosage (intravenous infusion) reduced AMI-ST segment increases and AMI changes in hemodynamics."( Cardioprotective effects of defibrotide in acute lethal and nonlethal myocardial ischemia in the cat.
Berti, F; Mantovani, M; Niada, R; Pescador, R; Porta, R; Prino, G, 1986
)
0.27
"Nine patients who had been treated for hypertension for many years with atenolol in a dose of 100 mg/day took part in this 18-month study, during which the dosage alternated between 50 and 100 mg/day for two-month periods."( A comparison of the hypotensive and metabolic effects of 50 and 100 mg atenolol per day.
Aberg, H; Lithell, H; Selinus, I, 1986
)
0.74
" Dosage was a single tablet per day given in the morning."( Atenolol and chlorthalidone in combination in the management of older hypertensive patients: a randomized clinical trial.
Backhouse, CI; Edwards, KG; Hosie, J; Tweed, JA, 1985
)
1.71
" Blood pressure and heart rate were measured 22 hours after the last tablet of a 2-week dosing period."( Comparison of the duration of antihypertensive action of atenolol and metoprolol over a 24-hour period.
Crowe, PF; Ferguson, RJ, 1985
)
0.51
" A dose-response curve was then plotted after inhalation of the beta 2-adrenoceptor agonist terbutaline."( Ventilatory effects of atenolol and bevantolol in asthma.
Folgering, HT; Lammers, JW; van Herwaarden, CL, 1985
)
0.58
" Quinidine inhibited T3 formation, with a dose-response curve which was similar over the concentrations studied to that of DL-propranolol."( Inhibition by propranolol of 3,5,3'-triiodothyronine formation from thyroxine in isolated rat renal tubules: an effect independent of beta-adrenergic blockade.
Campbell, DG; Heyma, P; Larkins, RG, 1980
)
0.26
" Thus, for determination of administration frequency and dosage of beta-adrenoceptor blocking drugs, not only pharmacokinetic but also pharmacological data (duration of action) are essential."( Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs.
Himori, N; Honma, S; Ishimori, T; Izumi, A, 1981
)
0.26
" Thus shifts of the dose-response curves in BP and HR were observed."( A simple method to determine the ratio of cardiac to vascular beta-receptor blockade in the rat in vivo.
Kudo, Y; Sokabe, H; Zehr, JE, 1981
)
0.26
" Thus, it was of interest to study the dose-response relationship between an unselective (propranolol) and a beta 1-selective (atenolol) blocker and endurance exercise performance."( Running performance as a function of the dose-response relationship to beta-adrenoceptor blockade.
Kaiser, P, 1982
)
0.47
" Using three beta-adrenoceptor agonists: terbutaline (beta 2), dobutamine (beta 1), and isoprenaline and monitoring atenolol's antagonism of the agonist effects on heart rate, airway elastance and soleus muscle tension, parallel shifts in dose-response curves for each agonist were observed on each parameter."( The determination of beta-adrenoceptor antagonist cardioselectivity "in vivo": atenolol in anaesthetized cats.
Kiyingi, KS; Temple, DM, 1983
)
0.7
" These differences account for many of the observed variations in drug action and dosage scheduling as well as for some of the side effects."( Beta-adrenergic blockers. Choosing among them.
McGoon, MD; Vlietstra, RE, 1984
)
0.27
" The dose-response curves constructed with intra-arterial or intravenous isoprenaline behave similarly in the presence of both atenolol 50 mg and propranolol 40 mg."( Enhancement of physiological finger tremor by intravenous isoprenaline infusions in man: evaluation of its role in the assessment of beta-adrenoceptor antagonists.
Arnold, JM; McDevitt, DG, 1984
)
0.47
" Twenty-four-hour ambulatory ECG recordings showed a decrease in mean hourly heart rate throughout the dosing period, with preservation of diurnal variation."( Atenolol: once-daily cardioselective beta blockade for angina pectoris.
Harrison, DC; Jackson, G; Kates, RE; Schwartz, J; Winchester, M, 1980
)
1.7
" 2 Salbutamol airway dose-response curves were obtained by measuring the airway response as the change in specific airway conductance (sGaw) after increasing doses of inhaled salbutamol."( Bronchial and cardiac beta-adrenoceptor blockade--a comparison of atenolol, acebutolol and labetalol.
Baldwin, CJ; Gribbin, HR; Mackay, AD; Tattersfield, AE, 1981
)
0.5
" Full dose-response curves for isoproterenol were constructed in BP and HR."( The ratio of cardiac to vascular beta-receptor blockade of atenolol and propranolol in spontaneously hypertensive rats in vivo.
Kudo, Y; Sokabe, H, 1982
)
0.51
" Neither timolol (a nonselective beta-antagonist) nor atenolol (a beta 1-selective antagonist) had a significant effect on basal secretory rate, but both shifted the isoproterenol dose-response curve to the right without changing its slope, suggesting competitive antagonism."( Evidence that beta 1-adrenoceptor activation mediates isoproterenol-stimulated renin secretion in the rat.
Churchill, MC; Churchill, PC; McDonald, FD, 1983
)
0.51
"The relationship between the oral dosage and plasma concentration of the long-acting cardioselective beta-adrenoceptor blocker atenolol and the antihypertensive response to the the degree of beta-adrenoceptor blockade and change in plasma renin activity (PRA) was evaluated in patients with mild-to-moderate essential hypertension in a double-blind, randomized, between-patient, dose-ranging (25, 50 or 100 mg once daily for 4 weeks) study."( A dose ranging study of atenolol in hypertension: fall in blood pressure and plasma renin activity, beta-blockade and steady-state pharmacokinetics.
Ishizaki, T; Nakaya, H; Oyama, Y; Sasaki, T; Sato, T; Shibuya, T; Suganuma, T, 1983
)
0.78
" It is therefore concluded that the relationship between the serum chlorthalidone level and the fall in serum potassium level is in keeping with the flat dose-response curves for the thiazide and phthalimide diuretics."( The effects of two combinations of a beta-blocker and a diuretic on diuresis in normal subjects.
Schoeman, HS; Sommers, DK; van Wyk, M, 1984
)
0.27
"The effects of once daily dosage of the two cardioselective beta-adrenoceptor blocking agents, atenolol and metoprolol, were studied in 26 patients with primary hypertension."( A comparison of 100 mg atenolol and 100 mg metoprolol once a day at rest and during exercise in hypertensives.
Atterhög, JH; Castenfors, J; Jorfelt, L; Karlberg, BE; Nilsson, OR; Ohman, KP; Thulin, T; Tolagen, K; Wettre, S, 1984
)
0.8
" Thus at the dosage used felodipine was a potent dilator of systemic arterioles but had no direct effect on left ventricular function."( Acute haemodynamic effects of felodipine during beta blockade in patients with coronary artery disease.
Culling, W; Ruttley, MS; Sheridan, DJ, 1984
)
0.27
" Indobufen was first given as a single 200 mg dose and then for a 5 day period in a dosage of 200 mg twice daily, to six healthy volunteers."( Indobufen interacts with the sulphonylurea, glipizide, but not with the beta-adrenergic receptor antagonists, propranolol and atenolol.
Elvander-Ståhl, E; Melander, A; Wåhlin-Boll, E, 1984
)
0.47
"The pharmacokinetics of the cardioselective beta-adrenoreceptor blocking agent atenolol have been determined following intravenous and oral dosing to the dog."( Pharmacokinetic studies with atenolol in the dog.
Holmes, BF; McAinsh, J,
)
0.65
" Mean reduction in exercise tachycardia at 24 hours after dosing was significantly greater with atenolol and metoprolol SA than with metoprolol SR and conventional metoprolol."( Duration of beta-blockade with metoprolol and atenolol: influence of drug oxidation.
Freestone, S; Lennard, MS; Ramsay, LE; Silas, JH, 1983
)
0.74
" The average daily dosage was 144."( Hypertension in pregnancy: evaluation of two beta blockers atenolol and labetalol.
Blazquez, G; Chouty, F; Flouvat, B; Gerard, J; Lardoux, H, 1983
)
0.51
" Co-administration of metoprolol, but not atenolol, increased mean plasma phenprocoumon concentrations 4 and 6 h after dosing and was caused by a decrease in the apparent volume of distribution."( Pharmacokinetic and pharmacodynamic interactions between phenprocoumon and atenolol or metoprolol.
Kirch, W; Kitteringham, NR; Lögering, HJ; Mutschler, E; Ohnhaus, EE; Paar, D; Spahn, H, 1984
)
0.76
" Prolongation of elimination half life requires a dosage adjustment of atenolol in patients with renal failure."( Clinical pharmacokinetics of atenolol--a review.
Görg, KG; Kirch, W, 1982
)
0.79
" Both atenolol and metoprolol lowered resting heart rate and FEV1 significantly and produced a down- and rightward shift of the dose-response curves to infused terbutaline."( Cardioselectivity of atenolol and metoprolol. A study in asthmatic patients.
Löfdahl, CG; Svedmyr, N, 1981
)
1.06
"The effect of once-daily dosage of the two most widely prescribed cardioselective beta-adrenoceptor antagonists used to treat hypertension--namely, atenolol and metoprolol--was studied in nine carefully selected hypertensive outpatients."( Atenolol and metoprolol once daily in hypertension.
Hawksworth, GM; Lovell, HG; Petrie, JC; Rigby, JW; Scott, AK; Webster, J, 1982
)
1.91
" The dosage of each drug was adjusted at monthly clinic visits until satisfactory control of blood pressure was achieved (140/90 mm Hg or less by cuff) or the maximum dose in the study protocol was reached."( Ambulatory blood pressure during once-daily randomised double-blind administration of atenolol, metoprolol, pindolol, and slow-release propranolol.
Floras, JS; Hassan, MO; Jones, JV; Sleight, P, 1982
)
0.49
" A certain dosage of Atenolol could be defined, that does not increase labor activity under Fenoterol medication but does decrease cardiac frequency without influence on mean blood pressure."( [Tokolysis and dose-dependent effects of beta-blocking with atenolol in the rabbit].
Behr, J; Czekelius, P; Steib, L,
)
0.69
" The high incidence of side-effects was probably due to the high dosage used."( Evaluation of the antiarrhythmic efficacy of mexiletine in patients with chronic ventricular arrhythmias.
Van Durme, JP, 1980
)
0.26
" Patients who responded (diastolic BP less than 95 mmHg) continued on the initial dosage regimen."( Metoprolol and atenolol administered once daily in primary hypertension. A clinical comparison of the efficacy of two selective beta-adrenoceptor blocking agents.
Lyngstam, O; Rydén, L, 1981
)
0.62
" 4 In comparison to conventional metoprolol only metoprolol SA was associated with significantly higher plasma metoprolol concentrations at the end of a dosing interval (mean values: conventional, 25 ng/ml, SR 37 ng/ml, SA 51 ng/ml)."( Comparison of two long-acting preparations of metoprolol with conventional metoprolol and atenolol in healthy men during chronic dosing.
Freestone, S; Lennard, MS; Ramsay, LE; Silas, JH, 1982
)
0.49
" These findings show that atenolol at the 100-mg daily dose is as effective as the full dosage of methyldopa and in addition shows better tolerance, a simpler therapeutic scheme, and less incidence of side effects."( Comparison of antihypertensive activity of atenolol and methyldopa at rest and during exercise.
Ambrosioni, E; Costa, FV; Magelli, C; Magnani, B; Malini, PL, 1981
)
0.83
" 3 No significant differences in the pharmacokinetic profile of atenolol were evident between the values obtained following chronic dosing and an acute single-dose study."( Withdrawal of long-term therapy with atenolol in hypertensive patients.
Barber, HE; Hawksworth, GM; Jeffers, TA; Petrie, JC; Webster, J, 1981
)
0.77
" 6 These results suggest that dosage should be modified for these patients."( Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysis.
Aubert, P; Baglin, A; Decourt, S; Domart, M; Flouvat, B; Goupil, A; Potaux, L, 1980
)
0.58
" Dosing recommendations are suggested for patients with renal failure to take account of the effects of renal function on atenolol kinetics."( Atenolol kinetics in renal failure.
Holmes, BF; Hood, D; McAinsh, J; Smith, S; Warren, D, 1980
)
1.91
" In some test systems, replication of dose-response curves is not possible."( Use of resampling techniques to estimate the variance of parameters in pharmacological assays when experimental protocols preclude independent replication: an example using Schild regressions.
Corsi, M; Kenakin, TP; Krishnamoorthy, C; Lutz, MW; Menius, JA; Morgan, PH; Rimele, T, 1995
)
0.29
"Although the combined administration of atenolol and nifedipine has been shown to be effective in the treatment of angina pectoris the optimum dosage level of the combination has not yet been established."( A cross-over study comparing the efficacy of a combination of atenolol and nifedipine at different doses in angina pectoris.
Jennings, K; Metcalfe, MJ, 1995
)
0.8
" Six to 8 atenolol serum concentrations were collected in each patient during a 12-hour dosing interval and were determined by high-performance liquid chromatography with ultraviolet detection."( Absorption pharmacokinetics of atenolol in patients with the Marfan syndrome.
Alpert, BS; Lima, JJ; Phelps, SJ; Pieper, JA; Ward, JL, 1995
)
0.98
" Subjects (diastolic blood pressure > or = 100 and < or = 120 mm Hg) were randomly assigned to treatment for 12 months with either perindopril (n = 13, 4 to 8 mg/d) or atenolol (n = 12, 50 to 100 mg/d); the dosage was adjusted upward and in some cases combined (n = 5, perindopril; n = 2, atenolol) with thiazide diuretic to achieve target blood pressure (diastolic blood pressure below 90 mm Hg)."( Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension.
Aalkjaer, C; Cooper, A; Heagerty, AM; Mulvany, MJ; Stephens, N; Thybo, NK, 1995
)
0.49
" DSC and TGA were used to analyse finished dosage forms and their components."( The combined use of DSC and TGA for the thermal analysis of atenolol tablets.
Pyramides, G; Robinson, JW; Zito, SW, 1995
)
0.53
" Heart rate (EHR) after 5 min of exercise by bicycle ergometry (constant 75W), and parameters of renal function were assessed before (baseline) and during concomitant dosing of atenolol and tenoxicam."( Study on the possible interaction between tenoxicam and atenolol in hypertensive patients.
Güzelhan, C; Hartmann, D; Horsch, AK; Lingenfelder, M; Stief, G, 1995
)
0.73
" Our data show that markedly, but not completely attenuated nocturnal melatonin levels are sufficient to exert maximal thermoregulatory effects, indicating rather a threshold than a dose-response effect of melatonin action on human BT."( Melatonin-induced decrease of body temperature in women: a threshold event.
Cagnacci, A; Romagnolo, C; Soldani, R; Yen, SS, 1994
)
0.29
" The variability in plasma concentrations over the dosing interval was found to be markedly less with the felodipine-metoprolol combination than with the combination of nifedipine and atenolol."( Aiming for steady 24-hour plasma concentrations: a comparison of two calcium antagonist and beta-blocker combinations.
Bergstrand, R; Eriksson, M; Lidman, K; Nyberg, G; Olofsson, B, 1993
)
0.48
" After 4 weeks, the dosage was doubled if there was inadequate response."( Comparison of a new vasodilating beta-blocker, carvedilol, with atenolol in the treatment of mild to moderate essential hypertension.
Ruilope, LM, 1994
)
0.53
"This study investigated the effects of an osmotic release oral drug delivery system of metoprolol on the changes induced by cumulative doses of inhaled salbutamol on bronchomotor tone, skeletal muscle, and the circulatory system after single (day 1) and multiple (day 7) dosing in 18 hypertensive asthmatic patients (forced expiratory volume in 1 second > 50% predicted; diastolic blood pressure > 90 mm Hg)."( Osmotic release oral drug delivery system of metoprolol in hypertensive asthmatic patients. Pharmacodynamic effects on beta 2-adrenergic receptors.
Bauer, K; Kaik, B; Kaik, G, 1994
)
0.29
" After a 4-week placebo run-in period, each beta 1-adrenoceptor blocker was administered at a dosage of 100 mg once daily for 6 weeks."( Effects of 100 mg of controlled-release metoprolol and 100 mg of atenolol on blood pressure, central nervous system-related symptoms, and general well being.
Albrektsen, T; Dimenäs, E; Olofsson, B; Walle, PO; Westergren, G, 1994
)
0.53
" After 3 months the drug dosage was doubled if the systolic blood pressure goal (SBP < 160 mmHg and SBP reduction of at least 20 mmHg) had not been reached."( Antihypertensive efficacy and tolerability of different drug regimens in isolated systolic hypertension in the elderly.
Alli, C; Avanzini, F; Bettelli, G; Colombo, F; Corso, R; Mariotti, G; Radice, M; Tognoni, G; Torri, V, 1994
)
0.29
" Nifedipine coat-core, when combined with ATN in patients not controlled by ATN alone, had significant antihypertensive activity for the entire 24-hour dosing interval and was well tolerated by the majority of patients in the study."( The safety and efficacy of once-daily nifedipine coat-core in combination with atenolol in hypertensive patients. Adalat CC Cooperative Study Group.
Feig, PU; Gibson, L; Mac Carthy, EP; Pettis, PP; Schwartz, L,
)
0.36
" If the DBP did not reach 90 mmHg after four weeks, the dosage was doubled."( Randomised double-blind comparative study of efficacy and safety of hydroflumethiazide and reserpine and chlortalidone and atenolol in the treatment of mild to moderate hypertension in black patients.
Maharaj, B; van der Byl, K, 1993
)
0.49
" During maintenance, patients not at goal were "stepped up," and patients with uncontrolled DBP at maximum dosage were removed from the study."( Efficacy and safety of atenolol, enalapril, and isradipine in elderly hypertensive women.
Bartels, DW; Benz, JR; Due, DL; Hall, WD; Kostis, JB; Peng, A; Perry, HM; Sirgo, M; Townsend, RR, 1994
)
0.6
" Symptom frequency differed little among the three dosage levels, becoming maximal by the second visit at the same dosage level."( Efficacy and safety of atenolol, enalapril, and isradipine in elderly hypertensive women.
Bartels, DW; Benz, JR; Due, DL; Hall, WD; Kostis, JB; Peng, A; Perry, HM; Sirgo, M; Townsend, RR, 1994
)
0.6
" In the three areas of efficacy that the study compared-24-hour post dose blood pressure, control of blood pressure over the dosing period with particular reference to the waking day and attenuation of systolic blood pressure on exercise-atenolol and the fixed combination demonstrated greater efficacy than enalapril."( A double-blind crossover trial of atenolol, enalapril and the fixed combination of atenolol and nifedipine in mild and moderate hypertension.
Brennand-Roper, D; Chapman, CM; Flora, HK; Gupta, S; Jackson, G; Jackson, PG; Manivannan, A; Taylor, DJ; Thirkettle, JL; Vella, R,
)
0.59
"Previous studies have shown that the absorption rate of a lipophilic, but not hydrophilic, agent is faster after the night dosage than after the morning dosage in nocturnal rodents."( Differences of chronopharmacokinetic profiles between propranolol and atenolol in hypertensive subjects.
Ebihara, A; Fujimura, A; Ohashi, K; Shiga, T; Tateishi, T, 1993
)
0.52
" Office BPs were recorded at the end of the 24-hour dosing interval (trough)."( Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agents.
Fagan, TC; Kaplan, NM; Kazempour, MK; Lefkowitz, MP; Neutel, JM; Papademetriou, V; Ram, CV; Smith, DH; Weber, MA, 1993
)
0.29
"01) BPs were also noted for bisoprolol compared with atenolol during the final 4 hours of the dosing interval (-13."( Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agents.
Fagan, TC; Kaplan, NM; Kazempour, MK; Lefkowitz, MP; Neutel, JM; Papademetriou, V; Ram, CV; Smith, DH; Weber, MA, 1993
)
0.54
" A total of 179 patients with a pretreatment mean baseline BP of 172 +/- 17/112 +/- 18 mm Hg enrolled in the trial and BP was recorded 24 h after dosing at baseline and weeks 2, 4, 8 and the final week (10-12 weeks)."( Losartan potassium as initial therapy in patients with severe hypertension.
Chrysant, S; Dunlay, MC; Fitzpatrick, V; Francischetti, EA; Goldberg, AI; Sweet, CS, 1995
)
0.29
" The author assumes that in addition to the effectiveness of the administered drug the marked improvement of the patients is due to better collaboration of the patients and adherence to the prescribed dosage and lifestyle."( [Corotenol, its effectiveness and tolerance in light of new studies].
Uhlír, O, 1996
)
0.29
"The development of a capillary zone electrophoresis method for determination of the drug atenolol in the presence of its related substances in bulk and in a tablet dosage form is described."( Development and validation of a capillary zone electrophoretic method for the determination of atenolol in presence of its related substances in bulk and tablet dosage form.
Clark, BJ; Shafaati, A, 1996
)
0.73
" This dosage schedule for beta-blockade was chosen because catecholamines are persistently elevated by day 14 in this model of CHF."( Direct effects of chronic beta-adrenergic receptor blockade on left ventricular and myocyte function in a model of tachycardia-induced congestive heart failure.
Hebbar, L; Johnson, WS; Jones, BU; Mukherjee, R; Spinale, FG; Wang, Y; Wang, Z, 1996
)
0.29
"The gastrointestinal therapeutic system formulation of nifedipine enables a once-daily dosing resulting in predictable, relatively constant plasma concentrations."( Nifedipine gastrointestinal therapeutic system versus atenolol in stable angina pectoris. The Netherlands Working Group on Cardiovascular Research (WCN).
Bernink, PJ; Claessens, RJ; de Vries, RJ; Dunselman, PH; Kingma, JH; Lok, DJ; Pasteuning, WH; van den Heuvel, AF, 1996
)
0.54
"The aims of the present study were to determine (1) the beta 1-blocking potency and (2) the beta 1-adrenoceptor selectivity of nebivolol in man after repeated dosing (7 days) compared with that after a single oral intake and with that after atenolol for 7 days."( Pharmacological properties of nebivolol in man.
de Hoon, JN; Kool, MJ; Van Bortel, LM; Van Nueten, LG; Vertommen, CI; Wijnen, JA, 1997
)
0.48
" alpha 1-Blockade of nebivolol was measured using the phenylephrine dose-response test."( Pharmacological properties of nebivolol in man.
de Hoon, JN; Kool, MJ; Van Bortel, LM; Van Nueten, LG; Vertommen, CI; Wijnen, JA, 1997
)
0.3
"beta 1-Blockade of nebivolol 5 mg is larger after repeated dosing than after a single oral intake."( Pharmacological properties of nebivolol in man.
de Hoon, JN; Kool, MJ; Van Bortel, LM; Van Nueten, LG; Vertommen, CI; Wijnen, JA, 1997
)
0.3
" A similar rightward shift of the dose-response curve was observed for the effects of adenosine on developed left ventricular pressure (LVP) and of carbachol (0."( Beta-blockade reduces effects of adenosine and carbachol by transregulation of inhibitory receptors and Gi proteins.
Borst, MM; Kübler, W; Marquetant, R; Strasser, RH, 1997
)
0.3
" Each patient was prescribed 5 mg of felodipine ER or 50 mg of atenolol once daily and this daily dosage was doubled to twice daily if necessary."( Comparison of clinical efficacy and adverse effects between extended-release felodipine and atenolol in patients with mild and moderate essential hypertension.
Chern, MS; Lin, FC; Wu, D, 1997
)
0.76
"1% of the patients had responded to a total daily dosage of 5-10 mg of felodipine ER and 81."( Comparison of clinical efficacy and adverse effects between extended-release felodipine and atenolol in patients with mild and moderate essential hypertension.
Chern, MS; Lin, FC; Wu, D, 1997
)
0.52
" Dose-response effects on HR with celiprolol were evident in the presence of atenolol, unlike those with propranolol that abolished the HR increase between celiprolol, 200 mg and 800 mg."( Effects of beta-adrenoceptor agonists and antagonists on heart-rate variability in normal subjects assessed using summary statistics and nonlinear procedures.
Guy, S; Riddell, JG; Silke, B, 1997
)
0.53
"Anginal patients who remain symptomatic despite optimally dosed beta blockade may also be given dihydropyridine calcium antagonists."( Value of the addition of amlodipine to atenolol in patients with angina pectoris despite adequate beta blockade.
Bernink, PJ; Bouwens, LH; Dunselman, PH; Herweijer, AH; Holwerda, KJ; van Kempen, LH, 1998
)
0.57
" Measures of dosing interval--used-on-schedule rate and therapeutic coverage--averaged between 44% and 71%."( Noncompliance may render migraine prophylaxis useless, but once-daily regimens are better.
Mulleners, WM; Steiner, TJ; Whitmarsh, TE, 1998
)
0.3
"The purpose of this study was to evaluate the possible advantages of floating and high-density dosage forms and their influence on pharmacokinetic parameters."( Comparative pharmacokinetic study of a floating multiple-unit capsule, a high-density multiple-unit capsule and an immediate-release tablet containing 25 mg atenolol.
Allémann, E; Balant, L; Buri, P; Cole, ET; Doelker, E; Gex-Fabry, M; Rouge, N, 1998
)
0.5
" Observations on these variables were made 3 and 24 hours after dosing on the first and last days of therapy."( Nebivolol: comparison of the effects of dl-nebivolol, d-nebivolol, l-nebivolol, atenolol, and placebo on exercise-induced increases in heart rate and systolic blood pressure.
De Crée, J; Van Nueten, L, 1998
)
0.53
"This multicenter, randomized, double-blind, parallel group, placebo lead-in, placebo-controlled study compared the antianginal and anti-ischemic effects of once-daily bedtime dosing of controlled-onset extended-release (COER-24) verapamil to a once-daily morning dosing of amlodipine +/- atenolol in patients with chronic stable angina."( Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris.
Deedwania, PC; Fakouhi, TD; Frishman, WH; Glasser, S; Johnson, M; Stone, P, 1999
)
0.7
" For drugs with a narrow therapeutic window, indirect estimates of GFR appear to be an unreliable means for calculating correct dosage in the elderly."( Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged.
Bischoff, I; Block, S; Fliser, D; Hanses, A; Joest, M; Mutschler, E; Ritz, E, 1999
)
0.3
" through formulation of the chitosan into a particulate dosage form."( Chitosans as absorption enhancers of poorly absorbable drugs. 3: Influence of mucus on absorption enhancement.
Artursson, P; Lennernäs, H; Ocklind, G; Schipper, NG; Stenberg, P; Vârum, KM, 1999
)
0.3
"Nifedipine gastrointestinal therapeutic system (GITS) is a once-daily formulation of nifedipine that provides stable plasma concentrations over the entire 24 h dosing interval."( Effectiveness of nifedipine GITS in combination with atenolol in chronic stable angina.
Baird, MG; Bélanger, L; Erne, P; Klinke, P; Kostuk, WJ; Lotan, C; Marmor, A; Motro, M; Palant, A; Sclarowski, S; Stolero, D; Toal, CB; Turpie, A; Weiss, A; Zilberman, A, 1999
)
0.55
"01 M)-acetonitrile 96:4) was found to be suitable for the stability indicating determination of Atenolol in pharmaceutical dosage forms."( Photodegradation studies on Atenolol by liquid chromatography.
Andrisano, V; Cavrini, V; Gotti, R; Leoni, A, 1999
)
0.82
" Subsequent experiments under prazosin treatment established the apoptosis dose-response curves for the increasingly beta(2)-selective AR agonists isoproterenol (ISO) (beta(1) approximately beta(2)) and albuterol (ALB) (beta(2)>beta(1))."( Beta-adrenergic receptor subtypes differentially affect apoptosis in adult rat ventricular myocytes.
Jamali, NZ; Lucchinetti, E; Shafiq, SA; Siddiqui, MA; Xu, W; Zaugg, M, 2000
)
0.31
" According to EU guidelines, the bioequivalence of one dosage strength can also cover additional strengths when the pharmacokinetics of a given drug is linearly related with the dose."( Comparative bioavailability of two formulations containing atenolol and chlortalidone associated in a 4:1 fixed combination.
Crivelli, F; Dal Bo, L; Ismaili, S; Marzo, A; Mazzucchelli, P; Monti, NC; Porziotta, E; Ronchi, C; Tettamanti, RA; Uhr, MR, 2000
)
0.55
" Measurements were made in two ways, firstly, by pre-incubating the atria with a given concentration of atenolol followed by an isoprenaline dose-response curve and, secondly, by measuring the response to isoprenaline followed by addition of atenolol."( The relative importance of the time-course of receptor occupancy and response decay on apparent antagonist potency in dynamic assays.
Corsi, M; Kenakin, T, 2000
)
0.52
"Patients from 14 centers were randomized to receive either a DDD pacemaker provided with rate-drop response function or the beta-blocker atenolol at the dosage of 100 mg once a day."( Permanent cardiac pacing versus medical treatment for the prevention of recurrent vasovagal syncope: a multicenter, randomized, controlled trial.
Ammirati, F; Colivicchi, F; Santini, M, 2001
)
0.51
", dosing rate or enantiomer-enantiomer interaction) or the patient (e."( Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans.
Brocks, DR; Mehvar, R,
)
0.13
"A simple kinetic procedure is described for the determination of atenolol in its dosage forms."( Kinetic spectrophotometric determination of atenolol in dosage forms.
Al-Ghannam, SM; Belal, F,
)
0.63
"The optimal medical therapy for ischemia suppression and the impact of irregular dosing using agents with different pharmacologic properties has not been established in patients with coronary disease."( Medical treatment of myocardial ischemia in coronary artery disease: effect of drug regime and irregular dosing in the CAPE II trial.
Beckerman, B; Brennan, C; Bultas, J; Deanfield, JE; Detry, JM; Lichtlen, PR; Sellier, P; Thaulow, E; Young, ST, 2002
)
0.31
" Atenolol was either dosed separately or incorporated into one of the capsules."( The effect of ileal brake activators on the oral bioavailability of atenolol in man.
Chauhan, S; Davis, SS; Dobson, CL; Sparrow, RA; Wilding, IR, 2002
)
1.46
" Data indicate that once-a-day dosing can be performed with less fluctuation between peak and trough for talinolol in comparison to atenolol."( Comparison of talinolol and atenolol effects on blood pressure in relation to lipid and glucose metabolic parameters. Results from the TALIP study.
Derendorf, H; Schmidt, J; Sourgens, H, 2003
)
0.82
" At doses with equivalent effects on heart rate (2 microg kg(-1) nisoldipine; 10 microg kg(-1) nifedipine) acute dosing with nisoldipine caused a significantly greater fall in systemic vascular resistance and increase in cardiac index, whilst nifedipine caused a greater reduction in stroke volume index and left ventricular stroke work index."( A comparison of the acute haemodynamic effects of nisoldipine and nifedipine during treatment with atenolol in patients with coronary artery disease.
Dawkins, KD; Donaldson, KM; Waller, DG, 1993
)
0.5
" The dosage of beta-blockers should be modified in patients with an abnormal lipid profile in serum."( [Pharmacokinetic comparison of propranolol and atenolol in people with primary hypertension].
Telatyńska-Smieszek, B, 2002
)
0.57
" Treadmill exercise 12 hours (trough) and 4 hours (peak) after dosing was assessed after 2, 6 (trough only), and 12 weeks of treatment."( Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.
Chaitman, BR; Chumakova, G; Kuch, J; Parker, JO; Pepine, CJ; Skettino, SL; Skopal, J; Wang, W; Wolff, AA, 2004
)
0.62
" Moreover, the BP control effect was smooth and consistent throughout the 24-h dosing interval and BP reduction variability was lower than the one induced by atenolol."( Twenty-four-hour ambulatory blood pressure monitoring efficacy of perindopril/indapamide first-line combination in hypertensive patients: the REASON study.
Asmar, R; Battegay, E; Chamontin, B; De Leeuw, PW; Duprez, D; Hitzenberger, G; Mallion, JM; O'Brien, E; O'Rourke, MF; Rahn, KH; Romero, R; Safar, ME, 2004
)
0.52
" In the light of the results obtained, the following conclusions were drawn: 1) hyperlipidemia affects pharmacodynamic properties of lipophilic propranolol and hydrophilic atenolol, 2) a modification of the drug dosage in hyperlipidemia is warranted."( [Effect of hyperlipidemia on pharmacodynamics of propranolol and atenolol].
Droździk, M; Gawrońska-Szklarz, B; Sterna, R; Sulzyc-Bielicka, V; Telatyńska-Smieszek, B; Wójcicki, J, 2004
)
0.76
" Atenolol was given to the patient group at a dosage of 50 mg/day for 3 months and evaluations were repeated."( Effects of TSH-suppressive therapy on cardiac morphology and function: beneficial effects of the addition of beta-blockade on diastolic dysfunction.
Altuntas, F; Dincer, I; Erol, C; Gullu, S; Kamel, N, 2004
)
1.23
" The components in each mixture have been simultaneously determined in three commercial dosage forms with high accuracy and without interference from commonly encountered excipients and additives."( Determination of antihypertensive mixtures by use of a chemometrics-assisted spectrophotometric method.
Mohamed, Ael-M; Salem, H, 2005
)
0.33
" The pharmaceutical preparations used included atenolol 100 mg tablets, enalapril 20 mg tablets and acetylsalicylic acid (ASS) tablets of different dosage units."( Quality control of tablets by Near Infrared (NIR)-Spectroscopy.
Karas, M; Kaunzinger, A; Niemöller, A; Petri, J, 2005
)
0.59
"Tablets are the most common dosage form."( Comparative study of different formulations of atenolol.
Khalid, H; Shoaib, MH; Yasmeen, R, 2005
)
0.59
" Section headings with the least conformity with study references were those related to dosage (57 +/- 28%) and side effects (54 +/- 30%)."( Assessment of prescribing information for generic drugs manufactured in the Middle East and marketed in Saudi Arabia.
Al Haidari, K; Gebran, N,
)
0.13
"5 mg; n=22), captopril (50 mg twice daily; n=22) or a capsule containing each of the 4 above at one-quarter dosage (n=22) in a parallel group design for 4 weeks."( Low-dose quadruple antihypertensive combination: more efficacious than individual agents--a preliminary report.
Feely, J; Mahmud, A, 2007
)
0.34
"0 nmol) administered concurrently into the BLA potentiated the dose-response effects of OFQ/N."( Orphanin FQ/nociceptin interacts with the basolateral amygdala noradrenergic system in memory consolidation.
Civelli, O; Lengvilas, R; McGaugh, JL; Reinscheid, RK; Roozendaal, B,
)
0.13
"5 mg/day, with the dosage titrated to 25 mg/day if tolerated."( Association of beta-blocker dose with serum procollagen concentrations and cardiac response to spironolactone in patients with heart failure.
Camp, JR; Cavallari, LH; Groo, VL; Momary, KM; Stamos, TD; Viana, MA, 2007
)
0.34
" The proposed method was successfully applied to the pharmaceutical dosage forms containing the above-mentioned drug combination without any interference by the excipients."( Simultaneous high-performance liquid chromatographic determination of atenolol and amlodipine in pharmaceutical-dosage form.
Ahmed, M; Barman, RK; Hossain, MB; Ibne Wahed, MI; Islam, MA; Islam, R; Khan, A; Rahman, BM, 2007
)
0.57
" Atenolol is unstable in solutions and therefore the development of a liquid dosage form is a significant challenge."( Development, validation and stability study of pediatric atenolol syrup.
Foppa, T; Murakami, FS; Silva, MA, 2007
)
1.5
"The purpose of the study was to evaluate the pharmacokinetic effects obtained by gastroretentive dosage form (GRDF) for drugs absorbed by passive paracellular diffusion (atenolol, acyclovir) or active transport (valacyclovir)."( Selection of drug candidates for gastroretentive dosage forms: pharmacokinetics following continuous intragastric mode of administration in a rat model.
Hoffman, A; Kagan, L, 2008
)
0.54
" Further studies are needed to find an effective formulation and dosing scheme for transdermal administration of atenolol."( Comparison of pharmacodynamic variables following oral versus transdermal administration of atenolol to healthy cats.
Belmonte, AA; Boothe, DM; Freeman, LM; Macgregor, JM; Rozanski, EA; Rush, JE, 2008
)
0.78
" Repetitive once daily oral dosing (0."( Backbone cyclic peptidomimetic melanocortin-4 receptor agonist as a novel orally administrated drug lead for treating obesity.
Faier, A; Gabinet, Y; Gilon, C; Halbfinger, E; Haskell-Luevano, C; Hess, S; Hoffman, A; Lapidot, T; Linde, Y; Ovadia, O; Portillo, FP; Safrai, E; Shalev, DE; Swed, A; Winkler, I; Xiang, Z; Yarden, D, 2008
)
0.35
"Atenolol and metoprolol succinate, dosed once daily, have different pharmacokinetic profiles."( Comparative efficacy of two different beta-blockers on 24-hour blood pressure control.
Bakris, GL; Basta, E; Bogojevic, Z; Kirstner, E; Sarafidis, P, 2008
)
1.79
" All cats were treated with atenolol at a dosage of 1-2 mg/kg PO q 12h for a minimum of 5 days prior to reassessment and treatment with radioactive iodine."( Efficacy of atenolol as a single antihypertensive agent in hyperthyroid cats.
Dolson, MK; Henik, RA; Stepien, RL; Wenholz, LJ, 2008
)
1.02
" and atenolol at the commonly used dosage in clinical practice in patients with chronic stable angina pectoris produced additional efficacy with no untoward effect on safety or tolerability."( Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial.
Kahan, T; Ponikowski, P; Tardif, JC, 2009
)
0.87
" Lowering propranolol dosage or switching to atenolol was less efficient to reduce cortisol levels."( Adrenal Cushing's syndrome due to bilateral macronodular adrenal hyperplasia: prediction of the efficacy of beta-blockade therapy and interest of unilateral adrenalectomy.
Chabre, O; Chaffanjon, P; Martinie, M; Mazzuco, TL; Sturm, N, 2009
)
0.61
" Despite optimal dosing of HCTZ + atenolol, only two-thirds of the participants achieved BP control."( Hydrochlorothiazide and atenolol combination antihypertensive therapy: effects of drug initiation order.
Bailey, KR; Beitelshees, AL; Boerwinkle, E; Campbell, K; Chapman, AB; Cooper-DeHoff, RM; Gong, Y; Gums, JG; Johnson, JA; Schmidt, S; Schwartz, GL; Turner, ST, 2009
)
0.94
" These results suggest that caution be exercised when these solubilizing agents are included in preclinical oral dosing solutions as the perturbation of drug absorption barriers may heighten the risk of incorrectly classifying drug candidate PK-parameters."( Absorption barriers in the rat intestinal mucosa. 3: Effects of polyethoxylated solubilizing agents on drug permeation and metabolism.
Borchardt, RT; Mudra, DR, 2010
)
0.36
" Data were collected during 1 dosing interval from lactating women treated with atenolol for therapeutic reasons, at 2 to 4 weeks (n = 32), 3 to 4 months (n = 22), and 6 to 8 months (n = 17) postpartum."( Atenolol pharmacokinetics and excretion in breast milk during the first 6 to 8 months postpartum.
Anderson, GD; Brateng, DA; Buchanan, ML; Carr, D; Easterling, TR; Eyal, S; Hebert, MF; Kim, JD; Woodrum, DE, 2010
)
2.03
"The Biopharmaceutical Classification System (BCS) guidance issued by the FDA allows waivers for in vivo bioavailability and bioequivalence studies for immediate-release (IR) solid oral dosage forms only for BCS class I drugs."( The biowaiver extension for BCS class III drugs: the effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulation.
Amidon, GL; Tsume, Y, 2010
)
0.36
" In vivo studies revealed that the absolute bioavailability of microsphere formulations was higher than that of reference in spite of a lower dosage of drug, suggesting a possible dose reduction by AT microparticles orotransmucosal administration."( Poloxamer 407 microspheres for orotransmucosal drug delivery. Part II: In vitro/in vivo evaluation.
Albertini, B; Burgalassi, S; Chetoni, P; Monti, D; Passerini, N; Rodriguez, L; Rossato, MS, 2010
)
0.36
"Patients received atenolol therapy for at least 8 weeks, with 5 of those weeks at a dosage of 100 mg/day, and then underwent a 2-hour oral glucose tolerance test during a pharmacokinetic study visit."( Atenolol exposure and risk for development of adverse metabolic effects: a pilot study.
Cooper-Dehoff, RM; Frye, RF; Hall, K; Johnson, JA; Navare, HA; Schmidt, SO; Shuster, JJ; Turner, ST, 2010
)
2.14
" After a 4-week placebo period, 94 and 107 patients with uncomplicated hypertension were randomly assigned to treatment with atenolol (AT) at dosage of 50 mg per day or perindopril/indapamide (PER/IND) at dosage of 2/0."( Responses of the ambulatory arterial stiffness index and other measures of arterial function to antihypertensive drugs.
Dolan, E; Jin, Y; Li, Y; O'Brien, E; Protogerou, A; Richart, T; Safar, ME; Staessen, JA; Thijs, L; Wang, JG, 2011
)
0.58
"Two simple, accurate and reproducible spectrophotometric methods have been developed for the simultaneous estimation of Hydrochlorothiazide (Hctz), Atenolol (Atn) and Losartan potassium (Los) in combined tablet dosage forms."( Simultaneous spectrophotometric estimation of Hydrochlorothiazide, Atenolol and Losartan potassium in tablet dosage form.
Chavan, UB; Deshpande, AD; Dighe, SB; Jagdale, SN; Kothapalli, LP; Nanda, RK; Thomas, AB, 2009
)
0.79
" The more favorable characteristics of SRPs would make it more appropriate as a potential dosage form for the treatment of hypertension."( Evaluation of pharmacokinetic and pharmacodynamic relationship for oral sustained-release atenolol pellets in rats.
Cui, Y; Dong, C; Jia, J; Liu, J; Zhang, W, 2011
)
0.59
" Three drugs (celiprolol, fexofenadine, and atenolol) were orally administered as a cassette dosing following the MD (totally 97."( Microdosing clinical study: pharmacokinetic, pharmacogenomic (SLCO2B1), and interaction (grapefruit juice) profiles of celiprolol following the oral microdose and therapeutic dose.
Chiyoda, T; Doi, Y; Hirota, T; Ieiri, I; Irie, S; Iwasaki, K; Kimura, M; Maeda, K; Miyagawa, M; Sasaki, T; Sugiyama, Y, 2012
)
0.64
"7 kg) were dosed twice-daily with 12."( Comparative pharmacokinetics and pharmacodynamics of tablet, suspension and paste formulations of atenolol in cats.
Campbell, FE; Charles, BG; Greer, RM; Khor, KH; Mills, PC; Norris, RL; Rathbone, MJ, 2012
)
0.6
" This study utilises the methods of cassette dosing and the perfused ovine eye model - to reduce animal usage and therefore animal time - to show that for a series of beta adrenoreceptor antagonists, lipophilicity is a key physicochemical property that governs drug distribution within the eye."( A pharmacokinetic study of a combination of beta adrenoreceptor antagonists - in the isolated perfused ovine eye.
Mains, J; Tan, LE; Urquhart, A; Wilson, C, 2012
)
0.38
" Normally, an increase in chlorine dosage and pH resulted in faster degradation of these pharmaceuticals."( Reaction of β-blockers and β-agonist pharmaceuticals with aqueous chlorine. Investigation of kinetics and by-products by liquid chromatography quadrupole time-of-flight mass spectrometry.
Cela, R; Quintana, JB; Rodil, R, 2012
)
0.38
" They further investigated whether differences in DOS heart rate between atenolol and metoprolol could be explained by once-daily versus twice-daily dosing regimens."( Atenolol is associated with lower day-of-surgery heart rate compared to long- and short-acting metoprolol.
Brandt, C; Burg, MM; Dai, F; Feinleib, J; Schonberger, RB, 2013
)
2.06
" The heart rate difference is specific to the day of surgery and is not explained by once-daily versus twice-daily dosing regimens."( Atenolol is associated with lower day-of-surgery heart rate compared to long- and short-acting metoprolol.
Brandt, C; Burg, MM; Dai, F; Feinleib, J; Schonberger, RB, 2013
)
1.83
" Therefore, it is possible for the community pharmacist to crush atenolol 100-mg tablets and refill them in new capsules with each containing a precise amount of atenolol, calculated according to body surface area and kidney and liver functions without affecting the chemical stability of the active ingredient nor its dissolution profile and also have a cost effective dosage form."( Formulation and stability evaluation of extemporaneously prepared atenolol capsules from crushed atenolol tablets.
Abu Ghoush, A; Al-Ramahi, R; Kharoaf, M; Malkieh, N; Zaid, AN,
)
0.61
" However, the effect and mechanism of dosage form pH upon skin permeation of these weak bases is not well understood."( Evaluation of skin permeation of β-blockers for topical drug delivery.
Chantasart, D; Hao, J; Li, SK, 2013
)
0.39
" The floating-pulsatile concept was applied to increase the gastric residence of the dosage form by having lag phase followed by a burst release."( Formulation, development, and evaluation of floating pulsatile drug delivery system of atenolol.
Barhate, AL; Chabukswar, AR; Jagdale, SC; Kuchekar, BS; Sali, MS,
)
0.35
"Two stability-indicating chromatographic methods are described for simultaneous determination of amiloride hydrochloride (AMI), atenolol (ATE), and chlorthalidone (CHL) in combined dosage forms."( Validated stability-indicating methods for the simultaneous determination of amiloride hydrochloride, atenolol, and chlorthalidone using HPTLC and HPLC with photodiode array detector.
Barary, MH; El-Kimary, EI; Hassan, EM; Maher, HM; Youssef, RM,
)
0.55
" Though the main criterion for combining drugs in a single dosage form is the rationale, but consideration like stability of formulation is equally important, due to an added aspect of drug-drug interaction."( Characterization of a new degradation product of nifedipine formed on catalysis by atenolol: A typical case of alteration of degradation pathway of one drug by another.
Handa, T; Singh, IP; Singh, S, 2014
)
0.63
" It was found that increasing the specific dosage of the two peroxides ([peroxide]0/[ATL]0) ranging from 1:1 to 8:1 led to a faster degradation rate but also higher peroxide residual."( Comparison of Uv/PDS and UV/H2O2 processes for the degradation of atenolol in water.
Fang, L; Liu, X; Shao, Y; Zhang, T; Zhou, Y, 2013
)
0.63
" Colesevelam (3750mg once daily) was dosed throughout the pharmacokinetic sampling period."( Lack of effect of colesevelam HCl on the single-dose pharmacokinetics of aspirin, atenolol, enalapril, phenytoin, rosiglitazone, and sitagliptin.
He, L; Lee, J; Mendell-Harary, J; Tao, B; Walker, J; Wickremasingha, P; Wight, D, 2014
)
0.63
"Concomitant food intake can diminish oral absorption of drugs with limited permeability and an absorption window in the proximal intestine, due to viscosity-mediated decrease in dosage form disintegration time and drug dissolution rate."( Viscosity-mediated negative food effect on oral absorption of poorly-permeable drugs with an absorption window in the proximal intestine: In vitro experimental simulation and computational verification.
Cvijić, S; Langguth, P; Parojčić, J, 2014
)
0.4
" Atenolol may be a preferred therapeutic option compared with propanolol, in view of its convenient once-a-day dosing and better side effect profile."( Idiopathic aquagenic pruritus: pathogenesis and effective treatment with atenolol.
Cao, T; Tan, KB; Tey, HL; Yong, AA,
)
1.27
" The model formulations were representative for oral solutions (co-solvents), parenteral solutions (buffer species) and solid dosage forms (organic acids applicable for solubility enhancement)."( Evaluation of microwave oven heating for prediction of drug-excipient compatibilities and accelerated stability studies.
Cornett, C; Hansen, SH; Schou-Pedersen, AM; Østergaard, J, 2015
)
0.42
"We have used three dimensional (3D) extrusion printing to manufacture a multi-active solid dosage form or so called polypill."( 3D printing of five-in-one dose combination polypill with defined immediate and sustained release profiles.
Alexander, MR; Burley, JC; Khaled, SA; Roberts, CJ; Yang, J, 2015
)
0.42
" The specificity of the developed methods is investigated by analyzing laboratory prepared mixtures of the two drugs and their combined dosage form."( Spectrophotometric Methods for Simultaneous Determination of Amlodipine Besylate and Atenolol in Their Tablet Dosage Form.
Lamie, NT, 2015
)
0.64
" This study indicates that not all marketed products containing the same BCS III active pharmaceutical ingredient (API) in similar strength and dosage form are necessarily in vitro equivalent as per the WHO biowaiver criteria."( Investigation of Biowaivers for Immediate Release Formulations Containing BCS III Drugs, Acyclovir, Atenolol, and Ciprofloxacin Hydrochloride, Using Dissolution Testing.
Kanfer, I; Patnala, S; Reddy, NH, 2017
)
0.67
"The development of oral modified-release (MR) dosage forms requires an active pharmaceutical ingredient (API) with a sufficiently high absorption rate in both the small and large intestine."( Regional Intestinal Permeability in Dogs: Biopharmaceutical Aspects for Development of Oral Modified-Release Dosage Forms.
Abrahamsson, B; Dahlgren, D; Johansson, P; Lennernäs, H; Lundqvist, A; Roos, C; Sjögren, E; Tannergren, C, 2016
)
0.43
" This has hindered the validation of preclinical models with regard to absorption in the distal parts of the intestinal tract, which can be substantial for BCS class II-IV drugs, and drugs formulated into modified-release (MR) dosage forms."( Regional Intestinal Permeability of Three Model Drugs in Human.
Abrahamsson, B; Dahlgren, D; Hellström, PM; Lennernäs, H; Lundqvist, A; Roos, C; Sjögren, E; Tannergren, C, 2016
)
0.43
"5 times the initial dosing concentration."( Osmolality of Orally Administered Solutions Influences Luminal Water Volume and Drug Absorption in Intestine.
Funai, Y; Horiuchi, T; Ichijo, K; Inoue, K; Ishihara, M; Kishimoto, H; Moteki, Y; Oda, R; Okada, R; Shirasaka, Y, 2017
)
0.46
" Our SCAMP proposes guidelines for dosing and monitoring parameters."( Atenolol Versus Propranolol for Treatment of Infantile Hemangiomas During the Proliferative Phase: A Retrospective Noninferiority Study.
Bayart, CB; Golden, AB; Tamburro, JE; Vidimos, AT; Wang, L, 2017
)
1.9
"Knowledge about the region-specific absorption profiles from the gastrointestinal tract of orally administered drugs is a critical factor guiding dosage form selection in drug development."( Mass Spectrometry Imaging proves differential absorption profiles of well-characterised permeability markers along the crypt-villus axis.
Andrén, PE; Goodwin, RJA; Hayes, MA; Hilgendorf, C; Nilsson, A; Peric, A; Strimfors, M, 2017
)
0.46
"The developed atenolol-releasing buccal patches can be beneficial over the conventional drug delivery systems to decrease the dosing frequency and enhance patient compliance."( Buccal patches of atenolol formulated using fenugreek (Trigonella foenum-graecum L.) seed mucilage.
Adhikari, SNR; Panda, S,
)
0.83
" Atenolol is used for cardiovascular diseases and available as an immediate release (IR) tablet dosage form."( Effect of lipid and cellulose based matrix former on the release of highly soluble drug from extruded/spheronized, sintered and compacted pellets.
Ahmed, HF; Hussain, T; Iffat, W; Maboos, M; Nasiri, I; Shoaib, MH; Yousuf, RI, 2018
)
1.39
" Excipient concentrations were selected based on the amounts in oral immediate release dosage forms, which failed the test during the human bioequivalence studies."( Effect of Common Excipients on Intestinal Drug Absorption in Wistar Rats.
Bermejo, M; Gonzalez-Alvarez, I; Gonzalez-Alvarez, M; Ruiz-Picazo, A, 2020
)
0.56
"This study failed to identify an effect of subclinical HCM on owner-assessed QOL or activity or a treatment effect of atenolol on these variables at the dosage evaluated."( Atenolol in cats with subclinical hypertrophic cardiomyopathy: a double-blind, placebo-controlled, randomized clinical trial of effect on quality of life, activity, and cardiac biomarkers.
Atkins, CE; Coleman, AE; DeFrancesco, TC; Griffiths, EH; Keene, BW; Kleisch, DJ; Lascelles, BDX, 2020
)
2.21
" We have developed three sensitive, selective, fast, simple, green, accurate, precise, and robust isocratic high-performance liquid chromatography methods for simultaneous determination of valsartan and atenolol in dosage forms."( New liquid chromatography assays for simultaneous quantification of antihypertensives atenolol and valsartan in their dosage forms.
Abdel-Megied, A; Ahmed, H; Ezike, OF; Kovalenko, S; Logoyda, L; Peleshok, K; Piponski, M, 2021
)
1.03
"An important challenge to overcome in the solid dosage forms technology is the selection of the most biopharmaceutically efficient polymeric excipients."( Quantification of Compatibility Between Polymeric Excipients and Atenolol Using Principal Component Analysis and Hierarchical Cluster Analysis.
Gazda, M; Rojek, B; Wesolowski, M, 2021
)
0.86
"Swallowing oral solid dosage forms is challenging in patients with dysphagia who are at risk of aspiration or choking."( Do Thickening Agents Used in Dysphagia Diet Affect Drug Bioavailability?
Erdem, ÇE; Eroğlu, H; Eylem, CC; Gökmen-Özel, H; Ilgaz, F; Nemutlu, E; Timur, SS, 2022
)
0.72
" Small and mostly insignificant differences in average daily metoprolol dosage were found between patients treated with the various antidepressants."( Co-prescription of metoprolol and CYP2D6-inhibiting antidepressants before and after implementation of an optimized drug interaction database in Norway.
Gedde-Dahl, A; Molden, E; Spigset, O, 2022
)
0.72
"Fixed-dose combinations for treatment of hypertension are observed in many dosages in the global market because of their high efficacy compared to single component dosage forms."( Derivatization-free conventional and synchronous spectrofluorimetric estimation of atenolol and amlodipine.
Abd El-Aziz, H; Zeid, AM, 2024
)
1.67
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (6)

RoleDescription
beta-adrenergic antagonistAn agent that binds to but does not activate beta-adrenergic receptors thereby blocking the actions of endogenous or exogenous beta-adrenergic agonists. beta-Adrenergic antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches and anxiety.
anti-arrhythmia drugA drug used for the treatment or prevention of cardiac arrhythmias. Anti-arrhythmia drugs may affect the polarisation-repolarisation phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibres.
antihypertensive agentAny drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
sympatholytic agentAny compound which inhibits the postganglionic functioning of the sympathetic nervous system (SNS).
xenobioticA xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
environmental contaminantAny minor or unwanted substance introduced into the environment that can have undesired effects.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
ethanolamines
monocarboxylic acid amideA carboxamide derived from a monocarboxylic acid.
propanolamine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Atenolol Action Pathway478

Protein Targets (44)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
USP1 protein, partialHomo sapiens (human)Potency28.18380.031637.5844354.8130AID504865
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency39.81070.354828.065989.1251AID504847
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency12.58930.00798.23321,122.0200AID2546
gemininHomo sapiens (human)Potency17.05400.004611.374133.4983AID624296; AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency26.55660.005612.367736.1254AID624032; AID624044
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency0.07080.004023.8416100.0000AID485290
AR proteinHomo sapiens (human)Potency0.19490.000221.22318,912.5098AID743036
regulator of G-protein signaling 4Homo sapiens (human)Potency0.59730.531815.435837.6858AID504845
D(1A) dopamine receptorHomo sapiens (human)Potency0.16360.02245.944922.3872AID488982
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.12510.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency3.16230.004611.374133.4983AID624297
lamin isoform A-delta10Homo sapiens (human)Potency0.00500.891312.067628.1838AID1487
TAR DNA-binding protein 43Homo sapiens (human)Potency35.48131.778316.208135.4813AID652104
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency8.49210.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
Fatty acid-binding protein, liverRattus norvegicus (Norway rat)Ki717.00000.01501.24876.9200AID407366
UreaseCanavalia ensiformis (jack bean)IC50 (µMol)64.36000.45703.20238.5900AID1882614
Beta-2 adrenergic receptorHomo sapiens (human)IC50 (µMol)14.63400.00020.93267.2000AID625205
Beta-2 adrenergic receptorHomo sapiens (human)Ki9.80550.00000.66359.5499AID1350481; AID625205
Beta-1 adrenergic receptorHomo sapiens (human)IC50 (µMol)0.74680.00021.46819.0000AID1285613; AID1336305; AID255284; AID340236; AID346400; AID566241; AID625204; AID751900
Beta-1 adrenergic receptorHomo sapiens (human)Ki0.60430.00011.33919.9840AID1350482; AID346400; AID611927; AID625204; AID751900
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)Ki10.00000.00010.739610.0000AID4411
Alpha-1D adrenergic receptorHomo sapiens (human)IC50 (µMol)0.23000.00020.75688.8970AID752261
Alpha-1A adrenergic receptorHomo sapiens (human)IC50 (µMol)0.23000.00020.56145.4000AID752261
Alpha-1B adrenergic receptorHomo sapiens (human)IC50 (µMol)0.23000.00020.65268.3300AID752261
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-1 adrenergic receptor Cavia porcellus (domestic guinea pig)Kd0.09120.00000.53588.3176AID39943; AID42217
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Kd1.17490.00020.56294.4668AID40869
Beta-2 adrenergic receptorHomo sapiens (human)Kd16.06540.00000.62888.9130AID1626022; AID1626023; AID1798580
Beta-1 adrenergic receptorHomo sapiens (human)Kd26.28900.00010.803910.0000AID1798580
Beta-3 adrenergic receptorHomo sapiens (human)Kd26.28900.00010.76318.9130AID1798580
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Kd1.17490.00020.56294.4668AID40869
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Kd1.17490.00020.56294.4668AID40869
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Kd1.17490.00020.56294.4668AID40869
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)Kd1.17490.00012.29338.5114AID40869
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Kd1.17490.00020.56294.4668AID40869
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Kd1.17490.00020.56294.4668AID40869
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Kd1.17490.00020.56294.4668AID40869
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Kd1.17490.00020.56294.4668AID40869
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Kd1.17490.00020.56294.4668AID40869
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Kd1.17490.00020.56294.4668AID40869
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Kd1.17490.00020.56294.4668AID40869
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Kd1.17490.00020.56294.4668AID40869
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Kd1.17490.00020.56294.4668AID40869
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Kd1.17490.00020.56294.4668AID40869
Beta-2 adrenergic receptorCavia porcellus (domestic guinea pig)Kd1.17490.00020.54774.4668AID40869; AID40870
GABA theta subunitRattus norvegicus (Norway rat)Kd1.17490.00020.56294.4668AID40869
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Kd1.17490.00020.56294.4668AID40869
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (131)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
diet induced thermogenesisBeta-2 adrenergic receptorHomo sapiens (human)
regulation of sodium ion transportBeta-2 adrenergic receptorHomo sapiens (human)
transcription by RNA polymerase IIBeta-2 adrenergic receptorHomo sapiens (human)
receptor-mediated endocytosisBeta-2 adrenergic receptorHomo sapiens (human)
smooth muscle contractionBeta-2 adrenergic receptorHomo sapiens (human)
cell surface receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
activation of transmembrane receptor protein tyrosine kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
endosome to lysosome transportBeta-2 adrenergic receptorHomo sapiens (human)
response to coldBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of protein kinase A signalingBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of bone mineralizationBeta-2 adrenergic receptorHomo sapiens (human)
heat generationBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-2 adrenergic receptorHomo sapiens (human)
bone resorptionBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of smooth muscle contractionBeta-2 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of mini excitatory postsynaptic potentialBeta-2 adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of autophagosome maturationBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of lipophagyBeta-2 adrenergic receptorHomo sapiens (human)
cellular response to amyloid-betaBeta-2 adrenergic receptorHomo sapiens (human)
response to psychosocial stressBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of cAMP-dependent protein kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of AMPA receptor activityBeta-2 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of heart rate by epinephrine-norepinephrineBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of the force of heart contraction by epinephrine-norepinephrineBeta-1 adrenergic receptorHomo sapiens (human)
diet induced thermogenesisBeta-1 adrenergic receptorHomo sapiens (human)
response to coldBeta-1 adrenergic receptorHomo sapiens (human)
heat generationBeta-1 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-1 adrenergic receptorHomo sapiens (human)
fear responseBeta-1 adrenergic receptorHomo sapiens (human)
regulation of circadian sleep/wake cycle, sleepBeta-1 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-1 adrenergic receptorHomo sapiens (human)
regulation of postsynaptic membrane potentialBeta-1 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-1 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-1 adrenergic receptorHomo sapiens (human)
receptor-mediated endocytosisBeta-3 adrenergic receptorHomo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
diet induced thermogenesisBeta-3 adrenergic receptorHomo sapiens (human)
carbohydrate metabolic processBeta-3 adrenergic receptorHomo sapiens (human)
generation of precursor metabolites and energyBeta-3 adrenergic receptorHomo sapiens (human)
energy reserve metabolic processBeta-3 adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerBeta-3 adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
response to coldBeta-3 adrenergic receptorHomo sapiens (human)
heat generationBeta-3 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-3 adrenergic receptorHomo sapiens (human)
eating behaviorBeta-3 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-3 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-3 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-3 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-3 adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-1D adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1D adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1D adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of vasoconstrictionAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1D adrenergic receptorHomo sapiens (human)
MAPK cascadeAlpha-1A adrenergic receptorHomo sapiens (human)
negative regulation of heart rate involved in baroreceptor response to increased systemic arterial blood pressureAlpha-1A adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressureAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of heart rate by epinephrine-norepinephrineAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of the force of heart contraction by epinephrine-norepinephrineAlpha-1A adrenergic receptorHomo sapiens (human)
apoptotic processAlpha-1A adrenergic receptorHomo sapiens (human)
smooth muscle contractionAlpha-1A adrenergic receptorHomo sapiens (human)
signal transductionAlpha-1A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1A adrenergic receptorHomo sapiens (human)
activation of phospholipase C activityAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1A adrenergic receptorHomo sapiens (human)
adult heart developmentAlpha-1A adrenergic receptorHomo sapiens (human)
negative regulation of cell population proliferationAlpha-1A adrenergic receptorHomo sapiens (human)
response to xenobiotic stimulusAlpha-1A adrenergic receptorHomo sapiens (human)
response to hormoneAlpha-1A adrenergic receptorHomo sapiens (human)
negative regulation of autophagyAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of cardiac muscle hypertrophyAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicAlpha-1A adrenergic receptorHomo sapiens (human)
intracellular signal transductionAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of action potentialAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of vasoconstrictionAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of smooth muscle contractionAlpha-1A adrenergic receptorHomo sapiens (human)
calcium ion transport into cytosolAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of cardiac muscle contractionAlpha-1A adrenergic receptorHomo sapiens (human)
cell growth involved in cardiac muscle cell developmentAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of protein kinase C signalingAlpha-1A adrenergic receptorHomo sapiens (human)
pilomotor reflexAlpha-1A adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1A adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1A adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-1B adrenergic receptorHomo sapiens (human)
intracellular signal transductionAlpha-1B adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1B adrenergic receptorHomo sapiens (human)
regulation of cardiac muscle contractionAlpha-1B adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1B adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1B adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1B adrenergic receptorHomo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (50)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
amyloid-beta bindingBeta-2 adrenergic receptorHomo sapiens (human)
beta2-adrenergic receptor activityBeta-2 adrenergic receptorHomo sapiens (human)
protein bindingBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase bindingBeta-2 adrenergic receptorHomo sapiens (human)
potassium channel regulator activityBeta-2 adrenergic receptorHomo sapiens (human)
identical protein bindingBeta-2 adrenergic receptorHomo sapiens (human)
protein homodimerization activityBeta-2 adrenergic receptorHomo sapiens (human)
protein-containing complex bindingBeta-2 adrenergic receptorHomo sapiens (human)
norepinephrine bindingBeta-2 adrenergic receptorHomo sapiens (human)
beta-adrenergic receptor activityBeta-1 adrenergic receptorHomo sapiens (human)
beta1-adrenergic receptor activityBeta-1 adrenergic receptorHomo sapiens (human)
protein bindingBeta-1 adrenergic receptorHomo sapiens (human)
PDZ domain bindingBeta-1 adrenergic receptorHomo sapiens (human)
alpha-2A adrenergic receptor bindingBeta-1 adrenergic receptorHomo sapiens (human)
protein heterodimerization activityBeta-1 adrenergic receptorHomo sapiens (human)
G protein-coupled neurotransmitter receptor activity involved in regulation of postsynaptic membrane potentialBeta-1 adrenergic receptorHomo sapiens (human)
norepinephrine bindingBeta-3 adrenergic receptorHomo sapiens (human)
beta-adrenergic receptor activityBeta-3 adrenergic receptorHomo sapiens (human)
protein bindingBeta-3 adrenergic receptorHomo sapiens (human)
beta3-adrenergic receptor activityBeta-3 adrenergic receptorHomo sapiens (human)
beta-3 adrenergic receptor bindingBeta-3 adrenergic receptorHomo sapiens (human)
protein homodimerization activityBeta-3 adrenergic receptorHomo sapiens (human)
epinephrine bindingBeta-3 adrenergic receptorHomo sapiens (human)
protein bindingAlpha-1D adrenergic receptorHomo sapiens (human)
identical protein bindingAlpha-1D adrenergic receptorHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1D adrenergic receptorHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-1A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-1A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-1B adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-1B adrenergic receptorHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1B adrenergic receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (38)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
nucleusBeta-2 adrenergic receptorHomo sapiens (human)
lysosomeBeta-2 adrenergic receptorHomo sapiens (human)
endosomeBeta-2 adrenergic receptorHomo sapiens (human)
early endosomeBeta-2 adrenergic receptorHomo sapiens (human)
Golgi apparatusBeta-2 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
endosome membraneBeta-2 adrenergic receptorHomo sapiens (human)
membraneBeta-2 adrenergic receptorHomo sapiens (human)
apical plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
clathrin-coated endocytic vesicle membraneBeta-2 adrenergic receptorHomo sapiens (human)
neuronal dense core vesicleBeta-2 adrenergic receptorHomo sapiens (human)
receptor complexBeta-2 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
early endosomeBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-1 adrenergic receptorHomo sapiens (human)
Schaffer collateral - CA1 synapseBeta-1 adrenergic receptorHomo sapiens (human)
neuronal dense core vesicleBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-3 adrenergic receptorHomo sapiens (human)
receptor complexBeta-3 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-3 adrenergic receptorHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneAlpha-1D adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1D adrenergic receptorHomo sapiens (human)
nucleusAlpha-1A adrenergic receptorHomo sapiens (human)
nucleoplasmAlpha-1A adrenergic receptorHomo sapiens (human)
cytoplasmAlpha-1A adrenergic receptorHomo sapiens (human)
cytosolAlpha-1A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1A adrenergic receptorHomo sapiens (human)
caveolaAlpha-1A adrenergic receptorHomo sapiens (human)
nuclear membraneAlpha-1A adrenergic receptorHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-1A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1A adrenergic receptorHomo sapiens (human)
nucleusAlpha-1B adrenergic receptorHomo sapiens (human)
cytoplasmAlpha-1B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1B adrenergic receptorHomo sapiens (human)
caveolaAlpha-1B adrenergic receptorHomo sapiens (human)
nuclear membraneAlpha-1B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1B adrenergic receptorHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (477)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1769825Permeability of the compound across basolateral to apical membrane in human Caco-2 cells incubated for 2 hrs by LC-MS/MS analysis2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Discovery, Structure-Activity Relationships, and In Vivo Evaluation of Novel Aryl Amides as Brain Penetrant Adaptor Protein 2-Associated Kinase 1 (AAK1) Inhibitors for the Treatment of Neuropathic Pain.
AID1230204Permeability of the compound by PAMPA-BBB assay2015Journal of natural products, Jun-26, Volume: 78, Issue:6
In Vitro Inhibitory Effects of 8-O-Demethylmaritidine and Undulatine on Acetylcholinesterase and Their Predicted Penetration across the Blood-Brain Barrier.
AID1636796Apparent permeability from apical to basolateral side in Caco2 cells at 1 to 10 uM incubated for 90 mins by LC-MS/MS analysis2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Discovery and optimization of a series of imidazo[4,5-b]pyrazine derivatives as highly potent and exquisitely selective inhibitors of the mesenchymal-epithelial transition factor (c-Met) protein kinase.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID230146The cardioselectivity ratio was obtained by taking the antilog (pA2 beta1-pA2 beta2)1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Beta 1-selective adrenoceptor antagonists: examples of the 2-[4-[3-(substituted amino)-2-hydroxypropoxy]phenyl]imidazole class. 2.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1626024Binding affinity to inactive/G protein-uncoupled human beta2-AR by immobilized artificial membrane HPLC analysis2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
Uncoupling the Structure-Activity Relationships of β2 Adrenergic Receptor Ligands from Membrane Binding.
AID1668034Antiproliferative activity against human SK-MEL-28 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay2020Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9
Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents.
AID1381448Apparent permeability from basolateral to apical side in MDCK cells2018Journal of medicinal chemistry, Aug-09, Volume: 61, Issue:15
Identification of Morpholino Thiophenes as Novel Mycobacterium tuberculosis Inhibitors, Targeting QcrB.
AID1635248Efflux ratio of apparent permeability from basolateral to apical side over apical to basolateral side in human Caco2 cells at 10 uM incubated for 120 mins by LC-MS/MS analysis2016European journal of medicinal chemistry, Aug-08, Volume: 118Design and synthesis of novel bicalutamide and enzalutamide derivatives as antiproliferative agents for the treatment of prostate cancer.
AID1204626Apparent permeability of the compound at 50 uM after 5 hrs by PAMPA method2015European journal of medicinal chemistry, Jun-05, Volume: 97Exploring experimental and computational markers of cyclic peptides: Charting islands of permeability.
AID1895161Permeability across basal to apical side in human Caco-2 cells measured at 0.5 to 2 hrs by LC-MS analysis2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Interplay among Conformation, Intramolecular Hydrogen Bonds, and Chameleonicity in the Membrane Permeability and Cyclophilin A Binding of Macrocyclic Peptide Cyclosporin O Derivatives.
AID1407670Apparent permeability of the compound from basolateral to apical side in human Caco2 cells assessed as drug recovery after 120 mins by LC-MS/MS analysis2018European journal of medicinal chemistry, Sep-05, Volume: 157Hedgehog pathway inhibitors of the acylthiourea and acylguanidine class show antitumor activity on colon cancer in vitro and in vivo.
AID1907156Apparent permeability of the compound across basolateral to apical side in human Caco-2 cells at 10 uM incubated for 120 mins assessed as drug recovery and measured by LC-MS/MS analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Discovery, optimization and evaluation of 1-(indolin-1-yl)ethan-1-ones as novel selective TRIM24/BRPF1 bromodomain inhibitors.
AID28234% absorbed in human GI-tract2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID1350706Apparent permeability cross basolateral to apical side in MDCK-MDR1 cells at 5 uM after 90 mins by LC-MS/MS analysis2018Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14
Optimization of Isothiazolo[4,3- b]pyridine-Based Inhibitors of Cyclin G Associated Kinase (GAK) with Broad-Spectrum Antiviral Activity.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID659472Effective permeability across porcine polar brain lipid after 4 hrs by PAMPA2012Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4
5-imino-1,2,4-thiadiazoles: first small molecules as substrate competitive inhibitors of glycogen synthase kinase 3.
AID1365728Efflux ratio of apparent permeability from basolateral to apical over apical to basolateral side in human Caco2 cells monolayer at 10 uM after 1 hr by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21
The antitubercular activity of various nitro(triazole/imidazole)-based compounds.
AID1220980Dissociation constant, pKa of the compound2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID781009Apparent permeability of the compound in human Caco2 cells at 1 uM2013Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22
Acidic biphenyl derivatives: synthesis and biological activity of a new series of potent 5-HT(4) receptor antagonists.
AID1772564Apparent permeability of the compound across basolateral side to apical side in human Caco-2 cells incubated for 150 mins by LC-MS/MS analysis2021European journal of medicinal chemistry, Nov-05, Volume: 223Non-carboxylic acid inhibitors of aldose reductase based on N-substituted thiazolidinedione derivatives.
AID526528Metabolic stability of the compound in ICR mouse liver microsome assessed as compound remaining at 1 uM2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Property based optimization of δ-lactam HDAC inhibitors for metabolic stability.
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1404015Permeability of the compound after 2.5 hrs by PAMPA2018European journal of medicinal chemistry, Feb-10, Volume: 145Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors.
AID343619Apparent permeability across human Caco-2 cells2008Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14
Structure-based design, synthesis, and biological evaluation of 1,1-dioxoisothiazole and benzo[b]thiophene-1,1-dioxide derivatives as novel inhibitors of hepatitis C virus NS5B polymerase.
AID1566375Ratio of drug level in blood to plasma (unknown origin) at 500 nM incubated for 45 mins by LC-MS/MS analysis2019Bioorganic & medicinal chemistry letters, 12-15, Volume: 29, Issue:24
Green chemistry appended synthesis, metabolic stability and pharmacokinetic assessment of medicinally important chromene dihydropyrimidinones.
AID1365716Efflux ratio of apparent permeability from basolateral to apical over apical to basolateral side in human Caco2 cells monolayer at 10 uM after 2 hrs by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21
The antitubercular activity of various nitro(triazole/imidazole)-based compounds.
AID1740545Permeability of compound in pH 7.4 PBS/EtOH buffer (7:3) after 16 hrs by PAMPA-BBB assay2020European journal of medicinal chemistry, Sep-15, Volume: 202Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-β aggregation against Alzheimer's disease.
AID1209593Dissociation constant, pKa of the acidic compound by capillary electrophoresis-mass spectrometry analysis2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID1900029Apparent permeability across basolateral to apical side in human Caco-2 cells at 10 uM measured after 2 hrs by LC-MS/MS analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Design, Synthesis, and Biological Evaluation of 1-(Indolizin-3-yl)ethan-1-ones as CBP Bromodomain Inhibitors for the Treatment of Prostate Cancer.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID455986Permeability across human Caco-2 cells2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
AID26525Distribution coefficient measured in Octanol/buffer (0.15 M KCl)1998Journal of medicinal chemistry, Dec-31, Volume: 41, Issue:27
Evaluation of dynamic polar molecular surface area as predictor of drug absorption: comparison with other computational and experimental predictors.
AID1221016Intrinsic elimination clearance in healthy Wistar rat perfused liver assessed per gm of liver at 4 mM after 10 mins2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1772563Apparent permeability of the compound across apical side to basolateral side in human Caco-2 cells incubated for 150 mins by LC-MS/MS analysis2021European journal of medicinal chemistry, Nov-05, Volume: 223Non-carboxylic acid inhibitors of aldose reductase based on N-substituted thiazolidinedione derivatives.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1668041Antiproliferative activity against human SK-MEL-28 cells assessed as cell growth inhibition at 100 uM measured after 48 hrs by MTT assay relative to control2020Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9
Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents.
AID1404017Permeability of the compound at 500 uM after 8 hrs by PAMPA2018European journal of medicinal chemistry, Feb-10, Volume: 145Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors.
AID1220979Octanol-water apparent partition coefficient, logD of the compound at pH 7.42011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
AID310931Partition coefficient, log P of the compound2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1220974Drug distribution in healthy Wistar rat perfused liver assessed as equilibrium amount ratio charactering slow binding process at 4 mM after 10 mins2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
AID438775Apparent permeability from apical to basolateral side of human Caco-2 cells2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure mechanism insights and the role of nitric oxide donation guide the development of oxadiazole-2-oxides as therapeutic agents against schistosomiasis.
AID604024Unbound brain to plasma concentration ratio in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID1367014Permeability of compound at 25 ug/ml after 18 hrs by PAMPA-BBB assay2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Design, synthesis and biological activity of 3-pyrazine-2-yl-oxazolidin-2-ones as novel, potent and selective inhibitors of mutant isocitrate dehydrogenase 1.
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1635246Apparent permeability from apical to basolateral side in human Caco2 cells at 10 uM incubated for 120 mins by LC-MS/MS analysis2016European journal of medicinal chemistry, Aug-08, Volume: 118Design and synthesis of novel bicalutamide and enzalutamide derivatives as antiproliferative agents for the treatment of prostate cancer.
AID1181953Apparent permeability in human Caco2 cells2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Straightforward entry to pyrido[2,3-d]pyrimidine-2,4(1H,3H)-diones and their ADME properties.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID409956Inhibition of mouse brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID361986Lipophilicity, log D of compound at pH 7.4 by shake flask method2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Determination of log D via automated microfluidic liquid-liquid extraction.
AID1272411Permeability across apical to basolateral side in MDCK cells after 90 mins by LC-MS/MS analysis2016European journal of medicinal chemistry, Jan-27, Volume: 108Combating P-glycoprotein-mediated multidrug resistance with 10-O-phenyl dihydroartemisinin ethers in MCF-7 cells.
AID567091Drug absorption in human assessed as human intestinal absorption rate2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID386623Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID1533478Apparent permeability from basolateral to apical side in MDCK cells2019European journal of medicinal chemistry, Jan-15, Volume: 162Second generation of diazachrysenes: Protection of Ebola virus infected mice and mechanism of action.
AID1377752Effective permeability of the compound at 25 ug/ml by PAMPA assay2017European journal of medicinal chemistry, Sep-29, Volume: 138Leucine rich repeat kinase 2 (LRRK2) inhibitors based on indolinone scaffold: Potential pro-neurogenic agents.
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID604021Unbound volume of distribution in Sprague-Dawley rat brain measured per gram of brain tissue administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr b2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID467611Dissociation constant, pKa of the compound2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID1513921Apparent permeability across apical to basolateral side in human Caco2 cells at 10 uM after 120 mins by LC-MS/MS analysis2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Alkyl-guanidine Compounds as Potent Broad-Spectrum Antibacterial Agents: Chemical Library Extension and Biological Characterization.
AID303797Permeability across artificial membrane by PAMPA2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Multiple N-methylation by a designed approach enhances receptor selectivity.
AID28399Cellular permeability (Pc) (Caco-2 cell monolayer)2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Experimental and computational screening models for the prediction of intestinal drug absorption.
AID604025Unbound CSF to plasma concentration ratio in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID344616Apparent permeability from apical to basolateral side in human Caco-2 cell membrane at 10 uM2008Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18
Hexahydro-pyrrolo- and hexahydro-1H-pyrido[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase.
AID41487Selectivity towards beta-2 adrenergic receptor; Nonselective towards beta-2 adrenergic receptor1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists.
AID1272410Activity at MDR1 (unknown origin) expressed in MDCK cells assessed as permeability across basolateral to apical after 90 mins by LC-MS/MS analysis2016European journal of medicinal chemistry, Jan-27, Volume: 108Combating P-glycoprotein-mediated multidrug resistance with 10-O-phenyl dihydroartemisinin ethers in MCF-7 cells.
AID592681Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
QSAR-based permeability model for drug-like compounds.
AID752261Binding affinity to human adrenergic alpha1 receptor by radioligand displacement assay2013Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10
Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID751900Binding affinity to human adrenergic beta1 receptor by radioligand displacement assay2013European journal of medicinal chemistry, May, Volume: 63Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID340236Inhibition of human beta 1 adrenergic receptor2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity.
AID604020Unbound drug concentration in Sprague-Dawley rat plasma administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID24420Partition coefficient (logP)1998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID21271Mean apparent permeability through fuzzy rat skin1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
(Acyloxy)alkyl carbamates as novel bioreversible prodrugs for amines: increased permeation through biological membranes.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1566373Ratio of drug level in blood to plasma (unknown origin) at 500 nM incubated for 15 mins by LC-MS/MS analysis2019Bioorganic & medicinal chemistry letters, 12-15, Volume: 29, Issue:24
Green chemistry appended synthesis, metabolic stability and pharmacokinetic assessment of medicinally important chromene dihydropyrimidinones.
AID1895160Permeability across apical to basal side in human Caco-2 cells assessed as drug recovery measured at 0.5 to 2 hrs by LC-MS analysis relative to control2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Interplay among Conformation, Intramolecular Hydrogen Bonds, and Chameleonicity in the Membrane Permeability and Cyclophilin A Binding of Macrocyclic Peptide Cyclosporin O Derivatives.
AID1623078Effective permeability of the compound at 100 ug/ml after 10 hrs by BBB-PAMPA method2019European journal of medicinal chemistry, Feb-01, Volume: 163Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease.
AID230147The cardioselectivity ratio was obtained by taking the antilog of (pA2(beta-1)-pA2(beta2))1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Beta 1-selective adrenoceptor antagonists: examples of the 2-[4-[3-(substituted-amino)-2-hydroxypropoxy]phenyl]imidazole class.
AID25572Dissociation constant of the compound1998Journal of medicinal chemistry, Dec-31, Volume: 41, Issue:27
Evaluation of dynamic polar molecular surface area as predictor of drug absorption: comparison with other computational and experimental predictors.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID156202Binding to POPC (palmitoyl-oleolyl-phosphatidyl-choline) liposomes using biosensor system2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface: correlation with fraction absorbed in humans.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1907155Apparent permeability of the compound across apical to basolateral side in human Caco-2 cells at 10 uM incubated for 120 mins assessed as drug recovery and measured by LC-MS/MS analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Discovery, optimization and evaluation of 1-(indolin-1-yl)ethan-1-ones as novel selective TRIM24/BRPF1 bromodomain inhibitors.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID15711Calculated partition coefficient (clogP)1998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach.
AID637605Permeability of the compound by PAMPA2012European journal of medicinal chemistry, Feb, Volume: 48A small chemical library of 2-aminoimidazole derivatives as BACE-1 inhibitors: Structure-based design, synthesis, and biological evaluation.
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1703921Permeability of the compound by PAMPA-BBB assay2020European journal of medicinal chemistry, Oct-15, Volume: 204Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies.
AID346400Displacement of radiolabeled atenolol from human adrenergic beta-1 receptor2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1703908Permeability of the compound by PAMPA-TGI assay2020European journal of medicinal chemistry, Oct-15, Volume: 204Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies.
AID24183Distribution coefficient in octanol/water at pH 5.51998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach.
AID350218Octanol-water partition coefficient, log PC of the compound2009Journal of medicinal chemistry, May-28, Volume: 52, Issue:10
Lipophilicity of basic drugs measured by hydrophilic interaction chromatography.
AID1668042Antiproliferative activity against human A375 cells assessed as cell growth inhibition at 100 uM measured after 48 hrs by MTT assay relative to control2020Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9
Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID361719Apparent permeability from apical to basolateral side in human Caco-2 cells at 10 uM2008Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16
4-(1,1-Dioxo-1,4-dihydro-1lambda6-benzo[1,4]thiazin-3-yl)-5-hydroxy-2H-pyridazin-3-ones as potent inhibitors of HCV NS5B polymerase.
AID438776Apparent permeability from basolateral to apical side of human Caco-2 cells2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure mechanism insights and the role of nitric oxide donation guide the development of oxadiazole-2-oxides as therapeutic agents against schistosomiasis.
AID696005Permeability of the compound after 4 hrs by PAMPA assay2012European journal of medicinal chemistry, Dec, Volume: 58Microwave-assisted synthesis of hydroxyphenyl nitrones with protective action against oxidative stress.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID262717Permeability in Caco-2 cell2006Journal of medicinal chemistry, Apr-06, Volume: 49, Issue:7
Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis.
AID39943In vitro inhibitory activity against beta-1 adrenergic receptor measured by inhibition of positive chronotropic effect of isoproterenolin in isolated guinea pig atria1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Beta 1-selective adrenoceptor antagonists: examples of the 2-[4-[3-(substituted amino)-2-hydroxypropoxy]phenyl]imidazole class. 2.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID28392Apparent permeability coefficient (Papp) (Caco-2 cell monolayer)2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Experimental and computational screening models for the prediction of intestinal drug absorption.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID24184Distribution coefficient in octanol/water at pH 6.51998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID227700Anticonvulsant activity2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Topological virtual screening: a way to find new anticonvulsant drugs from chemical diversity.
AID1500949Passive permeability of the compound at 100 uM after 6 hrs by PAMPA2017European journal of medicinal chemistry, Oct-20, Volume: 139Hydroxy-substituted trans-cinnamoyl derivatives as multifunctional tools in the context of Alzheimer's disease.
AID1209583Unbound drug partitioning coefficient, Kp of the compound assessed as ratio of unbound concentration in Sprague-Dawley rat brain to unbound concentration in plasma2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID1245599Efflux ratio of apparent permeability across basolateral to apical side over apical to basolateral side in human Caco2 cells after 2 hrs2015Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19
Discovery of potent nitrotriazole-based antitrypanosomal agents: In vitro and in vivo evaluation.
AID1740544Permeability of compound at pH 7.4 measured after 18 hrs PAMPA-BBB assay2020European journal of medicinal chemistry, Sep-15, Volume: 202Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-β aggregation against Alzheimer's disease.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID42218In vitro beta-1 adrenergic receptor activity was determined via inhibition of the positive chronotropic actions of isoproterenol in isolated guinea pig atrial preparations1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Beta 1-selective adrenoceptor antagonists: examples of the 2-[4-[3-(substituted-amino)-2-hydroxypropoxy]phenyl]imidazole class.
AID1167550Permeability of the compound in 70:30 PBS:EtOH by PAMPA-BBB assay2014European journal of medicinal chemistry, Nov-24, Volume: 87Discovery of indanone derivatives as multi-target-directed ligands against Alzheimer's disease.
AID481440Dissociation constant, pKa of the compound2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID1882614Inhibition of jack bean urease assessed as reduction on ammonia production using urea as substrate preincubated for 15 mins followed by substrate addition and measured after 15 mins by indophenol method2022European journal of medicinal chemistry, Apr-15, Volume: 234An overview on the synthetic urease inhibitors with structure-activity relationship and molecular docking.
AID411201Cardiovascular effect in anaesthetized Wistar rat assessed as mean arterial pressure at 40 mg/kg, ip after 15 mins2009Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1
Design, synthesis and pharmacological screening of novel antihypertensive agents using hybrid approach.
AID1209581Fraction unbound in Sprague-Dawley rat brain homogenates at 5 uM by equilibrium dialysis analysis2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID135327BBB penetration classification2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
AID1874537Apparent permeability across basolateral to apical side in human Caco-2 cells measured after 120 mins by LC-MS/MS analysis2022Journal of medicinal chemistry, 09-08, Volume: 65, Issue:17
Development, Optimization, and In Vivo Validation of New Imidazopyridine Chemotypes as Dual TLR7/TLR9 Antagonists through Activity-Directed Sequential Incorporation of Relevant Structural Subunits.
AID1900247Permeability of the compound at pH 7.4 PBS/EtOH buffer (70:30) by PAMPA-BBB assay2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
TDP-43 Modulation by Tau-Tubulin Kinase 1 Inhibitors: A New Avenue for Future Amyotrophic Lateral Sclerosis Therapy.
AID1407671Efflux ratio of apparent permeability from basolateral to apical over apical to basolateral side in human Caco2 cells after 120 mins by LC-MS/MS analysis2018European journal of medicinal chemistry, Sep-05, Volume: 157Hedgehog pathway inhibitors of the acylthiourea and acylguanidine class show antitumor activity on colon cancer in vitro and in vivo.
AID627924Apparent permeability across apical to basolateral side of dog MDCK cells at 50 uM measured every 15 mins for 1.5 hrs by LC-MS/MS analysis2011Bioorganic & medicinal chemistry letters, Jul-15, Volume: 21, Issue:14
Anti-resorptive activity and pharmacokinetic study of N(1),N(1)-diisopropyl-N(2)-(diphenylphosphoryl)-2-(4-nitrophenyl)acetamidine.
AID18847Percent of drug absorbed by human intestine after oral administration2000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1456599Apparent permeability of compound at 20 uM at pH 7.4 after 16 hrs by PAMPA2017Bioorganic & medicinal chemistry letters, 05-15, Volume: 27, Issue:10
Y-shaped bis-arylethenesulfonic acid esters: Potential potent and membrane permeable protein tyrosine phosphatase 1B inhibitors.
AID1823666Efflux ratio of apparent permeability across basolateral to apical side over apical to basolateral side in human Caco-2 cells at 5 uM measured every 15 mins for 1 hr by LC-MS/MS analysis2021Journal of medicinal chemistry, 05-27, Volume: 64, Issue:10
Discovery of New Imidazo[2,1-
AID1573587Apparent permeability from basolateral to apical side in human Caco2 cells measured at 90 mins time interval by LC-MS/MS analysis2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Development of Macrocyclic Peptides Containing Epoxyketone with Oral Availability as Proteasome Inhibitors.
AID1365714Apparent permeability of the compound across apical side to basolateral side in human Caco2 cells monolayer at 10 uM after 2 hrs by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21
The antitubercular activity of various nitro(triazole/imidazole)-based compounds.
AID236268Fraction absorbed in human intestine after oral administration compound was measured2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Exploring the role of different drug transport routes in permeability screening.
AID361985Lipophilicity, log D of compound at pH 7.4 by microfluidic liquid-liquid extraction method2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Determination of log D via automated microfluidic liquid-liquid extraction.
AID332086Apparent permeability from apical to basolateral side of human Caco-2 cells at 10 uM2008Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11
Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones: Part 4. Optimization of DMPK properties.
AID319635Apparent permeability from apical to basolateral side in human Caco-2 cells at 10 uM2008Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11
Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 3: Further optimization of the 2-, 6-, and 7'-substituents and initial pharmacokinetic assessme
AID24185Distribution coefficient in octanol/water at pH 7.41998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach.
AID41349Beta-2 adrenergic receptor antagonism in rats anesthetized with pentobarbitone sodium (75 mg/kg ip)1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Beta 1-selective adrenoceptor antagonists. 3. 4-Azolyl-linked phenoxypropanolamines.
AID1764399Unbound plasma concentration in P-gp knock out Sprague-Dawley rat at 5 mg/ml/kg, po measured upto 4 hrs by LC-MS analysis2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Development of an
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1407667Apparent permeability of the compound from apical to basolateral side in human Caco2 cells after 120 mins by LC-MS/MS analysis2018European journal of medicinal chemistry, Sep-05, Volume: 157Hedgehog pathway inhibitors of the acylthiourea and acylguanidine class show antitumor activity on colon cancer in vitro and in vivo.
AID1242929Effective permeability by PAMPA method2015Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18
Re-exploring the N-phenylpicolinamide derivatives to develop mGlu4 ligands with improved affinity and in vitro microsomal stability.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1895164Permeability across apical to basal side in human Caco-2 cells preincubated with verapamil for 30 mins followed by compound addition measured at 0.5 to 2 hrs by LC-MS analysis2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Interplay among Conformation, Intramolecular Hydrogen Bonds, and Chameleonicity in the Membrane Permeability and Cyclophilin A Binding of Macrocyclic Peptide Cyclosporin O Derivatives.
AID481439Absolute bioavailability in human2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID481442Transcellular permeability at pH 6.5 calculated from in vitro P app values in Caco-2 and/or MDCK cells2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID1764402Unbound brain-to-plasma concentration ratio in P-gp knock out Sprague-Dawley rat2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Development of an
AID91481Binding constant against human serum albumin (HSA)2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
Cheminformatic models to predict binding affinities to human serum albumin.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1626022Displacement of [3H]DHA from inactive/G protein-uncoupled human beta2-AR expressed in CHO cell membranes by liquid scintillation counting2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
Uncoupling the Structure-Activity Relationships of β2 Adrenergic Receptor Ligands from Membrane Binding.
AID178339Beta-1 adrenoceptor blocking activity as the dose required to inhibit 50% of tachycardia in anesthetized rats1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
beta 1-selective adrenoceptor antagonists. 2. 4-ether-linked phenoxypropanolamines.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID28679Partition coefficient (logD6.8)2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID1365715Apparent permeability of the compound across basolateral side to apical side in human Caco2 cells monolayer at 10 uM after 2 hrs by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21
The antitubercular activity of various nitro(triazole/imidazole)-based compounds.
AID1209582Unbound volume of distribution in Sprague-Dawley rat brain slices at 100 nM after 5 hrs2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID1810686Agonist activity at TAE expressed in human HEK293T cells coexpressing human full-length TLX/Gal4-VP 16 assessed as renilla luciferase reporter activity incubated for 14 hrs by Dual-glo luciferase2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Propranolol Activates the Orphan Nuclear Receptor TLX to Counteract Proliferation and Migration of Glioblastoma Cells.
AID1533612Effective permeability of the compound at pH 7.4 after 18 hrs by PAMPA-BBB assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Design and development of some phenyl benzoxazole derivatives as a potent acetylcholinesterase inhibitor with antioxidant property to enhance learning and memory.
AID231333Ratio of [(apical to basal)/(basal to apical)] (Caco-2 cell monolayer)2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Experimental and computational screening models for the prediction of intestinal drug absorption.
AID27167Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1573588Efflux ratio of apparent permeability in human Caco2 cells measured at 90 mins time interval by LC-MS/MS analysis2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Development of Macrocyclic Peptides Containing Epoxyketone with Oral Availability as Proteasome Inhibitors.
AID568160Metabolic stability in ICR mouse liver microsomes assessed as compound remaining at 1 uM after 60 mins in presence of NADPH2011Bioorganic & medicinal chemistry letters, Feb-15, Volume: 21, Issue:4
Structure and property based design, synthesis and biological evaluation of γ-lactam based HDAC inhibitors.
AID1254934Efflux ratio of permeability from basolateral to apical side over apical to basolateral side in human Caco2 cells after 2 hrs by LC-MS/MS method2015European journal of medicinal chemistry, Oct-20, Volume: 1033-Nitrotriazole-based piperazides as potent antitrypanosomal agents.
AID387875Apparent permeability across human Caco-2 cell membrane2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 5: Exploration of pyridazinones containing 6-amino-substituents.
AID610066Efflux ratio of permeability from basolateral to apical side to apical to basolateral side in human Caco2 cells at 10 uM by LC/MS/MS analysis2011Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16
Effects of C7 substitutions in a high affinity microtubule-binding taxane on antitumor activity and drug transport.
AID1381447Apparent permeability from apical to basolateral side in MDCK cells2018Journal of medicinal chemistry, Aug-09, Volume: 61, Issue:15
Identification of Morpholino Thiophenes as Novel Mycobacterium tuberculosis Inhibitors, Targeting QcrB.
AID1759974Apparent permeability across apical to basolateral in human Caco2 cells by LC-MS/MS analysis2021European journal of medicinal chemistry, Jul-05, Volume: 219Ring-opening of five-membered heterocycles conjugated 4-isopropylresorcinol scaffold-based benzamides as HSP90 inhibitors suppressing tumor growth in vitro and in vivo.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1573586Apparent permeability from apical to basolateral side in human Caco2 cells measured at 90 mins time interval by LC-MS/MS analysis2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Development of Macrocyclic Peptides Containing Epoxyketone with Oral Availability as Proteasome Inhibitors.
AID481441Aqueous diffusivity at 37C2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID1810681Agonist activity at in human TLX LBD expressed in human HEK293T cells coexpressing Gal4-VP 16 assessed as increase in reporter activity measured after 14 hrs by luciferase reporter gene assay relative to control2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Propranolol Activates the Orphan Nuclear Receptor TLX to Counteract Proliferation and Migration of Glioblastoma Cells.
AID658937Apparent permeability from basolateral to apical side of human Caco2 cells at 100 uM up to 90 mins2012European journal of medicinal chemistry, Jun, Volume: 52Exploring the interplay of physicochemical properties, membrane permeability and giardicidal activity of some benzimidazole derivatives.
AID477503Apparent permeability from apical to basolateral side of the human Caco-2 cells at 10 uM after 2 hrs by LC-MS/MS analysis2009Bioorganic & medicinal chemistry letters, Nov-01, Volume: 19, Issue:21
Pyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione derivatives: their cytoprotection effect from rotenone toxicity and preliminary DMPK properties.
AID1311209Effective permeability of the compound at 100 uM at pH 7.4 after 3 to 6 hrs by PAMPA2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Design, synthesis and in vitro evaluation of benzothiazole-based ureas as potential ABAD/17β-HSD10 modulators for Alzheimer's disease treatment.
AID1350482Displacement of [3H]-CGP12177 from human beta1 ADR expressed in HEK293T cell membranes after 90 mins by scintillation counting2018Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12
Discovery of β-Adrenergic Receptors Blocker-Carbonic Anhydrase Inhibitor Hybrids for Multitargeted Antiglaucoma Therapy.
AID1407669Apparent permeability of the compound from basolateral to apical side in human Caco2 cells after 120 mins by LC-MS/MS analysis2018European journal of medicinal chemistry, Sep-05, Volume: 157Hedgehog pathway inhibitors of the acylthiourea and acylguanidine class show antitumor activity on colon cancer in vitro and in vivo.
AID1264249Permeability of the compound at 25 ug/ml after 18 hrs by PAMPA assay2015European journal of medicinal chemistry, Oct-20, Volume: 103Design, synthesis and biological evaluation of tricyclic diterpene derivatives as novel neuroprotective agents against ischemic brain injury.
AID407366Displacement of 1-anilinonaphthalene-8-sulphonic acid from rat recombinant L-FABP high binding affinity site expressed in Escherichia coli BL21 by competitive fluorescence displacement assay2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Characterization of the drug binding specificity of rat liver fatty acid binding protein.
AID156204Binding to POPC/GMI liposomes using biosensor system2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface: correlation with fraction absorbed in humans.
AID678834TP_TRANSPORTER: transepithelial transport in Caco-2 cells2003Pharmaceutical research, Aug, Volume: 20, Issue:8
pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions.
AID781326pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1446270Protein binding in mouse serum at 25 to 100 uM after 4 hrs by LC-MS method2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
Design, Synthesis, and Evaluation of Novel Prodrugs of Transition State Inhibitors of Norovirus 3CL Protease.
AID1220984Extraction ratio of the compound in healthy Wistar rat perfused liver at 4 mM after 10 mins2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1810691Effect on TLX regulated gene expression in human T98G cells assessed as decrease in TET3 mRNA expression at 50 uM after 8 hrs by qRT-PCR analysis2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Propranolol Activates the Orphan Nuclear Receptor TLX to Counteract Proliferation and Migration of Glioblastoma Cells.
AID1895165Permeability across apical to basal side in human Caco-2 cells assessed as drug recovery preincubated with verapamil for 30 mins followed by compound addition measured at 0.5 to 2 hrs by LC-MS analysis relative to control2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Interplay among Conformation, Intramolecular Hydrogen Bonds, and Chameleonicity in the Membrane Permeability and Cyclophilin A Binding of Macrocyclic Peptide Cyclosporin O Derivatives.
AID178337Inhibition of isoprenaline induced tachycardia in anaesthetised rats.1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Beta 1-selective adrenoceptor antagonists. 3. 4-Azolyl-linked phenoxypropanolamines.
AID1365726Apparent permeability of the compound across apical side to basolateral side in human Caco2 cells monolayer at 10 uM after 1 hr by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21
The antitubercular activity of various nitro(triazole/imidazole)-based compounds.
AID41350Beta-2 adrenergic receptor antagonist activity as the dose required to inhibit 50% of vasopressor response in anesthetized rats1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
beta 1-selective adrenoceptor antagonists. 2. 4-ether-linked phenoxypropanolamines.
AID604023Ratio of total drug level in brain to plasma in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID4411Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement1996Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1
Binding of arylpiperazines, (aryloxy)propanolamines, and tetrahydropyridylindoles to the 5-HT1A receptor: contribution of the molecular lipophilicity potential to three-dimensional quantitative structure-affinity relationship models.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID21264Effective permeability measured in human.1998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach.
AID29844Fraction absorbed after oral administration in humans2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Experimental and computational screening models for the prediction of intestinal drug absorption.
AID1810689Effect on TLX regulated gene expression in human T98G cells assessed as induction of SIRT1 mRNA expression at 50 uM after 8 hrs by qRT-PCR analysis2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Propranolol Activates the Orphan Nuclear Receptor TLX to Counteract Proliferation and Migration of Glioblastoma Cells.
AID588961Paracellular permeability at pH 5.5 in human Caco-2 cells2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID658372Antihypertensive activity in DOCA-salt treated Wistar rat assessed as decrease in systolic blood pressure at 10 mg/kg, po bid administered 29 days after DOCA-salt-challenge for 15 days 12 to 15 hrs post-last dose by plethysmography2011ACS medicinal chemistry letters, Dec-08, Volume: 2, Issue:12
Potent and Selective Inhibitors of Long Chain l-2-Hydroxy Acid Oxidase Reduced Blood Pressure in DOCA Salt-Treated Rats.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID610065Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM by LC/MS/MS analysis2011Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16
Effects of C7 substitutions in a high affinity microtubule-binding taxane on antitumor activity and drug transport.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID658930Influx ratio of permeability from basolateral to apical side over apical to basolateral side in human Caco2 cells at 100 uM up to 90 mins2012European journal of medicinal chemistry, Jun, Volume: 52Exploring the interplay of physicochemical properties, membrane permeability and giardicidal activity of some benzimidazole derivatives.
AID1769826Permeability of the compound across apical to basolateral membrane in human Caco-2 cells incubated for 2 hrs by LC-MS/MS analysis2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Discovery, Structure-Activity Relationships, and In Vivo Evaluation of Novel Aryl Amides as Brain Penetrant Adaptor Protein 2-Associated Kinase 1 (AAK1) Inhibitors for the Treatment of Neuropathic Pain.
AID1446269Protein binding in human serum at 25 to 100 uM after 4 hrs by LC-MS method2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
Design, Synthesis, and Evaluation of Novel Prodrugs of Transition State Inhibitors of Norovirus 3CL Protease.
AID1900028Apparent permeability across apical to basolateral side in human Caco-2 cells at 10 uM measured after 2 hrs by LC-MS/MS analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Design, Synthesis, and Biological Evaluation of 1-(Indolizin-3-yl)ethan-1-ones as CBP Bromodomain Inhibitors for the Treatment of Prostate Cancer.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID18861GOF value represents multisets of log P data1998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach.
AID1764401Ratio of drug concentration in brain to plasma of P-gp knock out Sprague-Dawley rat2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Development of an
AID1221020Intrinsic elimination clearance in perfused liver of high-fat emulsion-induced nonalcoholic steatohepatitis Wistar rat assessed per gm of liver at 4 mM after 10 mins2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1623705Apparent permeability of compound at 10 uM at pH 7.4 after 12 hrs by PAMPA2019European journal of medicinal chemistry, Feb-15, Volume: 164Investigation of stereoisomeric bisarylethenesulfonic acid esters for discovering potent and selective PTP1B inhibitors.
AID1338124Permeability of the compound at 100 uM up to 6 hrs by PAMPA2017European journal of medicinal chemistry, Jan-05, Volume: 125Design, synthesis and biological evaluation of new phthalimide and saccharin derivatives with alicyclic amines targeting cholinesterases, beta-secretase and amyloid beta aggregation.
AID568159Metabolic stability in ICR mouse liver microsomes assessed as compound remaining at 1 uM after 60 mins in absence of NADPH2011Bioorganic & medicinal chemistry letters, Feb-15, Volume: 21, Issue:4
Structure and property based design, synthesis and biological evaluation of γ-lactam based HDAC inhibitors.
AID389958Apparent permeability across human Caco-2 cells at 50 uM2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1).
AID1900032Apparent permeability across basolateral to apical side in human Caco-2 cells assessed as drug recovery at 10 uM measured after 2 hrs by LC-MS/MS analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Design, Synthesis, and Biological Evaluation of 1-(Indolizin-3-yl)ethan-1-ones as CBP Bromodomain Inhibitors for the Treatment of Prostate Cancer.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID781328pKa (acid-base dissociation constant) as determined by Luan ref: Pharm. Res. 20052014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1220988Extraction ratio of the compound in perfused liver of high-fat emulsion-induced nonalcoholic steatohepatitis Wistar rat at 4 mM after 10 mins2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
AID1204627Apparent permeability from apical to basolateral side in human Caco2 cells by LC-MS analysis2015European journal of medicinal chemistry, Jun-05, Volume: 97Exploring experimental and computational markers of cyclic peptides: Charting islands of permeability.
AID1377751Effective permeability of the compound after 2.5 hrs at 25 degC by PAMPA assay2017European journal of medicinal chemistry, Sep-29, Volume: 138Leucine rich repeat kinase 2 (LRRK2) inhibitors based on indolinone scaffold: Potential pro-neurogenic agents.
AID1823664Apparent permeability across apical to basolateral side in human Caco-2 cells at 5 uM measured every 15 mins for 1 hr by LC-MS/MS analysis2021Journal of medicinal chemistry, 05-27, Volume: 64, Issue:10
Discovery of New Imidazo[2,1-
AID1810688Effect on TLX regulated gene expression in human T98G cells assessed as induction of mRNA expression at 50 uM after 8 hrs by qRT-PCR analysis2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Propranolol Activates the Orphan Nuclear Receptor TLX to Counteract Proliferation and Migration of Glioblastoma Cells.
AID1136327Intrinsic activity at beta2 adrenoceptor in guinea pig trachea after 20 mins1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
2-Methoxyphenylethanolamines, potential beta-adrenergic blocking agents.
AID1136324Antagonist activity at beta1 adrenoceptor in guinea pig atrium assessed as inhibition of isoproterenol-induced response after 20 mins1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
2-Methoxyphenylethanolamines, potential beta-adrenergic blocking agents.
AID26400pKa value of the compound. (extrapolated value)1998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach.
AID1576360Permeability coefficient of compound in phosphate buffer containing 0.5% DMSO at pH 7.4 incubated for 18 hrs by PAMPA-BBB assay based spectrophotometric analysis2019MedChemComm, Nov-01, Volume: 10, Issue:11
Druggability profile of stilbene-derived PPAR agonists: determination of physicochemical properties and PAMPA study.
AID1533611Effective permeability of the compound by PAMPA2019European journal of medicinal chemistry, Feb-01, Volume: 163Design and development of some phenyl benzoxazole derivatives as a potent acetylcholinesterase inhibitor with antioxidant property to enhance learning and memory.
AID1810692Cytotoxicity against human T98G cells assessed as cell viability by WST-1 assay2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Propranolol Activates the Orphan Nuclear Receptor TLX to Counteract Proliferation and Migration of Glioblastoma Cells.
AID1370632Effective permeability of the compound at 25 ug/ml after 18 hrs by BBB-PAMPA method2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Identification of novel allosteric inhibitors of mutant isocitrate dehydrogenase 1 by cross docking-based virtual screening.
AID237585Tested for fraction of oral dose absorbed orally in humans2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID1602919Apparent permeability from apical to basolateral side in human Caco2 cells at 5 uM after 90 mins2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Optimization of Blood-Brain Barrier Permeability with Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibitors Having a 2-Aminopyridine Scaffold.
AID237685Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID1220978Drug distribution in perfused liver of high-fat emulsion-induced nonalcoholic steatohepatitis Wistar rat assessed as equilibrium amount ratio charactering slow binding process at 4 mM after 10 mins2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
AID236916Percentage of mass balance in hexadecane membranes model2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Exploring the role of different drug transport routes in permeability screening.
AID1576578Fraction absorbed of the compound by PAMPA2019MedChemComm, Dec-01, Volume: 10, Issue:12
Synthesis of new lophine-carbohydrate hybrids as cholinesterase inhibitors: cytotoxicity evaluation and molecular modeling.
AID658938Efflux ratio of permeability from apical to basolateral side over basolateral to apical side in human Caco2 cells at 100 uM up to 90 mins2012European journal of medicinal chemistry, Jun, Volume: 52Exploring the interplay of physicochemical properties, membrane permeability and giardicidal activity of some benzimidazole derivatives.
AID15120Percent of the drug absorbed after administration to humans was determined1999Journal of medicinal chemistry, May-20, Volume: 42, Issue:10
Molecular hashkeys: a novel method for molecular characterization and its application for predicting important pharmaceutical properties of molecules.
AID1383661Permeability of the compound at 25 ug/ml after 18 hrs by PAMPA-BBB assay2018European journal of medicinal chemistry, Apr-25, Volume: 150Development of Piperazinediones as dual inhibitor for treatment of Alzheimer's disease.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID610064Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM by LC/MS/MS analysis2011Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16
Effects of C7 substitutions in a high affinity microtubule-binding taxane on antitumor activity and drug transport.
AID1626023Displacement of [3H]DHA from inactive/G protein-uncoupled human beta2-AR expressed in CHO cell membranes assessed as intrinsic Kd by liquid scintillation counting2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
Uncoupling the Structure-Activity Relationships of β2 Adrenergic Receptor Ligands from Membrane Binding.
AID1384013Effective permeability of the compound dissolved in PBS containing 1% F-127 at 100 uM after 3 to 6 hrs by PAMPA2018European journal of medicinal chemistry, Apr-25, Volume: 150The concept of hybrid molecules of tacrine and benzyl quinolone carboxylic acid (BQCA) as multifunctional agents for Alzheimer's disease.
AID526529Metabolic stability of the compound in ICR mouse liver microsome assessed as compound remaining at 1 uM in presence of NADPH2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Property based optimization of δ-lactam HDAC inhibitors for metabolic stability.
AID40870In vitro inhibitory activity against beta-2 adrenergic receptor was measured by the inhibition of isoproterenol-induced relaxation of PGF2-alpha contracted guinea pig trachea1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Beta 1-selective adrenoceptor antagonists: examples of the 2-[4-[3-(substituted amino)-2-hydroxypropoxy]phenyl]imidazole class. 2.
AID481444Octanol-water partition coefficient, log P of the compound2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID1056992Permeability of the compound by PAMPA2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Inhibition of cholinesterase and monoamine oxidase-B activity by Tacrine-Homoisoflavonoid hybrids.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1703887Permeability of the compound incubated for 165 mins by PAMPA-BBB assay2020European journal of medicinal chemistry, Oct-15, Volume: 204Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies.
AID1566376Ratio of drug level in blood to plasma (unknown origin) at 500 nM incubated for 60 mins by LC-MS/MS analysis2019Bioorganic & medicinal chemistry letters, 12-15, Volume: 29, Issue:24
Green chemistry appended synthesis, metabolic stability and pharmacokinetic assessment of medicinally important chromene dihydropyrimidinones.
AID1602920Apparent permeability from basolateral to apical side in human Caco2 cells at 5 uM after 90 mins2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Optimization of Blood-Brain Barrier Permeability with Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibitors Having a 2-Aminopyridine Scaffold.
AID1703889Permeability of the compound incubated for 8 hrs by PAMPA-TGI assay2020European journal of medicinal chemistry, Oct-15, Volume: 204Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies.
AID1668032Antiproliferative activity against human SK-MEL-5 cells assessed as cell growth inhibition at 100 uM incubated for 48 hrs by MTT assay relative to control2020Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9
Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents.
AID1576576Effective permeability of compound by PAMPA2019MedChemComm, Dec-01, Volume: 10, Issue:12
Synthesis of new lophine-carbohydrate hybrids as cholinesterase inhibitors: cytotoxicity evaluation and molecular modeling.
AID1272414Efflux ratio of permeability across basolateral to apical side over apical to basolateral side in MDCK cells2016European journal of medicinal chemistry, Jan-27, Volume: 108Combating P-glycoprotein-mediated multidrug resistance with 10-O-phenyl dihydroartemisinin ethers in MCF-7 cells.
AID725903Apparent permeability in human Caco2 cells after 2 hrs2013Bioorganic & medicinal chemistry, Feb-01, Volume: 21, Issue:3
Design, synthesis, and structure-activity relationships of a series of 4-benzyl-5-isopropyl-1H-pyrazol-3-yl β-D-glycopyranosides substituted with novel hydrophilic groups as highly potent inhibitors of sodium glucose co-transporter 1 (SGLT1).
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID29813Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID604026Unbound CSF to plasma concentration ratio in human2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID1136326Antagonist activity at beta2 adrenoceptor in guinea pig trachea assessed as inhibition of isoproterenol-induced response after 20 mins1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
2-Methoxyphenylethanolamines, potential beta-adrenergic blocking agents.
AID1890739Permeability of the compound across blood brain barrier incubated for 18 hrs by UV plate reader based PAMPA assay2022Bioorganic & medicinal chemistry, 04-15, Volume: 60Synthesis and evaluation of dual fatty acid amide hydrolase-monoacylglycerol lipase inhibition and antinociceptive activities of 4-methylsulfonylaniline-derived semicarbazones.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1220992Mean transit time of the compound in healthy Wistar rat perfused liver at 4 mM after 10 mins2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
AID41890Tested for intrinsic sympathomimetic activity (ISA); Pure antagonist1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists.
AID1576348Permeability coefficient of compound in phosphate buffer containing 5% DMSO at pH 7.4 incubated for 7 hrs by HDC/NOPE PAMPA based spectrophotometric analysis2019MedChemComm, Nov-01, Volume: 10, Issue:11
Druggability profile of stilbene-derived PPAR agonists: determination of physicochemical properties and PAMPA study.
AID1056993Permeability of the compound at 100 mg/mL after 10 hrs by PAMPA2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Inhibition of cholinesterase and monoamine oxidase-B activity by Tacrine-Homoisoflavonoid hybrids.
AID1480849Permeability of the compound at pH 7.4 after 18 hrs by PAMPA-BBB assay2017European journal of medicinal chemistry, Apr-21, Volume: 130Design, synthesis and evaluation of 2-arylethenyl-N-methylquinolinium derivatives as effective multifunctional agents for Alzheimer's disease treatment.
AID177029Beta agonistic activity as the dose required to increase heart rate by 30 beats/min in anesthetized rats upon intravenous administration1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
beta 1-selective adrenoceptor antagonists. 2. 4-ether-linked phenoxypropanolamines.
AID1764398Substrate activity at P-gp (unknown origin) assessed as net efflux ratio2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Development of an
AID1608501Apparent permeability in human Caco2 cells by LC-MS/MS analysis2019European journal of medicinal chemistry, Nov-01, Volume: 181Novel reverse thia-analogs of fosmidomycin: Synthesis and antiplasmodial activity.
AID1617371Apparent permeability across apical to basolateral side in human Caco2 cells at 10 uM after 15 to 90 mins by LC-ESI-MS/MS analysis2019Journal of medicinal chemistry, 11-27, Volume: 62, Issue:22
Development of Robust 17(
AID1552590Permeability of compound at 25 ug/ml at pH 7.4 incubated for 18 hrs by PAMPA-BBB assay2019Bioorganic & medicinal chemistry, 08-15, Volume: 27, Issue:16
Design, synthesis, and evaluation of novel N-(4-phenoxybenzyl)aniline derivatives targeting acetylcholinesterase, β-amyloid aggregation and oxidative stress to treat Alzheimer's disease.
AID702956Plasma protein binding in human plasma at 10 uM2012Journal of medicinal chemistry, Jun-28, Volume: 55, Issue:12
Identification, synthesis, and biological evaluation of the metabolites of 3-amino-6-(3'-aminopropyl)-5H-indeno[1,2-c]isoquinoline-5,11-(6H)dione (AM6-36), a promising rexinoid lead compound for the development of cancer chemotherapeutic and chemopreventi
AID781325pKa (acid-base dissociation constant) as determined by Liao ref: J Chem Info Model 20092014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1475282Apparent permeability in human Caco2 cells at 10 uM2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Discovery of N-{4-[5-(4-Fluorophenyl)-3-methyl-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-acetamide (CBS-3595), a Dual p38α MAPK/PDE-4 Inhibitor with Activity against TNFα-Related Diseases.
AID40537Selectivity for beta-1 adrenergic receptor1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists.
AID453203Lipophilicity, log D of the compound2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Development of an in silico model for human skin permeation based on a Franz cell skin permeability assay.
AID1617372Apparent permeability across basolateral to apical side in human Caco2 cells at 10 uM after 15 to 90 mins by LC-ESI-MS/MS analysis2019Journal of medicinal chemistry, 11-27, Volume: 62, Issue:22
Development of Robust 17(
AID1350705Efflux ratio of apparent permeability in MDCK-MDR1 cells at 5 uM after 90 mins by LC-MS/MS analysis2018Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14
Optimization of Isothiazolo[4,3- b]pyridine-Based Inhibitors of Cyclin G Associated Kinase (GAK) with Broad-Spectrum Antiviral Activity.
AID311367Permeability coefficient in human skin2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds.
AID1668033Antiproliferative activity against human SK-MEL-5 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay2020Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9
Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents.
AID453204Permeability in human skin after 48 hrs by Franz cell permeability assay2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Development of an in silico model for human skin permeation based on a Franz cell skin permeability assay.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1810693Induction of apoptosis in human T98G cells assessed as viable cells at 100 nM measured after 72 hrs by propidium iodide staining based flow cytometry2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Propranolol Activates the Orphan Nuclear Receptor TLX to Counteract Proliferation and Migration of Glioblastoma Cells.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID611927Displacement of [3H](-)-CGP12177 from human adrenergic beta1 receptor2011Journal of medicinal chemistry, Aug-11, Volume: 54, Issue:15
Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators.
AID1917372Permeability of compound by PAMPA-BBB assay2022Bioorganic & medicinal chemistry letters, 11-15, Volume: 76Design, synthesis, in-vitro, in-vivo and ex-vivo pharmacology of thiazolidine-2,4-dione derivatives as selective and reversible monoamine oxidase-B inhibitors.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID411204Cardiovascular effect in anaesthetized Wistar rat assessed as mean arterial pressure at 40 mg/kg, ip after 60 mins2009Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1
Design, synthesis and pharmacological screening of novel antihypertensive agents using hybrid approach.
AID737301Permeability of the compound2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
Triazolopyridazine LRRK2 kinase inhibitors.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1765292Permeability of compound by PAMPA-BBB assay2021European journal of medicinal chemistry, Oct-15, Volume: 222Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
AID1810694Antiproliferation activity against human T98G cells measured after 72 hrs by crystal violet staining based assay2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Propranolol Activates the Orphan Nuclear Receptor TLX to Counteract Proliferation and Migration of Glioblastoma Cells.
AID236914Permeability Coefficient in hexadecane membranes model2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Exploring the role of different drug transport routes in permeability screening.
AID1602921Efflux ratio of apparent permeability in human Caco2 cells at 5 uM after 90 mins2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Optimization of Blood-Brain Barrier Permeability with Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibitors Having a 2-Aminopyridine Scaffold.
AID1772565Efflux ratio of apparent permeability in human Caco-2 cells2021European journal of medicinal chemistry, Nov-05, Volume: 223Non-carboxylic acid inhibitors of aldose reductase based on N-substituted thiazolidinedione derivatives.
AID1764400Unbound brain concentration in P-gp knock out Sprague-Dawley rat at 5 mg/ml/kg, po measured upto 4 hrs by LC-MS analysis2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Development of an
AID20050Human absorption A (%)1998Journal of medicinal chemistry, Mar-26, Volume: 41, Issue:7
Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.
AID255284Percent inhibition against Beta-1 adrenergic receptor at 1 uM2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID1730594Permeability of compound in PBS buffer at pH 7.4 incubated for 18 hrs by PAMPA-BBB assay2021European journal of medicinal chemistry, Mar-05, Volume: 213Design, synthesis, and biological evaluation of novel xanthone-alkylbenzylamine hybrids as multifunctional agents for the treatment of Alzheimer's disease.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID28681Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1772562n-Octanol/PBS buffer distribution coefficient, logD of the compound at pH 7.42021European journal of medicinal chemistry, Nov-05, Volume: 223Non-carboxylic acid inhibitors of aldose reductase based on N-substituted thiazolidinedione derivatives.
AID21254Mono layer permeability of human intestinal Caco-2 cells1998Journal of medicinal chemistry, Dec-31, Volume: 41, Issue:27
Evaluation of dynamic polar molecular surface area as predictor of drug absorption: comparison with other computational and experimental predictors.
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID28925Highest effective permeability across hexadecane membrane (pH 4-8)2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID1324901Apparent permeability from apical to basolateral side in human Caco2 cells at 10 uM by HPLC-MS analysis2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Free fatty acid receptor 1 (GPR40) agonists containing spirocyclic periphery inspired by LY2881835.
AID1136325Intrinsic activity at beta1 adrenoceptor in guinea pig atrium after 20 mins relative to control1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
2-Methoxyphenylethanolamines, potential beta-adrenergic blocking agents.
AID1703888Drug absorption of the compound incubated for 8 hrs by PAMPA-TGI assay2020European journal of medicinal chemistry, Oct-15, Volume: 204Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies.
AID1230203Permeability of the compound using PDVF membrane after 2 hrs 45 mins by PAMPA-BBB assay2015Journal of natural products, Jun-26, Volume: 78, Issue:6
In Vitro Inhibitory Effects of 8-O-Demethylmaritidine and Undulatine on Acetylcholinesterase and Their Predicted Penetration across the Blood-Brain Barrier.
AID1576577Effective permeability of compound incubated for 8 hrs by PAMPA2019MedChemComm, Dec-01, Volume: 10, Issue:12
Synthesis of new lophine-carbohydrate hybrids as cholinesterase inhibitors: cytotoxicity evaluation and molecular modeling.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1895162Permeability across basal to apical side in human Caco-2 cells assessed as drug recovery measured at 0.5 to 2 hrs by LC-MS analysis relative to control2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Interplay among Conformation, Intramolecular Hydrogen Bonds, and Chameleonicity in the Membrane Permeability and Cyclophilin A Binding of Macrocyclic Peptide Cyclosporin O Derivatives.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID177028Beta agonist activity against heart rate in rats1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Beta 1-selective adrenoceptor antagonists. 3. 4-Azolyl-linked phenoxypropanolamines.
AID331213Apparent permeability from apical to basolateral side in human Caco-2 cells at 10 uM2008Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12
Pyrrolo[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase.
AID1810695Inhibition of cell migration in human T98G cells at 75 uM incubated for 24 hrs by crystal violet staining based by Boyden chamber method2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Propranolol Activates the Orphan Nuclear Receptor TLX to Counteract Proliferation and Migration of Glioblastoma Cells.
AID1900031Apparent permeability across apical to basolateral side in human Caco-2 cells assessed as drug recovery at 10 uM measured after 2 hrs by LC-MS/MS analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Design, Synthesis, and Biological Evaluation of 1-(Indolizin-3-yl)ethan-1-ones as CBP Bromodomain Inhibitors for the Treatment of Prostate Cancer.
AID604022Fraction unbound in Sprague-Dawley rat plasma administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1874536Apparent permeability across apical to basolateral side in human Caco-2 cells measured after 120 mins by LC-MS/MS analysis2022Journal of medicinal chemistry, 09-08, Volume: 65, Issue:17
Development, Optimization, and In Vivo Validation of New Imidazopyridine Chemotypes as Dual TLR7/TLR9 Antagonists through Activity-Directed Sequential Incorporation of Relevant Structural Subunits.
AID1221008Apparent distribution ratio of the compound in healthy Wistar rat perfused liver at 4 mM after 10 mins2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
AID236912Permeability Coefficient in 2/4/A1 cell model2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Exploring the role of different drug transport routes in permeability screening.
AID1442849Apparent permeability in human Caco2 cells at 10 uM at pH 7.4 by LC-MS/MS analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120.
AID349880Permeability across porcine brain lipid coated polyvinylidene fluoride membrane by PAMPA2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease.
AID467612Fraction unbound in human plasma2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID1566374Ratio of drug level in blood to plasma (unknown origin) at 500 nM incubated for 30 mins by LC-MS/MS analysis2019Bioorganic & medicinal chemistry letters, 12-15, Volume: 29, Issue:24
Green chemistry appended synthesis, metabolic stability and pharmacokinetic assessment of medicinally important chromene dihydropyrimidinones.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID8002Observed volume of distribution2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID1465453Permeability in MDCK cells2017Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20
Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor.
AID7783Unbound fraction (plasma)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID658932Apparent permeability from apical to basolateral side of human Caco2 cells at 100 uM up to 90 mins2012European journal of medicinal chemistry, Jun, Volume: 52Exploring the interplay of physicochemical properties, membrane permeability and giardicidal activity of some benzimidazole derivatives.
AID1350481Displacement of [3H]-CGP12177 from human beta2 ADR expressed in HEK293T cell membrane after 90 mins by scintillation counting2018Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12
Discovery of β-Adrenergic Receptors Blocker-Carbonic Anhydrase Inhibitor Hybrids for Multitargeted Antiglaucoma Therapy.
AID19419Partition coefficient (logD7.4)1998Journal of medicinal chemistry, Mar-26, Volume: 41, Issue:7
Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.
AID26362Ionization constant (pKa)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID1730604Permeability of compound in pH 7.4 PBS/EtOH buffer (7:3) incubated for 18 hrs by UV plate reader based PAMPA-BBB assay2021European journal of medicinal chemistry, Mar-05, Volume: 213Design, synthesis, and biological evaluation of novel xanthone-alkylbenzylamine hybrids as multifunctional agents for the treatment of Alzheimer's disease.
AID1129167Permeability of the compound by PAMPA2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Protein kinase CK-1 inhibitors as new potential drugs for amyotrophic lateral sclerosis.
AID1336305Displacement of [3H]CGP 12177 from human recombinant beta1 adrenergic receptor expressed in HEK293 cells measured after 60 mins by scintillation counting method2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH
AID1810690Effect on TLX regulated gene expression in human T98G cells assessed as decrease in PTEN mRNA expression at 50 uM after 8 hrs by qRT-PCR analysis2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Propranolol Activates the Orphan Nuclear Receptor TLX to Counteract Proliferation and Migration of Glioblastoma Cells.
AID1895159Permeability across apical to basal side in human Caco-2 cells measured at 0.5 to 2 hrs by LC-MS analysis2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Interplay among Conformation, Intramolecular Hydrogen Bonds, and Chameleonicity in the Membrane Permeability and Cyclophilin A Binding of Macrocyclic Peptide Cyclosporin O Derivatives.
AID1221012Apparent distribution ratio of the compound in perfused liver of high-fat emulsion-induced nonalcoholic steatohepatitis Wistar rat at 4 mM after 10 mins2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
AID1513922Efflux ratio of apparent permeability in human Caco2 cells at 10 uM after 120 mins by LC-MS/MS analysis2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Alkyl-guanidine Compounds as Potent Broad-Spectrum Antibacterial Agents: Chemical Library Extension and Biological Characterization.
AID1272413Activity at MDR1 (unknown origin) expressed in MDCK cells assessed as efflux ratio of permeability across basolateral to apical side over apical to basolateral side2016European journal of medicinal chemistry, Jan-27, Volume: 108Combating P-glycoprotein-mediated multidrug resistance with 10-O-phenyl dihydroartemisinin ethers in MCF-7 cells.
AID1136332Selectivity ratio for beta1 adrenoceptor in guinea pig atrium over beta2 adrenoceptor in guinea pig trachea1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
2-Methoxyphenylethanolamines, potential beta-adrenergic blocking agents.
AID1533477Apparent permeability from apical to basolateral side in MDCK cells2019European journal of medicinal chemistry, Jan-15, Volume: 162Second generation of diazachrysenes: Protection of Ebola virus infected mice and mechanism of action.
AID40869In vitro beta-2 adrenergic receptor activity was determined by measuring inhibition of the isoproterenol induced relaxation in isolated guinea pig tracheal chains contracted with PGF2-alpha1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Beta 1-selective adrenoceptor antagonists: examples of the 2-[4-[3-(substituted-amino)-2-hydroxypropoxy]phenyl]imidazole class.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID321772Permeability across human Caco-2 cells2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Backbone cyclic peptidomimetic melanocortin-4 receptor agonist as a novel orally administrated drug lead for treating obesity.
AID1381449Efflux ratio of apparent permeability from basolateral to apical side over apical to basolateral side of MDCK cells2018Journal of medicinal chemistry, Aug-09, Volume: 61, Issue:15
Identification of Morpholino Thiophenes as Novel Mycobacterium tuberculosis Inhibitors, Targeting QcrB.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1404016Permeability of the compound by PAMPA2018European journal of medicinal chemistry, Feb-10, Volume: 145Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID679593TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical)(Digoxin: 0.1 uM, Atenolol: 50 uM) in MDR1-expressing LLC-PK1 cells2002Life sciences, Feb-15, Volume: 70, Issue:13
Interaction of digoxin with antihypertensive drugs via MDR1.
AID1272409Activity at MDR1 (unknown origin) expressed in MDCK cells assessed as permeability across apical to basolateral after 90 mins by LC-MS/MS analysis2016European journal of medicinal chemistry, Jan-27, Volume: 108Combating P-glycoprotein-mediated multidrug resistance with 10-O-phenyl dihydroartemisinin ethers in MCF-7 cells.
AID29845Estimation of fraction absorbed (Fa) in the human intestine using biosensor technology.2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface: correlation with fraction absorbed in humans.
AID1384014Effective permeability of the compound dissolved in PBS at 100 uM after 3 to 6 hrs by PAMPA2018European journal of medicinal chemistry, Apr-25, Volume: 150The concept of hybrid molecules of tacrine and benzyl quinolone carboxylic acid (BQCA) as multifunctional agents for Alzheimer's disease.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID481446Effective permeability across human jejunum2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID28924Effective permeability (Pe) across a hexadecane membrane (pH 6.8)2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID1221004Permeability surface area product in perfused liver of high-fat emulsion-induced nonalcoholic steatohepatitis Wistar rat assessed per gm of liver at 4 mM after 10 mins2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
AID1907152Apparent permeability of the compound across apical to basolateral side in human Caco-2 cells at 10 uM incubated for 120 mins and measured by LC-MS/MS analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Discovery, optimization and evaluation of 1-(indolin-1-yl)ethan-1-ones as novel selective TRIM24/BRPF1 bromodomain inhibitors.
AID1350727Aqueous solubility in PBS buffer at pH 7.4 at 100 uM after 1 hr by LC-MS/MS analysis2018Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14
Optimization of Isothiazolo[4,3- b]pyridine-Based Inhibitors of Cyclin G Associated Kinase (GAK) with Broad-Spectrum Antiviral Activity.
AID1895163Efflux ratio of permeability from apical to basolateral side over basolateral to apical side in human Caco2 cells measured at 0.5 to 2 hrs by LC-MS analysis2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Interplay among Conformation, Intramolecular Hydrogen Bonds, and Chameleonicity in the Membrane Permeability and Cyclophilin A Binding of Macrocyclic Peptide Cyclosporin O Derivatives.
AID411203Cardiovascular effect in anaesthetized Wistar rat assessed as mean arterial pressure at 40 mg/kg, ip after 45 mins2009Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1
Design, synthesis and pharmacological screening of novel antihypertensive agents using hybrid approach.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID16351Percent diffusion through fuzzy rat skin after 48 h of incubation1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
(Acyloxy)alkyl carbamates as novel bioreversible prodrugs for amines: increased permeation through biological membranes.
AID608394Permeability of the compound at 100 uM after 5 hrs by PAMPA2011Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14
Imidazo[1,2-a]pyridin-3-amines as potential HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1823665Apparent permeability across basolateral to apical side in human Caco-2 cells at 5 uM measured every 15 mins for 1 hr by LC-MS/MS analysis2021Journal of medicinal chemistry, 05-27, Volume: 64, Issue:10
Discovery of New Imidazo[2,1-
AID350219Lipophilicity, log K at pH 2 by by hydrophilic interaction chromatography using 95% acetonitrile as mobile phase2009Journal of medicinal chemistry, May-28, Volume: 52, Issue:10
Lipophilicity of basic drugs measured by hydrophilic interaction chromatography.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID350220Lipophilicity, log K at pH 2 by by hydrophilic interaction chromatography using 100% water as mobile phase2009Journal of medicinal chemistry, May-28, Volume: 52, Issue:10
Lipophilicity of basic drugs measured by hydrophilic interaction chromatography.
AID1602640Ratio of drug level in blood to plasma (unknown origin) at 500 nM by LC-MS/MS analysis2019Bioorganic & medicinal chemistry letters, 04-15, Volume: 29, Issue:8
Pharmacokinetic evaluation of medicinally important synthetic N,N' diindolylmethane glucoside: Improved synthesis and metabolic stability.
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1407668Apparent permeability of the compound from apical to basolateral side in human Caco2 cells assessed as drug recovery after 120 mins by LC-MS/MS analysis2018European journal of medicinal chemistry, Sep-05, Volume: 157Hedgehog pathway inhibitors of the acylthiourea and acylguanidine class show antitumor activity on colon cancer in vitro and in vivo.
AID42217Activity at beta-1 adrenergic receptor1992Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25
Computer-aided mapping of the beta-adrenoceptor. 1. Explanation for effect of para substitution on blocking activity at the beta-1-adrenoceptor.
AID1566372Ratio of drug level in blood to plasma (unknown origin) at 500 nM measured immediately by LC-MS/MS analysis2019Bioorganic & medicinal chemistry letters, 12-15, Volume: 29, Issue:24
Green chemistry appended synthesis, metabolic stability and pharmacokinetic assessment of medicinally important chromene dihydropyrimidinones.
AID603955In-vivo blood to lung partition coefficients of the compound, logP(lung) in rat2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
AID1668035Antiproliferative activity against human A375 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay2020Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9
Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents.
AID236913Permeability Coefficient in Caco-2 cell culture model2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Exploring the role of different drug transport routes in permeability screening.
AID1285613Displacement of [3H](-)CGP12177 from human recombinant Beta-1 adrenergic receptor expressed in HEK293 cells2016Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8
Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
AID350216Dissociation constant, pKa of the compound2009Journal of medicinal chemistry, May-28, Volume: 52, Issue:10
Lipophilicity of basic drugs measured by hydrophilic interaction chromatography.
AID411202Cardiovascular effect in anaesthetized Wistar rat assessed as mean arterial pressure at 40 mg/kg, ip after 30 mins2009Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1
Design, synthesis and pharmacological screening of novel antihypertensive agents using hybrid approach.
AID1272412Permeability across basolateral to apical side in MDCK cells after 90 mins by LC-MS/MS analysis2016European journal of medicinal chemistry, Jan-27, Volume: 108Combating P-glycoprotein-mediated multidrug resistance with 10-O-phenyl dihydroartemisinin ethers in MCF-7 cells.
AID1907153Apparent permeability of the compound across basolateral to apical side in human Caco-2 cells at 10 uM incubated for 120 mins and measured by LC-MS/MS analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Discovery, optimization and evaluation of 1-(indolin-1-yl)ethan-1-ones as novel selective TRIM24/BRPF1 bromodomain inhibitors.
AID1220996Mean transit time of the compound in perfused liver of high-fat emulsion-induced nonalcoholic steatohepatitis Wistar rat at 4 mM after 10 mins2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
AID1350707Apparent permeability cross apical to basolateral side in MDCK-MDR1 cells at 5 uM after 90 mins by LC-MS/MS analysis2018Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14
Optimization of Isothiazolo[4,3- b]pyridine-Based Inhibitors of Cyclin G Associated Kinase (GAK) with Broad-Spectrum Antiviral Activity.
AID1635247Apparent permeability from basolateral to apical side in human Caco2 cells at 10 uM incubated for 120 mins by LC-MS/MS analysis2016European journal of medicinal chemistry, Aug-08, Volume: 118Design and synthesis of novel bicalutamide and enzalutamide derivatives as antiproliferative agents for the treatment of prostate cancer.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1623120Effective permeability of the compound by BBB-PAMPA method2019European journal of medicinal chemistry, Feb-01, Volume: 163Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease.
AID1365727Apparent permeability of the compound across basolateral side to apical side in human Caco2 cells monolayer at 10 uM after 1 hr by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21
The antitubercular activity of various nitro(triazole/imidazole)-based compounds.
AID467613Volume of distribution at steady state in human2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID1221000Permeability surface area product in healthy Wistar rat perfused liver assessed per gm of liver at 4 mM after 10 mins2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
AID1874538Efflux ratio of apparent permeability across basolateral to apical side to apical to basolateral side in human Caco-2 cells measured after 120 mins by LC-MS/MS analysis2022Journal of medicinal chemistry, 09-08, Volume: 65, Issue:17
Development, Optimization, and In Vivo Validation of New Imidazopyridine Chemotypes as Dual TLR7/TLR9 Antagonists through Activity-Directed Sequential Incorporation of Relevant Structural Subunits.
AID566241Inhibition of human alpha1 adrenoceptor2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: de
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID635079Permeability of the compound after 2.5 hrs by PAMPA-BBB assay2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1346260Human beta1-adrenoceptor (Adrenoceptors)2004Naunyn-Schmiedeberg's archives of pharmacology, May, Volume: 369, Issue:5
Binding of (-)-[3H]-CGP12177 at two sites in recombinant human beta 1-adrenoceptors and interaction with beta-blockers.
AID1346260Human beta1-adrenoceptor (Adrenoceptors)1999European journal of pharmacology, Feb-19, Volume: 367, Issue:2-3
LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors.
AID1346250Human beta2-adrenoceptor (Adrenoceptors)1999European journal of pharmacology, Feb-19, Volume: 367, Issue:2-3
LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors.
AID1346250Human beta2-adrenoceptor (Adrenoceptors)2005British journal of pharmacology, Feb, Volume: 144, Issue:3
The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
AID1346260Human beta1-adrenoceptor (Adrenoceptors)2005British journal of pharmacology, Feb, Volume: 144, Issue:3
The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
AID17985803H-CGP 12177 Whole Cell Binding Assay from Article 10.1038/sj.bjp.0706048: \\The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.\\2005British journal of pharmacology, Feb, Volume: 144, Issue:3
The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5,224)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901723 (32.98)18.7374
1990's1317 (25.21)18.2507
2000's1203 (23.03)29.6817
2010's801 (15.33)24.3611
2020's180 (3.45)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 107.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index107.68 (24.57)
Research Supply Index8.91 (2.92)
Research Growth Index4.40 (4.65)
Search Engine Demand Index204.42 (26.88)
Search Engine Supply Index2.01 (0.95)

This Compound (107.68)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.72%)5.53%
Trials1,950 (35.63%)5.53%
Reviews1 (1.72%)6.00%
Reviews202 (3.69%)6.00%
Case Studies3 (5.17%)4.05%
Case Studies344 (6.29%)4.05%
Observational0 (0.00%)0.25%
Observational10 (0.18%)0.25%
Other53 (91.38%)84.16%
Other2,967 (54.21%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (102)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Clinical Trial to Assess the Efficacy and Safety of Losartan Versus Atenolol in the Prevention of Progressive Dilation of the Aorta in Patients With Marfan Syndrome. [NCT01145612]Phase 3140 participants (Actual)Interventional2008-10-31Active, not recruiting
Use of Beta-blockers and Risk of New Onset Diabetes [NCT01587638]12,336 participants (Actual)Observational2009-04-30Completed
A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy [NCT00338260]Phase 3496 participants (Actual)Interventional1995-06-30Completed
A Randomized, Double-Blind, Two Arm, Parallel Group Health Assessment Study of Losartan or Atenolol in Patients With Mild to Moderate Hypertension [NCT00541684]Phase 3143 participants (Actual)Interventional2001-07-11Completed
N-of-1 Trials for Deprescribing Beta-blockers in HFpEF [NCT04767061]Phase 49 participants (Actual)Interventional2021-04-01Completed
Evaluation of Perioperative Biochemical Stress Factors in Craniotomy Neurosurgical Procedure With Respect to Preoperative Hypertension [NCT02441842]Phase 485 participants (Actual)Interventional2006-03-31Completed
EffecTs of Amlodipine and Other Blood PREssure Lowering Agents on Microvascular FuncTion in Small Vessel Diseases [NCT03082014]Phase 3101 participants (Actual)Interventional2018-02-22Terminated(stopped due to completed for the primary study group of sporadic SVD patients, halted prematurely for the additional study group due to slow recruitment at 26 of 30 CADASIL patients in December 2022)
Prospective, Randomized, Placebo-controlled, Phase 2 Study of 4-aminopyridine, Atenolol, or Placebo in the Treatment of Patients With Vestibular Migraine [NCT03578354]Phase 20 participants (Actual)Interventional2019-01-31Withdrawn(stopped due to Funding not acquired)
Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism [NCT02467400]Early Phase 1165 participants (Actual)Interventional2015-07-01Completed
The Impact of Heart Rate on Central Hemodynamics in Sick Sinus Syndrome Patients With a Permanent Cardiac Pacemaker [NCT03245996]Phase 427 participants (Actual)Interventional2015-06-30Completed
Hypertension in Hemodialysis Patients [NCT00582114]Phase 3200 participants (Actual)Interventional2005-08-31Terminated(stopped due to Stopped by data safety monitoring board)
Drugs in Breast Milk [NCT05543122]304 participants (Anticipated)Observational2022-03-09Recruiting
Matão Controlling Hypertension (MatCH Study): Rationale and Design. Project to Reduce Incidence of Arterial Hypertension in City of Matão, Brazil. [NCT03147092]Early Phase 115,000 participants (Anticipated)Interventional2018-02-01Not yet recruiting
Efficacy and Safety of Propranolol Versus Atenolol on the Proliferative Phase of Infantile Hemangioma [NCT02342275]Phase 3377 participants (Actual)Interventional2013-10-31Completed
Post-Traumatic Stress Disorder and Cardiovascular Disease Risk: Role of Sympathetic Overactivity and Angiotensin II [NCT02560805]Phase 2134 participants (Anticipated)Interventional2015-10-31Suspended(stopped due to Enrollment and study activities are temporarily suspended due to COVID-19.)
Effects of Angiotensin-Receptor Blockade With Olmesartan on Carotid Atherosclerosis in Patients With Hypertension: The Confirmatory Olmesartan Plaque Regression Study [NCT01132768]Phase 4114 participants (Actual)Interventional2010-05-31Terminated(stopped due to Low recruitment)
Effects of Atenolol, Perindopril and Verapamil on Haemodynamic and Vascular Function in Marfan Syndrome - A Randomised Double-Blind Crossover Trial [NCT01295047]Phase 418 participants (Actual)Interventional2006-07-31Completed
Single-center, Open-label, Randomized, Multiple-dose, Parallel-group Study to Investigate Safety and Effects on Heart Rate, Blood Pressure, and Pharmacokinetic Interactions of ACT-334441 Combined With Calcium-channel Blocker (Diltiazem) or Beta-blocker (A [NCT02479204]Phase 110 participants (Actual)Interventional2015-04-28Terminated(stopped due to Based on results from the pilot phase, the study is terminated. No safety events leading to discontinuation were reported)
A Prospective, Multi-center, Randomized, Open-label, Clinical Trial to Compare the Aortic Pulse Pressure Effects of Bisoprolol and Atenolol in 12 Weeks Treatment of Hypertension [NCT01079962]Phase 4209 participants (Actual)Interventional2009-12-31Completed
Effect of the Fixed Dose Combination Amlodipine/Valsartan on Central Aortic Blood Pressure in Uncontrolled Essential Hypertension With Amlodipine 5 mg [NCT00687973]Phase 4393 participants (Actual)Interventional2008-01-31Completed
Evaluation of the Anti-anginal Efficacy and Safety of Ivabradine Used in Patients With Stable Effort Angina Pectoris. A 12 Weeks Randomised, Double-blind Controlled, Parallel-group, Multicentre Study [NCT02623569]Phase 2336 participants (Anticipated)Interventional2014-10-31Recruiting
Bioavailability of Atenolol Tablets [NCT00913965]Phase 124 participants (Actual)Interventional1989-07-31Completed
The Effect of Nitrendipine/Atenolol Combination on Blood Pressure Variability of Patients With Grade 1 Hypertension Compared With Nitrendipine or Atenolol Monotherapy. [NCT04931108]Phase 432 participants (Anticipated)Interventional2021-09-27Recruiting
TREatment With Beta-blockers After myOcardial Infarction withOut Reduced Ejection fracTion [NCT03596385]Phase 48,468 participants (Anticipated)Interventional2018-10-31Recruiting
Trial of Beta Blocker Therapy (Atenolol) Versus Angiotensin II Receptor Blocker Therapy (Losartan) in Individuals With Marfan Syndrome (A Trial Conducted by the Pediatric Heart Network) [NCT00429364]Phase 3608 participants (Actual)Interventional2007-01-31Completed
Vascular Improvement With Olmesartan Medoxomil Study [NCT00772499]Phase 4100 participants (Actual)Interventional2002-11-30Completed
Effect of Ivabradine vs Atenolol on Heart Rate and Effort Tolerance in Patients With Mild to Moderate Mitral Stenosis and Normal Sinus Rhythm [NCT01022463]Phase 350 participants (Actual)Interventional2009-11-30Completed
A Trial to Compare the Effects of Nebivolol Versus Atenolol on Various Cardiovascular Measurements Including Insulin Sensitivity [NCT00125853]54 participants (Actual)Interventional2006-07-31Completed
Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans [NCT04467931]22,213 participants (Actual)Observational2020-01-19Completed
Genetic Mechanisms in Human Hypertension RAAS Inhibition Study [NCT01009944]0 participants (Actual)Interventional2007-01-31Withdrawn(stopped due to Not funded.)
A Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Carvedilol Modified Release Formulation (COREG MR) and Atenolol in Combination With and Compared to an Angiotensin Converting Enzyme Inhibitor (Lisinopril) on Left Ventricular Mass Re [NCT00108082]Phase 3287 participants (Actual)Interventional2005-01-31Completed
Effects of Losartan vs Atenolol on Aortic Stiffness and Diastolic Function in Adults With Marfan Syndrome [NCT00723801]Phase 340 participants (Actual)Interventional2007-10-31Completed
Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment [NCT00741585]Phase 421,983 participants (Actual)Interventional2008-09-01Completed
A Randomized, Open-label, Active Control Trial to Evaluate the Effect of LOSARTAN Therapy on the Progression of Aortic Root Dilation in Patients With Marfan Syndrome [NCT00651235]Phase 244 participants (Anticipated)Interventional2007-02-28Recruiting
Comparison of Carvedilol and Atenolol on Anti-anginal and Metabolic Effects in Patients With Stable Angina Pectoris [NCT02547597]Phase 499 participants (Actual)Interventional2011-04-30Completed
A Comparative Study to Assess the Efficacy of Nicorandil+Atenolol vs Atenolol in Treatment naïve Patients of Chronic Stable Angina. [NCT01397994]Phase 440 participants (Anticipated)Interventional2011-09-30Recruiting
The Evaluation of The Effects of Nebivolol in Comparison to Atenolol on Wall Shear Stress and Rupture Prone Coronary Artery Plaques in Patients With Moderate Coronary Artery Disease [NCT01230892]Phase 429 participants (Actual)Interventional2010-02-28Completed
Captopril Versus Atenolol to Prevent Expansion Rate of Thoracic Aortic Aneurysms [NCT04224675]424 participants (Anticipated)Interventional2020-03-07Not yet recruiting
Neurohumoral and Oxidative Influences of Candesartan, Atenolol, Hydrochlorothiazide and Drug Combinations in Essential Hypertensive Patients. [NCT00232882]Phase 486 participants (Actual)Interventional2003-12-31Completed
Single Dose Two-Way Crossover Fasted Bioequivalence Study of Atenolol 100 mg Capsules in Healthy Volunteers [NCT00775580]36 participants (Actual)Interventional2005-05-31Completed
A Comparative Bioavailability Study of Atenolol Tablets, 100 mg [NCT00946725]Phase 128 participants (Actual)Interventional2000-11-30Completed
N-of-1 Trials for Deprescribing Beta-blockers in HFpEF [NCT04757584]Phase 49 participants (Actual)Interventional2021-04-01Completed
[NCT00000478]Phase 30 participants Interventional1990-11-30Completed
Beta Blockers and Angiotensin Receptor Blockers in Bicuspid Aortic Valve Disease Aortopathy (BAV Study) [NCT01202721]Phase 385 participants (Actual)Interventional2011-06-30Terminated(stopped due to Terminated early due to lack of study feasibility and poor patient recruitment)
Comparative Trial of the Effects of Irbesartan vs Atenolol on the Endothelial Function of Hypertensive Patients With Metabolic Syndrome [NCT00529750]Phase 4108 participants (Actual)Interventional2002-07-31Completed
A 26-week Double-blind, Randomized, Multicenter Parallel-group Trial to Compare the Effects of Valsartan Versus Atenolol on Exercise Capacity in Hypertensive Overweight Postmenopausal Women With Impaired Exercise Tolerance [NCT00171132]Phase 464 participants (Actual)Interventional2004-08-31Completed
A Double-blind, Double-dummy, Multi-centre, Randomized, Active Controlled, Parallel Group Pilot Trial to Compare the Effects of Valsartan and Atenolol on the Pro-thrombotic State in Patients With Mild to Moderate Hypertension. [NCT00171756]Phase 492 participants (Actual)Interventional2004-06-30Completed
Effect of Active Telephone Calls in the Compliance of Hypertensive Patients With Treatment: An Open and Randomized Clinical Trial [NCT00813722]Phase 4400 participants (Actual)Interventional1999-03-31Active, not recruiting
A Randomized, Parallel Group Safety Evaluation of Electrocardiographic Intervals and Blood Pressure in Normal Healthy Volunteers After Nebivolol, Atenolol, Moxifloxacin, or Placebo Administration After Single and Repeated Doses [NCT00158093]Phase 1260 participants Interventional2003-06-30Completed
Blood Pressure Response During Resistance Exercise in Hypertensives: Influence of Beta-blockers [NCT01030016]Phase 410 participants (Actual)Interventional2007-05-31Completed
A Randomized, Open-label, Multicenter, Cross-over Trial to Evaluate the Efficacy of a 20 Week Treatment of Valsartan 320 mg Versus Atenolol 100 mg in Combination With Hydrochlorothiazide on Microcirculation in Hypertensive Patients [NCT00396656]Phase 330 participants (Actual)Interventional2005-12-31Completed
[NCT01904981]Phase 419 participants (Actual)Interventional2014-01-31Completed
Beta1-Selective Blockade for Prevention of Postmenopausal Bone Loss: A Phase 2, Multi-Center, Double-Blinded, Randomized Placebo-Controlled Trial [NCT04905277]Phase 2420 participants (Anticipated)Interventional2021-07-27Recruiting
The Effect of Perioperative Atenolol on Post-Operative Cytokines [NCT00202358]Phase 460 participants (Anticipated)Interventional2002-11-30Active, not recruiting
Comparison of the Hemodynamic Changes in Patients Under Treatment With Bisoprolol Versus Atenolol [NCT01939509]Phase 480 participants (Anticipated)Interventional2012-02-29Completed
[NCT00000514]Phase 30 participants Interventional1984-06-30Completed
An Exploratory Trial of a Multimodal Treatment Strategy for Cancer Cachexia [NCT00625742]15 participants (Actual)Interventional2008-02-29Terminated(stopped due to Low Accrual)
Effects of Bisoprolol and Atenolol on Resting Heart Rate and Sympathetic Nervous System's Activity in Patients With Essential Hypertension [NCT01251146]Phase 4177 participants (Actual)Interventional2010-11-30Completed
Antihypertensive Effects of a Fixed-dose Combination of Losartan and Hydrochlorothiazide Plus Amlodipine Versus a Hydrochlorothiazide and Atenolol Combination Plus Amlodipine in Subjects With Ambulatory Systolic Hypertension. [NCT00140959]Phase 4120 participants Interventional2003-02-01Completed
The Effects of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on Insulin Sensitivity in Overweight and Obese Subjects With Hypertension [NCT00185094]Phase 460 participants Interventional2004-02-29Completed
A Double-Blind, Randomized, Multi-Center, Active Comparator, Five Treatment Study of the Effects of Nebivolol Compared to Atenolol on Cardiovascular Hemodynamics and Exercise Capacity in Patients With Mild to Moderate Hypertension [NCT00200421]Phase 2110 participants Interventional2002-05-31Completed
Multi-Centre Olmesartan Atherosclerosis Regression Evaluation (MORE) [NCT00185185]Phase 3165 participants (Actual)Interventional2001-11-30Completed
A Randomized Double-blind Study Assessing the Effects of Losartan Versus Atenolol on Pulse Wave Velocity and the Biophysical Properties of the Aorta in Patients With Marfan Syndrome [NCT00593710]Phase 217 participants (Actual)Interventional2008-01-31Completed
Uncoupling Protein Polymorphisms and Cardiometabolic Responses to Beta-Blockers [NCT00925119]Phase 431 participants (Actual)Interventional2009-12-31Terminated
Genetically Determined Response to Atenolol in Patients With Persistent Atrial Fibrillation [NCT01719367]38 participants (Actual)Interventional2013-01-31Completed
The Surrogate Marker of Rate Control in Patients With Atrial Fibrillation [NCT04513509]50 participants (Anticipated)Interventional2020-08-07Not yet recruiting
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Propranolol/Carvedilol Versus Atenolol/Bisoprolol/Sotalol [NCT05794997]817,337 participants (Actual)Observational2022-11-30Active, not recruiting
INternational VErapamil SR Trandolapril STudy [NCT00133692]Phase 422,000 participants Interventional1997-09-30Completed
A Randomized Double Blind Controlled Trial of the Efficacy and Safety of POLYCAP (Quintapill)Versus Its Components in Subjects With at Least One Additional Cardiovascular Risk Factor [NCT00443794]2,050 participants (Actual)Interventional2007-03-31Completed
A Randomized Controlled Study: Effects of Bisoprolol and Atenolol on Sympathetic Nervous Activity and Central Aortic Pressure in Patients With Essential Hypertension [NCT01762436]Phase 4109 participants (Actual)Interventional2010-11-30Completed
Atrial Substrate Modification With Aggressive Blood Pressure Lowering to Prevent AF [NCT00438113]Phase 4184 participants (Actual)Interventional2009-12-31Completed
Elder Surgery - Functional Recovery Following Beta Blockade [NCT00507663]Phase 4359 participants (Actual)Interventional2002-09-30Completed
A Double-Blind, Randomized, Placebo- and Active-Controlled, Forced Titration Study Evaluating the Effects of Nebivolol on Blood Pressure and Heart Rate in African American Patients With Hypertension [NCT00145210]Phase 3630 participants (Anticipated)Interventional2005-04-30Completed
Cognitive and Cerebrovascular Sequelae of Hypertension [NCT00151138]50 participants Interventional2002-09-30Completed
Glucagon, Ghrelin and Growth Hormone as Counterregulatory Hormones [NCT01795235]6 participants (Anticipated)Interventional2012-12-31Recruiting
Nephropathy in Type 2 Diabetes: Effects of an Intensive Multifactorial Intervention Trial on Cardio-renal Events. [NCT00535925]Phase 4850 participants (Actual)Interventional2005-10-31Completed
Black Education and Treatment of Hypertension (BEAT HTN) [NCT00661895]Phase 499 participants (Actual)Interventional2005-08-31Completed
[NCT01839253]75 participants (Actual)Interventional2012-08-31Completed
Non-Invasive Determination of Central Aortic Blood Pressure in Hypertensive Patients Treated With Controlled-Release Carvedilol or Atenolol [NCT00669279]Phase 441 participants (Actual)Interventional2008-04-30Completed
Evaluation of a Primary Health Care Intervention for the Prevention of Cardiovascular Disease in Rural Andhra Pradesh [NCT00263393]Phase 43,712 participants (Actual)Interventional2005-12-31Completed
Prognostic Value of Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of Chronotherapy in Relation to Risk (the MAPEC Study). [NCT00295542]Phase 43,344 participants (Actual)Interventional2000-03-31Completed
Effects of Sodium Intake on Pharmacokinetic/Pharmacodynamic Relationship of a Single Dose of a Renin Angiotensin System-Blocker, or a Beta-Blocker in Normotensive Sodium-Depleted or Replated Volunteers in a Cross-Over Study [NCT00310778]Phase 164 participants (Actual)Interventional2006-03-31Completed
Genetic Determinants of Response to Beta Blockade [NCT00837902]154 participants (Actual)Interventional2009-01-31Completed
Estimation of the Long Term Effectiveness of Routine Use of Cardiac Shock Wave Therapy in the General System of Noninvasive, Invasive, and Surgical Treatment of Ischemic Heart Disease in the Conditions of a Large General City Hospital [NCT01631409]0 participants (Actual)Observational2013-09-30Withdrawn(stopped due to The study has been withdrawn due to organizational problems)
A Randomized, Double-Blind, Phase IV Clinical Study to Evaluate the Antihypertensive Efficacy and Changes of Neurohormonal Markers of Fimasartan and Atenolol With Exaggerated Blood Pressure Response During Exercise in Essential Hypertensive Patients [NCT01736488]Phase 425 participants (Actual)Interventional2012-10-31Completed
Comparison Study of the Effect of Aliskiren Versus Negative Controls on Aortic Stiffness in Patients With Marfan Syndrome Under Treatment With Atenolol [NCT01715207]Phase 330 participants (Actual)Interventional2010-06-30Completed
A Double-blind, Placebo-controlled, Randomized Study Examining the Effects of Nebivolol Compared to Atenolol on Endothelial Function and Cardiovascular Risk in Patients With Early Vascular Disease [NCT01522950]Phase 276 participants (Actual)Interventional2010-05-31Completed
[NCT00000513]Phase 30 participants Interventional1984-04-30Completed
An Open-label, Single-dose, Three-treatment, Three-period Study to Investigate the Effect of SLCO2B1 Genotype and Apple Juice on Pharmacokinetics of Atenolol After Oral Administration in Healthy Male Korean [NCT01445964]Phase 412 participants (Actual)Interventional2011-05-31Completed
Drug Interaction Study of Apixaban and Atenolol in Healthy Subjects [NCT02262533]Phase 115 participants (Actual)Interventional2007-06-30Completed
Effect of Polipill on Patients at High Cardiovascular Risk : a Randomized Controlled Trial [NCT01313702]Phase 30 participants (Actual)Interventional2012-10-31Withdrawn
Premedication With Atenolol Versus Metoprolol for Controlled Hypotensive Anesthesia During Nasal Surgeries. A Randomized Clinical Trial [NCT04914234]Phase 460 participants (Anticipated)Interventional2022-12-15Recruiting
The Effect of Labetalol, Atenolol, and Nifedipine on Maternal Hemodynamics Measured by Impedance Cardiography in Early Pregnancy [NCT04755764]60 participants (Anticipated)Observational2021-03-03Recruiting
A Double-Blinded, Placebo-Controlled Study To Assess Hemodynamic Changes, Orthostatic Tolerance, Out-Patient Fatigue And Quality Of Life In Neuropathic And Non-Neuropathic POTS Patients In Response To Adrenoreceptor Agonist And Antagonist [NCT03070730]Phase 1/Phase 28 participants (Actual)Interventional2011-08-15Terminated(stopped due to Recruitment was slow and subjects declined participation after signing the ICF.)
Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) [NCT00246519]Phase 41,701 participants (Actual)Interventional2005-10-31Completed
The Efficacy and Safety of Beta-blockers Drugs in Adults With Spinal Hemangioma: a Prospective Cohort Study [NCT05106179]Phase 41,000 participants (Anticipated)Interventional2021-12-31Enrolling by invitation
Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol [NCT02403349]Phase 4105 participants (Actual)Interventional2012-05-31Active, not recruiting
Use of Impedance Cardiography to Decrease the Risk of Preeclampsia in Obese Patients [NCT03105661]Early Phase 1400 participants (Anticipated)Interventional2017-04-04Recruiting
Reducing Total Cardiovascular Risk in an Urban Community [NCT00241904]Phase 4525 participants (Actual)Interventional2006-05-31Completed
Randomized, Double-blind Evaluation of the Effects of Irbesartan and Atenolol on Cardiovascular Structure and Function in Subjects With Hypertension and Left Ventricular Hypertrophy [NCT00389168]Phase 2/Phase 3115 participants (Actual)Interventional1995-04-30Completed
Use of Impedance Cardiography to Decrease the Risk of Preeclampsia [NCT03245970]Early Phase 10 participants (Actual)Interventional2017-04-24Withdrawn(stopped due to Investigator retired. Other investigators did not want to continue study.)
Comparative Study to Evaluate the Effectiveness of Atenolol and Propranolol in the Treatment of Infantile Hemangiomas [NCT03237637]Phase 360 participants (Anticipated)Interventional2017-03-24Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00108082 (14) [back to overview]Model-adjusted Ratio to Baseline as Percentage Change From Baseline in Log Transformed C-Reactive Protein (CRP) at Month 12
NCT00108082 (14) [back to overview]Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed by Height (LVMIH) as Measured by Echocardiography at Month 12
NCT00108082 (14) [back to overview]Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed (LVMI) by Body Surface Area as Measured by Magnetic Resonance Imaging (MRI) at Month 12
NCT00108082 (14) [back to overview]Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed (LVMI) by Body Surface Area as Measured by Echocardiography at Month 12
NCT00108082 (14) [back to overview]Model-adjusted Mean Change From Baseline in Left Ventricular (LV) Mass as Measured by MRI at Month 12
NCT00108082 (14) [back to overview]Model-adjusted Mean Change From Baseline in LV Mass as Measured by Echocardiography at Month 12
NCT00108082 (14) [back to overview]Model-adjusted Ratio to Baseline as Percentage Change From Baseline in Log Transformed Albumin Creatinine Ratio (ACR) at Month 12
NCT00108082 (14) [back to overview]Model-adjusted Ratio to Baseline as Percentage Change From Baseline in Log Transformed B-type Natriuretic Peptide (BNP) at Month 12
NCT00108082 (14) [back to overview]Mean Change From Baseline in LV Filling Parameters as Measured by MRI at Month 12
NCT00108082 (14) [back to overview]Model-adjusted Mean Change From Baseline in LV End Systolic and Diastolic Volumes and Ejection Fraction as Measured by Echocardiography at Month 12
NCT00108082 (14) [back to overview]Model-adjusted Mean Change From Baseline in LV End Systolic and Diastolic Volumes and Ejection Fraction as Measured by MRI at Month 12
NCT00108082 (14) [back to overview]Model-adjusted Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) at Month 12
NCT00108082 (14) [back to overview]Percentage Change From Baseline in Log Transformed Lipid Parameters at Month 12
NCT00108082 (14) [back to overview]Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed by Height (LVMIH) as Measured by MRI at Month 12
NCT00125853 (5) [back to overview]Insulin Sensitivity Index (ISI)
NCT00125853 (5) [back to overview]HbA1c
NCT00125853 (5) [back to overview]BMI
NCT00125853 (5) [back to overview]24 Hour Systolic Blood Pressure
NCT00125853 (5) [back to overview]Total Cholesterol
NCT00241904 (4) [back to overview]Systolic Blood Pressure
NCT00241904 (4) [back to overview]Patients' Satisfaction With Care and Health Care Utilization
NCT00241904 (4) [back to overview]HbA1c
NCT00241904 (4) [back to overview]Low-density Lipoprotein Cholesterol
NCT00246519 (1) [back to overview]Blood Pressure Response (Delta BP (After 18 Weeks of Medication - Baseline)).
NCT00389168 (6) [back to overview]Left Ventricular Diastolic Function Assessed by the E/A Ratio
NCT00389168 (6) [back to overview]Changes of Venous Plasma Angiotensin II as a Marker of the Renin-Angiotensin-Aldosterone System
NCT00389168 (6) [back to overview]Changes in Left Ventricular Mass Index
NCT00389168 (6) [back to overview]Number of Participants With Serious Adverse Events
NCT00389168 (6) [back to overview]Effects on Carotid Artery Wall Thickness
NCT00389168 (6) [back to overview]Blood Pressure
NCT00396656 (6) [back to overview]Mean Post-treatment Microcirculation at NaCl Injected Sites
NCT00396656 (6) [back to overview]Difference in Mean Post-treatment Microcirculation at Acetylcholine (ACH) Plus L-NMMA Injected Sites Compared to NaCl Injected Sites
NCT00396656 (6) [back to overview]Difference in Mean Post-treatment Microcirculation at Acetylcholine (ACH) Injected Sites Compared to NaCl Injected Sites
NCT00396656 (6) [back to overview]Difference in Mean Post-treatment Microcirculation at a Sodium Nitroprusside Injected Site Compared to NaCl Injected Sites
NCT00396656 (6) [back to overview]Arterial Pressure Waveform Pulse Wave Velocity at the End of Treatment
NCT00396656 (6) [back to overview]Arterial Pressure Waveform Augmentation Index at the End of Treatment
NCT00429364 (26) [back to overview]Number of Participants With the Composite Adverse Clinical Outcomes, Including Aortic Dissection, Aortic-root Surgery and Death.
NCT00429364 (26) [back to overview]Adverse Drug Reactions Reported at the Baseline Visit
NCT00429364 (26) [back to overview]Adverse Drug Reactions Reported During Routine Follow-up Surveillance
NCT00429364 (26) [back to overview]Annual Rate of Change in Weight
NCT00429364 (26) [back to overview]Annual Rate of Change in Arm Span to Height Ratio
NCT00429364 (26) [back to overview]Annual Rate of Change in Aortic Root (Sinuses of Valsalva) Absolute Dimension
NCT00429364 (26) [back to overview]Annual Rate of Change in Aortic Root (Sinuses of Valsalva) Body-surface-area-adjusted Z-score
NCT00429364 (26) [back to overview]Annual Rate of Change in Aortic-annulus-diameter Z Score, Adjusted by Body-surface Area
NCT00429364 (26) [back to overview]Annual Rate of Change in Ascending-aorta-diameter Z Score, Adjusted by Body-surface-area.
NCT00429364 (26) [back to overview]Annual Rate of Change in Body Mass Index
NCT00429364 (26) [back to overview]Annual Rate of Change in Body Mass Index for Age Z-score
NCT00429364 (26) [back to overview]Annual Rate of Change in Height
NCT00429364 (26) [back to overview]Annual Rate of Change in Height-for-age Z-score
NCT00429364 (26) [back to overview]Annual Rate of Change in the Absolute Diameter of the Aortic Annulus
NCT00429364 (26) [back to overview]Annual Rate of Change in the Absolute Diameter of the Ascending Aorta
NCT00429364 (26) [back to overview]Annual Rate of Change in Total Aortic Proximal Regurgitant Jet Area Indexed to Body-surface-area
NCT00429364 (26) [back to overview]Annual Rate of Change in Upper to Lower Segment Ratio
NCT00429364 (26) [back to overview]Annual Rate of Change in Weight-for-age Z-score
NCT00429364 (26) [back to overview]Annual Rate of Change in Weight-for-height Z-score
NCT00429364 (26) [back to overview]Event Rate of Aortic Dissection.
NCT00429364 (26) [back to overview]Event Rate of Aortic-Root Surgery
NCT00429364 (26) [back to overview]Event Rate of Death
NCT00429364 (26) [back to overview]Event Rate of the Composite Adverse Clinical Outcomes, Including Aortic Dissection, Aortic-root Surgery and Death.
NCT00429364 (26) [back to overview]Number of Death.
NCT00429364 (26) [back to overview]Number of Participants With Aortic Dissection.
NCT00429364 (26) [back to overview]Number of Participants With Aortic-root Surgery.
NCT00535925 (2) [back to overview]"Number of Participants With Overall Fatal and Non-fatal, Major Adverse Cardiovascular Events (MACEs)"
NCT00535925 (2) [back to overview]"Number of Participants Who Achieved of BP, HbA1c and Total, HDL and LDL Cholesterol Goals at the End of Intervention Phase"
NCT00582114 (2) [back to overview]Serious Adverse Events and Cardiovascular Events That Led to Trial Termination
NCT00582114 (2) [back to overview]The Primary End Point is the Regression of Left Ventricular Hypertrophy (LVH) by Echocardiographic Criteria From Baseline to 1 Year.
NCT00661895 (1) [back to overview]Percentage of Subjects Achieving Blood Pressure Goals
NCT00669279 (1) [back to overview]Central Aortic Blood Pressure
NCT00687973 (11) [back to overview]Change From Baseline of SBP/DBP at Week 24 (Office BP)
NCT00687973 (11) [back to overview]Change From Baseline of Brachial SBP/DBP at Week 24 (Tonometry Center)
NCT00687973 (11) [back to overview]Change From Baseline of Pulse Wave Velocity at Week 24 (Radial Measurement)
NCT00687973 (11) [back to overview]Change From Baseline of Pulse Pressure at Week 24 (Office BP)
NCT00687973 (11) [back to overview]Change From Baseline of Central Systolic Blood Pressure (SBP) at Week 8 (Radial Measurement)
NCT00687973 (11) [back to overview]Change From Baseline of Central Systolic Blood Pressure (SBP) at Week 24 (Radial Measurement)
NCT00687973 (11) [back to overview]Change From Baseline of Brachial Pulse Pressure at Week 24 (Tonometry Center)
NCT00687973 (11) [back to overview]Change From Baseline of Augmentation Index (Aix) at Week 8
NCT00687973 (11) [back to overview]Change From Baseline of Aix Corrected to Heart Rate at Week 24
NCT00687973 (11) [back to overview]Change From Baseline of Aix at Week 24
NCT00687973 (11) [back to overview]Change From Baseline of Central Pulse Pressure at Week 24 (Radial Measurement)
NCT00723801 (2) [back to overview]Diastolic Function - Ejection Fraction
NCT00723801 (2) [back to overview]Aortic Biophysical Properties - Pulse Wave Velocity
NCT00837902 (1) [back to overview]Reduction in Heart Rate
NCT00925119 (5) [back to overview]Change in Triglycerides
NCT00925119 (5) [back to overview]Change in Free Fatty Acid Kinetics
NCT00925119 (5) [back to overview]Change in HDL
NCT00925119 (5) [back to overview]Change in Insulin
NCT00925119 (5) [back to overview]Change in Insulin Sensitivity
NCT01079962 (11) [back to overview]Change From Baseline in Aortic Augmentation Index (AIx) at Week 4 and Week 12
NCT01079962 (11) [back to overview]Change From Baseline in Aortic Pulse Pressure (APP) at Week 4
NCT01079962 (11) [back to overview]Change From Baseline in Blood Glucose Levels at Week 12
NCT01079962 (11) [back to overview]Number of Participants With Adverse Events (AEs)
NCT01079962 (11) [back to overview]Change From Baseline in Aortic Blood Pressure (BP) at Week 4 and Week 12
NCT01079962 (11) [back to overview]Change From Baseline in Aortic Pulse Pressure (APP) in Intention to Treat (ITT) Population at Week 12
NCT01079962 (11) [back to overview]Change From Baseline in Aortic Pulse Pressure (APP) in Per Protocol (PP) Population at Week 12
NCT01079962 (11) [back to overview]Change From Baseline in Brachial Blood Pressure (BP) at Week 4 and Week 12
NCT01079962 (11) [back to overview]Change From Baseline in Carotid-femoral Pulse Wave Velocity (cfPWV) at Week 4 and Week 12
NCT01079962 (11) [back to overview]Change From Baseline in Heart Rate at Week 4 and Week 12
NCT01079962 (11) [back to overview]Change From Baseline in Lipid Levels at Week 12
NCT01202721 (2) [back to overview]Change From Baseline in Ascending Aorta Size, as Evaluated by MRI
NCT01202721 (2) [back to overview]Rate of Change in Ascending Aorta Size Evaluated by Transthoracic Echocardiography (TEE)
NCT01230892 (1) [back to overview]Number of Participants With Reduction of Thin-cap Fibroatheromas (TCFA) as Defined by VH-IVUS
NCT01251146 (8) [back to overview]Change From Baseline in Baroreflex Sensitivity (BRS) at Attainment of Heart Rate Goal
NCT01251146 (8) [back to overview]Change From Baseline in Heart Rate Variability (HRV) for Low Frequency Power (LF) and for High Frequency Power (HF) at Attainment of Heart Rate Goal and End of Follow-up
NCT01251146 (8) [back to overview]Change From Baseline in Ratio of Heart Rate Variability (HRV) for Low Frequency Power (LF) to Heart Rate Variability Power (HRV) for High Frequency (HF) (LF/HF) at Attainment of Heart Rate Goal and End of Follow-up
NCT01251146 (8) [back to overview]Number of Participants Attaining Heart Rate Goal at Dosage 1, 2 and 3 of Study Treatment
NCT01251146 (8) [back to overview]Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT01251146 (8) [back to overview]Percentage of Participants Attaining Heart Rate Goal at Week 2, 4 and 6
NCT01251146 (8) [back to overview]Number of Participants Compliant With Study Treatment
NCT01251146 (8) [back to overview]Change From Baseline in Baroreflex Sensitivity (BRS) at End of Follow-up
NCT01522950 (4) [back to overview]Change in Diastolic Blood Pressure
NCT01522950 (4) [back to overview]Change in Large Artery Elasticity
NCT01522950 (4) [back to overview]Change in Small Artery Elasticity
NCT01522950 (4) [back to overview]Change in Systolic Blood Pressure
NCT01715207 (2) [back to overview]Central Aortic Distensibility by MRI
NCT01715207 (2) [back to overview]Central Aortic PWV(Pulsed Wave Velocity)
NCT01719367 (2) [back to overview]Change in Pre- and Post-atenolol Ventricular Rate Response After 5 Minutes of Exercise
NCT01719367 (2) [back to overview]Change in Pre- and Post-atenolol Ventricular Rate Response After 10 and 15 Minutes of Exercise
NCT02342275 (6) [back to overview]Complete Ulceration Healing Time
NCT02342275 (6) [back to overview]Number of Participants With Complete/Nearly Complete Response (96 Week)
NCT02342275 (6) [back to overview]Rebound Rate
NCT02342275 (6) [back to overview]Successful Initial Response
NCT02342275 (6) [back to overview]The Primary Outcome Measure Was Any Response at 6 Months
NCT02342275 (6) [back to overview]Hemangioma Activity Score (HAS)
NCT03070730 (42) [back to overview]Change in Blood Pressure From Baseline
NCT03070730 (42) [back to overview]Change in Blood Pressure From Baseline
NCT03070730 (42) [back to overview]Change in Blood Pressure From Baseline
NCT03070730 (42) [back to overview]Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline
NCT03070730 (42) [back to overview]Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline
NCT03070730 (42) [back to overview]Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline
NCT03070730 (42) [back to overview]Change in Heart Rate From Baseline
NCT03070730 (42) [back to overview]Change in Heart Rate From Baseline
NCT03070730 (42) [back to overview]Change in Heart Rate From Baseline
NCT03070730 (42) [back to overview]Change in Maximal Postural Tachycardia During Tilt
NCT03070730 (42) [back to overview]Change in Muscle Sympathetic Nerve Activity From Baseline
NCT03070730 (42) [back to overview]Change in Muscle Sympathetic Nerve Activity From Baseline
NCT03070730 (42) [back to overview]Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline
NCT03070730 (42) [back to overview]Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline
NCT03070730 (42) [back to overview]Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline
NCT03070730 (42) [back to overview]Change in Physical Functioning- HADS From Baseline
NCT03070730 (42) [back to overview]Change in Physical Functioning- HADS From Baseline
NCT03070730 (42) [back to overview]Change in Physical Functioning- HADS From Baseline
NCT03070730 (42) [back to overview]Change in Physical Functioning-CIS From Baseline
NCT03070730 (42) [back to overview]Change in Physical Functioning-CIS From Baseline
NCT03070730 (42) [back to overview]Change in Physical Functioning-CIS From Baseline
NCT03070730 (42) [back to overview]Change in Physical Functioning-EuroQOL From Baseline
NCT03070730 (42) [back to overview]Change in Physical Functioning-EuroQOL From Baseline
NCT03070730 (42) [back to overview]Change in Physical Functioning-EuroQOL From Baseline
NCT03070730 (42) [back to overview]Change in Physical Functioning-FSS From Baseline
NCT03070730 (42) [back to overview]Change in Physical Functioning-FSS From Baseline
NCT03070730 (42) [back to overview]Change in Physical Functioning-FSS From Baseline
NCT03070730 (42) [back to overview]Change in Physical Functioning-MFI From Baseline
NCT03070730 (42) [back to overview]Change in Physical Functioning-MFI From Baseline
NCT03070730 (42) [back to overview]Change in Physical Functioning-MFI From Baseline
NCT03070730 (42) [back to overview]Change in Muscle Sympathetic Nerve Activity From Baseline
NCT03070730 (42) [back to overview]Change in Physical Functioning-OI From Baseline
NCT03070730 (42) [back to overview]Change in Physical Functioning-OI From Baseline
NCT03070730 (42) [back to overview]Change in Physical Functioning-SF-36 Q From Baseline
NCT03070730 (42) [back to overview]Change in Physical Functioning-SF-36 Q From Baseline
NCT03070730 (42) [back to overview]Change in Vascular Resistance From Baseline
NCT03070730 (42) [back to overview]Change in Vascular Resistance From Baseline
NCT03070730 (42) [back to overview]Change in Vascular Resistance From Baseline
NCT03070730 (42) [back to overview]Change Maximal Postural Tachycardia During Tilt
NCT03070730 (42) [back to overview]Change Maximal Postural Tachycardia During Tilt
NCT03070730 (42) [back to overview]Change in Physical Functioning-SF-36 Q From Baseline
NCT03070730 (42) [back to overview]Change in Physical Functioning-OI From Baseline
NCT04767061 (10) [back to overview]Change in Lower Extremity Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by the Balance Portion of a Modified Version of the Short Physical Performance Battery.
NCT04767061 (10) [back to overview]Change in Exercise Capacity When on Beta-blocker Versus When Off Beta-blocker, as Measured by Peak Oxygen Consumption (VO2) During Cardiopulmonary Exercise Test (CPET)
NCT04767061 (10) [back to overview]Change in Lower Extremity Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by the Chair Rise Portion of a Modified Version of the Short Physical Performance Battery.
NCT04767061 (10) [back to overview]Change in Lower Extremity Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by the Gait Speed Portion of a Modified Version of the Short Physical Performance Battery.
NCT04767061 (10) [back to overview]Change in Patient-reported Cognitive Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by Patient-Reported Outcome Measurement Information System-Short Form 6a (PROMIS SF-6a)
NCT04767061 (10) [back to overview]Change in Patient-reported Health Status When on Beta-blocker Versus When Off Beta-blocker, as Measured by Kansas City Cardiomyopathy Questionnaire (KCCQ-12)
NCT04767061 (10) [back to overview]Change in Patient-reported Health When on Beta-blocker Versus When Off Beta-blocker, as Measured by the EuroQol-5D Visual Analogue System (EQ-5D VAS)
NCT04767061 (10) [back to overview]Change in Physical Activity When on Beta-blocker Versus When Off Beta-blocker, as Measured by Step Count on Wearable Activity Monitoring Device
NCT04767061 (10) [back to overview]Change in Patient-reported Quality of Life When on Beta-blocker Versus When Off Beta-blocker, as Measured by Patient-Reported Outcome Measurement Information System-29 (PROMIS-29)
NCT04767061 (10) [back to overview]Change in Patient-reported Sexual Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by Patient-Reported Outcome Measurement Information System-Sexual Function (PROMIS-Sexual Function)

Model-adjusted Ratio to Baseline as Percentage Change From Baseline in Log Transformed C-Reactive Protein (CRP) at Month 12

CRP concentration (milligrams per deciliter) was measured at Baseline and after 12 months of treatment/Month 12. Percentage change from Baseline was based on log transformed data and calculated as 100 x (exponent (mean change on log scale) - 1). [Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.] (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF was used)

Interventionpercentage of change (Geometric Mean)
Carvedilol CR-10.63
Atenolol-3.22
Lisinopril2.70

[back to top]

Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed by Height (LVMIH) as Measured by Echocardiography at Month 12

LVMIH was measured by echogradiography at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was available)

Interventiong/m raised to 2.7 (g/(m^2.7)) (Mean)
Carvedilol CR-11.78
Atenolol-12.51
Lisinopril-11.61

[back to top]

Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed (LVMI) by Body Surface Area as Measured by Magnetic Resonance Imaging (MRI) at Month 12

LVMI was measured by MRI at Baseline and after 12 months of treatment/Month 12. A reduction in left ventricular mass, calculated as LVMI, of 5 g/m^2 was assumed to be clinically meaningful. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the Last Observation Carried Forward [LOCF] analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)

Interventiongrams per meters squared (g/m^2) (Mean)
Carvedilol CR-6.34
Atenolol-6.67
Lisinopril-7.94

[back to top]

Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed (LVMI) by Body Surface Area as Measured by Echocardiography at Month 12

LVMI was measured by echogradiography at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)

Interventiongrams per meters squared (g/m^2) (Mean)
Carvedilol CR-20.35
Atenolol-20.06
Lisinopril-18.48

[back to top]

Model-adjusted Mean Change From Baseline in Left Ventricular (LV) Mass as Measured by MRI at Month 12

LV Mass was measured by MRI at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)

Interventiongrams (g) (Mean)
Carvedilol CR-13.74
Atenolol-14.17
Lisinopril-17.17

[back to top]

Model-adjusted Mean Change From Baseline in LV Mass as Measured by Echocardiography at Month 12

LV Mass was measured by echocardiography at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)

Interventiongrams (Mean)
Carvedilol CR-45.76
Atenolol-40.56
Lisinopril-38.58

[back to top]

Model-adjusted Ratio to Baseline as Percentage Change From Baseline in Log Transformed Albumin Creatinine Ratio (ACR) at Month 12

Urinary ACR (micrograms per milligram) was determined at Baseline and after 12 months of treatment/Month 12. Percentage change from Baseline was based on log transformed data and was calculated as 100 x (exponent (exponent (mean change on log scale) - 1. [Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.] (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF was used)

Interventionpercentage of change (Geometric Mean)
Carvedilol CR-27.1
Atenolol-20.1
Lisinopril-21.5

[back to top]

Model-adjusted Ratio to Baseline as Percentage Change From Baseline in Log Transformed B-type Natriuretic Peptide (BNP) at Month 12

BNP concentration (picagram per milliter) was measured at Baseline and after 12 months of treatment/Month 12. Percentage change from Baseline was based on log transformed data and was calculated as 100 x (exponent (mean change on log scale) -1) [Change is the Month 12 value (or value after 12 months of treatment) minus the Baseline value]. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF was used

Interventionpercentage of change (Geometric Mean)
Carvedilol CR51.7
Atenolol48.3
Lisinopril-39.1

[back to top]

Mean Change From Baseline in LV Filling Parameters as Measured by MRI at Month 12

LV filling parameters, LV E-Volume and LV A-Volume, were measured by MRI at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. These filling parameters represent the volumes of blood filling the ventricle during the passive filling phase (E-volume) and the active filling phase caused by atrial contraction (A-volume). (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)

,,
Interventionmilliliters (mL) (Mean)
LV E-volumeLV A-volume
Atenolol6.763-0.565
Carvedilol CR0.364-0.513
Lisinopril-3.4061.088

[back to top]

Model-adjusted Mean Change From Baseline in LV End Systolic and Diastolic Volumes and Ejection Fraction as Measured by Echocardiography at Month 12

LV End Systolic and Diastolic Volumes and Ejection Fraction were measured by echocardiography at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)

,,
Interventionmilliliters (mL) (Mean)
LV End Systolic VolumeLV End Diastolic VolumeLV Ejection Fraction
Atenolol-4.74-3.642.33
Carvedilol CR-3.38-3.071.03
Lisinopril-5.34-9.370.63

[back to top]

Model-adjusted Mean Change From Baseline in LV End Systolic and Diastolic Volumes and Ejection Fraction as Measured by MRI at Month 12

LV End Systolic and Diastolic Volumes and Ejection Fraction were measured by MRI at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. The ejection fraction is the fraction of the blood volume available at the end of diastole that is pumped out of the ventricules during systole. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)

,,
Interventionmilliliters (mL) (Mean)
LV End Systolic VolumeLV End Diastolic VolumeLV Ejection Fraction
Atenolol-4.29-2.452.16
Carvedilol CR-1.44-2.860.08
Lisinopril-3.04-7.45-0.01

[back to top]

Model-adjusted Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) at Month 12

Systolic and Diastolic BP were measured at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)

,,
InterventionmmHg (millimeters of mercury) (Mean)
Systolic blood pressureDiastolic blood pressure
Atenolol-21.12-14.05
Carvedilol CR-21.32-12.77
Lisinopril-22.53-11.13

[back to top]

Percentage Change From Baseline in Log Transformed Lipid Parameters at Month 12

Plasma lipid concentrations (milligrams per deciliter) were measured at Baseline and after 12 months of treatment/Month 12. Percentage change from Baseline was based on log transformed data and calculated as 100 x (exponent(mean change on log scale) - 1). [Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.] (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF was used)

,,
Interventionpercentage of change (Geometric Mean)
Total cholesterolLow-density lipid cholesterolHigh-density lipid cholesterolTriglycerides
Atenolol-1.3-4.0-4.77.1
Carvedilol CR0.70.0-4.311.0
Lisinopril-1.7-2.7-1.56.2

[back to top]

Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed by Height (LVMIH) as Measured by MRI at Month 12

LVMIH was measured by MRI at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. LV mass depends on body size. One method of determining whether an individual has LV hypertrophy relates LV mass to height raised to a power of 2.7. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)

Interventiong/m raised to 2.7 (g/(m^2.7)) (Mean)
Carvedilol CR-3.19
Atenolol-3.37
Lisinopril-3.98

[back to top]

Insulin Sensitivity Index (ISI)

"Patients were asked to fast for a minimum of 12 hours prior to each oral glucose tolerance test (OGTT). Venous blood was withdrawn for insulin and glucose analysis, 15 minutes and immediately prior to, and 30, 60, 90 and 120 minutes following an oral glucose load. For each OGTT, the Insulin Sensitivity Index (ISI) was calculated using the standard method for oral glucose tolerance testing.~For each OGTT, the Insulin Sensitivity Index (ISI) was calculated using the standard method for oral glucose tolerance testing." (NCT00125853)
Timeframe: Baseline, 15, 30, 60, 90, 120m following oral glucose load, at baseline and at the end of each phase(8 weeks treatment

,
Interventionfactor (Mean)
BeforeAfter
Atenolol82.3675.47
Nebivolol80.7081.54

[back to top]

HbA1c

Fasting blood samples were taken at the beginning and end of each treatment period. (NCT00125853)
Timeframe: Before and after 8 weeks of treatment

,
Interventionpercentage of glycosylated hemoglobin (Mean)
BeforeAfter
Atenolol5.75.7
Nebivolol5.75.7

[back to top]

BMI

Body weights and heights were taken at the beginning and end of each treatment period. (NCT00125853)
Timeframe: Before and after 8 weeks of treatment

,
Interventionkg/m^2 (Mean)
BeforeAfter
Atenolol28.128.0
Nebivolol28.228.3

[back to top]

24 Hour Systolic Blood Pressure

The 24-h Ambulatory Blood Pressure Monitoring (ABPM) was recorded at the beginning and end of each beta-blocker treatment period. BP was automatically recorded for 24 h at 30 min intervals. The time periods from 0700h to 2200h and from 2200h to 0700h were defined as daytime and night-time, respectively. (NCT00125853)
Timeframe: Before and after 8 weeks of treatment

,
InterventionmmHg (Mean)
SBP beforeSBP after
Atenolol128.4117.2
Nebivolol130.4121.2

[back to top]

Total Cholesterol

Fasting blood samples were taken at the beginning and end of each treatment period. (NCT00125853)
Timeframe: Before and after 8 weeks of treatment

,
Interventionmmol/L (Mean)
BeforeAfter
Atenolol5.04.9
Nebivolol5.15.1

[back to top]

Systolic Blood Pressure

Blood pressure measured with automatic blood pressure machine according to the guidelines of the American Heart Association. (NCT00241904)
Timeframe: Measured at 1 year

InterventionmmHg (Mean)
Comprehensive Intervention Group130.8
Less Intensive Intervention Group135.9

[back to top]

Patients' Satisfaction With Care and Health Care Utilization

Patient satisfaction with care and healthcare utilization was measured with the Patient Assessment for Chronic Illness Care Scale (PACIC). The scores range from 0-5, with 5 being the most satisfied (NCT00241904)
Timeframe: Measured at 1 year

Interventionunits on a scale (Mean)
Comprehensive Intervention Group2.9
Less Intensive Intervention Group1.8

[back to top]

HbA1c

Fasting for 12 hour blood sample was measured in standardized lab (NCT00241904)
Timeframe: Measured at 1 year

Interventionpercentage of hemoglobin (Mean)
Comprehensive Intervention Group8.3
Less Intensive Intervention Group8.2

[back to top]

Low-density Lipoprotein Cholesterol

Blood was drawn after a 12 hour fast and low density lipoprotein cholesterol was measured in a standardized lab (NCT00241904)
Timeframe: Measured at 1 year

Interventionmg/dL (Mean)
Comprehensive Intervention Group100.1
Less Intensive Intervention Group110.6

[back to top]

Blood Pressure Response (Delta BP (After 18 Weeks of Medication - Baseline)).

(NCT00246519)
Timeframe: baseline to 18 weeks of treatment

InterventionmmHg (Mean)
Atenolol +HCTZ Arm-12.06
HCTZ + Atenolol-13.33

[back to top]

Left Ventricular Diastolic Function Assessed by the E/A Ratio

Changes in left ventricular diastolic function from baseline to week 48 will be evaluated as the difference in E/A ratio. Conventional pulsed wave Doppler echocardiography was used for recordings of mitral inflow in. The peak of early (E) and late (A) mitral flow velocities were measured, and the E/A-ratio was calculated. Repeated measures MANOVA at time points 0, 12, 24, and 48 weeks. Some echocardiographic recordings at some time point may be of insufficient quality or missing, and the number of observations may not always correspond to the total number of participants at all time points. (NCT00389168)
Timeframe: Baseline to 48 weeks

,
Interventionratio (Mean)
Week 12Week 24Week 48
Atenolol0.180.160.13
Irbesartan0.100.040.10

[back to top]

Changes of Venous Plasma Angiotensin II as a Marker of the Renin-Angiotensin-Aldosterone System

Venous plasma concentrations of angiotensin II were measured in order to study the possible associations between the activity of the renin-angiotensin-aldosteone system and changes in left ventricular mass. Further analyses of other components of the renin-angiotensin-aldosterone system and of other hormonal system (e.g. the sympathetic nervous system) have also been performed and published. Repeated measures MANOVA at time points 0, 12, 24, and 48 weeks. Data were log-transformed to avoid skewness before statistical evaluation. However, tabular data are given as mean values with 95% confidence to improve readability. (NCT00389168)
Timeframe: Baseline to 48 weeks

,
Interventionpmol/L (Mean)
Weel 12Week 24Week 48
Atenolol-1.0-0.8-0.2
Irbesartan3.03.310.0

[back to top]

Changes in Left Ventricular Mass Index

Repeated measures multivariate analysis of variance (MANOVA) at time points 0, 12, 24, and 48 weeks. Data are presented as left ventricular mass in gram (g) indexed for body mass index (in m^2). (NCT00389168)
Timeframe: Baseline and 48 weeks

,
Interventiong/m^2 (Mean)
12 weeks24 weeks48 weeks
Atenolol-1-6-14
Irbesartan-9-14-26

[back to top]

Number of Participants With Serious Adverse Events

Safety was assessed by non-directed questions, and all observed and volunteered adverse events were recorded at each study visit. Serious adverse events were defined by, and reported according to the regulations of good clinical practice (GCP). none were considered related to the study medication. (NCT00389168)
Timeframe: Treatment period was baseline to 48 weeks

InterventionParticipants (Number)
Atenolol5
Irbesartan5

[back to top]

Effects on Carotid Artery Wall Thickness

Changes in common carotid artery intima-media thickness, assessed by ultrasonography. (NCT00389168)
Timeframe: Baseline to 48 weeks

Interventionmm (Mean)
Atenolol0.03
Irbesartan-0.01

[back to top]

Blood Pressure

Difference in Diastolic Blood Pressure. Repeated measures multivariable analysis of variance (MANOVA) at time points 0, 12, 24, and 48 weeks (NCT00389168)
Timeframe: Baseline to 48 weeks

Interventionmm Hg (Mean)
Atenolol-16.3
Irbesartan-18.8

[back to top]

Mean Post-treatment Microcirculation at NaCl Injected Sites

10 µl of NaCl was injected intra-dermally at 2 sites on the forearms. Microcirculation was measured using laser doppler velocimetry before and 12 times in the 30 minutes following injection. The mean difference of the 12 post-injection measurements to the pre-injection measurement was calculated. A mean for the 2 NaCl sites was calculated. Microcirculation was measured in perfusion units which is an arbitrary measure specific to each laser doppler scanner. (NCT00396656)
Timeframe: At end of each treatment period (Week 21 and Week 43)

InterventionPerfusion units (Mean)
Valsartan44.78
Atenolol + Hydrochlorothiazide50.96

[back to top]

Difference in Mean Post-treatment Microcirculation at Acetylcholine (ACH) Plus L-NMMA Injected Sites Compared to NaCl Injected Sites

10 µl of acetylcholine (ACH) at 3 concentrations (10-7, 10-8, 10-9 M) plus 10 µl L-NMMA (10-6 M) was injected intra-dermally at 3 sites on the forearms. NaCl was injected at 2 sites. Microcirculation was measured using laser doppler velocimetry before and 12 times in the 30 minutes following injection. The mean difference of the 12 post-injection measurements to the pre-injection measurement was calculated. Means for the 3 ACH and the 2 NaCl sites were calculated and compared. Microcirculation was measured in perfusion units which is an arbitrary measure specific to each laser doppler scanner. (NCT00396656)
Timeframe: At end of each treatment period (Week 21 and Week 43)

InterventionPerfusion units (Mean)
Valsartan-9.11
Atenolol + Hydrochlorothiazide-5.60

[back to top]

Difference in Mean Post-treatment Microcirculation at Acetylcholine (ACH) Injected Sites Compared to NaCl Injected Sites

10 µl of acetylcholine (ACH) at 3 concentrations (10-7, 10-8, 10-9 M) was injected intra-dermally at 3 sites on the forearms. NaCl was injected at 2 sites on the forearms. Microcirculation was measured using laser doppler velocimetry before and 12 times in the 30 minutes following injection. The mean difference of the 12 post-injection measurements to the pre-injection measurement was calculated. Means for the 3 ACH and the 2 NaCl sites were calculated and compared. Microcirculation was measured in perfusion units which is an arbitrary measure specific to each laser doppler scanner. (NCT00396656)
Timeframe: At end of each treatment period (Week 21 and Week 43)

InterventionPerfusion units (Mean)
Valsartan61.21
Atenolol + Hydrochlorothiazide61.04

[back to top]

Difference in Mean Post-treatment Microcirculation at a Sodium Nitroprusside Injected Site Compared to NaCl Injected Sites

10 µl of sodium nitroprusside at a concentration of 10-7 M was injected intra-dermally at 1 site on the forearms. NaCl was injected at 2 sites on the forearms. Microcirculation was measured using laser doppler velocimetry before and 12 times in the 30 minutes following injection. The mean difference of the 12 post-injection measurements to the pre-injection measurement was calculated. A mean for the 2 NaCl sites was calculated and compared to the sodium nitroprusside mean. Microcirculation was measured in perfusion units which is an arbitrary measure specific to each laser doppler scanner. (NCT00396656)
Timeframe: At end of each treatment period (Week 21 and Week 43)

InterventionPerfusion units (Mean)
Valsartan120.65
Atenolol + Hydrochlorothiazide128.14

[back to top]

Arterial Pressure Waveform Pulse Wave Velocity at the End of Treatment

Using applanation tonometry, the arterial pulse form measured at the wrist was analyzed using computerized pulse wave analysis. The arterial pressure waveform has two components; the first is the forward traveling wave when the left ventricle contracts and the second is the reflected wave returning from the periphery. Pulse wave velocity is the speed of the forward traveling wave and can be used as a measure of arterial stiffness since the more rigid the wall of the artery, the faster the wave moves. (NCT00396656)
Timeframe: At end of each treatment period (Week 21 and Week 43)

InterventionMeters per second (Mean)
Valsartan8.07
Atenolol + Hydrochlorothiazide7.60

[back to top]

Arterial Pressure Waveform Augmentation Index at the End of Treatment

Using applanation tonometry, the arterial pulse form measured at the wrist was analyzed using computerized pulse wave analysis. The arterial pressure waveform has two components; the first is the forward traveling wave when the left ventricle contracts and the second is the reflected wave returning from the periphery. The augmentation index is the ratio of the first and second systolic peaks and is used as a surrogate measure of arterial stiffness. (NCT00396656)
Timeframe: At end of each treatment period (Week 21 and Week 43)

InterventionRatio (Mean)
Valsartan139.05
Atenolol + Hydrochlorothiazide144.51

[back to top]

Number of Participants With the Composite Adverse Clinical Outcomes, Including Aortic Dissection, Aortic-root Surgery and Death.

(NCT00429364)
Timeframe: Up to 3 years following randomization.

Interventionparticipants (Number)
Atenolol10
Losartan19

[back to top]

Adverse Drug Reactions Reported at the Baseline Visit

(NCT00429364)
Timeframe: At baseline

,
Interventionparticipants (Number)
Headache, any severityHeadache, bothersomeFatigue, any severityFatigue, bothersomeMood alterations, any severityMood alterations, bothersomeBehavior changes, any severityBehavior changes, bothersomeInsomnia, any severityInsomnia, bothersomeNightmares, any severityNightmares, bothersomeDizziness with standing, any severityDizziness with standing, bothersomeDizziness - other, any severityDizziness - other, bothersomeFainting with loss of consciousness, any severityFainting with loss of consciousness, bothersomePalpitations, any severityPalpitations, bothersomeChest pain, any severityChest pain, bothersomeDyspnea, any severityDyspnea, bothersomeWheezing, any severityWheezing, bothersomeUpper respiratory/Nasal congestion, any severityUpper respiratory/Nasal congestion, bothersomeCough, any severityCough, bothersomeDysgeusia, any severityDysgeusia, bothersomeStomach pain/Indigestion, any severityStomach pain/Indigestion, bothersomeNausea, any severityNausea, bothersomeVomiting, any severityVomiting, bothersomeDiarrhea, any severityDiarrhea, bothersomeConstipation, any severityConstipation, bothersomeVascular (hands, feet), any severityVascular (hands, feet), bothersomeMuscle pain or Cramps, any severityMuscle pain or Cramps, bothersomeBack pain, any severityBack pain, bothersomePeriorbital edema, any severityPeriorbital edema, bothersomePedal edema, any severityPedal edema, bothersomeOther, any severityOther, bothersome
Atenolol1121084054721260252260025055600541433152106047110047030123035144035059260313020213
Losartan1141010504932316125335822719953058538014111725903061135023043135034158467215030161

[back to top]

Adverse Drug Reactions Reported During Routine Follow-up Surveillance

(NCT00429364)
Timeframe: From 6 months to 3 years following randomization.

,
Interventionparticipants (Number)
Headache, any severityHeadache, bothersomeFatigue, any severityFatigue, bothersomeMood alterations, any severityMood alterations, bothersomeBehavior changes, any severityBehavior changes, bothersomeInsomnia, any severityInsomnia, bothersomeNightmares, any severityNightmares, bothersomeDizziness with standing, any severityDizziness with standing, bothersomeDizziness - other, any severityDizziness - other, bothersomeFainting with loss of consciousness, any severityFainting with loss of consciousness, bothersomePalpitations, any severityPalpitations, bothersomeChest pain, any severityChest pain, bothersomeDyspnea, any severityDyspnea, bothersomeWheezing, any severityWheezing, bothersomeUpper respiratory/Nasal congestion, any severityUpper respiratory/Nasal congestion, bothersomeCough, any severityCough, bothersomeDysgeusia, any severityDysgeusia, bothersomeStomach pain/Indigestion, any severityStomach pain/Indigestion, bothersomeNausea, any severityNausea, bothersomeVomiting, any severityVomiting, bothersomeDiarrhea, any severityDiarrhea, bothersomeConstipation, any severityConstipation, bothersomeVascular (hands, feet), any severityVascular (hands, feet), bothersomeMuscle pain or Cramps, any severityMuscle pain or Cramps, bothersomeBack pain, any severityBack pain, bothersomePeriorbital edema, any severityPeriorbital edema, bothersomePedal edema, any severityPedal edema, bothersomeOther, any severityOther, bothersome
Atenolol2022715278913515108610071196602212186011414751362188311712901192990811941771730148613752206010510
Losartan208201535861346810749441050610161610101061723325186311311601218780752903660660124713482715010812

[back to top]

Annual Rate of Change in Weight

(NCT00429364)
Timeframe: Up to 3 years following randomization.

Interventionkg/year (Least Squares Mean)
Atenolol0.239
Losartan0.229

[back to top]

Annual Rate of Change in Arm Span to Height Ratio

(NCT00429364)
Timeframe: Up to 3 years following randomization.

Intervention1/year (Least Squares Mean)
Atenolol0.001
Losartan0.001

[back to top]

Annual Rate of Change in Aortic Root (Sinuses of Valsalva) Absolute Dimension

The rate of change in the absolute dimension of the aortic root over a 3-year period following randomization (NCT00429364)
Timeframe: Up to 3 years following randomization.

Interventioncm/year (Least Squares Mean)
Atenolol0.069
Losartan0.075

[back to top]

Annual Rate of Change in Aortic Root (Sinuses of Valsalva) Body-surface-area-adjusted Z-score

The rate of aortic root enlargement, expressed as the annual change in the maximum aortic-root-diameter z score indexed to body-surface area over a 3-year period following randomization (NCT00429364)
Timeframe: Up to 3 years following randomization.

Interventionz-score/year (Least Squares Mean)
Atenolol-0.139
Losartan-0.107

[back to top]

Annual Rate of Change in Aortic-annulus-diameter Z Score, Adjusted by Body-surface Area

(NCT00429364)
Timeframe: Up to 3 years following randomization.

Interventionz-score/year (Least Squares Mean)
Atenolol-0.279
Losartan-0.175

[back to top]

Annual Rate of Change in Ascending-aorta-diameter Z Score, Adjusted by Body-surface-area.

(NCT00429364)
Timeframe: Up to 3 years following randomization.

Interventionz-score/year (Least Squares Mean)
Atenolol-0.140
Losartan-0.114

[back to top]

Annual Rate of Change in Body Mass Index

(NCT00429364)
Timeframe: Up to 3 years following randomization.

Interventionkg/m^2 per year (Least Squares Mean)
Atenolol0.063
Losartan0.076

[back to top]

Annual Rate of Change in Body Mass Index for Age Z-score

(NCT00429364)
Timeframe: Up to 3 years following randomization.

Interventionz-score/year (Least Squares Mean)
Atenolol0.007
Losartan0.021

[back to top]

Annual Rate of Change in Height

(NCT00429364)
Timeframe: Up to 3 years following randomization.

Interventioncm/year (Least Squares Mean)
Atenolol0.822
Losartan0.935

[back to top]

Annual Rate of Change in Height-for-age Z-score

(NCT00429364)
Timeframe: Up to 3 years following randomization.

Interventionz-score/year (Least Squares Mean)
Atenolol0.046
Losartan0.019

[back to top]

Annual Rate of Change in the Absolute Diameter of the Aortic Annulus

(NCT00429364)
Timeframe: Up to 3 years following randomization.

Interventioncm/year (Least Squares Mean)
Atenolol0.015
Losartan0.030

[back to top]

Annual Rate of Change in the Absolute Diameter of the Ascending Aorta

(NCT00429364)
Timeframe: Up to 3 years following randomization.

Interventioncm/year (Least Squares Mean)
Atenolol0.039
Losartan0.044

[back to top]

Annual Rate of Change in Total Aortic Proximal Regurgitant Jet Area Indexed to Body-surface-area

(NCT00429364)
Timeframe: Up to 3 years following randomization.

Intervention(mm^2/m^2)/year (Least Squares Mean)
Atenolol0.005
Losartan0.001

[back to top]

Annual Rate of Change in Upper to Lower Segment Ratio

(NCT00429364)
Timeframe: Up to 3 years following randomization.

Intervention1/year (Least Squares Mean)
Atenolol-0.014
Losartan-0.015

[back to top]

Annual Rate of Change in Weight-for-age Z-score

(NCT00429364)
Timeframe: Up to 3 years following randomization.

Interventionz-score/year (Least Squares Mean)
Atenolol0.011
Losartan0.019

[back to top]

Annual Rate of Change in Weight-for-height Z-score

(NCT00429364)
Timeframe: Up to 3 years following randomization.

Interventionz-score/year (Least Squares Mean)
Atenolol-0.001
Losartan-0.157

[back to top]

Event Rate of Aortic Dissection.

Percentage of participants who had aortic dissection over a 3-year period following randomization. (NCT00429364)
Timeframe: Up to 3 years following randomization.

InterventionPercentage of participants (Number)
Atenolol0
Losartan0.7

[back to top]

Event Rate of Aortic-Root Surgery

Percentage of participants who had aortic-root surgery over a 3-year period following randomization. (NCT00429364)
Timeframe: Up to 3 years following randomization.

InterventionPercentage of participants (Number)
Atenolol3.4
Losartan6.0

[back to top]

Event Rate of Death

Percentage of participants who died over a 3-year period following randomization. (NCT00429364)
Timeframe: Up to 3 years following randomization.

InterventionPercentage of participants (Number)
Atenolol0
Losartan0.3

[back to top]

Event Rate of the Composite Adverse Clinical Outcomes, Including Aortic Dissection, Aortic-root Surgery and Death.

Percentage of participants who had aortic dissection, aortic-root surgery or death over a 3-year period following randomization (NCT00429364)
Timeframe: Up to 3 years following randomization.

InterventionPercentage of participants (Number)
Atenolol3.4
Losartan6.4

[back to top]

Number of Death.

(NCT00429364)
Timeframe: Up to 3 years following randomization.

Interventionparticipants (Number)
Atenolol0
Losartan1

[back to top]

Number of Participants With Aortic Dissection.

(NCT00429364)
Timeframe: Up to 3 years following randomization.

Interventionparticipants (Number)
Atenolol0
Losartan2

[back to top]

Number of Participants With Aortic-root Surgery.

(NCT00429364)
Timeframe: Up to 3 years following randomization.

Interventionparticipants (Number)
Atenolol10
Losartan18

[back to top]

"Number of Participants With Overall Fatal and Non-fatal, Major Adverse Cardiovascular Events (MACEs)"

number of MACEs in the two groups are reported. In addition, The primary endpoint was analyzed with event curves for the time-to-first event based on Kaplan-Meier analysis. Cox regression model was used to calculate hazard ratio (HR) and 95% Confidence Interval (CI). Due to the cluster randomized study design, a Cox shared-frailty model was fitted. multivariable model was adjusted for selected potential confounders: age, sex, systolic blood pressure (SBP), hemoglobin, estimated glomerular filtration rate (eGFR), albuminuria, HbA1c, total cholesterol and triglycerides (log-scaled) to reduce risk of bias. (NCT00535925)
Timeframe: 4 years (in the case the number of events needed by sample size is not reached at the expected 4-year time frame, primary end point will be assessed after the follow-up phase)

InterventionParticipants (Count of Participants)
Conventional Therapy146
Intensified Therapy116

[back to top]

"Number of Participants Who Achieved of BP, HbA1c and Total, HDL and LDL Cholesterol Goals at the End of Intervention Phase"

Achievement of targets at end of intervention was performed applying generalized estimating equation (GEE) models, further adjusting for baseline values as covariate. (NCT00535925)
Timeframe: 13 years

InterventionParticipants (Count of Participants)
Standard of Care (SoC) Therapy150
Multifactorial Intensified Therapy191

[back to top]

Serious Adverse Events and Cardiovascular Events That Led to Trial Termination

Cardiovascular events were counted by subject and included the following: myocardial infarction (MI), stroke, hospitalization for congestive heart failure (CHF), hospitalized angina, arrhythmias, cardiac arrest, coronary revascularization and heart valve replacement. Adverse events reported are those during the course of 12 months of participation in the trial. All serious adverse events were adjudicated by R.A. and A.D.S. who were masked to the drug assignment at the time of adjudication. The duration of participation in the study per subject, which according to the trial design could be up to 12 months, was determined. The cardiovascular event rate was calculated by treatment group assignment. Incidence rate ratio (IRR) by treatment was then determined along with the 95% confidence intervals (95% CIs). As a post hoc analysis, we also determined the narrower definition of cardiovascular events per group that included MI, stroke, CHF, or cardiovascular death. (NCT00582114)
Timeframe: 1 yr

,
Interventionevents/100 patient-years (Number)
Incidence rate, cardiovasular eventsIncidence rate, combined MI, stroke, CHF, CV deathIncidence rate, congest heart failureIncidence rate, all-cause hospitalizations
Atenolol24.613.56.289.9
Lisinopril583120.2144.3

[back to top]

The Primary End Point is the Regression of Left Ventricular Hypertrophy (LVH) by Echocardiographic Criteria From Baseline to 1 Year.

The primary outcome of the study was the average reduction in left ventricular mass indexed for body surface area from baseline to 1 year. A mixed model was used with left ventricular mass index (LVMI) as the outcome variable. Fixed effects were indicator variables for time, treatment and their interaction. Random effect was subject and statistical inference was made using the maximum likelihood estimator. No imputation was made for missing data. (NCT00582114)
Timeframe: Baseline, 6 months, 12 months

,
Interventiong/m^2 (Mean)
LVMI Change from baseline, 6 monthsLVMI Change from baseline, 12 months
Atenolol-8.4-21.5
Lisinopril-3.4-15.1

[back to top]

Percentage of Subjects Achieving Blood Pressure Goals

Percentage of subjects who achieved JNC-VII defined blood pressure goals. (NCT00661895)
Timeframe: 3 month intervals

Interventionpercentage of participants (Number)
Intervention81
Control57

[back to top]

Central Aortic Blood Pressure

(NCT00669279)
Timeframe: Measured at baseline and 4 weeks.

InterventionmmHg (Mean)
Carvedilol CR-16.1
Atenolol-16.0

[back to top]

Change From Baseline of SBP/DBP at Week 24 (Office BP)

(NCT00687973)
Timeframe: Baseline and Week 24

,
InterventionmmHg (Least Squares Mean)
SBPDBP
Atenolol/Amlodipine 100/10 mg-16.94-10.45
Valsartan/Amlodipine 160/10 mg-14.49-8.17

[back to top]

Change From Baseline of Brachial SBP/DBP at Week 24 (Tonometry Center)

Applanation tonometry is a measurement of aortic pressure and vascular stiffness. To assess the central aortic blood pressure, it is necessary to calibrate the applanation tonometry device using the brachial blood pressure. (NCT00687973)
Timeframe: Baseline and Week 24

,
InterventionmmHg (Least Squares Mean)
SBPDBP
Atenolol/Amlodipine 100/10 mg-11.78-7.94
Valsartan/Amlodipine 160/10 mg-12.93-7.85

[back to top]

Change From Baseline of Pulse Wave Velocity at Week 24 (Radial Measurement)

(NCT00687973)
Timeframe: Baseline and Week 24

Interventionm/s (Least Squares Mean)
Valsartan/Amlodipine 160/10 mg-0.98
Atenolol/Amlodipine 100/10 mg-0.95

[back to top]

Change From Baseline of Pulse Pressure at Week 24 (Office BP)

(NCT00687973)
Timeframe: Baseline and Week 24

InterventionmmHg (Least Squares Mean)
Valsartan/Amlodipine 160/10 mg-6.32
Atenolol/Amlodipine 100/10 mg-6.48

[back to top]

Change From Baseline of Central Systolic Blood Pressure (SBP) at Week 8 (Radial Measurement)

(NCT00687973)
Timeframe: Baseline and Week 8

InterventionmmHg (Least Squares Mean)
Valsartan/Amlodipine 160/10 mg-10.92
Atenolol/Amlodipine 100/10 mg-8.3

[back to top]

Change From Baseline of Central Systolic Blood Pressure (SBP) at Week 24 (Radial Measurement)

(NCT00687973)
Timeframe: Baseline and Week 24

InterventionmmHg (Least Squares Mean)
Valsartan/Amlodipine 160/10 mg-13.65
Atenolol/Amlodipine 100/10 mg-9.7

[back to top]

Change From Baseline of Brachial Pulse Pressure at Week 24 (Tonometry Center)

(NCT00687973)
Timeframe: Baseline and Week 24

InterventionmmHg (Least Squares Mean)
Valsartan/Amlodipine 160/10 mg-5.02
Atenolol/Amlodipine 100/10 mg-3.66

[back to top]

Change From Baseline of Augmentation Index (Aix) at Week 8

To calculate the blood pressure augmentation index, the inflection point of the pressure curve corresponding to the return of the reflection wave was determined. The ratio between the pressure located above and below the inflection point was calculated. (NCT00687973)
Timeframe: Baseline and Week 8

InterventionRatio (Least Squares Mean)
Valsartan/Amlodipine 160/10 mg-2.21
Atenolol/Amlodipine 100/10 mg3.61

[back to top]

Change From Baseline of Aix Corrected to Heart Rate at Week 24

The heart rate correction was computed by a multivariate model analysis (NCT00687973)
Timeframe: Baseline and Week 24

InterventionRatio (Least Squares Mean)
Valsartan/Amlodipine 160/10 mg-4.12
Atenolol/Amlodipine 100/10 mg-2.43

[back to top]

Change From Baseline of Aix at Week 24

(NCT00687973)
Timeframe: Baseline and Week 24

InterventionRatio (Least Squares Mean)
Valsartan/Amlodipine 160/10 mg-4.10
Atenolol/Amlodipine 100/10 mg2.40

[back to top]

Change From Baseline of Central Pulse Pressure at Week 24 (Radial Measurement)

(NCT00687973)
Timeframe: Baseline and Week 24

InterventionmmHg (Least Squares Mean)
Valsartan/Amlodipine 160/10 mg-5.5
Atenolol/Amlodipine 100/10 mg-1.7

[back to top]

Diastolic Function - Ejection Fraction

Two-dimensional echocardiography was performed using a 3.0 MHz transducer (General Electric VIVID 7). Left ventricular and left atrial dimensions were determined in parasternal long axis views. Left ventricular ejection fraction was calculated using the modified Simpsons calculation in the apical two and four chamber views. (NCT00723801)
Timeframe: Baseline and 6 months

InterventionChange in % ejection fraction (Mean)
Subjects Randomized to Atenolol1.31
Subjects Randomized to Losartan1.57

[back to top]

Aortic Biophysical Properties - Pulse Wave Velocity

Aortic stiffness was assessed using applanation tonometry (SphygmoCor®, AtCor Medical, West Ryde, NSW, Sydney, Australia) to measure carotid to femoral artery pulse wave velocity (PWV). With the patient lying supine in a quiet environment, a handheld micromanometer-tipped probe was applied to the skin surface over the carotid and femoral arteries, compressing the vessel wall so that transmural forces within the vessel wall were perpendicular to the arterial surface. The distance from the sternal notch to the sites of carotid and femoral pulse acquisition were measured and inputted into the device to represent the relative distance from the carotid to femoral artery. The calculation of distance divided by time of pulse upstroke relative to the upstroke of the QRS on a 3 lead surface EKG was used by the device to calculate velocity. All recorded measurements met the manufacturer's quality control standards integrated into the software package. (NCT00723801)
Timeframe: Baseline and 6 months

Interventionchange in meters/second (Mean)
Subjects Randomized to Atenolol-1.15
Subjects Randomized to Losartan-0.22

[back to top]

Reduction in Heart Rate

Reduction in heart rate based upon genotype while exercising. Participants exercised on a recumbent bike for 2 minutes at 25W, 2 minutes at 50W, and 2 minutes at 75W twice, once before taking atenolol, and once 2.5 hours after oral administration of 25 mg of atenolol. Data points represent unadjusted mean reduction in heart rate in the 3 genotype groups. (NCT00837902)
Timeframe: 2 exercise periods of 6 minutes each. 6 minutes of exercise before taking atenolol, and 6 minutes of exercise starting 2.5 hours after taking 25 mg of atenolol (2.5 hours + 6 minutes)

,,
Interventionbeats per minute (Mean)
0, baseline2 minutes from baseline, 2 minutes exercise at 25W4 minutes from baseline, 2 minutes exercise at 50W6 minutes from baseline, 2 minutes exercise at 75W
GLN/GLN7.99.611.714
GLN/LEU68.410.912.4
LEU/LEU3.37.49.110

[back to top]

Change in Triglycerides

(Post atenolol triglycerides - Pre atenolol triglycerides) (NCT00925119)
Timeframe: Baseline and Week 8

Interventionmg/dL (Mean)
Atenolol17

[back to top]

Change in Free Fatty Acid Kinetics

Estimate of peripheral lipolysis using modeling of free fatty acid levels collected during an IV glucose tolerance test. The change in threshold for insulin action (post-atenolol minus pre-atenolol) is the primary variable from this modeling that we analyzed. (NCT00925119)
Timeframe: Baseline and Week 8

InterventionmU/mL (Mean)
Atenolol2.02

[back to top]

Change in HDL

(NCT00925119)
Timeframe: Baseline and Week 8

Interventionmg/dL (Mean)
Atenolol-3.5

[back to top]

Change in Insulin

fasting insulin (post - pre atenolol) (NCT00925119)
Timeframe: Baseline and Week 8

InterventionmU/mL (Mean)
Atenolol-0.55

[back to top]

Change in Insulin Sensitivity

"As measured by the Homeostatic model assessment of insulin resistance (HOMA2-IR) (post atenolol - pre atenolol).~he Homeostatic model assessment (HOMA) is a method for assessing insulin sensitivity from fasting glucose and insulin. A higher HOMA value indicates higher insulin resistance. The widely-used formulae available for HOMA1 provide only linear approximations of HOMA_%B and HOMA_IR, the inverse of HOMA_%S. These are: HOMA1_IR = [FPI (uU/ml) x FPG (mmol/l) ]/22.5 HOMA1_%B = (20 x FPI)/(FPG - 3.5) The results obtained for HOMA2 may differ considerably from HOMA1 computer-calculated values, especially for more extreme glucose and insulin values. For this reason, no attempt has been made to provide linear approximations of HOMA2 calculated values of HOMA_%B, HOMA_IR and HOMA_%S. The software needed to calculate HOMA2 values is available on this website: https://www.dtu.ox.ac.uk/homacalculator/download.php, subject to the conditions specified on the downloads page." (NCT00925119)
Timeframe: Baseline and Week 8

Interventionarbitrary units (Mean)
Atenolol-0.05

[back to top]

Change From Baseline in Aortic Augmentation Index (AIx) at Week 4 and Week 12

Augmentation index is a composite measure of wave reflection and systemic arterial stiffness which was calculated as the difference between the second and first systolic peaks. The change in AIx at Week 4 and Week 12 was calculated as AIx at Week 4 and Week 12 minus AIx at baseline. (NCT01079962)
Timeframe: Baseline, Week 4 and Week 12

,
InterventionRatio (Mean)
Change in AIx at Week 4 (n=96, 95)Change in AIx at Week 12 (n=90, 89)
Atenolol-0.011.21
Bisoprolol-1.560.61

[back to top]

Change From Baseline in Aortic Pulse Pressure (APP) at Week 4

The APP was calculated as aortic systolic pressure minus aortic diastolic pressure. The change in APP at Week 4 was calculated as APP at Week 4 minus APP at baseline. (NCT01079962)
Timeframe: Baseline and Week 4

InterventionmmHg (Mean)
Bisoprolol-3.02
Atenolol-4.09

[back to top]

Change From Baseline in Blood Glucose Levels at Week 12

The change in blood glucose level at Week 12 was calculated as blood glucose level at Week 12 minus blood glucose level at baseline. (NCT01079962)
Timeframe: Baseline and Week 12

InterventionMillimoles per liter (mmol/L) (Mean)
Bisoprolol-0.23
Atenolol-0.45

[back to top]

Number of Participants With Adverse Events (AEs)

An adverse event (AE) was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an Investigational Medicinal Product (IMP), regardless of causal relationship and even if no IMP has been administered. (NCT01079962)
Timeframe: Baseline up to Week 14 (follow-up visit)

InterventionParticipants (Number)
Bisoprolol36
Atenolol32

[back to top]

Change From Baseline in Aortic Blood Pressure (BP) at Week 4 and Week 12

The change in aortic BP (aortic systolic blood pressure [SBP], aortic diastolic blood pressure [DBP] and aortic mean blood pressure [BP]) at Week 4 and Week 12 was calculated as aortic BP (aortic SBP, aortic DBP and aortic mean BP) at Week 4 and Week 12 minus aortic BP (aortic SBP, aortic DBP and aortic mean BP) at baseline. (NCT01079962)
Timeframe: Baseline, Week 4 and Week 12

,
InterventionmmHg (Mean)
Change in aortic SBP at Week 4 (n=96, 95)Change in aortic SBP at Week 12 (n=90, 89)Change in aortic DBP at Week 4 (n=96, 95)Change in aortic DBP at Week 12 (n=90, 89)Change in aortic mean BP at Week 4 (n=96, 95)Change in aortic mean BP at Week 12 (n=90, 89)
Atenolol-13.57-12.71-9.47-9.01-10.84-10.24
Bisoprolol-13.90-15.34-10.86-10.94-11.88-12.41

[back to top]

Change From Baseline in Aortic Pulse Pressure (APP) in Intention to Treat (ITT) Population at Week 12

The APP was calculated as aortic systolic pressure minus aortic diastolic pressure. The change in APP at Week 12 was calculated as APP at Week 12 minus APP at baseline. (NCT01079962)
Timeframe: Baseline and Week 12

,
InterventionMillimeter of mercury (mmHg) (Mean)
Baseline (n=96, 95)Change in APP at Week 12 (n=90, 89)
Atenolol45.93-3.69
Bisoprolol47.49-4.40

[back to top]

Change From Baseline in Aortic Pulse Pressure (APP) in Per Protocol (PP) Population at Week 12

The APP was calculated as aortic systolic pressure minus aortic diastolic pressure. The change in APP at Week 12 was calculated as APP at Week 12 minus APP at baseline. (NCT01079962)
Timeframe: Baseline and Week 12

,
InterventionmmHg (Mean)
BaselineChange in APP at Week 12
Atenolol46.53-3.89
Bisoprolol46.87-4.33

[back to top]

Change From Baseline in Brachial Blood Pressure (BP) at Week 4 and Week 12

The change in brachial BP (brachial SBP, brachial DBP and brachial mean BP) at Week 4 and Week 12 was calculated as brachial BP (brachial SBP, brachial DBP and brachial mean BP) at Week 4 and Week 12 minus brachial BP (brachial SBP, brachial DBP and brachial mean BP) at baseline. (NCT01079962)
Timeframe: Baseline, Week 4 and Week 12

,
InterventionmmHg (Mean)
Change in brachial SBP at Week 4 (n=96, 95)Change in brachial SBP at Week 12 (n=90, 89)Change in brachial DBP at Week 4 (n=96, 95)Change in brachial DBP at Week 12 (n=90, 89)Change in brachial mean BP at Week 4 (n=96, 95)Change in brachial mean BP at Week 12 (n=90, 89)
Atenolol-17.52-17.63-11.36-10.61-13.41-12.95
Bisoprolol-17.45-19.10-12.70-13.39-14.28-15.29

[back to top]

Change From Baseline in Carotid-femoral Pulse Wave Velocity (cfPWV) at Week 4 and Week 12

Pulse wave velocity (PWV) is used as a measure of arterial stiffness, which is a measure of the cushioning functioning of major vessels like the aorta. The velocity of the Pulse wave (PW) along an artery is dependent on the stiffness of that artery. The change in cfPWV at Week 4 and Week 12 was calculated as cfPWV at Week 4 and Week 12 minus cfPWV at baseline. (NCT01079962)
Timeframe: Baseline, Week 4 and Week 12

,
InterventionMeters per second (m/s) (Mean)
Change in cfPWV at Week 4 (n=96, 95)Change cfPWV at Week 12 (n=90, 89)
Atenolol-0.81-0.87
Bisoprolol-0.60-0.72

[back to top]

Change From Baseline in Heart Rate at Week 4 and Week 12

The change in heart rate at Week 4 and Week 12 was calculated as heart rate at Week 4 and Week 12 minus heart rate at baseline. (NCT01079962)
Timeframe: Baseline, Week 4 and Week 12

,
InterventionBeats per minute (bpm) (Mean)
Change in heart rate at Week 4 (n= 96, 95)Change heart rate at Week 12 (n= 90, 89)
Atenolol-6.20-7.84
Bisoprolol-6.21-8.64

[back to top]

Change From Baseline in Lipid Levels at Week 12

The lipid levels evaluated were total cholesterol, low density lipoprotein (LDL) cholesterol, and high density lipoprotein (HDL) cholesterol blood concentrations. The change in lipid levels at Week 12 was calculated as lipid levels at Week 12 minus lipid levels at baseline. (NCT01079962)
Timeframe: Baseline and Week 12

,
InterventionMilligram/decilitre (mg/dL) (Mean)
Change in Total cholesterol at Week 12Change in LDL-cholesterol at Week 12Change in HDL-cholesterol at Week 12
Atenolol-0.371.31-3.02
Bisoprolol-3.43-2.29-1.58

[back to top]

Change From Baseline in Ascending Aorta Size, as Evaluated by MRI

The primary analyses include the evaluation of the effects of monotherapy (atenolol vs. placebo, telmisartan vs. placebo) on the change in aortic root size measured at 3 years. Change is measured in centimeters squared (final measurement - baseline measurement). Original outcome measure time frame was scheduled for 5 years, however due to poor study participant and site recruitment study was closed early and final outcome measures taken at approximately 3 years. (NCT01202721)
Timeframe: The difference between baseline measures (2012-2013) and Year 3 measure (2015-2016)

Interventioncentimeters squared (Mean)
Atenolol.6
Telmisartan.4
Atenolol Placebo.7
Telmisartan Placebo1

[back to top]

Rate of Change in Ascending Aorta Size Evaluated by Transthoracic Echocardiography (TEE)

Rate of change in ascending aorta size evaluated by transthoracic echocardiography (ECHO) at 3 years. Change is measured in centimeters squared (final measurement - baseline measurement). Time frame was scheduled for 5 years, however due to poor study participant and site recruitment study was closed early and final outcome measures taken at approximately 3 years. (NCT01202721)
Timeframe: The difference between baseline measures (2012-2013) and Year 3 measure (2015-2016)

Interventioncentimetres squared (Mean)
Atenolol-.9
Telmisartan-.2
Atenolol Placebo-1.6
Telmisartan Placebo.3

[back to top]

Number of Participants With Reduction of Thin-cap Fibroatheromas (TCFA) as Defined by VH-IVUS

Presence of thin-cap fibroatheroma as defined by virtual histology-intravascular ultrasound (VH-IVUS) (NCT01230892)
Timeframe: 1 year

Interventionparticipants (Number)
Nebivolol4
Atenolol6

[back to top]

Change From Baseline in Baroreflex Sensitivity (BRS) at Attainment of Heart Rate Goal

Baroreflex sensitivity (BRS) is an important characteristic of baroreflex control and often noninvasively assessed by relating heart rate (HR) fluctuations to blood pressure (BP) fluctuations. Heart rate goal was defined as attainment of heart rate less than or equal to 65 beats per minute (bpm). (NCT01251146)
Timeframe: Baseline and attainment of heart rate goal (Week 2 or Week 4 or Week 6)

,
Interventionmillisecond per millimeter of mercury (Mean)
Baseline (n=75,79)Change at attainment of heart rate goal (n=67,66)
Atenolol7.922.88
Bisoprolol7.783.27

[back to top]

Change From Baseline in Heart Rate Variability (HRV) for Low Frequency Power (LF) and for High Frequency Power (HF) at Attainment of Heart Rate Goal and End of Follow-up

Heart rate variability (HRV) is used to describe the variations of both instantaneous HR and resting rate (RR) intervals and was evaluated for low frequency power (LF) and for high frequency power (HF). Heart rate goal was defined as attainment of heart rate less than or equal to 65 bpm. (NCT01251146)
Timeframe: Baseline, attainment of heart rate goal (Week 2 or Week 4 or Week 6) and end of follow-up (Week 4 or Week 6 or Week 8)

,
Interventionmillisecond square (ms^2) (Mean)
HRV for LF at Baseline (n=75,79)Change for LF: heart rate goal (n=71,71)Change at end of follow-up for LF (n=71,66)HRV for HF at Baseline (n=75,79)Change for HF: heart rate goal (n=71,71)Change at end of follow-up for HF (n=71,66)
Atenolol322.0926.14-22.00193.48136.67178.05
Bisoprolol261.8090.0489.40171.26148.91186.46

[back to top]

Change From Baseline in Ratio of Heart Rate Variability (HRV) for Low Frequency Power (LF) to Heart Rate Variability Power (HRV) for High Frequency (HF) (LF/HF) at Attainment of Heart Rate Goal and End of Follow-up

Heart rate variability (HRV) is used to describe the variations of both instantaneous HR and resting rate (RR) intervals and was evaluated for low frequency power (LF) and for high frequency power (HF). Heart rate goal was defined as attainment of heart rate less than or equal to 65 bpm. (NCT01251146)
Timeframe: Baseline, attainment of heart rate goal (Week 2 or Week 4 or Week 6) and end of follow-up (Week 4 or Week 6 or Week 8)

,
Interventionratio (Mean)
Baseline (n=75,79)Change at attainment of heart rate goal (n=71,71)Change at end of follow-up (n=71,66)
Atenolol2.40-0.90-1.15
Bisoprolol2.16-0.70-0.69

[back to top]

Number of Participants Attaining Heart Rate Goal at Dosage 1, 2 and 3 of Study Treatment

Dosage 1, 2 and 3 for bisoprolol group was defined as 5 mg, 7.5 mg and 10 mg once daily and for atenolol group as 50 mg, 75 mg and 100 mg once daily, respectively. Heart rate goal was defined as attainment of heart rate less than or equal to 65 bpm. (NCT01251146)
Timeframe: Baseline up to attainment of heart rate goal (Week 2 or Week 4 or Week 6)

,
Interventionparticipants (Number)
Dosage 1Dosage 2Dosage 3
Atenolol7260
Bisoprolol7271

[back to top]

Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: Any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was a medically important condition (NCT01251146)
Timeframe: Baseline up to end of follow-up (Week 4 or Week 6 or Week 8)

,
Interventionparticipants (Number)
Number of participants with AEsNumber of participants with SAEs
Atenolol60
Bisoprolol60

[back to top]

Percentage of Participants Attaining Heart Rate Goal at Week 2, 4 and 6

Heart rate goal was defined as attainment of heart rate less than or equal to 65 bpm. (NCT01251146)
Timeframe: Attainment of heart rate goal (Week 2 or Week 4 or Week 6)

,
Interventionpercentage of participants (Number)
Week 2Week 4Week 6
Atenolol79.1285.7185.71
Bisoprolol83.7291.8693.02

[back to top]

Number of Participants Compliant With Study Treatment

Participants compliant with study treatment were the participants who have completed the study treatment regimen. (NCT01251146)
Timeframe: Baseline up to end of follow-up (Week 4 or Week 6 or Week 8)

Interventionparticipants (Number)
Bisoprolol83
Atenolol81

[back to top]

Change From Baseline in Baroreflex Sensitivity (BRS) at End of Follow-up

Baroreflex sensitivity (BRS) is an important characteristic of baroreflex control and often noninvasively assessed by relating heart rate (HR) fluctuations to blood pressure (BP) fluctuations. Heart rate goal was defined as attainment of heart rate less than or equal to 65 bpm. (NCT01251146)
Timeframe: Baseline and end of follow-up (Week 4 or Week 6 or Week 8)

Interventionmillisecond per millimeter of mercury (Mean)
Bisoprolol4.08
Atenolol3.31

[back to top]

Change in Diastolic Blood Pressure

Change in diastolic blood pressure as measured by sphygmomanometer from baseline to 9 months after intervention initiation. (NCT01522950)
Timeframe: baseline, 9 months

InterventionmmHg (Mean)
Nebivolol-8.5
Atenolol-8.5
Placebo-2.9

[back to top]

Change in Large Artery Elasticity

Change in large artery elasticity (a marker for endothelial function) from baseline to 9 months after intervention initiation. (NCT01522950)
Timeframe: baseline, 9 months

Intervention(ml/mmHg × 10) (Mean)
Nebivolol3.2
Atenolol2.9
Placebo0.2

[back to top]

Change in Small Artery Elasticity

Change in small artery elasticity (a marker for endothelial function) from baseline to 9 months after intervention initiation. (NCT01522950)
Timeframe: baseline, 9 months

Intervention(ml/mmHg × 100) (Mean)
Nebivolol2.4
Atenolol1.0
Placebo0.4

[back to top]

Change in Systolic Blood Pressure

Change in systolic blood pressure as measured by sphygmomanometer from baseline to 9 months after intervention initiation. (NCT01522950)
Timeframe: baseline, 9 months

InterventionmmHg (Mean)
Nebivolol-9
Atenolol-13
Placebo-3.2

[back to top]

Central Aortic Distensibility by MRI

Analyses of the MRIs were performed using commercial software (Argus version 4.02, Siemens Medical Systems, Germany) by experienced observers who were blinded to patient information. To measure central aortic distensibility, the systolic and diastolic cross-sectional areas were measured by manual contouring of the aorta through the cardiac cycle on the cine image. Distensibility at the four regions was calculated as the mean of values obtained from the following equation: Distensibility = (Amax - Amin)/[Amin × (Pmax - Pmin)](10-3mm/Hg), where Amax is the maximal (systolic) aortic area, Amin is the minimal (diastolic) aortic area, Pmax is the systolic blood pressure (SBP), and Pmin is the diastolic blood pressure (DBP). Central aortic blood pressure measured non-invasively by SphygmoCor was used for systolic and diastolic blood pressure. (NCT01715207)
Timeframe: 6 months

,
Intervention(mmHg ^ -1) x 10 ^ -3 (Mean)
initial ascending aortainitial upper descending aortainitial lower descending aortainitial abdominal aortafollow up ascending aortafollow up upper descending aortafollow up lower descending aortafollow up abdominal aorta
Atenolol4.75.16.32.75.06.07.13.5
Atenolol & Aliskiren3.75.77.52.45.28.39.74.5

[back to top]

Central Aortic PWV(Pulsed Wave Velocity)

Aortic PWV was measured according to the well-validated method using MRI 19. From the velocity-encoded MRIs, aortic contours were automatically detected and manually adjusted in each slice area throughout the cardiac cycle. The transit time between the flow curves of each region of the aorta was determined from the midpoint of the systolic up-slope on the flow versus time curve 26-28. The up-slopes were identified by drawing a line between the points of 40% and 60% maximum velocity on the waveform. The distance between each aortic level was measured on black blood images using a curved line along the center of the aorta. Based on these data, the regional PWV was calculated as the ratio of the distance between levels and the time differences between the arrival of the pulse wave at each level. The PWV was measured at two regions: the proximal aorta (proximal PWV between level 1 and level 2) and the entire aorta (PWV-total between level 1 and level 4). (NCT01715207)
Timeframe: 6 months

,
Interventionm/s (Mean)
baseline regional PWV Abaseline PWV totalfollow up regional PWV Afollow up PWV total
Atenolol3.85.03.64.9
Atenolol and Aliskiren3.34.53.24.7

[back to top]

Change in Pre- and Post-atenolol Ventricular Rate Response After 5 Minutes of Exercise

After baseline vital signs and ECG are recorded, patients will be asked to perform a baseline standardized (modified Bruce) exercise protocol. Heart rate will be recorded during each stage of the exercise protocol. Patients will be asked to exercise to sub-maximal exertion. After the baseline exercise protocol, patients will be given a single dose of oral atenolol. After a two hour waiting period to allow for peak effect of atenolol, patients will repeat the exercise protocol. The primary study outcome measure will be the difference in pre- and post-atenolol ventricular rate response to exercise. The primary outcome measure will be compared in patients with various polymorphisms in genes that might play a role in the inter-individual response to atenolol. (NCT01719367)
Timeframe: after 5minutes of exercise

Interventionbeats per minute (Mean)
Atenolol: Ancestral Alleles-10
Atenolol: Variant Carriers-13

[back to top]

Change in Pre- and Post-atenolol Ventricular Rate Response After 10 and 15 Minutes of Exercise

After baseline vital signs and ECG are recorded, patients will be asked to perform a baseline standardized (modified Bruce) exercise protocol. Heart rate will be recorded during each stage of the exercise protocol. Patients will be asked to exercise to sub-maximal exertion. After the baseline exercise protocol, patients will be given a single dose of oral atenolol. After a two hour waiting period to allow for peak effect of atenolol, patients will repeat the exercise protocol. The primary study outcome measure will be the difference in pre- and post-atenolol ventricular rate response to exercise. The primary outcome measure will be compared in patients with various polymorphisms in genes that might play a role in the inter-individual response to atenolol. (NCT01719367)
Timeframe: after 10 amd 15 minutes of exercise

,
Interventionbeats per minute (Mean)
After 10 minutesAfter 15 minutes
Atenolol: Ancestral Alleles-11-25.5
Atenolol: Variant Carriers-19.7-35.2

[back to top]

Complete Ulceration Healing Time

The complete healing time of the ulceration was defined as the time from the first dosage of propranolol or atenolol until complete healing of the hemangioma ulceration (assessed up to 6 months). Ulceration is defined as a break in the integrity of the hemangioma surface epithelium (or skin) with or without infection. The information included the extent of ulceration, complications of ulceration, prior duration of ulceration (before treatment), concurrent treatments, and complete healing time. Prior duration of ulceration was defined as the time from the first sign of ulceration until before β-blocker treatment. The complete healing time of the ulceration was defined as the time from the first dosage of propranolol or atenolol until complete healing of the hemangioma ulceration. Concurrent treatments, including oral pain medication, oral antibiotics, topical ointment antibiotics and/or wound dressings, were permitted to treat ulcerated IH and were recorded. (NCT02342275)
Timeframe: from the first dosage of propranolol or atenolol until complete healing ofthe hemangioma ulceration.

Interventionweeks (Mean)
Propranolol4.94
Atenolol4.82

[back to top]

Number of Participants With Complete/Nearly Complete Response (96 Week)

A complete/nearly complete response at week 96 was considered median-term efficacy. (NCT02342275)
Timeframe: 96 week

InterventionParticipants (Count of Participants)
Propranolol156
Atenolol149

[back to top]

Rebound Rate

Regrowth of more than 20% in hemangioma appearance (including changes in color and/or volume) after stopping the medication was considered significant rebound. The inclusion criteria for rebound analysis were as follows: (1) patients who completed 6 months of treatment and (2) patients who discontinued therapy or were tapering treatment after achieving an any response. The exclusion criteria were as follows: (1) patients who were noncompliant with treatment and (2) patients who did not respond to treatment. Whether a patient had hemangioma rebound was based on the site investigators' assessments after the week 24 treatment. In patients with significant rebound, reinitiation of systemic therapy (either propranolol or atenolol) was recommended. Minor rebound, which was defined as those patients in whose rebound was noted but no reinitiation of systemic therapy or further treatment was necessary, was not included in the analysis. (NCT02342275)
Timeframe: between weeks 24 and 96

InterventionParticipants (Count of Participants)
Propranolol19
Atenolol12

[back to top]

Successful Initial Response

"A successful initial response was defined as a HAS score decrease at 1 week after treatment.~A successful initial response was assessed by using HAS in the intention-to-treat population. Previous studies demonstrated that HAS decreases over time after β-blocker treatment, with a dramatic drop occurring in the first week, indicating an immediate therapeutic response. HAS can reflect the rapid effect of β-blocker (either propranolol or atenolol) therapy shortly after initiation." (NCT02342275)
Timeframe: 1 week after treatment

InterventionParticipants (Count of Participants)
Propranolol171
Atenolol163

[back to top]

The Primary Outcome Measure Was Any Response at 6 Months

"Changes in IH size and color were classified as a complete response, nearly complete response, partial response or no response. The primary outcome measure was any response at 6 months in the intention-to-treat population of all patients who underwent randomization. The any response included compete, nearly complete and partial responses.~A complete response was defined as no redundant tissue or telangiectasia was identified.~A nearly complete response was defined as a minimal degree of telangiectasis, erythema and skin thickening.~A partial response was defined as a size reduction or change in color that did not meet the nearly complete resolution criteria." (NCT02342275)
Timeframe: 6 month

InterventionParticipants (Count of Participants)
Propranolol178
Atenolol173

[back to top]

Hemangioma Activity Score (HAS)

"HAS was measured at baseline and at 1, 4, 12, and 24 weeks, including the degree of deep swelling, the color of the hemangioma, and the ulceration assessment:~Assessment of the degree of swelling. It was scored as follows:~6 points if the swelling was tense;~4 points if the swelling was'neutral;~2 points when the swelling was reduced by 50% or more at follow-up; or~0 point when there was no more visible swelling at a follow-up.~Assessment of the color of the IH.~5 points if the hemangioma lesion was bright red all over;~3 points if the hemangioma lesion was matte red or reddish-purple;~1 point if the hemangioma lesion was totally or partially gray;~0 points if the hemangioma lesion was totally or partially skin-colored after involution.~(2) Assessment of the ulceration. -0.5 point for an ulcer ≤1.0 cm2;~One point for an ulcer >1.0 cm2 but <25 cm2;~Two points for an ulcer ≥25 cm2. The HAS score= (Swelling score + color score)/2 +Ulceration score." (NCT02342275)
Timeframe: Baseline and at 1, 4, 12, and 24 weeks

,
Interventionscore on a scale (Mean)
BaselineWeek 1Week 4Week 12Week 24
Atenolol4.543.472.331.540.82
Propranolol4.613.312.421.540.82

[back to top]

Change in Blood Pressure From Baseline

(NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Blood Pressure From Baseline

(NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Blood Pressure From Baseline

(NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline

A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue. (NCT03070730)
Timeframe: 2 weeks after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline

A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue. (NCT03070730)
Timeframe: 2 weeks after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline

A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue. (NCT03070730)
Timeframe: up to 3 days after randomization

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Heart Rate From Baseline

(NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Heart Rate From Baseline

(NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Heart Rate From Baseline

(NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Maximal Postural Tachycardia During Tilt

Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test. (NCT03070730)
Timeframe: Up to 3 days after randomization

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Muscle Sympathetic Nerve Activity From Baseline

(NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Muscle Sympathetic Nerve Activity From Baseline

(NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline

"Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better to very much worse." (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline

"Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better to very much worse." (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline

"Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better to very much worse." (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Physical Functioning- HADS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales. (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Physical Functioning- HADS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales. (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Physical Functioning- HADS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales. (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Physical Functioning-CIS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS). (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Physical Functioning-CIS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS). (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Physical Functioning-CIS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS). (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Physical Functioning-EuroQOL From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL. (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Physical Functioning-EuroQOL From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL. (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Physical Functioning-EuroQOL From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL. (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Physical Functioning-FSS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale. (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Physical Functioning-FSS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale. (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Physical Functioning-FSS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale. (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Physical Functioning-MFI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI). (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Physical Functioning-MFI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI). (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Physical Functioning-MFI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI). (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Muscle Sympathetic Nerve Activity From Baseline

(NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Physical Functioning-OI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire. (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Physical Functioning-OI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire. (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Physical Functioning-SF-36 Q From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire. (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Physical Functioning-SF-36 Q From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire. (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Vascular Resistance From Baseline

(NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Vascular Resistance From Baseline

(NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Vascular Resistance From Baseline

(NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change Maximal Postural Tachycardia During Tilt

Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test. (NCT03070730)
Timeframe: 2 weeks after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change Maximal Postural Tachycardia During Tilt

Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test. (NCT03070730)
Timeframe: 2 weeks after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Physical Functioning-SF-36 Q From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire. (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Physical Functioning-OI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire. (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Lower Extremity Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by the Balance Portion of a Modified Version of the Short Physical Performance Battery.

"The Short Physical Performance Battery assesses gait speed, core strength when rising from a chair without using the upper extremities, and balance while standing without a cane or walker. The balance test portion of the SPPB assesses the subject's ability to stand unassisted without the use of a cane or walker. Balance test scores range from 0 - 4 with higher scores indicating better ability to stand unassisted. Our research team conducted the balance test according to SPPB standards. Due to the nature of N-of-1 trials, the duration of a subject's period varies based on the subject's home dose of beta-blocker prior to enrollment, therefore, each subject's respective time period for the OFF and ON periods could range between 3 - 6 weeks. The outcome measure data is the mean of the data collected during the span of the outcome measure time frame." (NCT04767061)
Timeframe: The maximum amount of time a subject could have been assessed for this outcome measure is 24-weeks. This outcome was measured at baseline and at each end of period visit.

Interventionscore on a scale (Mean)
ON Beta Blockers3.9
OFF Beta Blockers3.6

[back to top]

Change in Exercise Capacity When on Beta-blocker Versus When Off Beta-blocker, as Measured by Peak Oxygen Consumption (VO2) During Cardiopulmonary Exercise Test (CPET)

"Cardiopulmonary exercise testing (CPET) measures breath-by-breath oxygen production during symptom-limited exercise on a stationary bike. This permits the calculation of peak oxygen consumption (VO2). Percent predicted peak VO2 for body weight will also be calculated. Due to the nature of N-of-1 trials, the duration of a subject's period varies based on the subject's home dose of beta-blocker prior to enrollment, therefore, each subject's respective time period for the OFF and ON periods could range between 3 - 6 weeks. The outcome measure data is the mean of the data collected during the span of the outcome measure time frame." (NCT04767061)
Timeframe: The maximum amount of time a subject could have been assessed for this outcome measure is 6-weeks. This outcome was measured at the end of the first and second visit.

Interventionml/kg/min (Mean)
ON Beta Blockers10.0
OFF Beta Blockers11.4

[back to top]

Change in Lower Extremity Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by the Chair Rise Portion of a Modified Version of the Short Physical Performance Battery.

"The Short Physical Performance Battery assesses gait speed, core strength when rising from a chair without using the upper extremities, and balance while standing without a cane or walker. The chair rise portion of the SPPB assesses core strength. When comparing the number of seconds it takes to complete 5 chair rises, quicker speeds indicate better core strength. Our research team has chosen on comparing the speed at which subjects were able to complete the test. Due to the nature of N-of-1 trials, the duration of a subject's period varies based on the subject's home dose of beta-blocker prior to enrollment, therefore, each subject's respective time period for the OFF and ON periods could range between 3 - 6 weeks. The outcome measure data is the mean of the data collected during the outcome measure time frame." (NCT04767061)
Timeframe: The maximum amount of time a subject could have been assessed for this outcome measure is 24-weeks. This outcome was measured at baseline and at each end of period visit.

Interventionseconds (Mean)
ON Beta Blockers16
OFF Beta Blockers15.1

[back to top]

Change in Lower Extremity Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by the Gait Speed Portion of a Modified Version of the Short Physical Performance Battery.

"The Short Physical Performance Battery assesses gait speed, core strength when rising from a chair without using the upper extremities, and balance while standing without a cane or walker. The gait speed portion of the SPPB assesses the subject's lower extremity function. When comparing the number of seconds it takes to complete the 4-meter gait speed test, quicker speeds indicate better lower extremity function. Our research team conducted the 4-meter gait speed test according to SPPB standards, but have chosen on comparing the speed at which subjects were able to complete the test. Due to the nature of N-of-1 trials, the duration of a subject's period varies based on the subject's home dose of beta-blocker prior to enrollment, therefore, each subject's respective time period for the OFF and ON periods could range between 3 - 6 weeks. The outcome measure data is the mean of the data collected during the span of the outcome measure time frame." (NCT04767061)
Timeframe: The maximum amount of time a subject could have been assessed for this outcome measure is 24-weeks. This outcome was measured at baseline and at each end of period visit.

Interventionseconds (Mean)
ON Beta Blockers4.3
OFF Beta Blockers4.6

[back to top]

Change in Patient-reported Cognitive Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by Patient-Reported Outcome Measurement Information System-Short Form 6a (PROMIS SF-6a)

"Patient-Reported Outcome Measurement Information System-Short Form 6a (PROMIS SF-6a) is a survey of patient-perceived cognitive deficits. Questions are ranked on a 5-point Likert scale, with higher scores indicating better cognitive function. Scores are mapped so the values follow a normal distribution with a population mean T-score of 50 and an SD of 10. Instead of having a min or max, the raw scores have been transformed into t-scores for comparison to a reference population (the US general population) with a mean of 50 and SD of 10. Scores lower than 50 indicate worse cognitive function compared to the US general population. Due to the nature of N-of-1 trials, the duration of a subject's period varies based on the subject's home dose of beta-blocker prior to enrollment, therefore, each subject's respective time period for the OFF and ON periods could range between 3-6 weeks. The outcome measure data is the mean of the data collected during the span of the measured time points." (NCT04767061)
Timeframe: The maximum amount of time a subject could have been assessed for this measure is 76-weeks (24-week max intervention phase,1-year follow-up phase). This outcome was measured at baseline, weekly, end of period and intervention visits, and during follow-up.

Interventionscore on a scale (Mean)
ON Beta Blockers53.8
OFF Beta Blockers52.4

[back to top]

Change in Patient-reported Health Status When on Beta-blocker Versus When Off Beta-blocker, as Measured by Kansas City Cardiomyopathy Questionnaire (KCCQ-12)

"The Kansas City Cardiomyopathy Questionnaire (KCCQ-12) is a heart failure-specific health status survey. Questions are ranked on 5- to 7-point Likert scales, with higher scores indicating better health status. KCCQ scores are scaled from 0 to 100 and frequently summarized in 25-point ranges, where scores represent health status as follows: 0 to 24: very poor to poor; 25 to 49: poor to fair; 50 to 74: fair to good; and 75 to 100: good to excellent. Due to the nature of N-of-1 trials, the duration of a subject's period varies based on the subject's home dose of beta-blocker prior to enrollment, therefore, each subject's respective time period for the OFF and ON periods could range between 3 - 6 weeks. The outcome measure data is the mean of the data collected during the span of the outcome measure time frame." (NCT04767061)
Timeframe: The max amount of time a subject could have been assessed for this measure is 76-weeks (24-week max intervention phase,1-year follow-up phase). This outcome was measured at baseline, bi-weekly, end of period and intervention visits, and during follow-up.

Interventionscore on a scale (Mean)
ON Beta Blockers58.7
OFF Beta Blockers66.0

[back to top]

Change in Patient-reported Health When on Beta-blocker Versus When Off Beta-blocker, as Measured by the EuroQol-5D Visual Analogue System (EQ-5D VAS)

"The EuroQol-5D Visual Analogue System (EQ-5D VAS) indicates patient-perceived health on a vertical visual analogue scale. The scale ranges from 0, indicating poorest health, to 100, indicating the best health. Due to the nature of N-of-1 trials, the duration of a subject's period varies based on the subject's home dose of beta-blocker prior to enrollment, therefore, each subject's respective time period for the OFF and ON periods could range between 3 - 6 weeks. The outcome measure data is the mean of the data collected during the span of the outcome measure time frame." (NCT04767061)
Timeframe: The maximum amount of time a subject could have been assessed for this outcome measure is 24-weeks. This outcome was measured at baseline and at each end of period visit.

Interventionscore on a scale (Mean)
ON Beta Blockers68.9
OFF Beta Blockers67.8

[back to top]

Change in Physical Activity When on Beta-blocker Versus When Off Beta-blocker, as Measured by Step Count on Wearable Activity Monitoring Device

"The wearable activity monitoring device measures daily step count. Due to the nature of N-of-1 trials, the duration of a subject's periods varies based on the subject's home dose of beta-blocker prior to enrollment, therefore, each subject's respective time period for the OFF and ON periods could range between 3 and 6 weeks. We will compare average step counts over 2-week periods, which will be the final 2 weeks of each period when subjects are either on their home (ON Beta Blockers) or minimally tolerated (OFF Beta Blockers) dose. The outcome measure data is the mean collected during the outcome measure time frame." (NCT04767061)
Timeframe: The maximum amount of time a subject could have been assessed for this outcome measure is 8-weeks (last 2 weeks of each period for up to 4 periods).

InterventionCount of Steps (Mean)
ON Beta Blockers2790.5
OFF Beta Blockers3167.3

[back to top]

Change in Patient-reported Quality of Life When on Beta-blocker Versus When Off Beta-blocker, as Measured by Patient-Reported Outcome Measurement Information System-29 (PROMIS-29)

"The PROMIS-29 assesses 7 domains with 4 questions with an additional pain intensity numeric rating scale. The patients' answers to the PROMIS-29 are scored from 1-5 (except for the pain numeric rating scale). The sum of the PROMIS-29 is the raw score transformed into a final T-score metric. Scores are mapped so that the values follow a normal distribution with a population mean T-score of 50 and an SD of 10. Instead of having a min or max, the PROMIS-29 raw scores have been transformed into t-scores for comparison to a reference population (the US general population) with a mean of 50 and SD of 10. Scores lower than 50 indicate worse health compared to the US general population. Due to the nature of N-of-1 trials, the duration of a subject's period varies based on the subject's home dose of beta-blocker before enrollment, therefore, each subject's respective period for the OFF and ON periods could range between 3 - 6 weeks. The values measured over the time points were averaged." (NCT04767061)
Timeframe: The maximum amount of time a subject could have been assessed for this measure is 76-weeks (24-week max intervention phase,1-year follow-up phase). This outcome was measured at baseline, weekly, end of period and intervention visits, and during follow-up.

,
Interventionscore on a scale (Mean)
Physical Health ComponentMental Health Component
OFF Beta Blockers40.047.9
ON Beta Blockers39.846.8

[back to top]

Change in Patient-reported Sexual Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by Patient-Reported Outcome Measurement Information System-Sexual Function (PROMIS-Sexual Function)

"Patient-Reported Outcome Measurement Information System-Sexual Function (PROMIS-Sexual Function) measures self-reported sexual function and satisfaction. Questions are ranked on a 6-point Likert scale, with higher scores indicating poorer sexual function and satisfaction. Due to the nature of N-of-1 trials, the duration of a subject's period varies based on the subject's home dose of beta-blocker prior to enrollment, therefore, each subject's respective time period for the OFF and ON periods could range between 3 - 6 weeks. The outcome measure data is the mean of the data collected during the span of the outcome measure time frame. The score ranges from 0-10 with higher scores meaning worsened sexual function." (NCT04767061)
Timeframe: The maximum amount of time a subject could have been assessed for this measure is 76-weeks (24-week max intervention phase,1-year follow-up phase). This outcome was measured at baseline, end of period and intervention visits, and during follow-up.

Interventionscore on a scale (Mean)
ON Beta Blockers1.8
OFF Beta Blockers2.1

[back to top]